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ABSTRACT
Developments in immunoassay have led to the
availability of (a) analogue radioimmunoassays (RIA)
which purport to measure the minute concentrations of
free thyroid hormones in plasma and (b) highly sensitive
immunometric assays for thyrotrophin (TSH) which could
potentially distinguish, in a basal plasma sample, the
normal TSH levels in euthyroidism from the suppressed
levels found in hyperthyroidism. In this thesis, the per¬
formance of these tests has been assessed in terms of
their analytical precision, accuracy and diagnostic effec¬
tiveness in various clinical settings and compared with
standard tests of thyroid function. The results of these
studies are summarised below:-
Free thyroid hormones
Measurements by several analogue RIAs were pre¬
cise, robust and simple but significant differences in
analytical accuracy were shown compared to direct
equilibrium dialysis reference methods which were deve¬
loped specifically for this evaluation. In uncomplicated
patients presenting to an endocrine clinic, the free hor¬
mone results had a higher predictive value than those for
total hormones. This was probably attributable to the
free hormone measurements being unaffected by changes in
plasma thyroxine-binding globulin. However, in pregnancy
and in patients with systemic illness, many low values
(iv)
were found by analogue RIA compared to equilibrium dialy¬
sis. The analogue assays were also affected by changes in
albumin concentration and affinity, and also the presence
of autoantibodies to thyroid hormones.
Sensitive TSH measurements
Two immunoradiometric assays (IRMA) for TSH were
evaluated and these showed good reproducibility and analy¬
tical recovery with greater sensitivity, specificity and
working range than RIA methods. Samples from hypothyroid
patients with very high TSH could therefore be analysed
without sample pre-dilution. Of more importance was the
demonstration that basal TSH results by IRMA reliably pre¬
dicted results of the TSH-releasing hormone test (TRH
test) in hospital in-patients and patients attending a
thyroid clinic for initial assessment or follow-up. They
were also independent of changes in plasma proteins. A
small number of undetectable TSH results was found in
early pregnancy, the severely ill and in the elderly.
The test was inappropriate in the early follow-up of
patients treated for hyperthyroidism but in hypothyroid
patients treated with thyroxine, it provided the best
biochemical indicator of both over- and under-replacement.
Although measurement of free thyroid hormones
represents a significant advance compared to total hor¬
mones, the measurement of basal TSH by immunometric assay
provides a more sensitive and specific test in the diagno¬
sis of thyroid dysfunction and in monitoring thyroxine
(v)
therapy. Advantages of (1) decreasing the number of unne¬
cessary tests and (2) identifying subclinical disease has
led to the proposal of a new strategy of thyroid function
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1.1 THE HYPOTHALAMIC-PITUITARY-THYROID AXIS
1.1.1 Thyroid Hormone Production and Metabolism
In man, the thyroid gland is the site of synthe¬
sis of all the circulating thyroxine (Tij) and 15% of tri¬
iodothyronine (T3), most of the T3 being derived from
outer-ring monodeiodination of T4 in the liver, kidney and
muscle, Figure 1.1 (Sterling £t aJL., 1970; Schimmel &
Utiger, 1977).
important thyroid hormone, since its concentration in
plasma is approximately 55-fold higher than T3, and it has
a longer half-life (7 days cf. 1 day). However, it has
since been shown that T3 is metabolically more active than
T4, binding to nuclear receptors with ten-fold greater
affinity (Oppenheimer et_ al., 1976). Thyroxine is, there¬
fore, regarded by many as a pro-hormone. Monodeiodin¬
ation also occurs on the inner ring of T4 giving the meta¬
bolically inactive isomer reverse T3 (^3), 90% of which
is formed in peripheral tissues (Schimmel & Utiger, 1977).
The structures of T4, T3 and rT3 are shown below:-







3,3'»5'Tri-iodothyronine (Reverse T3, rT3)
- 3 -
Hypotholomic-Pituitory-Thyroid Axis
Tissue Metabolism of Thyroid Hormones
Plasma
Figure 1.1 The Hypothalamic-pituitary-thyroid Axis and
~~
Tissue Metabolism of Thyroid Hormones.
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In the cells of the thyroid gland, tyrosyl resi¬
dues, which are attached to the large glycoprotein thyro-
globulin (MW 670,000) in the colloid matrix, are iodinated
and coupled together to form thyroid hormone precursors.
The processes of iodine-trapping and oxidation, iodothyro-
nine synthesis, colloid endocytosis, proteolysis and hor¬
mone secretion are all stimulated by thyrotrophin (TSH)
secreted from the anterior pituitary gland (Figure 1.1).
Thyrotrophin regulates adenyl cyclase activity by binding
to high affinity receptors on the thyroid cell membrane.
This increases the intracellular concentration of cyclic
AMP which mediates the effects of TSH on thyroid hormone
production (Lefort e_t al., 1984).
Thyroid hormones are excreted either unchanged by
the kidney, as glucuronide and sulphate esters in bile or
they are deiodinated and deaminated in the liver and kid¬
ney with re-cycling of the released iodide.
1.1.2 Thyroid Hormone Transport in Blood
Thyroid hormones are predominantly protein-bound
in plasma. This protein-binding possibly facilitates
transport to target tissues, prevents excessive loss into
the urine or flooding into cells and may provide a readily
available reservoir of hormone if needed (Hoffenberg &
Pamsden, 1983). The specific oC 2 globulin, thyroxine
binding globulin (TBG), binds 70% and 80% of the plasma
total T24 and T3, respectively (Table 1.1) with less
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binding to thyroxine-binding prealbumin (TBPA) and the low
affinity, high capacity sites of albumin. The high affi¬
nity and capacity of the binding proteins results in less
than 0.05% T4 and 0.5% T3 circulating in the free form,
but it is generally accepted that it is this fraction
which can cross plasma membranes and affect intracellular
metabolism (Robbins & Rail, 1979). Theories of the kine¬
tics of this process are still controversial, the relative
importance of the dissociation of T4 from albumin, TBPA
and TBG in the capillaries being disputed (Ekins et_ al.,
1982; Pardridge, 1982).
In pregnancy, the TBG concentration and hence the
total thyroid hormone concentrations in blood rise whereas
the free levels remain relatively constant (Ekins et al.,
1982). This has led to further speculation as to the
physiological role of TBG and whether a rise in hormone-
binding proteins redirects hormone delivery to either
tissues with long capillary transit times (e.g. the liver)
to meet the requirement for increased protein synthesis in
pregnancy (Pardridge, 1982) or to the foetus before the
development of the foetal thyroid (Ekins e_t al., 1982).
Although entry of thyroid hormones into cells has
previously been regarded as a passive process, active
transport of thyroid hormones via membrane receptors has
been reported in rat hepatocytes (Rao e_t al.,1976; Krenning
et al., 1981) and cultured fibroblasts (Cheng et al., 1980) .
- 7 -
The concept of the free hormone concentration being the
sole determinant of cellular utilisation, therefore,
represents an over-simplification but provides a working
model to explain the clinical findings observed in
situations where changes in protein binding cause large
changes in the total but not the free hormone con¬
centrations, for example in pregnancy, and in the benign
familial conditions of TBG excess and deficiency (Burr et_
al., 1980). The overall metabolic status in such
situations correlates more closely with the plasma free
hormone fraction than with bound hormone. The availabi¬
lity of routine tests of the free hormone level has there¬
fore been regarded as most important by clinicians and
clinical chemists.
1.1.3 The Cellular Action of Thyroid Hormone
Thyroid hormones exert a wide range of physiolo¬
gical effects for example stimulating somatic growth,
neural development, oxygen consumption, heat production
and regulating cellular metabolism. Their mode of action
at the cellular level remains unclear although binding
sites have been demonstrated in the cytosol (Hamada et_ al.,
1970), nucleus (Oppenheimer et al., 1972), mitochondria
(Sterling & Milch, 1975), plasma membrane (Pliam &
Goldfine, 1977) and endoplasmic reticulum of rat liver
cells (Fekkes £t al., 1979).
The binding of T3 to nuclear receptors in the
chromatin increases mRNA transcription (Tata & Widnell,
- 8 -
1966 ; Dillman et_ al_., 1978) and subsequent increases have
been shown in the activities of malic enzyme in the cyto-
sol and glycerophosphate dehydrogenase and cytochromes in
the mitochondria of rat liver (Degroot, 1979). The
strongest evidence in favour of the central role of
T3 nuclear receptors in hormone action, is that children
with peripheral resistance to thyroid hormones have absent
or abnormal receptors in their lymphocytes (Degroot, 1979).
When compared to nuclear receptors, the cytosolic
binding proteins for thyroid hormones have low affinity
but a high capacity (Hamada £t al., 1970). Initially, it
was thought that these were not intracellular transport
proteins analogous to those described for steroid hormones
(O'Malley et_ a_l., 1972) but acted solely as a reservoir
(Dillman et_ al., 1974; Degroot, 1979). However, more
recently, evidence for a role in transport between the
cytosol and mitochondria has been reported (Hashizume et_
al., 1986).
Whether T3 has direct effects on ATP generation
and oxidative phosphorylation via the binding sites in the
mitochondria is still a matter of controversy (Degroot,
1979; Menezes-Ferreira & Torresani, 1983; Hashizume et al♦,
1986). The plasma membrane Na+/K+-ATPase is activated by
thyroid hormone and it is argued that depletion of the ATP
pool stimulates mitochondrial respiration, oxygen consump¬
tion and thermogenesis (Smith & Edelman, 1979).
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1.1.4 Regulation of Thyroid Hormone Secretion
Thyroid gland activity is controlled by the
plasma TSH level which, in turn, is regulated by
thyrotrophin-releasing hormone (TRH) and the negative
feedback control of free thyroid hormones (Figure 1.1).
Thyrotrophin is a glycoprotein (MW 28,000) com¬
posed of two dissimilar polypeptide subunits ( o( andy8) and
20% carbohydrate. The c< subunit is immunologically simi¬
lar and structurally homologous with the c< subunit of
human chorionic gonadotrophin (HCG), luteinizing hormone
(LH) and follicle stimulating hormone (FSH); the p> subu¬
nit possesses the biological activity of TSH but requires
combination with the e< subunit for activity (Pierce &
Parsons, 1981). The secretion of TSH from the
thyrotrophs is pulsatile as shown from recent work
(Greenspan e_t £l., 1986) and is modulated by TRH via the
hypothalamic-pituitary portal system (Harris et al., 1978).
The glycoprotein composition of TSH is also regulated by
TRH and this may affect its hepatic clearance and there¬
fore its biological activity (Gesundheit et_ al., 1986).
The tripeptide TRH (pyroglutamyl-histidyl-
prolinamide) is derived from a larger pro-hormone which
has recently been localised in higher brain centres and
the olfactory lobes (Lechan et_ al., 1986). Release of
TRH in the hypothalamus is thought to be regulated by
- 10 -
neural input (Morley, 1981), and possibly by thyroid hor¬
mones (Larsen, 1982). Its action at the thyrotroph may
be further modulated, however, by thyroid hormones and the
hypothalamic regulators, dopamine and somatostatin
(Morley, 1981; Greenspan et_ al_., 1986). Regulation of
the activity of the hypothalamic-pituitary-thyroid (HPT)
axis by changes in temperature, day length and nutritional
status probably involves several of these mechanisms.
Extracellular calcium is required for TRH to induce TSH
release, involving the inositol phosphate-calcium
signalling system (Berridge, 1984; Gershengorn & Paul,
1986).
The negative feedback control of thyroid hormones
on the pituitary is the main regulator of TSH secretion.
Administration of T3 and T4 results in a rapid decrease in
TSH secretion and, over a prolonged time-period, TSH
synthesis is suppressed due to inhibition of the synthesis
of TSH messenger RNA (Larsen, 1982; Gurr £t al., 1986).
Mechanisms postulated for this inhibition are:- (1) the
synthesis of an inhibitory protein which interferes with
the cell's response to TRH (Vale £t a_l. , 19 6 8; Reichlin,
1978) and (2) inhibition by T3 of calcium uptake by the
thyrotroph, leading to uncoupling of TRH from its second
messenger system (Larsen, 1982).
In the liver and kidney, most of the nuclear T3
is derived from plasma T3 whereas in the pituitary, about
- 11 -
50% is derived from local T3 production (Silva et_ al.,
1978). In addition, there is greater nuclear receptor
occupancy by T3 in the pituitary (80%) than in the liver
or kidney (50%). The pituitary gland may, therefore, be
much more sensitive to circulating T4 levels than other
peripheral tissues (Larsen, 1982; Kaplan, 1984).
1.2 DISORDERS OF THYROID FUNCTION
1.2.1 Primary Thyroid Failure
The main causes of primary hypothyroidism are:
spontaneous atrophy of the thyroid, Hashimoto's thyroidi¬
tis and following treatment of hyperthyroidism. All
forms are about ten times more common in women and there
is a higher incidence in the elderly (Tunbridge et_ al.,
1977). Spontaneous atrophy of the thyroid is associated
with other autoimmune disorders (pernicious anaemia,
diabetes mellitus, Addison's disease). Lithium therapy
used for depressive illness can also lead to hypo¬
thyroidism as it inhibits thyroid hormone synthesis.
In some clinically euthyroid patients, there is
impaired thyroid reserve and TSH secretion is increased to
maintain thyroid hormone concentrations. If not drug-
induced, this "subclinical hypothyroidism" slowly
progresses to overt hypothyroidism (Toft £t al., 1981).
Thyroxine replacement therapy is usually withheld in such
patients until there is biochemical and clinical evidence
- 12 -
of hypothyroidism (e.g. weight gain, tiredness, cold into¬
lerance, bradycardia etc.).
1.2.2 Secondary Hypothyroidism
In rare cases, hypothyroidism may be secondary to
anterior pituitary failure (as a result of hypophysectomy
or a pituitary adenoma) or hypothalamic disease. An
expanding pituitary tumour tends to alter the secretion
of other pituitary hormones before TSH, with resultant
clinical manifestations.
1.2.3 Hyperthyroidism
Hyperthyroidism is commonly due to Graves'
disease, toxic multinodular goitre and, less frequently,
an autonomous solitary nodule. All forms occur about six
times more often in women than men. Graves' hyperthyroid¬
ism, which tends to be more severe, presents at an earlier
age (30-50 years). Immunoglobulins in the serum of
patients with Graves' disease (a) bind and stimulate the
TSH receptor, (b) stimulate growth of the thyroid and (c)
bind and cause hypertrophy of eye muscle. Their varying
titres cause most patients to have goitres and about half
to have ophthalmopathy. Some euthyroid patients may
exhibit only the eye signs of Graves' disease (Ophthalmic
Graves' disease). The hyperthyroidism of toxic multi¬
nodular goitre develops insidiously from the proliferation
of foci of thyroid follicles with excessive iodine turn¬
over. The inhibition of TSH secretion due to a thyroid
- 13 -
adenoma results in atrophy of the rest of the thyroid.
Depending on the aetiology, history and age of the
patient, hyperthyroidism is treated with radioiodine,
surgery or anti-thyroid drugs e.g. carbimazole which
blocks the oxidation of iodide. Hyperthyroidism due to
hypersecretion of TSH from the pituitary, is very rare.
Patients with suppressed TSH secretion but normal
thyroid hormone levels are described as having subclinical
hyperthyroidism, and those with multinodular goitre or a
solitary nodule may progress to overt disease with symp¬
toms of weight loss, heat intolerance, palpitation, tremor
etc. Anti-thyroid treatment is considered in such
patients if there is unexplained atrial fibrillation or an
autonomous nodule (Toft et_ al., 1981).
1.3 BIOCHEMICAL TESTS OF THYROID FUNCTION
It can be seen from the physiology of the HPT
axis, that the level of thyroid activity can be assessed
in two ways i.e. by measurement of circulating thyroid
hormone concentrations or by determining the end-organ
response; this is most readily achieved by measuring
thyrotroph responsiveness. If thyroid dysfunction is
detected, other tests may be required to indicate the
cause of the disease e.g. thyroid isotope scans and
measurement of serum autoantibodies. In the past few
years, there have been considerable improvements in our
-in¬
ability to measure thyroid hormone and TSH concentrations
in plasma. These will now be reviewed.
1.3.1 Total Thyroid Hormone Measurements
Prior to the availability of specific anti-Tjj
antisera in the 1960s, most laboratories estimated the
protein-bound iodide of plasma by releasing the iodide
with acid and quantitating its catalytic effect on the
cerate-arsenite reaction (Blackburn & Power, 1955) but
this was a hazardous procedure which gave misleadingly
high results in the presence of iodine-containing drugs
or X-ray contrast media (Toft et_ al_. , 1973). Competitive
protein binding assays for T4 using TBG as the binding
agent had the disadvantage of requiring extraction of
serum before assay and problems of cross-reaction with T3
were encountered. The technique of radioimmunoassay
(RIA), first described by Yalow and Berson in 1960, per¬
mitted the specific measurement of both total T4 and T3 in
unextracted plasma.
In general, total T4 measurements discriminated
both hyper- and hypothyroidism adequately from the
euthyroid state, with total T3 being a particularly
valuable investigation in suspected hyperthyroidism since
twice the increase in values, above the upper limit of
normal, were found with T3 compared to T4 (Toft e_t al. ,
1973; Seth at al., 1976). In hyperthyroidism, thyroidal
T3 production is increased, as is the extra-thyroidal pool
- 15 -
size of T3, which may account for the greater rise in
plasma levels. Total T3 measurements have also proved
useful in the relatively rare cases of T3~thyrotoxicosis,
where total T4 concentrations are normal. The measure¬
ment of T3 is of little value in investigating hypo¬
thyroidism where normal levels are often found (Seth ejt
al., 1976).
Since total thyroid hormone levels change with
alterations in protein binding, these measurements give
misleadingly high results due to oestrogen-induced
increases in TBG e.g., in patients who are pregnant or
receiving oral oestrogens (e.g. the oral contraceptive
pill) or who have the rare condition of hereditary TBG
excess. Euthyroid hyperthyroxinaemia due to abnormally
increased binding to TBPA (Moses et_ al., 1982) and albumin
(Stockigt et_ al., 1981) has also been described recently.
Misleadingly low total thyroid hormone con¬
centrations occur in patients with hereditary TBG defi¬
ciency and in hypoproteinaemic states such as chronic
liver disease and nephrotic syndrome. Some drugs cause
low values by displacing T4 and T3 from their binding
sites (e.g. salicylate, fenclofenac), while others e.g.
androgens, corticosteroids and phenytoin increase the
clearance of thyroid hormones from plasma. Levels of
total T3 are also frequently reduced in non-thyroidal
illness due to decreased peripheral conversion of T4 to
- 16 -
T3 (Chopra et_ al., 1975). This has confused the issue as
to whether there is an age-related decline in plasma total
T3 concentrations (Olsen et_ al., 1978). Fasting also
reduces total T3 levels due to decreased 5'-deiodinase
activity (Eraverman & Vagenakis, 1979).
In order to overcome the problems with total
thyroid hormone measurements due to changes in protein
binding, several indirect and direct methods for esti¬
mating the free fraction have been devised.
1.3.2 Free Thyroid Hormone Measurement
(a) Indirect Methods
Indirect methods are those in which the free hor¬
mone concentration is calculated from measurements of both
the total hormone concentration and either the percentage
free fraction (commonly measured by equilibrium dialysis,
ultrafiltration or sephadex adsorption) or the total serum
binding capacity. A classification of indirect methods
according to Ekins (1979) is shown in Table 1.2a.
Although methods for quantitating the free fraction were
developed in the 1960s (Sterling & Hegedus, 1962), these
were too technically demanding for routine applications
(see 1.3.2b). Consequently, measurements of either the
serum binding capacity by an uptake test or the TBG con¬
centration, with calculation of the free T4 index (FT4I)
or TzpTBG ratio, were widely adopted.
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Table 1.2 Free Thyroid Hormone Measurements
(a) INDIRECT METHODS
Equilibrium:
1 . Measurement of total T4 or T3 and the percentage free
hormone using radiolabelled hormone as indicator
after dialysis, ultrafiltration etc.
2. Measurement of total T4 and serum binding proteins to
give either T4:TBG ratio or a calculated free hormone
concentration from known binding constants.
3. Measurement of total T4 or T3 and the unoccupied
binding sites to give FT4I or FT3I.
Dynamic:
1. Measurement of the rate of transfer of radiolabelled
hormone from one compartment to another (Ross, 1978).
2. Measurement of the rate of association of labelled
hormone to antibody in the presence and absence of a




1. Quantitation (by RIA or gas chromatography) of free
hormone after separation from the bound hormone by
dialysis, ultrafiltration or sephadex adsorption
(e.g. Lepetit Lisophase sephadex column method).
Dynamic:
1. Sequential exposure of antiserum first to serum and
then to back titration with label. Separation of
antiserum from serum is either by a dialysis membrane
or by using a solid-phase antibody (e.g. Clinical
Assays two-step method).
Equilibrium Immunoassay:
2. Simultaneous incubation of antiserum, label and
sample with separation of antiserum from serum
binding proteins effected by:-
- microencapsulation of antibody (e.g. Damon
Liquisol method)
- use of a chemically-modified T4 radiolabel which
does not bind to serum binding proteins (e.g.
Amerlex analogue method)
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Thyroid hormone uptake tests involved determining
the partition of radiolabelled T3 between plasma proteins
and an adsorbent to estimate the unoccupied binding sites
(U-TBP). The equilibrium between free t4, t4 bound to
protein (TBP-t4) and U-TBP can be described as:
Free t4 + U-TBP - N TBP-t4
Since the equilibrium favours protein binding, the total
t4 by RIA effectively measures [TBP-t4]. From the law
of mass action, therefore:-
[Free t4] = [Total t4] where K is the
K [U-TBP]
association constant, and the ft4i = [Total t4]
[u-tbp;
The ft4i has been shown to correct for small
changes in TBG levels e.g. due to the effects of oestro-
gens but not for the changes in protein binding found in
sick, elderly patients (Witherspoon £t al. , 1981) or those
with hereditary TBG abnormalities (Burr et_ al., 1977).
Although the t4:TBG ratio is satisfactory for wide changes
in TBG concentration, two measurements still have to be
made with combination of the results. These tests have
therefore not replaced total t4 measurements but are used
in certain patients if a TBG abnormality is suspected.
Other indirect methods (Table 1.2a), involved
measurements of the rate of dialysis of radiolabelled hor¬
mone from serum to a buffer compartment or the rate of
association of radiolabel to an added antibody. Although
- 19 -
shorter incubations compared to equilibrium dialysis were
possible with the dialysis-rate method of Ross (1978), it
has not been widely used. Corning Medical developed the
first free T4 (fT/|) kit in 1978 which involved the
measurement of the rate of association of labelled T4 to
antibody coupled to glass beads in the presence and
absence of a serum binding protein blocking agent. The
former represents a total T4 measurement, and the latter
was assumed to be proportional to the fT4 concentration,
the ratio being compared to that for standards calibrated
against equilibrium dialysis. This kit, however, lost
favour in the light of the low values found in pregnancy
sera (Boss & Kingstone, 1979), abnormal values found in
patients with congenital TBG abnormalities (Witherspoon £t
al., 19 8 0 ; Symons et_ al., 1983) and criticisms of the
mathematical manipulations employed to calculate results.
Until the availability of high avidity antisera
in the late 1970s, the indirect equilibrium techniques,
which do not rely on calibration (Table 1.2a), were
regarded as the reference methods for free thyroid hormone
measurement.
(b) Sources of Methodological Error in Early
Reference Methods
There is considerable variation in reported nor¬
mal values for fT4 when radiolabelled (^311 or 125i)
- 20 -
hormone is used to measure the free hormone fraction
(Table 1.3a). This can be attributed partly to the pre¬
sence of radioactive contaminants (mainly iodide and
iodothyronine breakdown products) which do not reflect
the distribution of unlabelled hormone between bound and
free compartments in the dialysis or ultrafiltration
system. Steps taken to reduce this interference were (a)
chromatography of the dialysates prior to radioassay
(Sterling & Hegedus, 1962), (b) the use of diluted serum
to dilute out the effects of tracer impurities
(Oppenheimer & Surks, 1964) and (c) concentration of the
T4 in dialysates either by use of the thyroxine-binding
capacity of serum (Ingbar e_t a_l. , 1965) or precipitation
of iodothyronines with magnesium chloride (Sterling &
Brenner, 1966). Purification of the radiolabel by prior
dialysis or specific immunoprecipitation, and immunopreci-
pitation of the serum dialysate to remove contaminants,
further reduced the estimates of fT4 by indirect dialysis
procedures to 0.03% (Schussler & Plager, 1967; Beckett et_
al., 1983a).
Fewer indirect assays for free T3 (fT3) have been
developed and the lack of consensus in the accepted
reference range for total T3 in serum has contributed to
the greater divergence in fT3 values reported by early
workers (Table 1.3b).
Disagreement about the effects of serum dilution
on the measured percentage of fTzj, highlighted further























































































factors influencing the T4 binding equilibrium.
Oppenheimer and Surks (1964) demonstrated mathematically
that serum dilution should have a relatively minor effect
on the fTi| concentration, due to the very small percentage
of total T4 existing in the free state. Experimentally,
however, lower values for fT4 were found in dilute serum
(Oppenheimer & Surks, 1964 ; Ingbar et_ al_. , 1965) and this
was thought to be due to a reduction of contamination in
the dialysate of non-T4 radioactivity. Spaulding and
Gregerman (1972) showed that the dialysable fraction
increased with increasing concentrations of phosphate and
particularly chloride ion and reasoned that, when
phosphate buffer is used to dilute serum prior to dialy¬
sis, endogenous chloride ions are progressively diluted
and replaced by buffer ions with a consequent decrease in
the measured fT4. The different ionic composition of the
buffers used to dilute serum in the methods outlined in
Table 1.3> therefore, represents another source of
methodological variation in addition to the degrees of
purification of the radiolabel (Pedersen, 1974b).
The pH and temperature sensitivity of the
binding of T4 to binding proteins shown in early studies
(Schussler & Plager, 1967; Spaulding & Gregerman, 1972),
led to more rigorous maintenance of incubations at 37°C
and at pH 7.4. Temperature control was easier using
equilibrium dialysis than ultrafiltration but it was
- 23 -
recognised that ultrafiltration had the advantage of
shorter incubations (approx. 1 h) compared to dialysis
(approx. 24 h) where the possibility of the degradation of
labelled iodothyronines, denaturation of protein and bac¬
terial contamination was increased. With both tech¬
niques, practical difficulties still remained in avoiding
the leakage of protein-bound hormone through the dialysis
membrane or ultrafilter and in reducing the absorption of
hormone onto the ultrafiltration apparatus.
It is clear, therefore, that free thyroid hormone
values obtained by any indirect method can only be
regarded as numerical indices of the absolute con¬
centrations in blood and will be defined by the set of
analytical conditions used.
(c) The Validity of Direct Equilibrium Methods
The direct measurement of fT4 and fTg following
the physical separation at equilibrium of the free and
bound moieties (by dialysis, ultrafiltration etc) has
been facilitated by the development of highly sensitive
RIA techniques (Table 1.2b). Modifications to the
original method by Ellis and Ekins (1975) are shown in
Table 1.4 together with the normal values obtained.
In spite of the different diluents and separation
methods used in the RIAs, these direct methods gave
values which were in reasonably close agreement but
generally lower than those obtained by indirect reference
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methods (Table 1.3). This direct approach avoids
problems due to contaminants of the radiolabel in the
dialysis system and the error involved in combining two
results i.e. total T4 and the percentage free fraction.
All direct equilibrium methods for fT4 measure¬
ment described to date use diluted serum. This dilution
will produce a perturbation of the equilibrium originally
present in undiluted serum. In a similar way,
sequestration of T4 by the addition of absorbents in
chromatographic methods (e.g. Lepetit) or by addition of a
specific antibody in the equilibrium immunoassay tech¬
niques (see later), will enhance this disturbance.
However, mathematical modelling of the T4 binding
equilibrium between all the serum binding proteins
(Geiseler & Ritter, 1983; Kamikubo et_ al., 1984), suggests
an absence of any substantial dependence of fT4 on dilu¬
tions up to 50-fold and this has been confirmed experimen¬
tally by the direct dialysis-RIA techniques of Ellis and
Ekins (1975) and Weeke and Orskov (1979). Since T3 is
more weakly bound to protein than T4 with 0.3-0.5% cir¬
culating in the free form, it is likely that serum dilu¬
tion will cause a greater perturbation of the equilibrium.
Indeed it has been shown both theoretically and experimen¬
tally, that a 50-fold dilution of serum results in a 20%
decrease of fT3 values (Ellis & Ekins, 1975; Weeke &
Orskov, 1979; Kamikubo et al., 1984). Since alterations
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in buffer ion concentrations with serum dilution affect
the binding equilibria, there has been a move towards the
use of 0.01 M HEPES buffer, pH 7.^ for direct dialysis
methods.
A second consequence of sample dilution is
simultaneous dilution of serum constituents which, by
interacting with TBG and other binding proteins, modu¬
late the fT4 concentration in undiluted serum. This is
of particular importance in patients taking certain drugs
that are known to interact with Tzj-binding proteins, and
in non-thyroidal illness where inhibitors of binding may
be present (Ekins, 1979; Chopra et_ al., 1982).
It is evident that results by any methodology may
not represent the true free hormone concentration present
in undisturbed, undiluted serum. It is argued, however,
that the direct equilibrium dialysis and ultrafiltration
techniques come closest to satisfying the physicochemical
criteria of validity applicable to a free hormone assay
method (Ekins, 1979 & 1983a) and, as such, have been
widely accepted as the best reference methods for fTij. and
fT3 measurement.
(d) Direct Dynamic Free T4 Methods
As an alternative to using a dialysis membrane or
ultrafilter to separate protein-bound from free hormone,
the reaction between radiolabel and serum binding proteins
is prevented in the commercial Clinical Assays two-step
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fT4 method, by a sequential exposure of assay antibody
first to serum and subsequently to labelled material.
The antiserum is adsorbed to the walls of plastic tubes
and serum is readily removed from the antibody after the
first incubation by aspiration and washing. The unoc¬
cupied antibody binding sites are then back-titrated with
125i_T4 in the second stage. This assay, which first
became available in 1979, is unaffected by serum dilution
but has not been used widely due to the vulnerability of
the assay to drift, variations in the timing of incuba¬
tions and the practical inconvenience of sequential incu¬
bations (Ekins, 1983a).
(e) Micro-encapsulated Antibody Methods
An alternative methodology marketed in 1979 by
Damon Diagnostics utilises anti-Tzj antiserum micro¬
encapsulated within a semi-permeable membrane. Radio-
labelled T4 is bound to this antiserum and, in the
presence of serum, the amount of displaced from
the antibody to the outside of the microcapsule, is
proportional to the fT4 concentration in the sample.
Free and bound antigen can then be separated by centrifu-
gation. This system has been likened to equilibrium
dialysis in which the diffusion rate is 400 times faster
(Ashkar et_ al. , 1979) but assay results so far have not
been completely independent of the concentration of total
T4 and of endogenous binding proteins (Witherspoon et al.,
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1980). Poor precision has also resulted from the fragi¬
lity of the microcapsules.
(f) Equilibrium Analogue RIA Methods
Commercial assays which are being increasingly
used are those which use simultaneous incubation of serum,
and a labelled hormone analogue which binds to the assay
antibody in the normal way but is chemically restricted
from reaction with serum binding proteins (Midgley &
Wilkins, 1981). The principle of this technique is
contrasted with that of a conventional RIA in Figure 1.2.
In a conventional RIA, a small mass of radiolabelled anti¬
gen which is similar or identical to the analyte is incu¬
bated with the analyte and a limited amount of specific
antibody (Figure 1.2a). By the law of mass action, the
amount of radiolabel bound to the antibody at equilibrium
is inversely proportional to the analyte concentration in
the sample (Ekins, 197*0. Provided the antibody-bound
ligand can be separated from the free ligand, the distri¬
bution of radiolabel can be quantitated and calibrated
against standard analyte concentrations. In the RIA of
total T4, a protein-binding inhibitor e.g. anilino-
k
naphthalene sulphonic acid (ANS) is used to dissociate
T4 from TBG and allow equilibration with the radiolabel.
In the fT4 analogue RIA (Figure 1.2b), the labelled
T4 derivative only equilibrates with the fT24. pool and,
therefore, the binding to the antibody is inversely pro¬
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(b) The equilibrium between serum binding-
proteins and T4 is not perturbed and the
radiolabel cannot bind to serum protein.
Figure 1♦2 The Principle of a Conventional Total T4 RIA
(a) and of a Labelled Analogue RIA for Free
T4 (b).
The amount of label bound to the antibody in
(a) and (b) is inversely related to the
concentration of the analyte.
- 30 -
In this analogue assay system, provided the
antibody binding does not perturb the equilibrium signifi¬
cantly (i.e. <1? of total T4 antibody-bound) and the serum
proteins do not bind the analogue, this method should pro¬
vide a valid fT4 measurement (Ekins, 1983a). Amersham
International produced the first analogue fT4 assay and
subsequently similar kits have been marketed by other
manufacturers differing mainly in the hormone analogue,
the reference method used for calibration of standards and
the RIA separation system. Initial clinical studies
suggest that these assays are independent of changes in
TBG concentration (Wilke, 1982) and are technically con¬
venient. They are consequently replacing the FT4I in
routine clinical laboratories and their wider application
in a variety of clinical situations is now being actively
researched. However, there is much controversy pertain¬
ing to the validity of such assays (Stockigt et_ al.,
1982a & b; Amino et_ al., 1982; Midgley & Wilkins, 1982).
The development of commercial kits for fT3 has
been less prolific, the analogue methods being the main
alternative at present (a column adsorption method by
Lepetit has proved too slow and technically demanding for
routine use). This has largely been due to the fact that
the clinical utility of this test has yet to be fully
established.
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1.3.3 Basal Thyrotrophin Measurements
The release of TSH by the pituitary thyrotrophs
is a sensitive indicator of the adequacy of circulating
thyroid hormone levels. In the mid-1960s, purification
of human TSH led to the generation of TSH antisera and the
replacement of bioassays with specific RIA systems (Odell
et al., 1965). These systems are sufficiently sensitive to
detect elevated TSH concentrations but preparation of
serum concentrates (Wehmann e_t al. , 1979) or use of
extended incubation times (Wide & Dahlberg, 1980) are
needed to distinguish, reliably, suppressed values from
normal; these do not provide convenient methods for
routine investigations. The main clinical application of
TSH measurements by RIA has therefore been in the detec¬
tion of primary hypothyroidism.
Many antisera to TSH show some cross-reaction
with other human glycoprotein hormones, particularly LH
and HCG and this has also limited the attainable sen-
sitivies of RIAs. This may be due to similar epitopes on
the different hormones or to the preparation used as an
immunogen being only partially pure. This problem has
been circumvented by absorbing the TSH antiserum with an
excess of HCG to saturate cross-reacting LH binding sites
(Odell et_ al. , 1965 ; Wehmann £t al_., 1979).
In patients with primary hypothyroidism, the TSH
concentration in serum is raised regardless of the
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aetiology (Hersham & Pittman, 1971). In mild or sub¬
clinical hypothyroidism, total T4 concentrations are
within normal limits, and the increase in TSH secretion is
the first measurable sign of declining thyroid secretion
(Irvine et al,, 1973). Slight changes in thyroid hormone
concentration within the population reference range may,
therefore, produce marked effects on the negative feedback
system and TSH secretion of the individual (Snyder &
Utiger, 1972a; Saberi & Utiger, 1975). Basal TSH
measurement is an accepted screening test for congenital
hypothyroidism but it has not been used to screen for
thyroid dysfunction in adults because present assays can¬
not reliably identify hyperthyroidism. In clinical prac¬
tice, therefore, basal TSH measurement has served mainly
as a follow-up test to further analyse the cause of low
total T4 concentrations (Figure 1.3).
Basal TSH measurements, by contrast, have a well-
established role in the assessment of the adequacy of T4
replacement therapy, the normalisation of serum TSH being
an accepted therapeutic goal which has resulted in a
marked reduction in the recommended dosage given (Evered
et al., 1973).
Physiological changes in basal TSH levels have
been detected using sensitive RIA methods e.g. the diurnal
variation of TSH (Wehmann & Nisula, 1984) and the reduction
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Figure 1.3 A Strategy Commonly Used in the Selection of






Figure 1.4 A Schematic Representation of the Principle
of Immunometric Assay.
The label bound to the solid-phase antibody-
analyte complex is directly proportional to
the concentration of analyte. Separation
of bound from free label is required before
quantitation of the bound label.
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Croxon et_ al. , 1977). There are conflicting reports as
to whether TSH concentrations increase or decrease in
pregnancy (Braunstein & Hershman, 1976; Braverman &
Vagenakis, 1979; Yamamoto £t al_., 1979). However, these
changes are not sufficient to obscure the rise in basal
TSH levels due to primary hypothyroidism.
The development of monoclonal antibodies to TSH
has provided reagents for use in labelled-antibody
immunoassays (immunometric) for TSH, with the potential
for greater sensitivity, specificity and speed of assay
(Hunter £t_ al., 1983). The principle of immunometric
assay which was proposed by Miles and Hales in 1968 is
illustrated in Figure 1.4. In contrast to RIA, an excess
of labelled monoclonal antibody is incubated with analyte,
and the labelled antibody-analyte complex is removed from
solution by an excess of solid-phase antibody. The use
of excess reagents enhances the kinetics, reproducibility
and hence the sensitivity compared to RIA and the use of
two monoclonals, directed to two differing antigenic
sites, increases the specificity of the measurement. The
first labels used in such assays were radioisotopes (125i)
and therefore these assays were termed immunoradiometric
assays (IRMA). Fluorescent, chemiluminescent, lumi¬
nescent and enzyme labels have all since been attached to
monoclonal antibodies for immunometric assays. The role
of sensitive TSH immunometric measurements in strategies
of thyroid function testing has still to be investigated.
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1.3.4 The Thyrotrophin-Releasing Hormone Test
The response of the pituitary to the administra¬
tion of synthetic TRH greatly extended the value of plasma
TSH RIA measurements in assessing the function of the HPT
axis (Ormston et al., 1971). The test is now performed
by injecting 200 ;ag of TRH intravenously and measuring TSH
before and 20 min after the injection. Normally, there
is a marked increase in the plasma TSH concentration at 20
min whereas in hyperthyroidism the response is absent due
to suppression of the thyrotrophs by high circulating
thyroid hormone levels. However, an absent response may
also occur when thyroid hormone levels increase within the
reference range (subclinical hyperthyroidism) and in
patients either receiving T4 replacement or in remission
after treatment for hyperthyroidism (Toft et_ al_. , 198 1 ).
There is also a temporary failure in the response to TRH
during the first 4-8 weeks after treatment of hyperthyroid¬
ism due to a delay in the recovery of the previously
suppressed thyrotrophs.
Reduced responses may also occur in some non-
thyroidal conditions e.g. in patients with Cushing's
syndrome, chronic renal failure (Gomez-Pan et_ al_. , 1979),
depression (Extein et al_., 1980), starvation (Carlson et_
al. , 1977) and in some severely ill patients (Heinen £t
al. , 1981 ; Vierhapper et al., 1982). In most cases,
however, the TRH test is thought to provide a reliable
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indication of thyroid status (Lamberg & Gordin, 1978;
Braverman & Vagenakis, 1979). Drugs known to suppress
TSH secretion include dopamine agonists (Morley, 1981) and
glucocorticoids (Re et al. , 1976). The TRH test is,
therefore, of most use in excluding the diagnosis of
hyperthyroidism.
In primary hypothyroidism, there is an
exaggerated response of TSH to TRH, but this is not
generally helpful in diagnosis in view of the raised
basal level. In secondary hypothyroidism, basal TSH
measurements may be low or normal and there is an impaired
response to TRH. However, this condition is usually
diagnosed with the help of other pituitary function tests
which become abnormal before the TRH test.
Recently, Wide and Dahlberg (1980) have shown
with an RIA optimised for high sensitivity, that a good
correlation exists between the basal TSH concentration and
the magnitude of the TSH response to TRH. Since the TRH
test requires personnel to administer TRH and collect two
blood samples, and since adverse reactions to TRH have
been reported (Editorial, 1984), the possibility of its
replacement by a single basal measurement has major advan¬
tages. The development of reliable and robust high sen¬
sitivity immunometric assays for TSH has made the eva¬
luation of such a replacement, feasible.
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1.3.5 Strategies of Thyroid Function Testing
For reasons of economy, most laboratories do not
perform both thyroid hormone and TSH measurements on all
samples where thyroid function tests have been requested.
The shortcoming of TSH RIA methods for detecting hyper¬
thyroidism means that, in general, the strategy shown in
Figure 1.3 is commonly used with total T4 as the first-
line test. Such a strategy is used to:-
1. Confirm the presence of thyroid dysfunction.
2. Screen for thyroid dysfunction in the elderly and in
the presence of non-thyroidal illness.
3. Monitor the treatment of thyroid disease.
The improvements in methods for free thyroid hormone and
TSH measurement may allow the development of more effec¬
tive strategies of thyroid function testing.
1 AIMS OF THE STUDY
The general aims of this study were:-
1. To evaluate the laboratory and clinical performance
of analogue fT4 and fT3 RIAs and a sensitive TSH IRMA.
2. To ascertain their role in strategies of thyroid
function testing.
3. To apply them in situations which might increase







2.1.1 Reagents for Total Ti|, and In-house TSH RIA
All antisera, unless otherwise stated, were from
the Scottish Antibody Production Unit (SAPU), Law
Hospital, Carluke, U.K. Normal sheep serum (NSS) and
normal rabbit serum (NRS) were also from SAPU.
The radiolabels 125i_t4 and (Specific
activity (SA) >1200 pCi/yig) were from Amersham
International, Amersham, Bucks., U.K. (Amersham
International). The 125l-TSH was made by staff at the
Immunoassay Section, Department of Clinical Chemistry,
Royal Infirmary, Edinburgh, U.K., by a direct chloramine T
method (Hunter & Greenwood, 1962).
Solid T4 (sodium salt pentahydrate) and T3 (free
acid) were from Sigma Chemical Co., Poole, Dorset, U.K.
(Sigma) and of >95% quoted purity. The TSH standard was
the first WHO International Reference Preparation (IRP)
68/38.
Normal human pooled serum was from outdated donor
collections tested for hepatitis B (and more recently,
HIV) by the Blood Transfusion Service. Horse serum was
from Wellcome Diagnostics, Dartford, Kent, U.K.
(Wellcome).
Norit A activated charcoal powder (C5260),
tv
triton-X-100 and 8-anilino-1-na^thalene sulphonic acid
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(ANS) were from Sigma. All other chemicals were of ana¬
lytical grade from British Drug Houses Chemicals Ltd.,
Poole, Dorset, U.K. (BDH).
2.1.2 Thyroid Function Test Kits
Kits used to measure free thyroid hormones were
from Amersham International (Amerlex/Amerlex magnetic fT4
and fTg), Corning Medical and Scientific, Halstead, Essex,
U.K. (Corning Magic fT2|), Becton Dickinson Ltd., Cowley,
Oxford, U.K. (Becton Dickinson fT4, fT3 and the SimulTRAC
fT4/TSH kit) and Diagnostic Products Ltd., Wallingford,
Oxon, U.K. (Coat a Count fT4 and fT3). The Riagnost kit
for TBG was from Behring Diagnostics, Hounslow, Middlesex,
U.K. Kits used to measure TSH were from Becton Dickinson
Ltd., (Becton Dickinson 125I-TSH RIA and the SimulTRAC
fT4/TSH Kit), Boots-Celltech Diagnostics Ltd., Slough,
Berks., U.K. (Boots-Celltech Sucrosep TSH IRMA) and
Amersham International (Amerwell TSH IRMA).
2.1.3 Detection of Abnormal Binding Proteins and the
Measurement of Non-esterified Fatty Acid's
Radiolabelled thyroid hormones were from Amersham
International, agarose gel universal plates from Corning
Medical and Scientific and the Wako NEFAC kit for non-
esterified fatty acids (NEFA) from Alpha Laboratories,
Eastleigh, Hants., U.K. (Alpha Laboratories).
2.1.4 Serum Markers of Thyroid Status
The sex hormone binding globulin (SHBG) kit was
from Farmos Diagnostica, General Diagnostics, Science
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Park, Cambridge, U.K., and the kit for creatine kinase
(CK) was from Randox Laboratories Ltd., Crumlin, Co.
Antrim, Northern Ireland. Purified human BiBi
glutathione S-transferase (GST), ^25j_GST B -j B -j and rabbit
anti-GST B1B-j were gifts from Dr J D Hayes, Miss A Hussey
and Dr G J Beckett, Department of Clinical Chemistry,
Royal Infirmary, Edinburgh, U.K. Microcrystalline cellu¬
lose was from Merck, Darmstadt, West Germany, Brij-35 sur¬
factant and other Technicon Clinical Chemistry reagents
from Technicon Instruments Co., Basingstoke, Hants., U.K.,
and furylacryloyl-phenylalanyl-glycylglycine (FAPGG) was
from Sigma.
2.1.5. Equipment
Polystyrene tubes (75 x 12 mm) for immunoassay
were from Alpha Laboratories. The Microlab-M micro¬
processor-controlled diluter/dispenser and the cryofuge
6-4 with diagnostic rotor were from V.A. Howe and Co. Ltd.,
London, U.K. The multiwell gamma counter was an NE1600
from Nuclear Enterprises Ltd., Edinburgh, U.K. The
single-well dual channel gamma counter was from LKB
Instruments Ltd., Selsdon,S. Croydon, Surrey, U.K., and
the Kemtek 3000 was from Kemble Instruments Ltd., Burgess
Hill, Sussex, U.K. The sucrose separator was from Boots-
Celltech Diagnostics Ltd., and the Amerwell washer from
Amersham International. The electrophoresis tank was
from Corning-EEL, Halstead, Essex, U.K., the Cobas Bio
centrifugal analyser from Roche Diagnostica, Welwyn
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Garden City, Herts., U.K., and the Sequential Multiple
Analyser plus Computer (SMAC) was from Technicon.
2.1.6 Curve-fitting and Data Processing of Immunoassays
Unless otherwise stated, RIA data processing and
curve-fitting was performed using a non-linear 4 parameter
log-logistic model (Healy, 1972) using an iterative least-
squares technique on a Hewlett Packard 9821 calculator.
The Edinburgh Immunoassay Package (Raab &
McKenzie, 1979) which involves a 5 parameter log-logistic
curve-fit and the WHO immunoassay program based on a mass
action model (Edwards & Ekins, 1983) were used in the data
processing of TSH IRMA counts with a Superbrain and an
Apple II microcomputer, respectively.
2.2 THYROID FUNCTION TESTS
2.2.1 Assays for Total Thyroid Hormones
(a) Preparation of standards in charcoal-stripped serum
Iodothyronines were removed from serum by mixing
with Norit A activated charcoal (100 g/1) at room
temperature for 4 h. To assess the effectiveness of this
procedure, radiolabelled T4 was pre-incubated for 1 h with
the serum before charcoal treatment. The charcoal was
removed by centrifugation at 30,000 g on a MSE 18 high
speed centrifuge (20 min) followed by filtration of the
serum through two Sartorius membrane filters (0.45 H and
0.2 jj) under reduced pressure. Radioactive counting
showed that >98% of T4 was removed by this process.
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Concentrations of total protein and albumin were not
changed significantly by this procedure.
Stock solutions of T4 and T3 were made by
dissolving 20 mg of T4 sodium salt in 50% polyethylene
glycol (PEG) (20 ml) made alkaline with a few drops of
ethanolamine and by dissolving 10 mg of T3 (free acid) in
methanol (10 ml) rendered alkaline with concentrated NaOH.
The accuracy of these solutions was assessed spectrophoto-
metrically by diluting the stocks (0.2 ml) with freshly
prepared 0.04 M sodium hydroxide (2 ml) and measuring the
absorbance at wavelengths of 325 nm (T4) and 320 nm (T3)
against appropriate solvent blanks (Malan et_ al., 1983).
The concentration (C) was calculated from the equation:
C = Absorbance x Dilution factor
Pathlength x £
where £. is the molar extinction coefficient taken as 6200
and 4660 1/mol.cm for T4 and T3 respectively (Gemmil,
1955; Edelhoch, 1962). If the agreement between the
spectrophotometric values and those calculated gravimetri-
cally was within 2%, the stock solutions were diluted
serially in charcoal-stripped human serum to give working
standards: T^, 25-300 nmol/1; T^, 0.5-10 nmol/1. These
were stable at -20°C for at least 6 months.
(b) Radioimmunoassay procedures
Staff of this Clinical Chemistry Department
measured total T4 and T3 for the routine investigations of
patients attending the thyroid clinic (Chapters 4 & 7);
all other assays were performed by myself.
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The RIA procedure was based on the method of
Ratcliffe et_ al. (1974) using 0.05 M barbitone buffer
pH 8.6 containing 0.1% gelatine and 0.01% thiomersal, as
diluent. Primary sheep antibody, tracer (radiolabel) and
standard or sample were incubated in duplicate with ANS to
block the binding of T4 or T3 to serum protein-binding
sites but with minimal effect on antibody binding. The
antibody-bound fraction was separated from the free
radiolabel by precipitation with donkey anti-sheep serum
(DAS) with the addition of carrier immunoglobulins (NSS)
to permit cross-linking of the immune complexes and preci¬
pitate formation. These double-antibody reagents were
included in the RIA incubates and, for complete precipita¬
tion, assays were incubated overnight at 4°C followed by
centrifugation at 4°C for 30 min at 2,000 g. The proce¬
dures for RIA of total T4 and T3 were similar and are
summarised below:
Total T4 Total T^
20 jjI sample/standard 50 ,pl sample/standard
600 jjI tracer reagent 660 jjI tracer reagent
(DAS, 125I_T4) (DAS, 125I_T3, ANS)
200 .pi primary antibody 300 .pi primary antibody
reagent reagent
(Anti-T4, NSS, ANS) (Anti-T3, NSS)
Vortex
Incubate 4°C overnight




Samples were dispensed with tracer/DAS reagent followed by
the repeat dispensing of primary antibody reagent.
(c) Optimisation of the methods
Optimal precipitating dilutions of DAS and NSS
used in the double-antibody separation were determined by
using a matrix of DAS/NSS combinations to separate zero
standard RIA incubates (B0) containing primary antibody,
tracer and ANS. The results of such an experiment are
shown in Table 2.1 for the precipitation of tracer bound
to anti-T^ antiserum used at 1:10,000 final dilution (FD),
as recommended by SAPU. The combination giving the
greatest precipitation (1:80 DAS, 1:3300 NSS) on the pla¬
teau region outlined in Table 2.1 was chosen for the
T4 assay. Optimal conditions were slightly different for
the total T3 assay, Table 2.2.
Table 2.1 Optimisation of Double-Antibody Precipitation
of Antibody-Bound '^oi- T4
% Tracer Bound Final NSS Dilution
Final DAS Dilution x825 X1650 x3300 x6600 X13200
x40 55% 54% 53% 53% 51%
x60 58% 59% 59% 58% 56%
x80 59% 60% 62% 62% 59%
x 100 58% 60% 62% 58% 58%
x 120 54% 56% 58% 58% 57%
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Table 2.2
. Final Conditions for Total Tzj and T3 Assays
Final Dilution T4 T3
Primary antibody 1: 7,000 1: 15,000
DAS 1: 80 1: 70
NSS 1: 3,300 1: 2,000
ANS 320 Hg/tut>e 100 Hg/tube
Padiolabel 20 pg/tube 15 pg/tube
The primary antibody final dilutions were opti¬
mised by the use of precision profiles generated from the
duplicates of standards and samples (Ekins, 1983b). The
dilutions giving the best profiles and widest working
ranges at values of most clinical interest were chosen.
Working assay reagents were:-
T4 primary antibody reagent: Diluent (40 ml), Anti-Tzj
(24 HD
NSS (50 hD ANS (64 mg)
TZj tracer reagent: Diluent (115 ml), DAS (2 ml),
125l-T2| (100 HD
T3 primary antibody reagent: Diluent (210 ml), Anti-T3
(47 Hi)
NSS (350 HD
T3 tracer reagent: Diluent (150 ml), DAS (3.2 ml),
125i_t3 (200 hD ANS (23 mg)
(d) The precision and bias of the total T^ and T3 methods
The mean within-assay precision profiles for the
total T4 and T3 assays calculated from the duplicates of









Figure 2.1 Total Thyroid Hormone RIA Within-assay Precision
Profiles (Mean ± SD, n = 10).
Reference ranges are shown (-^ ► ).
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reference ranges (Tjj 60-150 nmol/1, 1.1-2.8 nraol/1)
were derived from normal volunteers and from patients
attending a thyroid clinic who were established as being
euthyroid by clinical examination and the results of other
thyroid function tests (Seth e_t al., 1976).
Quality control pools used to assess between-
assay precision were normal human serum either untreated
(medium pool), diluted with charcoal-stripped serum (low
pool) or containing added T4 or T3 (high pool). These
were stored in aliquots at -20°C. In addition, 2 or 3
patient samples were reassayed subsequently (repeat analy¬
sis control, RAC) and the results were used to calculate
between-assay precision (Table 2.3).
2.2.2 Free Thyroid Hormones by Analogue RIA
The principle of the measurement of free thyroid
hormones by analogue RIA is now common to many commercial
kits (Figure 1.2b). The assays involve the incubation of
sample or standard with solid-phase antibody (solid par¬
ticles or coated-tube) and a ^25X—T4 or 125i-T3 derivative
(manufacturer-specific) which binds to the assay antibody
but. which is chemically modified to inhibit its binding to
serum proteins. A detailed evaluation of several fT4 and


















































































































































* Combineddatafromassaysperformedbys lfndthr utinei gn sticservic . NS=otsignificant.
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2.2.3 Measurement of Thyroxine Binding Globulin (TBG)
The freeze-dried kit reagents and standards were
reconstituted in distilled water and the RIA performed as






Incubate 2-4 h, room temperature
Add 1 ml PEG solution
Vortex
Centrifuge 20 min, >1500 g
Decant supernatant
Count pellets
A control serum was supplied with each kit and
the mean bias from the quoted value in 9 assays was +5-7
±1.9?. A mean within-assay precision profile is
illustrated in Figure 2.2 and the between-assay precision
data is shown in Table 2.3. At present there is no
international reference standard for TBG. The manufac¬
turer's recommended reference ranges derived from 368
healthy adults aged 17-60 years were used (males: 8.7-
30.7, females: 10.5-31.7 mg/1).
2.2.4 Measurement of TSH by In-house RIA
Staff at the Immunoassay Section of this Clinical
Chemistry Department measured TSH for the routine investi¬
gation of new patients attending the thyroid clinic. The
RIA used was an in-house double-antibody method (Toft et_
al. , 1973) using 0.05 M phosphate buffer pH 7.5, con¬
taining 2% horse serum, 0.05? triton -X-100 and 0.02?
Figure 2.2 Within-assay Precision Profiles (Mean ± SD)
for TBG (n = 8) and the In-house TSH (n r 12)
Assays.
Reference Ranges (< ^).
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sodium azide as assay diluent. Standards in assay
diluent (0.46-14.8 mU/1) and samples (100 pi) were incu¬
bated in duplicate with rabbit anti-TSH (50 pi, FD
1:200,000) and assay diluent (200 pi) for 24 h at room
temperature. This antiserum was from Professor Butt,
Birmingham and Midland Hospital for Women, Birmingham,
U.K. The TSH tracer was cleaned of inorganic iodide and
TSH aggregates before use by gel filtration (G10/G150
Sephadex) and diluted to 1.5 ng/ml for use. After adding
NRS to the tracer solution, 50 pi was added to RIA incuba¬
tes (FD NRS 1:9,000) for the second incubation of 24 h at
room temperature. Donkey anti-rabbit serum (DARS) in
diluent containing 9 mmol/1 EDTA (50 pi, FD 1:450) was
then added to precipitate the bound fraction, overnight at
4°C. The Kemtek 3000 was used to filter, wash and count
the precipitated fraction of tracer. Data processing was
with a 4-parameter logistic curve fit.
The mean within-assay precision profile and typi¬
cal between-assay precision data for this assay are shown
in Figure 2.2 and Table 2.3, respectively. The mean 6
month bias from the all-method mean in the Birmingham
External Quality Assessment Scheme (EQAS) was typically
+3.6% ± 10.6. The mean recovery of the method assessed
in 3 recovery experiments by EQAS was 93% ± 13 compared
with the all-method mean recovery of 97% ± 6.
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The upper reference limit for TSH by this method
(5.7 mU/1) was derived from euthyroid patients attending
a thyroid clinic (Toft et al., 1973) and the normal range
of TSH response 20 min after TRH injection (200 jig) was
3.9 -25.3 mU/1 (Toft et al., 1978).
2.2.5 Measurement of TSH by Commercial Assay
Details of the analytical and diagnostic perfor¬
mance of the various commercial RIA and IRMA methods for
TSH are given in Chapter 4. In the Becton Dickinson
single and dual-analyte RIA kits, there were two incuba¬
tion options. In this thesis, the 4 h high sensitivity
option which omits the top standard supplied, was eva¬
luated for both kits.
2.3 THE DETECTION OF ABNORMAL BINDING PROTEINS
2.3.1 A Screening Test for Anti-Ta or T-; Autoantibodies
Samples were screened initially for the presence
of circulating anti-T^ and anti-T^ antibodies by com¬
parison of 125i_T2j or 125j_t^ binding by patient and nor¬
mal sera. Sera (10 jul) were incubated with 200 jil 0.05 M
barbitone buffer pH 8.6 containing 7 fmol 125i_iabelled
T4 or T3 for >2 h at room temperature. Gamma globulin-
bound radiolabel was precipitated by the addition of 50%
saturated ammonium sulphate solution (3 ml) followed by
centrifugation at 2,000 g for 15 min. The percentage of
total counts in the pellet was generally <5% in normal
sera.
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2.3.2 Measurement of the Distribution of Thyroid
Hormone Binding to Serum Proteins
The patient's serum (50 ;jl) was incubated at room
temperature for 2 h with ^25j_iabelled T4 or T3 (70 fmol).
The proteins in 1 yy~l of serum were then separated by
agarose electrophoresis. Electrophoresis buffer was
0.05 M pH 8.6 sodium barbitone containing 0.035% EDTA.
Samples were run in triplicate for 30 min and after
electrophoresis, one sample was stained for protein with
amido black (5% acetic acid destain) whilst the other
samples were sliced into 0.5 cm strips and counted for
125i_radioactivity (T4 and T3 binding). A control sample
with no known abnormality in binding was electrophoresed
in triplicate with each test serum. The percentage
distribution of T3 or T4 between the serum proteins was
calculated from the total counts of the electrophoresis
segments (Beckett et al., 1983b).
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2.4 THE MEASUREMENT OF NON-ESTERIFIED FATTY ACIDS
Serum NEFA were measured by the Wako enzymatic
method with the colorimetric endpoint monitored at 550 nm
using the Cobas Bio Analyser. The principle of the test
is summarised below:-
ACS
RCOOH + ATP + Coenzyme A ^AcylCoA + AMP + PPi
(NEFA) (CoA)
ACOD




4-aminoantipyrine POD 'Condensation + 4 H2O
Product
(ACS = AcylCoA synthetase; ACOD = AcylCoA oxidase;
POD = Peroxidase)
The assay was calibrated with 1 mM oleic acid and adapted
for use on the Cobas Bio as follows to give the recom¬
mended final reaction conditions:-
Colour reagent A (ACS, Ascorbate oxidase, CoA, ATP, 4-
aminoantipyrine) was reconstituted in 10 ml of supplied
solvent A as described for the manual method. Colour
reagent B (ACOD, POD, MEHA) was reconstituted in 2.5 ml of
supplied solvent B. Sample (10 yil) was preincubated with
reagent A (200 ^1) at 37°C for 10 min then reagent B (50
,Ul) was added as start reagent and 17 absorbance readings
were taken at 20 s intervals. Serum samples were used
for assay, where possible, since heparin is known to
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cause an increase of 10% in NEFA values (Knox & Jones,
1934). The within-rotor reproducibility (n = 28) and the
between-assay precision (n = 10) were estimated as 3.1%
and 6.2% respectively.
NEFA values in serum increased two-fold if left
at room temperature for 48 h whereas little change
occurred at 4°-C for 48 h and samples stored at -20°C were
stable for at least four weeks. The manufacturer's
expected reference range for fasting patients is 0.1 - 0.6
mmol/1.
2.5 MEASUREMENT OF SERUM MARKERS OF THYROID STATUS
The between-assay data for the following methods
are shown in Table 2.4.
2.5.1 Assay of Sex Hormone Binding Globulin (SHBG)
The commercial method for measurement of SHBG is
based on a liquid-phase IRMA (Hammond et_ suL., 1985).
Samples and standards were diluted 100-fold in assay buffer
and 100 >j1 aliquots incubated with 200 ,ul of anti-SHBG
polyclonal antiserum and 125i_anti-SHBG monoclonal anti¬
body at room temperature for 1 h. A solid-phase second
antibody was then added, followed 15 min later by 2 ml
0.9% NaCl. After centrifugation (2,000 g 15 min), the
supernatants were decanted to waste. Curve-fitting and
data interpolation were performed manually using linear-
linear graph paper. Over the range 7-110 nmol/1 SHBG,
the within-assay precision ranged from 1.8 to 4.9%. In
10 samples issued by the SHBG EQAS (Clinical Chemistry,
























































































































































City Hospital, Nottingham, U.K.) the mean bias was -0.2%
± 8.3%. The reference ranges from the kit insert were
used in this thesis: males 10-50, females 30-90 nmol/1.
2.5.2 Assay of Glutathione S-Transferase (GST)
The human liver-specific (B1B1) form of GST was
measured in serum by the RIA method of Beckett and Hayes,
1984. The assay employed a delayed addition of tracer
followed by double-antibody separation. Assay diluent
was 0.05 M potassium phosphate, pH 7«5> containing
bovine serum albumin (1 g/1) and sodium azide (0.2 g/1).
Standards (purified GST B1B1 enzyme) were made up in assay
diluent and stored at -20°C. Standards and samples (100
jul) were incubated in duplicate with primary antibody/NRS
reagent (100 jul; FD 1:38,000 anti-GST B1B1 and 1:1,000 NRS)
for 24 h 4°C. Radiolabelled GST B-jB1 in assay diluent (50
/Ul; 20,000 cpm) was then added and the tubes incubated at
4°C for a further 24 h. Precipitating antiserum (DARS)
was then added (100 jul; final dilution 1:105) and the
tubes incubated at 4°C for a further 16 h. A wash solu¬
tion (2 ml) of 0.01% microcrystalline cellulose and 0.1%
Brij in distilled water was added to incubates prior to
centrifugation at 2000 g for 30 min at 4°C. Supernatants
were decanted and the pellets counted in the NE1600 gamma
counter. A mean within-assay precision profile for
patient samples is shown in Figure 2.3. The upper
reference limit for the assay of 4.0 jug/1 was determined
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GST (;igjl)
Figure 2,3 The Within-assay Precision Profile for GST RIA
(Mean * SD, n=8).
Reference Range (< >■).
- 60 -
from 135 blood donors and 40 laboratory volunteers
(Beckett et_ a_l., 1985 ) -
2.5« 3 Assay of Angiotensin-Converting Enzyme (ACE)
The concentration of ACE (EC 3.4.15.1) in serum
was determined by continuous spectrophotometric monitoring
of the hydrolysis of FAPGG to furyl-acrylyl phenylalanine
and glycylglycine at 37°C based on the method of Maguire
and Price, 1985- The decrease in absorbance at 344 nm
was monitored on a Cobas Bio centrifugal analyser using a
reagent blank. The assay buffer was 0.05 M Tris con¬
taining 0.4 M sodium chloride, pH 8.3 at room temperature.
The substrate was 2 mmol/1 FAPGG in assay buffer and the
volumes added to the reaction cuvette were: 30 ;al serum
sample, 20 ;j1 assay buffer and 50 jul substrate reagent.
Absorbance readings were made after 8 min and at 30 s
intervals thereafter for 7 min. The within rotor repro¬
ducibility of the method was 3 - 9% - The assay was linear
up to values of 200 U/l. The enzyme activity in U/l was
calculated by multiplication of the absorbance change per
minute by the conversion factor 5367 (derived from the
molar extinction coefficient, pathlength and sample dilu¬
tion in the cuvette). The reference range for serum ACE
(9-109 U/l) was derived from 100 surgical in-patients with
no known condition which would cause raised ACE levels
e.g. sarcoid, diabetes mellitus or hyperthyroidism.
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2.5.4 Assay of Creatine Kinase (CK)
Creatine kinase (EC 2.7.3.2) in serum was
measured by the optimised standard method at 37°C using
the following coupled reaction system:
CK
Creatine phosphate + ADP }Creatine + ATP
HK
Glucose + ATP >Glucose-6-P + ADP
G6P-DH ,
Glucose-6-P + NADP+ \ 6-phosphogluconic acid7
+ NADPH + H+
(HK = Hexokinase, G6P-DH = Glucose-6-P dehydrogenase)
The increase in absorbance at 340 nm was moni¬
tored on a Cobas Bio analyser with the first reading 80 s
after mixing followed by nine readings at 20 s intervals.
The volumes used in the reaction mixture were; 5
sample, 20 jal diluent and 200 jjI reagent. The conversion
factor to U/l was 5358. The laboratory reference ranges
for this assay were: males 30 - 200, females 30 - 150 U/l.
2.5.5 Other Clinical Chemistry Analyses
Alanine aminotransferase (ALT) (EC 2.6.1.2),
gamma-glutamyltransferase (GGT) (EC 2.3.2.2) and creati¬
nine were measured in serum by standard methods on a
SMAC II analyser. The laboratory reference ranges for
these analytes were: ALT, 10-40 U/l; GGT, 10-55 U/l males
and 5-35 U/l females; creatinine, 55-150 ^imol/l. The
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principles of the methods were:-
ALT: measurement of the decrease in absorbance at 340 nm.
ALT
Alanine + ketoglutarate > Pyruvate + glutamate
LDH
Pyruvate + NADH »NAD + lactate
(LDH = lactate dehydrogenase)
GGT: measurement of the increase in absorbance at 410 nm,
^-glutamyl p-nitroanilide + glycylglycine
I GGT
X-glutamylglycylglycine + p-nitroaniline
Creatinine; measurement of the absorbance at 505 nm.
0H-




DEVELOPMENT OF EQUILIBRIUM DIALYSIS REFERENCE METHODS
FOR FREE THYROID HORMONFS
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In this chapter the experiments performed to
develop sensitive RIA methods for T4 and T3 are described.
In addition, various factors which affect the free thyroid




Primary sheep antisera to T4 were from (a) SAPU
(batch no. 056G) (b) the RAST Allergy Unit, Benenden Chest
Hospital, Cranbrook, Kent, U.K. (Code ST4H H/38) (c)
Advanced Laboratory Techniques, Tunbridge Wells, Kent, U.K.
(ALS) (d) Amersham International (personal gift). The
high-titre sheep anti-T3 antiserum was also from Amersham
International. Soluble double-antibody reagents were from
SAPU, SacCel anti-sheep cellulose-coupled antibody from
Wellcome and Sephacryl-linked SAPU anti-sheep antibody
from Dr J Wright, MRC Immunoassay Section, Edinburgh, U.K.
125i-T4 and 125I-T3 were from Amersham International,
reverse T3 (L—3,3' >5* Tri-iodothyronine) from Cambridge
Bioscience, Cambridge, U.K., and other thyroid hormone
solids were from Sigma.
3.1.2 General Materials and Equipment
HEPES (N-2-hydroxyethylpiperazine-N '-2-ethane-
sulfonic acid), gentamicin sulphate and bovine gamma glo¬
bulin (G-5009) were from Sigma. All other reagents were
from BDH. The diluent for RIA was 0.01M HEPES containing
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106 mM sodium chloride and 1 mM sodium azide, pH 7.4 at
37°C.
Dialysis membranes were Visking tubing 32/32 from
Scientific Instrument Centre Ltd., London, U.K., and
Spectrapor membrane (No.2) from Spectrum Medical
Industries Inc., Los Angeles, U.S.A. The equilibrium
dialysis system was from Dianorm, Fisons Ltd., Crawley,
Sussex, U.K., with paired teflon macro half—cells (1.2 ml
volume each) and the water bath with immersion heater was
from Grant Instruments, Cambridge, U.K.
3.2 CHOICE OF SEPARATION SYSTEM FOR RIA
Various non-specific methods for separating bound
and free ligand have been used in the RIA of free thyroid
hormones in serum dialysates e.g. dextran-coated charcoal
adsorption (Ellis & Ekins, 1975; Jiang & Tue, 1977;
Romelli A Pennisi 1979), paper chromatography (Weeke &
Orskov, 1979) and, more recently, precipitation of the
protein-bound ligand with polyethylene glycol (PEG)
(Helenius & Liewendahl, 1983)- In this thesis, a speci¬
fic separation system was developed and compared with PEG
precipitation.
The use of first antibody coupled to micro-
crystalline cellulose particles (Seth et_ al., 1976) was
tried, initially. This system was not investigated
further due to the following disadvantages:-
(a) Cyanogen bromide was used to activate the cellulose.
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(b) A fall of at least 50% in antibody titre after
coupling to the cellulose was observed as described
previously (Wide, 1969).
(c) An overnight incubation was required for equilibrium
to be reached in the RIA.
(d) Experience with the SAPU anti-T^j antiserum showed
that in solid-phase, the antibody binding showed a
marked pH optimum of pH 10.5 , making the measure¬
ment of fT4 in dialysates which had a pH of 7.4 a
problem.
Specific separation by a soluble double-antibody
precipitation method was described for the measurement of
total T4 and T3 in Chapter 2. Modifications of this
technique include:-
1. Covalent coupling of DAS to an insoluble matrix used
to separate primary antibody-antigen complexes.
2. Post-precipitation of soluble antisera i.e. primary
antibody, analyte and radiolabel incubated in the pre¬
sence of DAS and NSS (cf. total T4 and T3 RIA).
3. Pre-precipitation of NSS with DAS to form a non-
covalent solid-phase which may be used to separate
primary antibody-antigen complexes (Brown et_ al.,
1 980).
4. Pre-precipitation of the primary antibody with DAS and
NSS. This forms a non-covalent solid-phase which is
added to RIA incubates (Hales & Randle, 1963).
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These variations of the double-antibody technique
were investigated in the development of a high sensitivity
assay for Tq and then applied to the measurement of T3.
3.2.1 T4 RIA Incubation Mixtures
Details of the procedures used to optimise the RIA
and to prepare stable T4 standards (3-100 pmol/1) are
described in subsequent sections of this chapter. In the
evaluation of the separation systems described below,
standards in HEPES buffer pH 7.4 with 0.3% gelatine
(250 ;j1) were incubated with RAST primary antiserum (40 >il;
FD 1:200,000 and 3.5 fmol 125l-T4 (40 ;ul). When this
antibody was used in solution, equilibrium for the primary
binding reaction was reached after 3 h at room temperat¬
ure, after which the various separation methods were
employed.
3.2.2 Separation by PEG Precipitation
The concentrations of added carrier protein
(bovine gamma globulin, 100 jul) and PEG (1.5 ml) which
gave maximum precipitation of antibody-bound radiolabel in
the absence of antigen (B0), but minimum precipitation of
radiolabel in the absence of primary antibody (non¬
specific binding, NSB), were determined by adding dif¬
ferent concentrations of these reagents to B0 and NSB
incubates (Table 3.1)« The concentrations of 20 g/1
gamma globulin and 300 g/1 PEG in HEPES buffer were used
in subsequent assays. A minimum incubation time of







^globulin(g/1) 5 10 20 30 40
8.5(3. ) 10.4(8.4) 13.4(7.0) 8.1(9.2) 7.7(11.7)
38.5(6.2) 45.7(9.0) 54.9(8.4) 57.6(8.7) 56.8(18.6)
53.4(6.0)
60.0(7.1)
61.7(7.9) 66.7(13.1) 70.8(15 5) 70.4(17.0) 72.7(21.0)
63.9(9.5) 64.7(10 2) 64.6(9. )
62.3(11.5) 67.1(10.9) 67.0(11 6)
68.0(15.3)
68.5(16.2)
*NSBvaluesarinbracketsndexpressedth%oftot lcou tadd d. Valuesrepresentingplat auregionaroutlin d.
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15 min at room temperature with PEG was necessary for
complete precipitation of protein. Incubates were then
centrifuged for 15 min at 2,000 g and the radioactivity in
the protein pellets counted. Pe-suspension of pellets in
300 g/1 PEG solution and centrifugation was necessary to
reduce NSB values to <5%.
3.2.3 Separating Antibody Covalently Linked to
Solid-Phase
The SAPU donkey anti-sheep antiserum linked to
sephacryl (Sephacryl-DAS) was made by coupling either the
whole antiserum or the IgG fraction only to sephacryl, by
the method of Wright and Hunter, 1982. Stock solutions
were stored at a ten-fold dilution of the original anti¬
serum at 4°C. A commercial anti-sheep antibody linked to
microcrystalline cellulose (SacCel) was also tried.
Separation was effected by addition of optimal con¬
centrations of these reagents to RIA incubates i.e. 1:20
dilution of SacCel (100 pi) or a 1:10 dilution of
Sephacryl-DAS (100 jul) with incubation at room temperature
for 30 min (SacCel) or 1 h with shaking (Sephacryl-DAS).
A distilled water wash was added to the tubes prior to
centrifugation at 2,000 g for 15 min.
The optimal dilutions of the separating reagents
described above were determined by using increasing dilu¬
tions of stock solutions to separate bound and free
I251-T4 in a series of B0 incubates. The SacCel and IgG
Sephacryl-DAS produced maximum precipitation of primary
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antibody up to a 30-fold dilution of stock reagents,
whereas with Sephacryl-DAS made from whole serum, the pre¬
cipitation of bound tracer declined rapidly at dilutions
greater than ten-fold. Use of SacCel at 1:20 and
Sephacryl-DAS at 1:10 dilutions of stock produced maximum
B0 values but re-suspension of the pellet with a further
1 ml wash and re-centrifugation was necessary, to achieve
NSB values of <5%.
3.2.4 Post-precipitation Double-Antibody Separation
Optimal final dilutions of DAS (1:80) and NSS
(1:3,300) for precipitation were as determined previously
for the total serum T4 method (Table 2.1). An overnight
incubation at 4°C was required for complete precipitation
and this was followed by centrifugation at 4°C (2,000 g)
for 30 min to sediment the precipitate.
The use of this method resulted in <10% binding
of tracer and increasing the amount of RAST anti-T^
antibody present from 1:2,000,000 to 1:200,000 FD produced
little improvement in tracer binding (Figure 3.1). The
removal of endogenous iodothyronines in these reagents by
pre-treatment of the DAS and NSS with charcoal (Section
2.2.1) also produced no significant increase in binding.
A sensitive RIA for T4 could not, therefore, be developed
using this method. In an attempt to remove the inter¬
ference found using the whole animal sera (DAS and NSS) in
RIA incubates, DAS was pre-precipitated with either NSS
alone or with NSS and anti-T}| antibody.
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Final Dilution of RAST Anti-T4
Figure 3.1 RAST Anti-T4 Dilution Curves with Zero ( )
and 50 pmol/1 Added T4 (- - -).
Separation of bound and free ligand was by
double-antibody post-precipitation using
untreated (A) and charcoal-stripped (A)
reagents or by a preformed DAS-NSS precipitate
with untreated (o) and charcoal-stripped (•)
DAS and NSS added at the end of the primary
reaction.
Dilution curves using an unwashed DAS-NSS
precipitate are also shown (x).
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3.2.5 Pre-precipitation of Separating Antibody with
Normal Sheep Serum
As an alternative to the post-precipitation
method described in Section 3.2.4, the possibility of
using a pre-formed DAS-NSS precipitate in a similar way to
the use of SacCel at the end of the primary reaction,
was investigated. DAS and NSS were mixed in the ratio
40:1 at 4°C in HEPES buffer and left overnight to allow
complete precipitation to occur. A suitable protocol for
making a stock solution involved mixing 20 ml DAS, 0.485
ml NSS and 8.5 ml buffer. The fine precipitate formed
was separated from the animal sera by centrifugation at
low speed (1,000 g, 10 min) and decanting the supernatant.
The precipitate was then re-suspended in the same volume
of fresh buffer and stored at 4°C. The binding of pri¬
mary antibody-tracer complexes with this reagent was
significantly improved by this resuspension step and by
washing the stock reagent several times with buffer, as
described below.
To separate the bound and free fractions in the
PIA incubates (total volume 330 nl), the stock DAS-NSS
precipitate was diluted three-fold in buffer and, with
continuous stirring, 40 >il was dispensed per tube. In
contrast to the short second incubations with separating
antibody covalently linked to solid-phase (e.g. SacCel),
the use of pre-precipitated DAS-NSS required an overnight
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incubation at 4°C. A HEPES buffer wash (1 ml) was added
to tubes prior to centrifugation (30 min 2000 g, 4°C).
The improvement in the RIA achieved by washing
the DAS-NSS stock reagent with buffer prior to use in the
separation of an anti-T4 antibody dilution curve, is shown
in Figure 3.1. This caused a shift of the curve to the
right, and a greater displacement of antibody-bound tracer
by 50 pmol/1 of added antigen was obtained. Use of
charcoal-treated DAS and NSS to remove endogenous animal
thyroid hormones from the initial preparation, did not
further improve the sensitivity potential of this separa¬
tion system, Figure 3.1.
3.2.6 Pre-precipitation of the Primary Antiserum
In this separation system, a pre-formed immune
precipitate was prepared as described in Section 3.2.5
but with the inclusion of the RAST primary antiserum in
the reagent. To prepare the reagent DAS, NSS and anti-T4
antibody (pre-diluted x 100) were mixed in the ratio
40:1:0.002. This stock reagent was stored in HEPES buffer
at three times the concentration used at the separation
stage and it was stable at 4°C for at least 3 months.
The calculated dilutions of components in this stock
reagent, the working reagent and the RIA incubate are
given in Table 3.2. Omission of primary antibody gave
the reagent used to assess NSB values. The RIA incubates
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DAS 20.000 1:1.45 1:4.35 1:36
NSS 0.485 1:60 1:180 1 :1 ,450




x 100 dilution of neat RAST antiserum,
consisted of 250 ^1 standard, 40 ;al tracer and 40 ,ul of
anti-T^ pre-precipitate (i.e. final volume 330 ^1). This
assay system appeared to be superior to the methods
described previously.
Washing the stock precipitate with HEPES buffer
improved the antibody binding of tracer as shown by the
increase in Bo from 14$ to 47$ of the dose-response curves
in Figure 3.2(A). The main effect was seen after only
one wash with relatively minor improvements in the assay
occurring with subsequent washes. The use of charcoal-
treated DAS and NSS to prepare the pre-precipitate
improved the characteristics of the assay still further
with a B0 of 58$ being achieved when this reagent was
washed and re-suspended in fresh buffer (Figure 3.2(A)).
Anti-Ti| dilution curves comparing the use of charcoal-
treated and untreated DAS and NSS to prepare washed pre-
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Figure 3.2(A)
Final Dilution of Preprecipitated RAST Anti-T<
Standard Curves for Tij Using Different
Preparations of Pre-precipitated Anti-Tzj
Antibody.
These were charcoal-treated DAS and NSS (•)
or untreated DAS and NSS (o) which were
either unwashed (a), washed x 1 (b) and
washed x 3 (c) with fresh buffer.
(B) RAST Anti-T4 Dilution Curves
The pre-precipitate was washed and made with
either charcoal-treated (•) or untreated (o)
DAS and NSS.
(zero antigen ; 50 pmol/1 T4 ).
- 76 -
precipitates (Figure 3.2(B)), confirmed the greater sen¬
sitivity potential of the former preparation.
As with other assays described using pre-
precipitated double-antibody separation systems (Wong et_
al., 1979; Giles, 1982; Gray et_ al., 1983), standard curves
for T4 with good sensitivity were produced using short
incubations at 37°C. The effects of altering the incuba¬
tion conditions on the anti-Ti| dilution curve are shown in
Figure 3.3. Incubation at 37°c for 31-4 h was used in
subsequent assays.
3.2.7 Comparison of Separation Methods
The main features of the different separation
systems studied are summarised in Table 3-3. In the
conventional post-precipitation double-antibody technique,
interference at the primary antigen-antibody reaction pro¬
duced low binding making it an unsuitable separation
system for the high sensitivity T4 RIA. It is likely
that the presence of animal T14 and TBG in the double-anti¬
body reagents caused this interference by reducing the
binding of 125j_T2| to the primary antibody. The use of a
DAS-NSS precipitate resuspended in buffer removed this
interference (Figure 3.1) whereas, in the use of pre-
precipitated primary antibody, the T4 binding sites would
be exposed to animal T4 during preparation of the reagent;
this explains the improvement found in this separation
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The Effect of Different Incubation Conditions
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The use of the DAS-NSS precipitate as separating
agent required a considerable incubation time. This may
have been due to steric hindrance of the binding of pri¬
mary antibody to unoccupied binding sites in the pre¬
formed DAS-NSS lattice. Thus, although this reagent was
readily prepared and produced low NSB values, the long
incubation time required was a disadvantage in view of the
proposed coupling of the RIA to the overnight dialysis of
serum.
The covalent solid-phase double-antibody methods
were expensive and tended to have high NSB. In addition,
frequent preparative chemistry was required to supply suf¬
ficient sephacryl-DAS for several assays.
The PEG precipitation system was simple and inex¬
pensive, the disadvantages being the number of pipetting
steps, the pipetting of the viscous PEG solution and the
high NSB.
Use of the pre-precipitated double-antibody
method reduced the number of incubations, pipetting steps
and wash steps required to produce acceptable NSB values,
making it the most convenient method to perform. The fine
precipitate formed, probably accounts for the improved
reaction kinetics observed with this system, compared to
those found for primary antisera covalently linked to
solid matrices e.g. micro-crystalline cellulose. The
necessity to use charcoal-stripped DAS and NSS with this
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system was not a major drawback since, after bulk prepara¬
tion, these reagents, could be stored in appropriate
quantities at -20°C until required. However, this method
has been criticised in the past since a loss in sen¬
sitivity compared to separations of soluble primary
antibody-antigen complexes may result (Hunter, 1973).
This may be due to a decrease in the affinity of the pri¬
mary antibody when pre-precipitated with the separating
antibody. (This point is addressed in Section 3-3). It
is of note that, whereas the chemical covalent coupling of
primary antisera to solid-phase results in a substantial
loss in antibody titre (Wide, 1969), there was little loss
using the more gentle process of double-antibody pre-
precipitation.
Since sensitivity is affected by many factors,
this system was further investigated and developed in
conjunction with the PEG precipitation method. The mean
within-assay precision profiles from 10 assays are com¬
pared for these two separation systems in Figure 3.4,
indicating a similar working range (CV <10%) for both
methods. The lower profile in the case of the pre-
precipitated double-antibody method indicated better
within-assay precision compensating for any loss in sen¬
sitivity arising from changes in antibody affinity.
10 100 1000
T< (pmol/l)
Figure 3.H Within-assay Precision Profiles for the
Sensitive RIA of T4 (Mean ± SD, n = 10).
Separation was by PEG precipitation (x x)
and pre-precipitated RAST antibody (• •).
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The pre-precipitated double-antibody method was
therefore chosen as the most simple, specific and suitable
separation system for the RIA of free thyroid hormones in
dialysates of serum. A similar method for the direct RIA
of T4 in serum dialysates has also been adopted by other
workers (Giles, 1982).
3.3 OPTIMIZATION OF THE T4 RIA FOR MAXIMUM SENSITIVITY
The theoretical sensitivity attainable in an RIA
can be expressed as:
experimental error in estimating the response (Ekins, 1974)
affinity constant
For maximum sensitivity it is desirable to select optimal
reagents and conditions which reduce the error in the
measurement of the bound radiolabel. This error combines
those due to counting radioactive disintegrations,
pipetting and the misclassification errors due to inef¬
ficiency of the separation system.
Since the error in counting radioactive disin¬
tegrations is approximated by Vcounts , this error can be
reduced to <1% by accumulating >10,000 counts per tube.
The combined counting and pipetting error (CV) found for
the repeat dispensing of 40 jil of T4 radiolabel by
Microlab M in the sensitive T4 RIA, was 1.8% when counts
were >10,000.
Errors in pipetting can be reduced by increasing
the volumes of solutions dispensed and by minimising the
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number of pipetting steps performed. In the measurement
of pmol/1 concentrations of T4 however, it is necessary to
add antiserum and radiolabel to RIA incubates in as small
a volume as possible to avoid excessive dilution of the
analyte and loss in assay sensitivity.
Misclassification errors occurring at the separa¬
tion stage of the RIA were least variable using the pre-
precipitated double-antibody method (Section 3.2) which
consistently gave NSB values less than 5%.
For very low concentrations of analyte, it beco¬
mes more important to use antisera with high avidity to
achieve the required assay sensitivity. In the measure¬
ment of T4 concentrations in dialysates of serum, primary
antisera with affinity constants (Ka) >10"! 1 1/mol were
thought to be suitable. In this thesis, four primary
anti-Tit antisera were investigated. Reagent volumes and
incubations were then -optimised to obtain the best preci¬
sion profiles for the measurement of T4 concentrations in
the range 5-100 pmol/1.
3.3.1 Choice of Primary Anti-Tit Antiserum
Primary antisera were assessed using incubations
in 0.01M HEPES buffer pH 7.4 and 125l-Tit tracer. The Ka
for each antiserum was calculated by transformation of
typical dose response curves into a Scatchard plot
(Scatchard et al., 1949) and determining the initial slope
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of the line obtained. The FD of antiserum required to
bind 50% of added ^25x_T4 (antibody titre) was determined
by incubation of doubling dilutions of antiserum with
I251-T4 (3.5 fmol) in 30O /il of buffer at 4°C overnight.
Separation was performed either by PEG precipitation
(Section 3.2.2) or by using the antiserum pre-precipitated
with DAS and NSS. The specificity details of the anti-
sera are expressed as the percentage crossreaction with
other iodothyronines by the method of Abraham, 1969-
Scatchard plots for the RAST antiserum used in
soluble and pre-precipitated form are shown in Figure 3-5.
The Ka values are shown in Table 3.4 with those calculated
similarly for the 3 other antisera. The SAPU antiserum
was approximately 10 times less avid than the 3 other
antisera which had similar Ka values of the order of
4 xio''"' 1/mol. Pre-precipitation of the antisera
reduced Ka values by approximately 40%.
Table 3.4 Affinity Constants (Ka) of Primary Anti-T4




SAPU 4.1 x 1010 2.8 x 1010
RAST 4.5 x 1011 2.3 x 1011
ALS 4.0 x 1011 —
Amersham — 2.2 x 1011
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Figure 3»5 Scatchard Analysis of the RAST Anti-Tij
Antiserum Used in Soluble (•) or Pre-
precipitated Form (o).
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The antibody titres using the antisera in the
soluble or pre-precipitated form are shown in Table 3.5.
Pre-precipitation resulted in a 20 - 30% reduction in
titre. The ALS antiserum had lowest titre but the
material obtained was at an undisclosed dilution of the
original neat antiserum. Five to ten times the number of
assays were possible with the RAST or Amersham antisera
compared to that from ALS.
Table 3*5 Antibody Titres of Primary Anti-T4 Antisera
Used in Soluble or Pre-precipitated Form
T4 Antiserum












The cross-reactivity data (Table 3.6) suggested
sufficient specificity of all the antisera for the
measurement of T4 in dialysates of serum. From the
literature, the ratio of 14:13 in the dialysates of normal
and hyperthyroid samples would be expected to be 3:1 and
2:1, respectively; the ratio of T4:rT3 in normal serum
dialysates being approximately 12:1 and in patients with
non-thyroidal illness, 3:1 (Yeo e_t al. , 1977). The
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maximum distortion of fT4 results due to high fT^ or
free rT3 concentrations with any of these antisera would
therefore be <2% and <3%, respectively.
Table 3.6 Cross-reactivity of Anti-Tij Antisera





The Amersham antiserum was not available until
the latter part of this study, the RAST antiserum was
therefore chosen for further use due to its high Ka and
titre. Although a decrease in sensitivity potential was
demonstrated when primary antisera were pre-precipitated,
overall effects on assay precision and hence the working
range, were more favourable with this system (Section
3.2.7). The FD of antiserum which gave the best preci¬
sion profiles over several assays using delayed tracer
addition (see below) was 1:1,600,000.
3.3.2 Addition of Radiolabel
Traditionally, high specific activity (SA) tra¬
cers have been used to reduce radiolabel counting errors
and the required counting time. However, sometimes rela¬
tively little improvement in assay precision and sen¬
sitivity is gained (Ekins, 1974 & 1983b).
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Comparison of SAPU anti-T4 dilution curves using
addition of SA >5590 juCi/jig (New England Nuclear
Research Products, Stevenage, Herts, UK) in varying con¬
centrations to produce a ten-fold difference in final con¬
centration of radiolabel (i.e. 0.7-7.0 pmol/1), resulted
in only a two-fold increase in the antibody titre.
Reduction of the tracer mass could not, therefore, signi¬
ficantly improve the sensitivity limit of assays using
this system.
Assays of adequate sensitivity (minimum detection
limit 2 pmol/1) were achieved using the more readily
available radiolabel from Amersham International (SA
> 1200- jiCi/;ag) with the more avid RAST or Amersham primary
antisera. The final concentration of radiolabel in the
incubates was kept initially at <5pmol/l (i.e. 3.5
fmol/tube, approx. 6000 cpm) and tubes were counted for
5 min. This tracer addition is similar to that described
by others using tracers with SA >1000 ;uCi/;jg (Jiang & Tue,
1977; Yeo et al., 1977a).
Sequential saturation analysis has been most
effectively applied to the RIA of large molecules e.g.
peptide hormones, where the binding of antigen to antibody
is essentially irreversible. A two to four-fold improve¬
ment in assay sensitivity can result (Hunter, 1973). For
small analytes re-equilibration occurs more quickly after
the delayed addition of radiolabel and little improvement
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in sensitivity results, unless the second incubation with
radiolabel is short.
The effect of delaying the tracer addition in the
sensitive RIA of T4 using RAST pre-precipitated antiserum
(FD 1:1,600,000) is shown in Figure 3.6(A). Standards
were incubated either with antiserum and radiolabel for
3 h 40 min or with antiserum (3 h) followed by radiolabel
(40 min). There was a reduction in Bo and NSB with the
delayed addition of tracer and, assessed over several
assays, the working range (CV <10%) was improved from
8-100 pmol/1 to 5-100 pmol/1, by this procedure.
In practice, it was found that with this sequen¬
tial addition of tracer, doubling the tracer mass added to
7 fmol/tube had no detrimental effect on the precision
profiles obtained, which permitted shorter counting times.
This was in agreement with Ekins's theoretical analysis
(Ekins, 1974) and with the method of Giles (1982) who
added 8-10 times the mass of (25 fmol) compared
to others (Ellis & Ekins, 1975; Jiang & Tue, 1977; Yeo e_t
al. , 1977a) who were using simultaneous antibody and
tracer incubation.
3.3.3 Incubation Volumes
Combining the addition of antibody and tracer
reagent in one step to reduce pipetting errors and mini¬
mise the dilution of dialysates resulted in poorer preci¬





Figure 3«6 (A) The Effect of Sequential Tracer Addition
on Standard Curves and Precision Profiles in
the Sensitive RIA for T4.
Simultaneous (A ▲) and sequential (A-
tracer addition.
—12-
(B) The Improvement in the Within-assay
Precision Profile (Mean ± SD, n = 10) Using
a 500jul (x x) Compared with 250 /il (• •)
Standard Volume.
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Mean within-assay precision profiles were com¬
pared for standards from 10 assays using delayed tracer
addition (7 fmol/tube), pre-precipitated RAST antibody (FD
1 : 1 , 600, 000) and (a) 250 pi standard + 20 pi antibody + 20
^pl tracer or (b) 500 pi standard + 40 pi antibody + 40 pi
radiolabel (Figure 3.6(B)). The larger volumes added
resulted in an improvement in the precision profile and
hence the sensitivity of the assays.
3.3.4 Procedures to Reduce Non-specific Binding
The presence of carrier protein (0.3% gelatine)
in the RIA incubates was essential to prevent adsorption
of tracer to the polystyrene tubes. The NSB of tracer to
the antibody pellet was investigated using a pre-
precipitate prepared omitting the primary antibody.
Effects on the NSB of the delayed tracer addition and the
use of buffer wash solutions containing different carrier
proteins, are shown in Table 3.7.
Table 3«7 The Effect of Sequential Tracer Addition and
Different Wash Solutions on NSB Values






0.3% 1 8.8% 5.3%
gelatin 2 6.0% 3.9%
0.01% 1 5.5% 3.0%
BSA 2 3.4% 2.2%
* 0.01M HEPES buffer pH 7.4 containing 0.1% Brij.
BSA = Bovine serum albumin.
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Inclusion of 0.01% BSA in the wash solution produced
acceptable NSB values using only one wash prior to centri-
fugation in the sequential incubation of RIA components
and, therefore, this was used in further assays.
3.3.5 Protocol for the Sensitive T4 RIA
The proposed protocol for the measurement of
T4 in serum dialysates is shown in Figure 3-7. Details
of the preparation of dilute standard solutions and the
addition of carrier protein to standards and dialysates
are described in Section 3.4. A four-parameter logistic
model was used for curve-fitting and data interpolation.
The sensitivity of this assay was calculated from 40
replicates of the B0. The concentration of T4 giving a
signal 2.5 SD from zero was 2.0 pmol/1. The working range
(CV <10%) for duplicate standards was 3.5 - 100 pmol/1
(Figure 3.6(B)) making the assay suitable for the measure¬
ment of T4 in dialysates of serum.
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500 pi HEPES Buffer
+40 pi Concentrated T4 standards in 5% gelatine soln.
or
500 pi Dialysate





Incubate 3 h 37°C
• 40 yxl 125l-T4 (7 fmol)
Vortex
Incubate 45 min 37°C
-1 ml HEPES buffer wash
(0.0155 BSA, 0.1% Brij)




Figure 3»7 Final Protocol for the Direct RIA of T4 in
Serum Dialysates.
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3.4 PREPARATION AND STORAGE OF Tzj STANDARDS
The stock T4 solution was prepared as described
previously for the total T4 assay (Section 2.2.1).
3.4.1 Preparation of Intermediate Standards
In order to avoid losses of T4 due to adsorption
onto glass or plastic, previous workers have used either
silanized (neutral) glassware (Giles, 1982) or buffer con¬
taining carrier protein (Jiang & Tue, 1977; Yeo et_ al.,
1977a) for dilutions of the stock standard. With inclu¬
sion of 0.2$ (w/v) gelatine in the HEPES buffer, satisfac¬
tory (>95$) recovery of T4 was demonstrated by monitoring
added radiolabelled T4 after each dilution stage, using
untreated glass volumetric flasks and pipettes to make
intermediate standards (10 ;jmol/l, 100 nmol/1, 1 nmol/1).
A further check on the accuracy of these solutions was
achieved by the analysis of dilutions made in T4-free
serum using the RIA for total T4 (Section 2.2.2). These
intermediate standards were used directly to make working
standards for the sensitive T4 RIA.
3.4.2 Preparation and Storage of Working Standards
Whereas other workers have diluted their stable
stock solution to working standards prior to each assay,
for ease of use and elimination of errors and con¬
tamination problems arising from making standards daily,
it was decided to find a method of storing bulk quantities
of working standards.
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Initially, working standards, made by doubling
dilutions (100, 50, 25, 12.5, 6.2, 3.1 pmol/1), were
stored at -20°C in 4 ml aliquots in polystyrene RIA tubes.
However, the standard curves generated using these large
aliquots of standards had variable reproducibility and
were dependent on the amount of carrier protein in the
buffer (Figure 3.8) indicating significant losses by
adsorption to the tube during storage. Two alternatives
were tried: (a) working standards were stored at -20°C in
RIA tubes at the correct volume which allowed the same
tubes to be used for the RIA and (b) standards were stored
in more concentrated form with a high concentration of
carrier protein (5% gelatine).
(a) Frozen Working Standards
A large volume of each working standard in HEPES
buffer containing 0.2% (w/v) gelatine was prepared and
stored at -20°C in aliquots (500 jil) in RIA tubes. Any
standard adsorbed to the plastic tube should be available
to bind to the higher affinity binding sites of the added
antibody. The standard curves produced were reproducible
and, even after one month of storage, remained superim-
posable to standard curves made by diluting down from
stock standard immediately prior to assay. When two
T4 pools in buffer were stored similarly to standards and
interpolated from the standard curves in 8 assays, the
between-assay precision (CV) was 14.1% and 7.8% at 12.0
and 23.5 pmol/1, respectively.
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T4 (pmol /I)
Figure 3.8 Free T4 Standard Curves Using Standards
Stored at -20°C Containing 0? (o), 0.2% (x)
and 5% (•) Gelatine.
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However, despite the potential of this method,
the large number of tubes required for standard curves for
50-100 assays, made storage at -20°C impracticable.
(b) Storage of Standards at an Intermediate Dilution
with a High Concentration of Carrier Protein
This method of storing standards had certain
potential advantages:-
1. reduction in adsorption losses and instability of
standards.
2. storage of standards for many assays.
3. addition of carrier protein to dialysates before RIA
could be made similar to the procedure for pipetting
the standard curve.
Since dialysates of serum would not contain
carrier protein, the addition of gelatine in a small
volume (and therefore high concentration) would be
necessary at the RIA stage to reduce the NSB. Both Yeo
et al. (1977a) and Giles (1982) added a small volume
(50 ;j1) of gelatine solution in buffer (2% or 5% w/v) to
their RIA incubates for this purpose. At 37°C the 5%
gelatine solution can be pipetted reproducibly (Giles,
1982) but it solidifies at room temperature. The incor¬
poration of carrier protein into dialysate and standard
RIA incubates is shown in Figure 3«7 which represents the
final protocol used in the clinical studies. The stan¬
dards stored were 12.5 times more concentrated than those
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described in (a) to allow for the dilution in the assay by
diluent i.e. 1250, 625, 312, 156, 78 and 39 pmol/1. In
solid gel form, these standards appeared equally stable
stored at 4°C or -20°C but the latter was thought pre¬
ferable for long time periods. Again this method pro¬
duced standard curves which were very similar to those
generated by dilution from the stock solution immediately
prior to assay, even after several months and gave accep¬
table within-assay precision (Figure 3-9).
The between-assay precision (CV) assessed using
three Tzj pools in buffer containing 5% gelatine (stored
similarly to the standards) over a period of 2 months in
18 assays, was 13-1 %> 12.8% and 10.1% at 7.7, 18.1 and
28.4 pmol/1, respectively. Further evidence for the sta¬
bility of this method of standardisation is shown by the
CUSUM plots for these pools over a period of 5 months with
3 changes of stock solutions used to make standards
(Figure 3.10). Slight changes in bias for these pools
tended to coincide with preparation of a new stock solu¬
tion of Tty and batch of standards. Further problems
might have been encountered, therefore, had standards been
diluted down from a stock solution prior to each assay.
3.4.3 The Choice of Diluent for Standards
Standards in T4-free serum dialysate rather than
buffer have been used by some workers to equalise any non¬












Figure 3»9 A: Comparison of T4 Standard Curves
Standards freshly diluted from stock (•)
and those stored concentrated in 5%
gelatine solution (x) were compared.
B: A within-assay precision profile (Mean ±
SD, n=8) of T4 standards stored concentrated























Figure 3»10 CUSUM Plots of Results for T4 Pools Stored
in 5% Gelatine Solution Over Five Months.
Each division on the y-axis is equivalent to
2 SD from the mean T4 value.
Changes in the batch of standards with new
stock solutions are indicated by an arrow.
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serum and standards (Yeo £t al., 1977a; Helenius &
Liewendahl, 1983) - However, others have found no detec¬
table differences between the use of these two diluents
Ellis & Ekins, 1975; Giles 1982).
In this RIA, the dialysate of charcoal-stripped
human serum caused a slight displacement of tracer binding
representing 1-3 pmol/1 T4. Standard curves using the two
diluents showed a convergence of antibody binding for
values greater than 12 pmol/1 suggestive of residual
T4 being present in the dialysate rather than a non¬
specific matrix effect more likely to cause a constant
displacement at all standard concentrations (Figure
3.11(A)). Pre-treatment of the dialysate with micro-
crystalline-coupled anti-T4 antiserum abolished the
difference between buffer and dialysate curves supporting
this explanation (Figure 3.11(B)).
Charcoal treatment of normal human serum removed
98.5% of T4 (Section 2.2.1) leaving approximately
2 nmol/1 of T4 present. In addition, the bound-free
equilibrium may be altered by charcoal treatment. It is
unlikely, therefore, that the dialysate from this serum
would be completely free of T4, accounting for the 1-3
pmol/1 displacement observed.
Dilution of four dialysates of serum three-fold
with buffer also confirmed good linearity and absence of
significant blank effects in the RIA (Table 3.8). It
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Figure 3.11 Comparison of T4 Standard Curves.
A: Using buffer (•) and charcoal-stripped
serum dialysate (x) as the diluent.
B: After pre-treatment of buffer (•) and
charcoal-stripped serum dialysate (x)
with solid-phase anti-Tij antiserum.
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was, therefore, decided to use buffer standard curves for
the RIA of T4 in dialysates of serum.
Table 3.8 Demonstration of the Lack of Blank Effects in





(x 3 diluted) % Recovery
1. 42.7 14.7 103
2. 27.4 10.3 11 3
3. 24.5 8.0 98
4. 43.8 15.0 103
3.5 EQUILIBRIUM DIALYSIS
3.5.1 Dialysis Buffer
The buffer used for dialysis and pre-dilution of
serum samples was 0.01 M HEPES containing 106 mmol/1
sodium chloride and 1 mmol/1 sodium azide. The pH at
37°C was adjusted to pH 7.4 by addition of sodium
hydroxide. This buffer has been widely used for
measuring free thyroid hormones (Ellis & Ekins, 1975;
Yeo et_ al., 1977a; Giles, 1982) but the inclusion of gen-
tamicin as an additional bacteriostat has been recommended
(Helenius & Liewendahl, 1983) - The addition of genta-
micin (15 mg/1) to the dialysis buffer did not affect
antibody binding in the RIA nor the binding of T4 to serum
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proteins. (No significant difference was found for the
fT4 value of pooled normal serum dialysed in 10 dialysis
cells using buffer ± gentamicin: fT4 (-) 16.1 ± 0.9;
fTjj. ( + ) 16.3 ± 1.3 pmol/1). It was therefore included in
the dialysis buffer as a precaution against bacterial
contamination.
Inclusion of 0.2% (w/v) gelatine in the dialysis
buffer had no significant effect on the measured fT4 in
10 paired samples dialysed against buffer ± gelatine.
This suggested the absence of significant T^-adsorption to
the teflon cells. In accord with other methods
described, carrier protein was therefore omitted in the
dialysis step.
3.5.2 Preparation of Dialysis Membranes
Squares cut from Visking or Spectrapor seam-less
tubing (7x7 cm) were opened out and soaked at 50°C in
distilled water for 30 min, washed 5 times with tap water
and 3 times with distilled water. Membranes were then
stored at 4°C in dialysis buffer for up to 2 weeks.
Washing the membranes in 10 mmol/1 EDTA as recommended by
Jiang and Tue (1977), was not necessary as interference
due to factors deriving from the dialysis tubing was not
evident in this system.
3.5.3 Dialysis Procedure ■
Membranes were clamped between the teflon half-
cells of the Dianorm dialyser system (Figure 3.12).
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Figure 3.12 The Equilibrium Dialysis Apparatus.
1. Teflon half-cells with semi-permeable
membrane.
2. Rotator and rack assembly.
3. Microlab with sampling probe.
- 106 -
Four racks each consisting of 5 cells could be assembled
on the rotator. Additions to and sampling from the half-
cells was by means of entry ports which could be sealed
with inert plastic stoppers. Diluted serum (1 ml) was
added to one half-cell and dialysis buffer (1.1 ml) to the
other. To aid sampling and the later washing of the
teflon cells, serum was always placed in the male half-cell
and buffer in the female half-cell. The dialysis was
performed in a water-bath at 37°C ± 0.5 with rotation at
8 rpm. Dialysates were sampled by means of a cannula
attached to the probe of a Microlab M diluter. The
program sequence used to dispense dialysates directly
into the tubes for RIA was:-
aspirate distilled water (200 pi)
sample air (50 pi)
sample dialysate (500 pi) )
sample air (40 pi) ) x 2
sample 5% gelatine at 37°C pi) )
dispense to RIA tube (600 pi) )
aspirate distilled water (700 pi)
dispense total volume to waste
Each dialysate was analysed in duplicate for T4 by RIA
and 20 cells could be sampled in 30 min. To avoid con¬
tamination of the diluter with T4, dialysates were always
added to tubes for RIA before diluting the standards.
After the addition of standards, the diluter tubing was
washed with distilled water for 10 min before priming with
the antibody reagent.
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The teflon half-cells were cleaned by initial
rinsing with tap water followed by overnight .soaking with
Pyroneg detergent. Half-cells were then rinsed several
times with tap water and three times with distilled water.
3.5.4 Optimisation of Dialysis Time and Choice
of Dialysis Membrane
A time-course of the dialysis using the Dianorm
apparatus and the two different dialysis membranes is
shown in Figure 3.13- Three patients' sera were pre-
diluted 1:20 before addition to the dialysis half-cells.
Plateau fT4 values were reached after 16 h for both
membranes. An overnight dialysis of 18-24 h was used in
further assays.
There was no significant difference found for
fT4 values in 27 patients' samples using either Visking or
Spectrapor membranes for dialysis: mean fT4 (Visking)
13.4±1.7; mean fT4 (Spectrapor) 14.1±2.6 praol/1, p = 0.09.
The Spectrapor membranes allowed slightly faster
equilibration but this was of little practical advantage.
The less expensive Visking tubing was therefore used for
subsequent measurements.
3.5.5 Effects of Serum Dilution on Free T4 Values
Free T4 values showed little change when sera
were diluted 2-80 fold before addition to the dialysis
cell. Dilution profiles were performed on sera from





• Spectra por tubing
* k Visking tubing
Figure 3.13 Time-course of Equilibrium Dialysis for Free
Tl|.
Three patients' samples (A,B,C) were
dialysed after 1:20 dilution.
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pools containing added T4 or charcoal-stripped serum
(Figure 3-14). For further assays, serum was therefore
diluted 1:20 with dialysis buffer prior to dialysis ,
reducing the requirement for serum to 50 jul per dialysis
cell.
3.5.6 The Stability of Free T4 in Samples at 4°C
Eight paired sera and plasma samples from patients
attending a thyroid clinic were analysed for fTi| on 4 days
storing samples at 4°C. No significant difference in
fT4 values was found using serum or plasma comparing data
within each dialysis run or using the mean values for each
sample analysed on 4 days. Similarly there was no evi¬
dence of deterioration of measured fT4 values in samples
stored at 4°C for 4 days. Results for 6 paired samples
which span a range of fT4 values are shown in Figure 3.15.
Slight changes in the values measured on different days
could be attributed to between-assay variation assessed by
the dialysis of freshly thawed serum pools on each day.
3.5.7 Within-assay Precision of the Free T4 Dialysis-RIA
The mean within-assay precision profile for the
RIA of dialysates of patients' sera (Figure 3.16) was very
similar that for the analysis of standards (Figure 3.9).
The working range of the RIA coupled to dialysis was
6.6-100 pmol/1 fT4.
1 I 1 1 1 1 1
2 5 10 20 CO 80
Serum Dilution Factor
Figure 3.14 The Effects of Serum Dilution Prior to
Dialysis-RIA of Free T4.
Sera were from thyrotoxic patients (A,B),
euthyroid patients (• • E,A A D on
OCP) and a hypothyroid patient (G). Two
serum pools (x -x) with added T4 (C) or






Figure 3.15 Dialysis Free T4 Values in Paired Serum and
Plasma Samples Stored at H°C Over 4 Days.
Figure 3»16 Within-assay Precision Profile (mean ± SD,
n=30) for T4 Measured in Dialysates of
Patients' Sera.
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The precision between cells in the same dialysis-
RIA was assessed (a) by the dialysis of pooled serum in
several cells and (b) by analysis of the variation in
fTjj values for patient samples dialysed in duplicate cells.
The within-dialysis run CVs for 3 serum pools are shown in
Table 3.9; the precision using the RIA with half volumes
was also compared for two of the pools.
Table 3.9 Within-assay Precision of the Free T4
Dialysis-RIA
Pool n Mean (pmol/1)
CV (%)








The poorer reproducibility using 250 pi of dialysate
compared to 500 jal, precluded the dual measurement of both
fT4 and fT3 in the dialysate from one cell. The
variation in fT4 results between two cells (RIA full
volumes, 500 pi sample) was calculated for patient
samples, Table 3*10. This analysis showed very good
reproducibility only at high fTty concentrations therefore
two dialysis cells per serum sample were used for sub¬
sequent fTjj measurements, taking the mean result for the
two cells.
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Table 3»10 Within-assay Precision for Duplicate
Dialysis Cell's
FT4 range (pmol/1)
2 - 9.5 7.1 - 15.9 22.4 - 117.5
n 16 31 14
xi (pmol/1) 6.1 11.7 54.3
X2 (pmol/1) 6.1 12.8 55.1
SD (pmol/1) CMt-•O 1.50 3-70
t 0.07 - 2.9 - 0.6
CV (%) 11.8 12.5 6.9
3.5.8 Between-assay Precision of the Free T4
Dialysis-RIA
The between-assay precision of the fT4
measurement was calculated in 2 ways (a) by the dialysis
and RIA of quality control serum pools (in duplicate) for
several dialysis runs and (b) by the repeat analysis of
patients' sera between dialysis runs (RAC).
Outdated human serum pooled from blood trans¬
fusion service donors was used as the base material for
dialysis-RIA pools. This pooled serum had a total
T4 concentration of 110 nmol/1 and constituted the medium
level pool. A low fTjj. level pool was prepared by mixing
medium pool with charcoal-treated serum 1:1 by volume and
a high fTzj pool was prepared by adding T4 standard to the
base material to give a total T4 concentration of
160 nmol/1. These pools were stable for at least six
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months stored at -20°C in 0.2 ml aliquots and the preci¬
sion (CV) calculated from their analysis in 20 dialysis-
RIA runs is shown in Table 3.11.
Table 3.11 Dialysis-RIA Free T4 Between-assay Precision
(.Serum Pools;
Pool *Mean (pmol/1) SD (pmol/1) CV (%)
Low 7.2 0.85 11.9
Medium 13.0 1.98 15.3
High 27.8 2.73 vo • OO
*n = 20
The precision (CV) for RAC sera is shown in
Table 3.12 for two ranges of values.
Table 3.12 Dialysis-RIA Free T4 Between-assay Precision
(RAC Sera)
n Range Mean SD
(pmol/1) (pmol/1) (pmol/1) t CV (%)
1 2
68 5-30 13.8 13.6 1.6 0.63 11.9
25 29 -106 49.5 49.8 3.7 -0.24 7.5
This reference fT4 method, therefore, had accep¬
table between-assay precision and CUSUM plots for the
quality control sera over a period of 3 months with 3
changes of standards confirmed the reproducibility of the
dialysis and RIA steps achieved over a prolonged time
period (Figure 3.17).
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High pool Mean Free T4,27 5pmol/l
Medium pool Mean Free U,13 Opmol/I
Low pool Mean Free K,70 pmol/l
f | —p.
1 10 20
Figure 3.17 The Variability of the Free T4 Values
by Dialysis-RIA for Quality Control Sera.
The data are plotted as CUSUMS with the
batch No. on the x-axis and each division
on the y-axis equivalent to 2 SD from the
target value for fT4 (pmol/1).
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3.5.9 Validation of the Reference Free Tu Method
Serum samples collected from 162 patients
attending a thyroid clinic were measured for fTij. by the
dialysis-RIA method (these were the first samples
collected in a large series; a full description of these
patients and criteria used to categorise them are given in
Section 4.1). Samples from patients in different
diagnostic categories were dispersed in separate dialysis
runs. A clear separation between overt thyroid disease
and euthyroidism was obtained for most patients (Figure
3.18). One 66 year old lady with Graves' disease who had
no TSH response to TRH and who had total T4 and T3 results
of 164 and 2.9 nmol/1 respectively, had a normal
fT/j concentration. A fT4 result within reference limits
was also obtained using an Amerlex fTij kit although
fT3 (Amerlex) was at the upper limit of normal in this
sample. There was a greater degree of overlap at the
euthyroid-hypothyroid border which could be attributed to
the poorer precision of the fT4 dialysis-RIA at lower
values. Some of the patients with subclinical thyroid
disease had abnormal fT4 values indicating the potential
for greater discrimination of mild degrees of thyroid dys¬
function using a measurement of free rather than total
thyroid hormone concentrations.
The fT4 results from the 63 patients classified


























HYPO. SUBCLIN. EUTHYROID SUBCLIN. HYPER.
HYPO. HYPER.
Figure 3.18 Free Tq Concentrations by Dialysis-RIA in
162 Patients from a Thyroid Clinic.
Two euthyroid patients were taking an OCP
(x) and one had high-affinity binding of Tq
to albumin (+).
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distribution and these were used to derive a reference
interval (mean ± 2SD) of 8-17 pmol/1 for the method.
Three euthyroid patients had altered hormone-binding
proteins in their serum; two had high TBG levels induced
by oestrogen and one, described later in more detail
(Section 5.2.2), had increased binding of T4 to variant
albumin. The reference method was clearly unaffected by
altered distribution of total hormone binding in serum.
3.5.10 Comparison of Direct Equilibrium Methods
for Free In
Other direct methods for the measurement of fT4
in serum were described during and after the development
of this dialysis-RIA method (Table 3.13). In general,
these and earlier direct methods (Table 1.3) have similar
reproducibility, sensitivity and reference values as the
present method. These other studies have also confirmed
the absence of significant dilution effects on fT4 values
for overall dilutions of serum in the dialysis cell of
1:4 - 1:80. Nelson & Weiss (1985) have also reported
little increase in values when neat serum is dialysed
against the same buffer volume (overall dilution 1:2) for
euthyroid and hyperthyroid fT4 values <100 pmol/1; this
does not, therefore, account for the higher reference
values found using their method (Table 3.13). Slight
differences in the ionic composition of the HEPES buffer
used to maintain the dialysis of neat serum at pH 7.4 may
be partly responsible.




































































Weeke £t al. (1986) have developed an ultra-
filtration-RIA method for fT^ which should avoid any
r»
pejturbation of the fT4 equilibrium due to serum dilution
and altered ionic composition. However, this method is
less precise and more susceptible to temperature changes
and leakage of protein-bound hormone through the ultra-
filter. These factors may account for the higher
reference values they obtained (Table 3-13)-
3.6 FREE T^ MEASUREMENT BY DIALYSIS-RIA
The main interest in the measurement of fT3
levels in serum is in distinguishing hyperthyroid from
euthyroid states and, therefore, optimum assay precision
is required at the upper limit of normal. Previous esti¬
mates by other workers using direct dialysis suggested
this to be between 10 and 15 pmol/1 (Ellis & Ekins, 1975;
Yeo et_ al., 1977a; Weeke & Orskov, 1979). The assay was,
therefore, designed to have optimal precision between 5
and 20 pmol/1.
3.6.1 Optimisation of the Sensitive T^-RIA Procedure
The procedures developed for the sensitive T4
RIA e.g. the use of pre-precipitated primary antiserum,
the storage of standards in buffer containing 5% gelatine
and the incubation conditions were all successfully
applied to the assay of picomolar T3 concentrations. The
final protocol is shown below with a typical method for
preparing the pre-precipitated antiserum (Table 3.14).
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Protocol for the Direct RIA of in Serum Dialysates:
500 .ul Dialysate
40 jil 5% gelatine in
HEPES buffer OR
500 jul HEPES Buffer




40 jjI Pre-precipitated anti-T^
(FD 1:2,300,000)
4/
Incubate 37°C 3 h
40 )il 125i^3 (3 fmol)
Incubate^5 min 37°C
4/
1 ml HEPES buffer wash (0.01? BSA, 0.1* Brij)
4/
Centrifuge at 4°C 2,000 g for 20 min
4/
Decant, blot and count pellets

































x 100 dilution of neat antiserum.
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Precision profiles for a series of standard curves using
different dilutions of primary antibody were examined to
optimise the anti-T^ dilution (Figure 3 - 19)-
In the pre-precipitated form, the affinity
constant (Ka) of the primary antiserum was calculated by
Scatchard analysis as 8 x10^ 1/mol.
Standards were prepared from a 1 mmol/1 stock
T3 solution (Section 2.2.1) by dilution in HEPES buffer
with 5% gelatine and stored at -20°C (400, 200, 100, 50,
25 pmol/1). These were diluted 12.5-fold in the RIA
protocol. As an additional check on the accuracy of the
dilutions, a suitable intermediate dilution (approx.
2 nmol/1) in charcoal-stripped serum was measured for
in the serum total T3 assay (Section 2.2.2).
3.6.2 Precision and Sensitivity of the T3 RIA
The mean within-assay precision profile calcu¬
lated from duplicates of standards and dialysates for 12
assays is shown in Figure 3«20. The working range of the
RIA was 2-32 pmol/1. The sensitivity of the assay,
defined as 2.5 SD above zero from 40 replicates of the
zero standard was 0.5 pmol/1. The between-assay reprodu¬
cibility of the RIA was assessed using two buffer pools
stored with 5% gelatine. In 25 assays, the CVs at 4.3 and
9.0 pmol/1 were 11.4% and 7.0% respectively.
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Figure 3»19 Standard Curves and Precision Profiles at
Different Final Dilutions of Anti-T3
Antiserum.
Final dilutions were: •—• 1:1x10^;
x x 1:2x10°;A—A1:3x1O°;0 a 1:4 x 10°.
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Tj(pmol/t)
Figure 3.20 Within-assay Precision Profiles (Mean±SD,
n = 12) for the RIA of T3 in Standards and
Dialysates.
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3.6.3 Optimisation of the Equilibrium Dialysis
Procedure for Free Tq Measurement
There was little difference in the fT3 values of
serum and the time to reach equilibrium in the dialysis
step using either Visking or Spectrapor dialysis membra¬
nes, Figure 3.21. Plateau values for fTg were reached
after 16-18 h dialysis at 37°C. An overnight dialysis
with Visking membranes for 18-24 h at 37°C was used in
subsequent assays.
A greater effect on fT3 compared to fT4 values
was observed when serum was pre-diluted with HEPES buffer
prior to dialysis (Figure 3.22). This is in agreement
with the theoretical study of Kamikubo et_ al., 1984. On
average, dialysis using a 1:10 dilution of serum versus
1:20 produced 15% higher fT3 values. Slightly higher
values were produced using less dilute serum. Further
dialysis runs were performed using a 1:10 dilution of
serum i.e. 100 jil of serum per dialysis cell.
3.6.4 Precision of the Free T3 Dialysis-RIA
The mean precision profile for the T3 RIA using
serum dialysates was very similar to that for standards
(Figure 3.20). The within-run precision for dialysis
cells assessed by dialysing a euthyroid and a hyperthyroid
sample in 10 cells each was 6.7% and 7.6% at fT3 values of
3.3 and 25.7 pmol/1, respectively. The variation in
values using two dialysis cells per patient sample was
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•—• Spectra per tubing
0 10 20 30
Dialysis Time ( h)
Figure 3.21 Free T3 Equilibrium Dialysis Time-course for
Three Serum Samples (A,B,C).
too-.
Serum Dilution Factor
Figure 3*22 The Effect of Sample Pre-dilution Prior to
Dialysis-RIA of Free T3.
Sera from a thyrotoxic patient (A),
euthyroid patients (D,E,F), pooled normal
serum (C) and a serum pool with added
T3 (B) were analysed.
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7.2% (range 1.3-6.0 pmol/1) and 8.3$ (range 6.0 -
36.0 pmol/1). Because of this satisfactory within-assay
precision, patients' samples used in the method validation
were dialysed in singleton.
The overall between-assay precision was calcu¬
lated in 12 dialysis runs from the analysis of pooled nor¬
mal serum and this pool with added T3. These pools were
stored at -20°C. The CVs were 7.9$ at 6.7 pmol/1 and
10.3$ at 12.2 pmol/1. The variation in fT^ values for
RAC sera from patients over 10 assays is summarised in
Table 3.15.











4.58 4.54 0.55 0.25 12.0
46 6.0-39.0 15.62 16.46 1.68 -2.4 10.5
3.6.5 Validation of the Reference Free T^ Method
Sera collected from 162 patients attending the
thyroid clinic (Section 4.1) were analysed for fT3 by
dialysis-RIA. Samples from patients in different
diagnostic categories were dispersed in separate dialysis
runs and their fT3 results are shown in Figure 3.23.
All patients with overt hyperthyroidism and 3 of




Hypo. Subclin. Euthyroid Subclin. Hyper.
Hypo. Hyper.
Figure 3.23 Free Concentrations by Dialysis-RIA in
162 Patients from a Thyroid Clinic.
Two euthyroid patients were taking an OCP
(x) and one had high affinity binding of T4
to albumin (+).
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fTg concentrations. Euthyroid patients taking the OCP
and one patient with abnormal T4 binding to albumin had
normal fT3 concentrations. The 95% reference range
derived from the 63 euthyroid patients was 3.2-6.7 pmol/1.
Normal fT3 results were found in a number of hypothyroid
patients.
The reference values for this method agreed well
with those reported for several indirect fT3 assays
(Table 1.3) but were generally lower than those quoted for
other direct methods (Table 1.4 and 3.16).
Table 3.16 The Performance and Reference Values










































A LABORATORY AND CLINICAL EVALUATION
OF FREE THYROID HORMONE AND SENSITIVE TSH MEASUREMENTS
IN PATIENTS WITH SUSPECTED THYROID DISEASE
- 131 -
4.1. SAMPLES USED IN THE STUDY
Serum samples were collected from 285 consecutive
patients referred to a thyroid clinic either for further
investigation of suspected thyroid disease or for ^31i_
treatment of hyperthyroidism. There were 247 females
and 38 males (age range 13-80 years, mean 47.6). The
diagnosis in each case was made on clinical grounds and
using results for total T4, T3, basal TSH (in-house RIA)
and the TSH response 20 min after the intravenous admi-
nistration of 200 yig TRH. The iodine- 131 uptake test,
thyroid scans and tests for thyroid autoantibodies were
also used to assist in the diagnosis • The distribution
of thyroid pathology in the group is shown in Table 4.1.





Toxic multinodular goitre 16
Toxic solitary nodule 8
Multinodular goitre 27
Subclinical Graves' disease 9
Non-toxic solitary nodule 14
Simple goitre 6
Cold nodule or cyst 6
Ophthalmic Graves' disease 2
Hashimoto's thyroiditis 20
Primary atrophic hypothyroidism 5
No thyroid pathology 49
Eight of these patients were known to be taking an oestro¬
gen containing oral contraceptive (OOP) and one was
pregnant.
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The biochemical tests were used to assign
patients to diagnostic categories as shown in Table 4.2.
Table 4.2. The Distribution of Patients in Five
Diagnostic Categories
Category Test Results n
Hyperthyroid Absent response to TRH




Absent response to TRH
Normal total T4 and T3
16
Euthyroid Normal response to TRH
Basal TSH not raised




Increased basal TSH and
exaggerated response to
TRH. Normal total T4
16
Hypothyroid Increased basal TSH and
exaggerated response to
TRH. Low total T4
9
The reference ranges used for TSH (RIA) pre- and post-TRH,
total Ti| and T3 were those described in Chapter 2. A TSH
increment at 20 min after TRH of less than 1.0 mU/L above
the basal value was considered an absent response.
Patients with normal total thyroid hormone concentrations
but either an absent TSH response to TRH or a raised basal
TSH concentration were described as having subclinical
hyperthyroidism or subclinical hypothyroidism, respec¬
tively. Hyperthyroid patients with normal total T4 but
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raised total T3 concentrations were described as T3-
thyrotoxic. There were 11 such patients in this series.
Three patients with normal TRH tests who were categorised
as euthyroid had marginally increased total T4 (no thyroid
pathology) or T3 levels (one with a multinodular goitre
and one with ophthalmic Graves' disease).
The first 200 samples collected in this series
were used in the evaluation of the free thyroid hormone
kits (Section 4.2 and 4.3) and both TSH IRMA methods.
In the evaluation of TSH IRMA methods (Section 4.5), the
subclinical disease categories were supplemented with
additional samples. All of the 285 samples were used to
evaluate a new thyroid function test strategy (Section
4.6). Sera from a separate series of 116 consecutive
patients were used in the evaluation of the SimulTRAC
dual-analyte assay (Section 4.4). All sera were split
into three portions and stored at -20°C until assay.
4.2 FREE Tu MEASUREMENT BY ANALOGUE RIA
This section deals with the evaluation of various
analogue RIA kits in thyroid clinic patients. Data from
other groups of patients are described in subsequent chap¬
ters .
4.2.1 Comparison of Free T4 RIA Procedures
The manufacturers' protocols are summarised in
Table 4.3. All assays were performed using an automatic








































diluter dispensing sample with tracer in one step within
10 min to minimise effects of drift, particularly in the
coated-tube assays. All tests were performed in dupli¬
cate, with a maximum of 50 duplicates per assay. The
Amerlex Magnetic (Amerlex-M) kit was introduced after the
original Amerlex kit. Both kits contain identical anti¬
body, analogue and standards but the Amerlex-M kit also
contains an "albumin blocker" which is claimed to remove
interference in the fTzj assay due to changes in albumin
concentration.
4.2.2 Within-assay and Between-assay Precision
The mean within-assay precision profiles (from
duplicates of samples) for each kit and the reference
dialysis method from 15 assays are shown in Figure 4.1.
The relatively poor precision of the reference method
represents the combination of imprecision from the dialy¬
sis and RIA steps. The Amerlex and Amerlex-M assays
showed the best profiles whilst the Corning Magic kit
showed poor precision at low values. For practical pur¬
poses all of the kits had adequate precision between 3 and
100 pmol/1.
The average number of tests per run where there
was less good agreement between duplicate tubes
("duplicate error") was compared. This provided an
important indicator of within-assay precision, since
"duplicate errors" are not included in the derivation of
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FREE T4 (pmol/l)
Figure 4.1 Mean Within-assay Precision Profiles for 15
Assays of Free T4 by Each Method.
Reference intervals (pmol/l) were:
11-23 Coat A Count ( A ),
8-17 Becton Dickinson (•),




Bars indicate 1 SD.
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the within-assay precision profile. A duplicate error
was indicated if the variance ratio of the replicate
counts to the mean counts exceeded the arbitrary value of
20 (Baxter, 1982). For each kit the mean percentage of
duplicate errors per run was: Amerlex 27%, Amerlex-M 14%,
Becton Dickinson 18%, Coat A Count 24%, Corning Magic 13%-
This represents the number of tests where the replicate
values required further scrutiny to determine if re-
analysis was necessary. The kits using magnetic separa¬
tion had fewer duplicate errors than the other separation
systems. The beads used in the Amerlex separation step
did not form a robust compact pellet after centrifugation
leading to a loss of antibody at the decanting stage and
thus to imprecision and an unacceptably high number of
samples requiring re-analysis. The wash step employed in
the Becton Dickinson assay may account for the lower
number of duplicate errors compared to the Coat A Count
kit.
The between-assay precision was assessed using
two human Commercial control sera (RIATRAC II and III,
Becton Dickinson Lot No. HL4000) and a low serum pool
(Table 4.4). In addition, a patient's sample from the
previous run was re-analysed in the next assay (repeat
analysis control, RAC) and, for values within the range
5-50 pmol/1, the precision (CV) calculated from the two
results on each RAC from 10 assays was: Amerlex 9%,
















































































Amerlex-M 5%, Becton Dickinson 9%, Coat A Count 7%,
Corning Magic 6%. The magnetic separation (Amerlex-M,
Corning Magic) and Amerlex fTlj kits had better between-
assay precision than the coated-tube assays and this has
been confirmed in other studies (Wilke, 1982; Witherspoon
et al,, 1985; Jackson & Ekins, 19 8 6 ).
4.2.3 Investigation of Assay Drift
One sample in each of 10 assays was analysed at
the beginning and the end of batches containing 50 dupli¬
cate tubes. There was no significant drift in the
Amerlex, Amerlex-M and Corning Magic assays but both
coated-tube assays showed a positive drift of 7 - 8%
(p<0.05) contributing to their poorer precision. Wilke
(1982) also detected drift using the Coat A Count kit and
noted that this assay had not reached equilibrium in the
recommended incubation time.
4.2.4 Standardisation Compared to the Reference Method
The standards provided with each kit were
analysed in the same assay by the reference fT4 dialysis
method. The mean dialysis values from 5 runs were com¬
pared with the quoted values (Figure 4.2). Regression
analysis showed that the Amerlex (or Amerlex-M) and Becton
Dickinson standards were targeted in agreement with the
reference method whereas Coat A Count and Corning Magic
standards were assigned values significantly higher
(p<0.001) than those measured by dialysis. This is in
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Figure 4.2 Free T4 Kit Standards Measured by Equilibrium
Dialysis.
Regression equations for fT4 values were:
Dialysis = 1.0 Amerlex -0.5,
Dialysis = 1.0 Becton Dickinson +1.0,
Dialysis = 1.2* Coat A Count -2.0,
Dialysis = 1.2* Corning Magic -2.6.
*Significant differences from y = x ( )
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broad agreement with the findings of the recent DHSS sur¬
vey of fTzj. methods with the exception of the Becton
Dickinson standards which were found to be targetted too
high in that study (Jackson & Ekins, 19 86).
4.2.5 Comparison of Free T4 Results with the
Reference Method
For the first 162 of the 200 study patients, fT4
values by analogue RIA were compared with those by dialy¬
sis (Section 3.5.9). Free T4 values <100 pmol/1 were
used in the comparison and results for four of the kits
are shown in Figure 4.3 (values by Amerlex-M did not
differ significantly from Amerlex fT4 values). Correl¬
ation coefficients of r>0.94 were obtained for all the
analogue methods.
Free T4 values by Amerlex, Amerlex-M and Becton
Dickinson kits, did not differ significantly .from the
reference method but Coat A Count and Corning Magic values
at low concentrations fell below the regression line
drawn, indicating that this relationship was not recti¬
linear. In general, the Coat A Count kit gave lower
values than those by dialysis at high fT4 concentrations
consistent with the standardisation difference
demonstrated. Corning Magic however, gave higher values
throughout than dialysis, resulting in the higher
reference range for this kit. (Several values which were
greater than the top standard (80 pmol/1) provided with
the Corning Magic kit were not included in Figure 4.3).
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Figure 4.3 Comparison of Free T4 Values by Analogue RIA
and Equilibrium Dialysis in Patients' Samples.
Regression equations (y = mx + c) were:
Amerlex = 1.04 dialysis + 1.3,
Becton Dickinson = 0.97„dialysis -0.5,
Coat A Count = 0.84 dialysis +5.8j!>Corning Magic = 1.00 dialysis +10.0 .
("significant differences, p<0.001, from y=x)
Amerlex-M = 0.97 dialysis +2.3 (data not
shown).
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This is not consistent with the negative bias of the kit
standard values compared with those measured by dialysis
and suggests that some other feature of this kit e.g. the
analogue or the matrix of the standards is responsible for
the difference in accuracy using patient samples.
Similar relationships have been reported for the
Coat A Count versus the Amerlex kit (Kubasik et_ al., 1983)
and, more recently, for the Amerlex, Becton Dickinson and
Coat A Count kits versus direct dialysis (Jackson & Ekins,
1986). Discrepant results for standards and samples with
respect to dialysis were also found for the non-magnetic
Corning analogue RIA in the latter report.
4.2.6 Diagnostic Accuracy in Patient Samples
Despite the differences in accuracy, all of the
fT4 kits performed equally well in categorising patients.
Results by four of the kits used for 200 sera from the
thyroid clinic series are shown in Figure 4.4. The
Amerlex-M kit categorised the patients in an identical
manner to the Amerlex kit and therefore this data is not
shown.
The reference intervals (mean±2SD) derived from
62 euthyroid patients were: Amerlex '10-21; Amerlex-M
10-22; Becton Dickinson 8-17; Coat A Count 11-23; Corning
Magic 17-30, pmol/1. All but one kit correctly
classified the two euthyroid women with raised total
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Figure 4.4 Free T4 Values by Analogue RIA Kits in 200
Patients from a Thyroid Clinic.
Two patients were taking oral contraceptives
(x); one patient with high fT4 had an abnor¬
mal high affinity albumin (+).
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were studied, no conclusions could be drawn on the kits'
performance in this situation. One euthyroid man had an
abnormal high affinity albumin present in his serum
(Section 5.2.2); this gave raised values with all the
fTij kits, although fTzj was normal by equilibrium dialy¬
sis. His results were excluded when calculating the
reference intervals above.
Two patients with overt hyperthyroidism were mis-
classified by all the kits: one had T3-thyrotoxicosis,
the other had marginal elevations in total T4 and T3 with
a normal fT4 by the kits and by dialysis.
In the subclinical groups, a proportion of
f?4 results were outside the reference intervals. Out of
the 19 patients in these groups (Figure 4.4), abnormal
fT4 results were found in a maximum of 7 to 10 patients,
depending on the kit used. Many of these patients,
therefore, had fT4 levels more consistent with overt
thyroid disease. This improved resolution of borderline
cases contrasts with the findings of Braun et_ al. , 1983.
In conclusion, although the diagnostic accuracy
was comparable for all the analogue kits assessed as found
by other workers (Wilke 1982; Nasralla et_ al., 1983;
Witherspoon £t al., 1984 ; Jackson & Ekins, 1986), better
precision and analytical accuracy were obtained with the
Amerlex-M fT4 kit. Since this kit only became available
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in 1984 some of the earlier clinical studies in this the¬
sis were carried out using Amerlex fTzj kits. It should
also be noted that since 1985 the Coat A Count kit has
been modified further to negate any albumin effects.
4.3 FREE MEASUREMENT BY ANALOGUE RIA
4.3.1 Comparison of Free T3 RIA Procedures
The manufacturers' protocols for the fT3 assays
evaluated are outlined in Table 4.3- All assays were
limited to 50 duplicate tubes. Unlike fTzj, no drift was
found for any of the fT3 assays. This may be due to the
greater incubation times employed for the latter (2-3 h).
Amersham International replaced their Amerlex
fT3 kit with the magnetic version late in 1984. An
"albumin-blocker" was not incorporated but the method of
standardisation was changed. A computer model is used by
the manufacturers to predict fT3 concentrations in the
standards from the measured total T3 concentrations. An
improved model was used in the Amerlex-M kit.
4.3.2 Within-assay and Between-assay Precision
The mean within-assay precision profiles for the
fTg kits and the reference dialysis method for 12 assays
are shown in Figure 4.5. The profile for the reference
method compared favourably with the kit methods despite
being more technically demanding. The Amerlex method
with centrifugal separation had the lowest profile but all




Figure 4.5 Mean Within-assay Precision Profiles for 12
^
Assays of Free by Each Method.
Reference intervals (pmol/l) were:
3.2-6.7 equilibrium dialysis (A),
5.3-10.0 Becton Dickinson (•),
3.0-6.9 Coat A Count (A),
4.2-7.8 Amerlex-M (B ),
4.0-7.8 Amerlex (o).
Bars indicate 1 SD.
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The mean percentages of duplicate errors per
assay were: Amerlex 11?, Amerlex-M 6?, Becton Dickinson
4?, Coat A Count 12?. Again the use of the magnetic
separation improved the performance of the Amersham kit in
this regard. There were fewer duplicate errors with all
the fT3 kits compared to their fT4 counterparts (Section
4.2.2). The larger sample volumes used in the coated-tube
fTg kits and the longer incubation times may account for
this.
The between-assay precision of the kits was
assessed using either human commercial control sera
(RIATRAC I, II, III Lot No. HL4000, from Becton Dickinson)
or serum pools used in the quality control of the total
T3 assay (Table 4.5). The precision (CV) calculated from
RAC results in the range 3-25 pmol/1 from 10 assays was:
Amerlex 6.9?, Amerlex-M 6.2?, Becton Dickinson 7.0? and
Coat A Count 8.7?. The Amerlex-M fT3 kit had the best
between-assay precision of the kits.
4.3.3 Standardisation Compared to the Reference Method
To determine the accuracy of the standardisation
of the analogue kits, kit standards were analysed by
fTg dialysis-RIA. The mean dialysis values from 3 runs
were compared with the values quoted by the manufacturers
(Figure 4.6). The assigned fT^ values over-estimated the




















































































Becton Dickinson Free T-j (pmol/1) Cool A Count Free (pmol/t)
Figure 4.6 Free Kit Standards Measured by
Equilibrium Dialysis
Regression equations for fT3 values were:
Dialysis = 0.84* Amerlex +0.7,
Dialysis = 0.92* Amerlex-M +0.4,
Dialysis = 0.54* Becton Dickinson +0.6,
Dialysis = 0.45* Coat A Count +1.2.
*Significant differences from y=x ( ).
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However, the discrepancy was most marked with the coated-
tube methods. At high concentrations, values assigned to
the Amerlex standards were higher compared to dialysis-RIA
than those assigned to Amerlex-M standards. This is con¬
sistent with the known re-targetting of the Amerlex-M
standards by the manufacturer.
4.3.4 Comparison of Free T9 Results with the
Reference Method
Free T3 values measured by dialysis-RIA (Section
3.6.5) and the analogue kits were compared for the first
162 patients in the study. Regression analysis was per¬
formed for pairs of fT^ values less than 32 pmol/1 (Figure
4.7). Correlation coefficients of r>0.92 were obtained
for all of the analogue methods. A lack of linearity at
low concentrations was evident for three of the kits which
had a significant y-intercept. Although fT3 values by
Amerlex, Amerlex-M and Becton Dickinson differed slightly,
Coat A Count values were much lower than dialysis values
particularly in hyperthyroid patients. There was much
better agreement between Coat A Count and dialysis values
in sera from euthyroid patients (Figure 4.7) and Wang et_
al. (1985) have confirmed this using an indirect ultra¬
filtration method.
The regression analysis for the two Amerlex
fT^ kits is shown in Figure 4.8. The relationship was
not rectilinear with the magnetic version giving lower
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Figure 4.7 Comparison of Free Values by Analogue RIA
and Equilibrium Dialysis in Patients' Samples.
Regression equations (y=mx+c) were:
Amerlex = 1.06 Dialysis +0.5±
Amerlex-M = 0.85* Dialysqs +1-4*'Becton Dickinson = 0.98„ Dialysis +2.4!!>
Coat A Count = 0.56 Dialysis +1.8 •
(*Significant differences, p<0.001, from y=x).
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Figure U.8 Regression Analysis of Free T3 Values by
Amerlex and Amerlex Magnetic Analogue RIA.
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fTg values at high concentrations in keeping with the
change in standardisation by the manufacturer.
The coated-tube kits produced the greatest
discrepancy in relation to dialysis values comparing
patient samples and standards. The assigned standard
values were approximately two times higher than those
measured by dialysis for both coated-tube kits. However,
in patient samples, the Becton Dickinson kit produced
similar values to dialysis whereas Coat A Count values
were generally lower than dialysis values. This
suggests that standards and patient samples behave dif¬
ferently in these methods. (A similar discrepancy was
observed for the Corning Magic fT4 kit). This effect may
be due to the different analogues and standard matrices
used by different manufacturers.
4.3.5 Diagnostic Accuracy in Patient Samples
The fT3 kits produced a greater disparity in the
categorisation of the 200 patients than the fT4 kits.
Results in the five patient categories for each kit are
shown in Figure 4.9.
The reference intervals (mean±SD) derived from 62
euthyroid patients were: Amerlex 4.0-7.8; Amerlex-M
4.2-7.8; Becton Dickinson 5.3-10.0; Coat A Count 3-0-6.9,
pmol/1. In the two euthyroid patients taking the OCP,
fT3 values were normal by all except the Coat A Count kit;
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Figure U.9 Free T3 Values by Analogue RIA Kits in 200
Patients from a Thyroid Clinic.
Two patients were taking oral contraceptives
(x); one patient with high fT3 had an abnor¬
mal high affinity albumin (+).
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In contrast, the Coat A Count fTg kit produced the only
value within reference limits for the euthyroid patient
with suspected high-affinity binding to albumin.
As expected, the fTg kits did not discriminate
effectively those with overt or subclinical hypothyroidism
from euthyroid patients. There were differing degrees of
overlap between results for hyperthyroid and euthyroid
patients with the four kits. The Amerlex method produced
the best discrimination; only two hyperthyroid patients
were mis-classified. The Coat A Count kit produced the
greatest overlap of fT3 values. Details of the thyroid
hormone measurements in these hyperthyroid patients, most
of whom had normal total T3 values, are given in Table
4.6. Free T^ by dialysis-RIA (when measured) was raised
in all of the patients mis-classified by the fTg kits.
In patients with subclinical hyperthyroidism, the
kits produced similar discrimination and did not appear to
resolve this sub-group from euthyroid patients any more
clearly than fT4 measurement (Figure 4.4).
In conclusion, the Amerlex and Amerlex-M
fT3 methods performed best in terms of precision, accuracy
and diagnostic effectiveness. The Coat A Count kit was
least precise, gave significantly lower fT3 results and
produced the greatest degree of overlap between diagnostic
categories. Wilke et al. (1984) confirmed these findings
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and demonstrated some TBG-dependence of Coat A Count
results which may explain the decreased sensitivity of
this test. This kit has since been modified by the
manufacturer.
4.4 FREE T4 AND TSH BY DUAL-ANALYTE RIA
The SimulTRAC fTjj/TSH dual RIA kit was developed
to combine the diagnostic strengths of TSH and fTij
measurements. Free Tzj. is measured using a 57co-labelled
T4 analogue which is claimed not to bind significantly to
the natural binding proteins in serum. A different label
(125i_TSH) is used in the estimation of TSH and,therefore,
the two measurements can be performed in the same tube
provided a gamma counter is used which is capable of
distinguishing the different emission energies of the two
radioisotopes.
4.4.1 The SimulTRAC Free Tq/TSH RIA Protocol
The manufacturer's protocol for the SimulTRAC
fT4/TSH RIA is shown in Figure 4.10. The standards pro¬
vided were calibrated against the 68/38 IRP for TSH and an
equilibrium dialysis procedure for fT4. Using the high
sensitivity option for the assay, the top standards used
had values of 15 mU/1 for TSH and 70 pmol/1 for fTij.
Standards A-F and samples (200 ;il) were incubated
in duplicate with rabbit dual antibody (100 ;al) for 2.5 h
at 37°C then for 1.5 h more after adding 100 p.1 of dual
tracer. The batch size was limited to 20 patient samples
- 159 -










Centrifuge at 1000g 15 min
DECANT
i
Count Pellets for 57Co and 125I
Figure U.10 The SimulTRAC Free Ti}/TSH RIA Protocol.
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as recommended by the manufacturer. Free ligand was
separated from bound by adding goat anti-rabbit antiserum
plus PEG to accelerate the precipitation and then centri-
fuging. Radioactivity from the two isotopes was counted
simultaneously in the LKB Wallac gamma counter. The per¬
centage spill-over in each channel, assessed using pure
57co and 125i counting standards, was less than 2% for
each assay. Pellets were counted for 60-90 sec to
achieve the recommended total counts for each tracer
(20,000 for 57Co and 25,000 for 125i).
4.4.2 The Precision and Bias of the Dual-Analyte Assay
The mean within-assay precision profiles
(Figure 4.11) were calculated from results for duplicate
sample analyses from 11 SimulTRAC assays. The fTi| assay
had excellent precision over a wide concentration range,
whereas the TSH assay was less precise with a mean CV of
10% at 1.0 mU/1.
The between-assay precision data for in-house
serum pools and Lyphochek human control serum (Bio-Rad
Richmond, California, U.S.A.; lot no. 07300) over 11
assays are shown in Table 4.7. In addition, the between-
assay CVs from 11 RACs (range 7.4-27.5 pmol/1 for"fT4, 0.3
- 58 mU/1 for TSH) were 6.8% for fT4 and 11.9% for TSH.
The SimulTRAC fT4 assay had better precision than
the Becton Dickinson coated-tube fT4 assay and compared
favourably with the Amerlex-M fT4 method (Table 4.4),
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Figure 4.11 Within-assay Precision Profiles (Mean±SD,
n=11) for the SimulTRAC TSH (A) and Free T4
(B) RIA.
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Table 4.7 Between-assay Precision of the SimulTRAC
Free T4/TSH Assay
Lyphochek Pooled sera
FT4, pmol/1 I II III 1 2
*Mean 3.2 9.7 38.9 15.6 41 .0
Target 3.3 9.3 37.3 15.0 40.0
Bias, % -3 +4 + 4 + 4 + 2
SD 0.2 0.4 0.9 1.0 2.6
CV, % 5.8 4.2 2.3 6.2 6.4
TSH, mU/1 I II III a b c
*Mean 1.5 10.9 30.2 3.0 9.0 42.9
Target 1.5 11.2 23.2 2.8 7.5 44.8
Bias, % 0 - 3 + 30 +7 +20 - 4
SD 0.1 1.0 2.7 0.2 0.5 2.2
CV, % 10.2 9.4 8.8 7.7 6.1 5.2
previously considered to be the analogue fT4 method
of choice. The SimulTRAC TSH assay had a slightly wider
working range (1.0-15 mU/1) than the in-house TSH RIA
(1.0-10 mU/1) shown in Figure 2.2, and the between-assay
precision from the quality control pools compared
favourably with that of the in-house TSH assay (Table
2.3). The CVs for Lyphochek controls and RACs however,
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were slightly higher than those seen for pools and RACs
using the in-house assay. The gamma counter window set¬
tings used to minimise spill-over tended to favour the
counting of 57g0 compared to '^It such that the counting
rate in total count tubes for 57g0 (fTij) was 40,000 cpm
and that for 125i (TSH) was 25,000 cpm. Since the
SimulTRAC TSH assay operates with a B0 of 30%, improved
precision may have resulted had the recommended counting
time been exceeded.
The average bias for the Lyphochek controls was
calculated from the quoted values. For the in-house
pools, bias was calculated from target values established
by the Amerlex-M fT4 assay for pools 1 and 2 and by the
in-house TSH RIA for pools a-c (Table 4.7). The
Lyphochek III and pool c were diluted five-fold in zero
standard before measuring TSH. This pre-dilution may
have contributed to the variable bias figures obtained for
the SimulTRAC TSH assay at the higher TSH concentrations.
4.4.3 Detection Limit and Recovery of the TSH Assay
The detection limit, determined conventionally
from the 97-5% (2.5 SD) confidence limits of 20 replicate
estimations of the zero standard (Rodbard, 1978) was
0.17 mtl/l. Since patient samples are not assayed in
replicates of 20, a more meaningful 2.5 SD estimate of
0.25 mU/1 was obtained from the mean intra-assay precision
profile by extrapolation of the asymptote of the SD pro-
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file to the SD value at zero dose (John & Jones, 1984;
Ekins, 1983b). This was lower than that of the in-house
RIA and not far removed from detection limits described
for TSH by IRMA in the following section.
The analytical recovery of the SimulTRAC TSH
assay was calculated from pooled euthyroid serum with 1,
4 and 20 mU/1 of added TSH IRP (final concentration)
measured in 3 assays. The mean recoveries for these
additions were 113%, 120% and 97%,respectively.
4.4.4 Correlation with other Methods
Regression analysis of fT4 results obtained by
SimulTRAC (y) and the Amerlex-M fT4 method (x) for 32
patients' samples analysed in the routine diagnostic
laboratory because of suspected alterations in protein
binding (range 4-35 pmol/1) gave the equation:
y = 1.13x-1.7 pmol/1. TSH values in 116 patient samples
from the thyroid clinic did not have a normal distribu¬
tion. SimulTRAC TSH values (y') were therefore compared
with the in-house TSH RIA (x') in only 50 samples where
TSH was detectable by both methods but less than 8 mU/1.
This gave the regression equation: y' = 1.08x' - 0.44.
These correlations were significantly different (p<0.001)
from y=x for the x slope and the y' intercept. TSH
values in 11 patients with TSH >8.0 mU/1 were signifi¬
cantly lower (p<0.05; paired t-test) by SimulTRAC (mean
60.9*40.2 mU/1) compared to the in-house assay (mean
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103.2±92.0 mU/1). However, this difference was not suf¬
ficient to affect the patient categorisation.
4.4.5 Diagnostic Accuracy in Patient Samples
The diagnostic performance of the SimulTRAC assay-
was assessed in 116 consecutive patients attending the
thyroid clinic. These were different patients from those
in other sections of this chapter but they were cate¬
gorised in the same way. Seven of 40 euthyroid patients
in this group were taking an OCP.
The 95$ confidence intervals calculated from the
40 euthyroid patients were 11.1-24.1 pmol/1 for fT4 and
0.6-5.7 (mean 1.8) mU/1 for TSH, after logarithmic trans¬
formation of the TSH data. These intervals were slightly
lower than those derived by the manufacturer from results
for 146 individuals: fTz*, 11.4-25.3 pmol/1; TSH, 0.9-6.7
mU/1. Use of the manufacturer's reference range for TSH
minimised the overlap between the different categories of
patients (Figure 4.12).
All hyperthyroid patients (overt and subclinical)
had TSH values <0.9 mU/1 and all hypothyroid patients
(overt and subclinical) had TSH values >6.7 mU/1. With
these reference limits, results overlapped for only two
euthyroid patients (5$) who had low concentrations of TSH
(0.6 and 0.8 mU/1). However, this degree of overlap in
basal SimulTRAC TSH would militate against the use of this
TSH method as a predictor of the TRH test response, as
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Figure 4.12 SimulTRAC Free T4/TSH RIA Results in
116 Patients from a Thyroid Clinic.
Dashed lines indicate reference ranges:
fT^ horizontal, TSH vertical.
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All patients with overt hyperthyroidism (n=56)
had fTij. values greater than 24.1 pmol/1, and all those
with overt hypothyroidism (n = 9) had fTzj values below 11.1
pmol/1. All but two patients with subclinical disease
(n=11) had fT4 concentrations within the reference inter¬
val: one patient with subclinical hyperthyroidism had a
fT4 value of 24.8 pmol/1, and one with subclinical hypo¬
thyroidism had a low fT4 result (6.9 pmol/1), Figure 4.12.
All euthyroid patients whose total T4 concentrations were
increased due to the OCP, had normal SimulTRAC results.
All patients with overt hyperthyroidism were
distinguished from euthyroid patients when TSH and
fTi| results were combined. Therefore, compared to our
standard strategy for investigating new patients referred
to a thyroid clinic, the SimulTRAC assay produced similar
categorisation in 112/116 (96.5%) of patients. This was
achieved using individual reference ranges for fT4 and TSH
without recourse to more complex linear discriminant ana¬
lysis which has been applied in the past to combinations
of older thyroid function tests (Barnett et_ al. , 1973) -
4.5 MEASUREMENTS OF TSH BY IMMUNORADIOMETRIC ASSAY
Two high sensitivity IRMA methods for TSH were
evaluated. Both employ a soluble 125j_iabelled mouse
monoclonal antibody and a second mouse monoclonal coupled
to solid-phase which is directed against a different epi¬
tope of TSH. In these sandwich assays, the radiolabel
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bound to the solid-phase is directly proportional to the
TSH concentration of the sample (Figure 1.4).
4.5.1 The Boots-Celltech Sucrosep TSH IRMA
The TSH standards (0-200 mU/1) were supplied in a
bovine serum-based matrix and calibrated against the 68/38
IRP and the 80/558 IRP. Standards and samples (100 ;al)
were pipetted manually in duplicate into assay tubes with
fresh pipette tips to avoid carry-over problems. A
repeat-dispenser (Hamilton) was used to add the
125i-anti-TSH (100 ,ul) and, after mixing, the tubes were
incubated at room temperature for 2 h. Anti-TSH, cova-
lently coupled to Sephacryl particles in suspension (100
jul), was then dispensed to all tubes and the incubates
shaken on an orbital agitator at 300-350 rpm for 1 h at
room temperature. Tubes were allowed to stand for 5 min
after the addition of pre-wash buffer (1 ml) and then the
"Sucrosep" reagent was layered beneath the incubates using
the manufacturer's 20-probe sucroseparator. As described
by Wright and Hunter (1983), excess radiolabel was washed
from the solid-phase by gravity sedimentation through 10%
sucrose (15 min) followed by aspiration to waste of the
sucrose layer containing the unbound 125j_antibody (Figure
4.13). This sucrose separation was repeated once to
achieve the required low (<0.1%) NSB values. The bound
radiolabel was then counted in the Wallac gamma counter


















Figure 4.13 The Sucrose Layering Technique for the
^ ~
Separation of Free and Bound Fractions
of Particulate Solid-phase Immunoassays.
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peak of the iodine spectrum. The Edinburgh Immunoassay
package was used for curve-fitting and data interpolation.
In this thesis, half of the assays by this method
were performed by staff of the Immunoassay Section of this
department (principally Chapter 4) and half by myself.
4.5.2 The Amerwell TSH IRMA
Each Amerwell TSH Kit contains a microtitre plate
consisting of 8 x 12 microwell strips coated with
anti-TSH, 8 human serum standards calibrated against the
2nd IRP (80/538) and soluble 125j_anti-TSH. Radiolabel
(50 ;il) was dispensed to each well followed by standards,
samples and controls (200 jul; Finn pipette) in duplicate
(20 min). The plates were incubated for 2 h at room tem¬
perature on an Amerwell shaker and then washed four times
with borate buffer (supplied by the manufacturer) using
the Amerwell 12-pronged washer/aspirator (Figure 4.14).
The individual wells were counted in the NE1600 multiwell
gamma counter for 120 s. Care was taken to ensure that
background counts in each counter-well and counting
cassettes were always <1 per second. Curve-plotting and
data interpolation were performed using the WHO immu¬
noassay package (single binding-site model). The lowest
three standards and corresponding 125i count rates were
re-plotted on linear-linear graph paper if there was evi¬
dence of misfitting of the low (0.2 raU/1) standard for
interpolation of low TSH concentrations. In general,
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Figure 4 .14 Equipment Used in the Amerwell TSH IRMA.
(a) Microtitre plate with numbered wells.
(b) Amerwell orbital shaker.
(c) Amerwell washer/aspirator.
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there was good agreement between the data interpolation
and precision profiles generated by the Edinburgh (x) and
WHO (y) immunoassay packages provided the 0.2 mU/1 stan¬
dard was correctly fitted by the latter (y = 1.02x-0.06,
n = 51 from 3 assays; TSH range 0.14-35 mU/1).
4.5.3 Comparison of IRMA and RIA Protocols for TSH
The requirement to reduce misclassification
errors and the NSB is important for immunometric assays if
their sensitivity potential is to be achieved (Jackson et_
al. , 1983); with RIA, the antibody affinity is the main
determinant of assay sensitivity. Wash procedures,
therefore, form a more prominent part of the IRMA compared
to the RIA. The main differences in the manipulations
and the total assay time of the two IRMA methods described
here arise because of the different solid supports of the
capture antibody and the wash steps adopted to reduce the
NSB values (Table 4.8). The washing of microtitre plates
was more convenient, rapid and could be readily automated
in contrast to the more time-consuming and less robust
sucrose separation.
Since the irma methods use excess reagents, the
reaction kinetics are favourable for the assay to be
completed in a relatively short incubation time. The in-
house assay, by comparison, requires a prolonged incuba¬
tion (48 h) with delayed tracer addition in order to
achieve good sensitivity (Section 2.2.4). The protocol
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demonstrates however, that same-day results can be pro¬
duced by RIA. This RIA employed delayed tracer addition
and PEG-accelerated double antibody precipitation, the
procedure being identical to that previously described for
the SimulTRAC RIA (Figure 4.10) but with use of the NE1600
multiwell gamma counter for counting the label.
4.5.4 Assay Sensitivity and the Working Range
For each TSH method the assay sensitivity was
calculated as the TSH concentration giving a signal 2.5SD
from the mean of 20 replicates of the zero standard
(Table 4.8). Using this definition of sensitivity
(Rodbard, 1978), a nine-fold and three-fold increase in
sensitivity were achieved with the IRMA methods compared
to the in-house and the Becton Dickinson RIA methods,
respectively. These values were comparable to the detec¬
tion limit calculated for each method from the mean
within-assay precision profiles of patient samples ana¬
lysed in duplicate (Figure 4.15) which showed that the
IRMA methods had three to four-fold lower detection limits
compared to RIA (Table 4.8). This raised the possibility
of distinguishing low from normal TSH concentrations in
serum. The IRMA methods also had better within-assay
precision and much wider working ranges (CV <10%) compared
to RIA which permitted the analysis of samples containing
high levels of TSH without prior dilution.
- 175 -
TSH (ml)/1)
Figure 4.15 Within-assay Precision Profiles (Mean±SD,
n=l2) for TSH Methods.
In-house RIA (o o),
Becton Dickinson RIA (x x),
Boots-Celltech IRMA (• • ),
Amerwell IRMA (A A).
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4.5.5 The Between-assay Precision of the IRMA Methods
Data for the between-assay precision from at
least 10 assays is given in Table 4.9. In-house pools
and control sera supplied by the manufacturers were used
in the evaluation. Data for the in-house RIA are shown
in Table 2.3. A low pool (pool a) was prepared from the
serum of patients with TSH levels <0.9 mU/1 by RIA to
assess the precision of the Amerwell IRMA at the lower
reference limit. Bias values were calculated from
in-house RIA targets for the pools or the manufacturers'
quoted values. The Amerwell IRMA appeared to be more
precise at low TSH values than the Boots-Celltech assay
but produced a marked negative bias with respect to the
target values for in-house pools.
Table 4.9 Between-assay Precision of the TSH Methods
Boots-Celltech IRMA Amerwell IRMA
Mean Bias + SD CV Mean Bias"1" SD CV
(mU/1) (%) (mU/1) (%) (mU/1) (%) (mU/1) (%)
In -house pools In-house pools
a _ _ _ _ 0.3 _ 0.03 11.1
1* 2.0 -13 0.25 12.6 1.7 -26 0.09 5.5
2 8.7 + 16 0.56 6.4 5.7 -24 0.26 4.6
3 21. 1 -10 1.15 5.5 — - - -
4 47.3 + 4 3.29 7.0 30.7 -32 3.29 10.7
Boots-Celltech Controls Amerwell Controls
1 0.3 -17 0.05 14.2 1.3 0 0.06 4.7
2 2.2 + 4 0.09 4.0 3.9 - 5 0.16 4.1
3 5.8 - 1 0.23 4.0 19.9 - 5 1.16 6.0
4 17.8 - 5 0.89 5.0
5 46.4 - 4 2.29 4.9
+See text.
*New in-house pool compared with Table 2.3
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In both IRMA methods a slight downwards drift in
values (Boots-Celltech -6.5%; Amerwell -4.0%) was observed
for samples analysed at the beginning and the end of an
assay. This was not found to be of any major signifi¬
cance in patient categorisation.
4.5.6 Correlations Between TSH Methods
Since the results from patients in the study were
not normally distributed, regression analysis was per¬
formed (a) after logarithmic transformation and (b) for
TSH values less than 8 mU/1 only. After logarithmic
transformation, all of the methods correlated well with
the in-house RIA (r >0.96; n = 80). There was also a good
correlation between the two TSH IRMA methods (Figure
4.16A). However, this transformation obscured the true
relationship between TSH values by different methods
(Figure 4.16B and Table 4.10).
Table 4.10 Correlation of TSH Values <8 mU/1
(y = mx + c )
y X r m(SE) c (SE)
IRMA (BC) RIA (I) 0.905 1 .08(0.07) -0.38*(0.16)
IRMA (AM) RIA (I) 0.877 0.62*(0.07) 0.15 (0.17)
RIA (BD) RIA (I) 0.922 0.99 (0.05) 0.54*(0.14)
IRMA (AM) IRMA (BC) 0.892 0.60*(0.04) 0.34*(0.10)
BC =Boots-Celltech ; I = In-house; AM=Amerwell; BD= Becton
Dickinson. Significant differences from y = x.
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Boots- Celltech TSH(mU/I)
Boots-Celltech T s H (mU/l)
Figure 4.16 Correlations of TSH Values by Two IRMA Methods
(A) Logarithmic transformation of all data
points and (B) linear regression for TSH
values <8 mU/l.
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Although there was good agreement between values
measured by the Boots-Celltech IRMA and the RIA methods,
values by the Amerwell IRMA were approximately 40% lower.
This discrepancy was not entirely due to poor analytical
recovery of the Amerwell method since, the mean recovery of
TSH when 0.5-20 mU/1 of IRP 80/558 was added to three
euthyroid serum pools was 94% (range 84-101, n=13) and when
0.5-1.5 mU/1 IRP was added to Tj-suppressed serum, 100% and
85% TSH was recovered, respectively. There was also no
evidence of nonlinearity for two-fold and four-fold dilu¬
tions of patients' sera, using sera collected from thyro¬
toxic patients as diluent.
4.5.7 Categorisation of Patients using TSH IRMA
The TSH results by IRMA are illustrated in Figures
4.17 and 4.18 for the 200 consecutive patients. The abso¬
lute ranges of values for the 63 euthyroid patients were
0.20-5.9 raU/1 (Boots-Celltech) and 0.36-4.5 mU/1 (Amerwell);
these were used as reference ranges in this section.
All hypothyroid patients (overt and subclinical)
had raised basal TSH concentrations by both assays. None
of the overt hyperthyroid patients had TSH detectable in
serum by either method. In the 15 patients with subclini¬
cal hyperthyroidism all but one had undetectable TSH by
Boots-Celltech IRMA, whereas by Amerwell assay, TSH was
detectable but low in 5 patients, 4 of whom had multinodu¬
lar goitres. Results for the TRH stimulation tests in
these patients are shown in Table 4.11 (Patients 1-4).
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Figure U.17 Values for Boots-Celltech TSH IRMA in 200
Patients from a Thyroid Clinic.















Figure 4.18 Values for Amerwell TSH IRMA in 200
Patients from a Thyroid Clinic.
The mean minimum detection limit is indicated
(-•-).
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Table 4.11 Basal TSH and the Response After TRH in Five
Patients with Subclinical Hyperthyroidism
TSH (mU/1)
Boots-Celltech Amerwell In-house
Patient IRMA IRMA RIA
0 min 20 min 0 min 20 min 0 min 20 min
1 <0.13 1.30 0.35 ND <1.0 1.2
2 <0.10 1.30 0.22 ND <0.9 1.8
3 <0.15 0.26 0.17 ND <1.1 <1.1
4 <0.10 0.58 0.12 ND <0.7 1.0
5 0.14 1.5 0.21 ND 1.0 1.9
ND = Not determined.
By Boots-Celltech IRMA and the in-house RIA, TSH was
undetectable in the basal sample. An increase in TSH
greater than 1.0 mU/1 after TRH was measured in sera from
patients 1 and 2 using the Boots-Celltech IRMA and a
smaller but discernible rise was measured in sera from
patients 3 and 4 who had the lower basal Amerwell TSH
concentrations. These results are consistent with
incomplete suppression of thyrotroph function. One
patient (Patient 5) had a low but detectable TSH con¬
centration by both IRMA methods. She was clinically
euthyroid, had normal serum total T^ and T3 and a margi¬
nally subnormal response to TRH as measured by RIA but
which was greater than 1.0 mU/1 by IRMA. She presented
with a solitary thyroid nodule which regressed spon¬
taneously after three months, suggesting a diagnosis of
haemorrhage into a cyst.
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The fact that TSH concentrations were undetec¬
table by Boots-Celltech IRMA but detected in the Amerwell
IRMA in four patients with subclinical hyperthyroidism,
may be a feature of the particular monoclonal antibody
combination used or different matrix effects in the two
kits. Wiersinga et_ al. (1986) have also found some
patients with subclinical hyperthyroidism who have little
response to TRH but a low basal TSH level detected by
immunofluororaetric assay. It is clear, however, from the
results in this study that TSH IRMA distinguished effec¬
tively euthyroid from hyperthyroid patients. This was
clearly not the case for TSH measured by RIA (Figure 4.19)
where some euthyroid patients (4/63) had values less than
the reporting limits (working range) of the RIA and some
hyperthyroid patients (9/103 overt; 3/15 subclinical) had
values >0.9 mU/1. In contrast to IRMA, measurements of
TSH by this RIA could not therefore be used to predict the
result of a TRH test.
4.6 AN EXTENDED CLINICAL STUDY FOR THE ASSESSMENT
AND COMPARISON OF THYROID FUNCTION TESTS
Measurements of free thyroid hormones and TSH
IRMA were performed in the complete series of 285 patients
(Table 4.2) using Amerlex fTjj and fTg kits and the
Boots-Celltech Sucrosep IRMA.
4.6.1 Basal TSH IRMA Concentrations
The concentrations of TSH in the 97 patients cate¬
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Figure 4.19 Basal TSH by In-house RIA in 200 Patients
from a Thyroid Clinic.
The lower reporting limit is indicated (- - -)
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ranged from 0.14 to 5.9 mU/1 (mean 1.9 mU/1), Figure 4.20.
This absolute range provided a good separation of euthyroid
patients from those with thyroid disease (overt and
subclinical) and was, therefore, used as the reference
interval in all further studies.
All but one patient with an absent TSH response to
TRH by RIA had an undetectable basal TSH by IRMA. This
patient whose TRH test was marginally abnormal appeared to
have had a transient episode of subclinical hyperthyroidism
with a palpable thyroid nodule which subsequently
regressed, as discussed previously (Section 4.5.7).
4.6.2 Free Ta Compared with Total T^ Concentrations
The Amerlex fT4 results are shown in Figure 4.21
and compared with total T4 values. The reference limits
shown for total T4 were those used in the patient cate¬
gorisation whereas those for fTij (10.0-22.5 pmol/1) repre¬
sent the mean±2SD for this euthyroid group, excluding the
one patient with abnormal albumin binding.
In patients with overt hyperthyroidism, fTjj
concentrations were more markedly elevated than total T4:
95% of hyperthyroid patients had fTzj. values greater than 4
SD above the mean euthyroid value compared to only 57% for
total T4. Free T4 concentrations were raised in 9 of the
11 patients with T^-thyrotoxicosis. In those with subcli¬
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Figure 4.20 Boots-Celltech TSH IRMA Values in Serum
from 285 Patients from a Thyroid Clinic.
Reference limits ( - - - )



















































Figure 4.21 Total and Free T4 Concentrations in Serum
from 285 Patients from a Thyroid Clinic.
Results for women taking the OCP (x), a
pregnant patient (A ), and a patient with
abnormal binding to albumin (+) are
indicated.
Reference ranges (- - -).
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fTzj and not total Ti\ there would have been a reclassifica¬
tion to overt hyperthyroidism in 9 of the 16 patients.
Most euthyroid patients with raised total T4 due
to altered protein binding (5/7) had normal fTjj results.
As with total T4, fwas low in all 9 patients
with overt hypothyroidism. Free T4 was also low in 2 of
the 16 patients considered to have subclinical hypo¬
thyroidism .
4.6.3 Free T3 Compared with Total T3 Concentrations
Free T3 concentrations showed a greater rise than
total T3 in patients with hyperthyroidism being greater
than 4 SD above the mean euthyroid value in 90% compared
with 72% for total T3 (Figure 4.22). The reference
limits shown for total T3 were those used to define
patient categories whereas those for fT3 (4.0-7.8 pmol/1)
were derived from the 97 euthyroid patient results in this
series. All but 4 of the 147 patients with overt
hyperthyroidism had raised f?3 levels but total T3
concentrations were normal in 15, usually associated
with drug treatment (e.g. propranolol) or non-thyroidal
illness .
All euthyroid patients with raised total T3 due
to altered protein binding had normal fT3 results.
In the 9 patients with overt hypothyroidism the
fT^ concentration was normal in two and total T3 was nor¬
mal in five. Free concentrations were normal in all














































Figure H.22 Total and Free T3 Concentrations in Serum
from 285 Patients from a Thyroid Clinic.
Results for women taking the OCP (x), a
pregnant patient ( A ) and one with abnormal
binding to albumin (+) are indicated.
Reference ranges ( ).
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4.6.4 The Predictive Value of the Thyroid Function
Tests
Using the TRH test result only for patient cate¬
gorisation (i.e. combining the overt and subclinical forms
of disease as a single entity), the predictive values (PV)
for TSH IRMA and thyroid hormone results were calculated
(Table 4.12).
Table 4.12 The Predictive Values of Thyroid Function
Tests in Patients from a Thyroid Clinic




































The PV of an abnormal result was calculated as the proba-
bility that the result indicates the presence of disease
i.e.:-
PV = No. of abnormal tests in disease
Total No. of abnormal results
Conversely, the PV of a normal result excluding the pre¬
sence of disease was calculated as:-
No. of normal results in the euthyroid patients
Total No. of normal results
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Cut-off points for calculating PVs are chosen to
minimise overlap between patient categories and are
usually estimated from a separate non-diseased population
prior to the evaluation of the test (Galen & Gambino,
1975). The reference limits for total T4 and by the
routine diagnostic clinical chemistry service (Section
2.2.1) were therefore used for this purpose. Since there
was minimal overlap between euthyroid and diseased groups
for basal TSH IRMA, the absolute range found in the 97
euthyroid patients was used to define the cut-off points
for this assay. There were no locally-derived reference
values available for fT4 and fTg in a separate population
and the manufacturer's suggested reference ranges
(fT4 8.8-23.0; fT3 2.9-8.9 pmol/1) did not minimise the
overlap between diagnostic groups. The reference limits
(mean±2SD) shown for the euthyroid group (Figures 4.21,
4.22), were therefore used to calculate PVs for the free
hormone assays.
A result for TSH had the highest PV for both the
presence and absence of all degrees of thyroid dysfunc¬
tion. This test was significantly better than measurement
of thyroid hormones for excluding thyroid disease thereby
making it the most suitable first-line test in these
patients. A normal, detectable TSH concentration would
have the same significance as a normal TSH response to TRH
in the exclusion of hyperthyroidism and primary
hypothyroidism.
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High results for fT^ and fT4 had similar PVs and
both were raised by a similar proportion in hyperthyroid
patients. However, as seen with total thyroid hormone
measurements, a low fT4 result had a higher PV for hypo¬
thyroidism than fTg. Measurements of free thyroid hor¬
mones had higher PVs than total thyroid hormone measure¬
ments .
The PV of an individual result indicating the
presence or absence of disease is dependent on the preva¬
lence of disease in the population studied (Vecchio, 1966;
Galen & Gambino, 1975). The calculated PVs shown in Table
4.12 therefore apply only to thyroid clinics referred a
similar patient population to this study. In clinics
with a lower prevalence of thyroid disease, the PV of a
positive result would be lower. In addition, the sen¬
sitivity and specificity of each test shown in Table 4.13
might also change in a different patient population e.g.
in hospital in-patients where changes in binding proteins,
drug therapy etc., may affect the number of false positive
and false negative results obtained. Thus, TSH IRMA may
not necessarily provide the best first-line test in dif¬
ferent clinical settings.
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Table 4.13 The Sensitivity and Specificity of Thyroid
Function Tests in Patients from a Thyroid
Clinic
Subclinical Euthyroidism Subclinical
& Overt & Overt
Test Hyperthyroidism Hypothyroidism
Sensitivity Specificity Sensitivity
TSH IRMA 99% 100% 100%
ftij 94% 94% 44%
ft3 89% 95% 32%
Total T4 84% 91% 36%
Total T3 81% 90% 16%
Sensitivity = TP x 100 TP = true positives
TP+FN FN = false negatives
TN = true negatives
Specificity = TN x 100 FP = false positives
TN+FP
4.7 SUMMARY AND DISCUSSION
In assessing the laboratory performance of the
one-step analogue assays for free thyroid hormones, a
range of imprecision and analytical inaccuracy was
demonstrated (this suggests that a greater heteroge¬
neity of performance would be expected with methods based
on alternative principles). However, in a population
with a high prevalence of thyroid disease, results by all
of the analogue fT4 kits correlated well with equilibrium
dialysis and had similar diagnostic accuracy in samples
from patients.
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All of the fTg kits except Coat A Count produced similar
patient categorisation. The measurement of free rather
than total thyroid hormones had two major advantages: (a)
results were less affected by alterations in TBG, (b)
results had a higher PV for the presence and absence of
thyroid disease. However, there was little evidence to
support a major role for fT3 measurement in addition to
fTjj. in this patient group. These conclusions are sup¬
ported by other studies of similar patients (Symons et
al. , 1983; Franklyn et_ al. , 1984) and two recent reviews
(Wilke 1986; Pearce & Byfield, 1986).
The coupling of analogue fT4 measurement with the
more sensitive measure of hypothyroidism, TSH (Irvine £t
al. , 1973), could provide an attractive thyroid function
'test' for both clinician and laboratory. Indeed the use
of the SimulTRAC fTjj/TSH assay could produce a large
reduction (approximately 2/3) in the number of analyses
performed in this context. In the evaluation of this
assay,there were no patients with T3~thyrotoxicosis but
since the majority of such patients tend also to have
increased fT^, it is unlikely that they would be
misclassified. The use of this dual RIA, could restrict
the number of TRH tests performed in the thyroid clinic to
the minority of patients who have normal fT4 but low TSH
results, in order to distinguish euthyroid patients from
those with subclinical hyperthyroidism.
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The two IRMA methods evaluated for TSH had
acceptable precision with advantages to the laboratory
arising from the wider working range compared to RIA.
The Amerwell IRMA was particularly suitable for handling
large workloads, a necessary pre-requisite for a first-
line test. Lower TSH results by IRMA compared to RIA
would be expected in view of the higher specificity of
sandwich assays. However, the reason for the discrepancy
between Amerwell and Boots-Celltech TSH values is less
clear. Measurement of TSH by immunofluorimetric assay
has also yielded lower results (28%) than the
Boots-Celltech IRMA (Paterson et_ al., 1985) leading to the
suggestion that different monoclonal antibodies may have
different relative specificities for endogenous and stan¬
dard TSH. The lower Amerwell reference range is also more
in keeping with those quoted for other new immunometric
assays (Weeks £t al., 1984; Kaihola et_ al., 1985; Clark &
Price, 1986) and research methods (Durham, 1985) -
The availability of TSH immunometric assays with
increased sensitivity and specificity compared to RIA has
raised the possibility that basal TSH could be used as a
first-line test of thyroid status making the TRH test
redundant. The absence of a TSH response to TRH is the
most sensitive indicator of thyroid hormone excess (Snyder
& Utiger, 1972a) and, therefore, the demonstration of the
- 196 -
resolution of 'nyperthyroid and euthyroid basal con¬
centrations of TSH IRMA and the strong relationship bet¬
ween the basal TSH IRMA and the TSH response to TRH in
euthyroid patients (Figure 4.23a), even for basal values
undetectable by RIA (Figure 4.23b), provides evidence that
basal TSH IRMA gives a reliable indicator of thyrotroph
activity throughout the entire spectrum of thyroid
disease.
Although an absent TSH response to TRH is con¬
sistent with hyperthyroidism, this may also be found in
other clinical situations as discussed earlier (Section
1.3.4). It is likely, therefore, that basal TSH (IRMA)
might be abnormal in other circumstances. The perfor¬
mance of basal TSH by IRMA and free thyroid hormone tests
by analogue RIA in other clinical situations, and the
development of a new thyroid testing strategy applicable
to the thyroid clinic (for diagnosis and monitoring
therapy) and for screening pregnant women, hospital in¬
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Figure 4.23 The Relationship Between TSH Responsiveness
to TRH and Basal TSH Measured by Boots-
Celltech IRMA.
(A) The euthyroid reference group




THYROID FUNCTION TESTS IN PREGNANCY AND IN OTHER
SITUATIONS OF ALTERED PROTEIN-BINDING OF THYROID HORMONES
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5.1 THYROID FUNCTION TESTS IN PREGNANCY
The diagnosis of hyperthyroidism in a pregnant
woman based purely on clinical examination may be dif¬
ficult because increased heart rate, heat intolerance and
tiredness are common features of both hyperthyroidism and
pregnancy. Biochemical tests of thyroid status may be of
considerable value for effective diagnosis particularly
since appropriate therapy is important for the health of
the mother and the development of the foetus (Woods et_
al. , 1984). An understanding of the normal function and
control mechanisms operating on the thyroid during
pregnancy is necessary for the correct interpretation of
biochemical tests.
Measurement of free rather than total thyroid
hormone concentrations should accurately reflect thyroid
status in pregnancy. However, it is known that FT4I
values remain unchanged fortuitously, since the T3~uptake
methods fail as TBG rises to high levels (Whitworth et_
al. , 1982). Early studies using indirect dialysis
methods have reported unchanged, increased and decreased
values (Ekins, 1979); direct dialysis has yielded
unchanged (Symons, 1983) and decreased values (Yeo et al.,
1977b; Lewis, 1979; Weeke et al., 1982; Giles, 1982 ;
Helenius & Liewendahl, 1983) and measurements by analogue
RIA have shown decreased concentrations as pregnancy
progresses (Whitworth et_ al., 1982; Tuttlebee, 1982;
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Symons et_ al., 1983; Hopton et_ al., 1983 ; Wilke, 1983 ;
Franklyn e_t al., 1983). Measurements using microencap¬
sulated antibodies, by contrast, show little or no change
with gestation (Boss & Kingstone, 1981; Amino _et al.,
1983). Since recent studies have shown that measurement
of free thyroid hormones may be spuriously affected by
changes in serum albumin and NEFA levels (Bayer 1983a & b;
Amino et_ al., 1982 & 1983 ; Stockigt et_ al., 19 8 3) both of
which are known to change with gestation (Amino et_ al. ,
1983; Burt, 1960), the true free thyroid hormone con¬
centrations circulating in late pregnancy are still
debated.
In pregnancy, the TRH test is contra-indicated
since it may produce undesirable reactions in a small
number of patients (Editorial, 1984). In addition, some
RIA methods for TSH show significant cross-reactivity of
the antisera to high circulating levels of HCG. The
measurement of TSH by sensitive IRMA may circumvent the
problems of assay specficity and allow the differentiation
of hyperthyroidism from euthyroidism in pregnancy without
TRH injection.
5.1.1 Subjects Studied
Ninety-three women in the first (7-12 wk, n=37),
second (13-27 wk, n = 32) and third (28-40 wk, n=24) tri¬
mesters of pregnancy were studied. Serum samples were
taken at their afternoon visit to the antenatal clinic.
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5.1.2 Concentrations of Total Thyroid Hormones,
TBG and Albumin in Serum
Total T4, total T3 and TBG concentrations
increased by 8?, 15? and 41?, respectively as pregnancy
progressed (Figure 5.1 and Table 5.1) whereas the T4/TBG
ratio decreased. Albumin concentrations decreased by
16? (i.e. an average of 7 g/1) between the first and third
trimesters.
5.1.3 Free Thyroid Hormone Concentrations by
Analogue RIA and Equilibrium Dialysis
There was a significant decrease in the con¬
centration of both fT4 and fT3 during pregnancy although
there was a marked difference in the magnitude of this
fall when measured by analogue RIA as compared to dialysis
(Figures 5.2 and 5.3). In addition, analogue RIA methods
produced by different manufacturers showed differing
degrees of change as pregnancy progressed (Table 5.1).
This was particularly evident for fT3 where low results
were found in 1? and 35? of women using the Coat A Count
and Becton Dickinson kits, respectively. Although no
women had fT4 or fT3 values below reference limits by
dialysis-RIA, several low values were found by
analogue-RIA depending on the kit (Table 5.1).
The correlations obtained between fT4 levels
measured by dialysis and analogue-RIA in the 93 pregnant
women were, in general, less significant than those in 62
non-pregnant euthyroid outpatients (Table 5.2), in view of
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Figure 5.1 Total Tt|, T3, TBG and Albumin Concentrations
(Mean ± 2SD) in Pregnancy.
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Figure 5.2 Free T4 Concentrations in the Three
Trimesters of Pregnancy.
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Figure 5.3 Free Concentrations in the Three
Trimesters of Pregnancy.
Reference ranges are indicated by dashed
lines.
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the smaller group in the latter. This was not the case
with fTg measurements where there was poorer correlation
between the analogue methods and dialysis in both groups
over the narrow concentration range studied (Table 5.2).
The Becton Dickinson fT3 kit gave the poorest correlation
with dialysis values in pregnancy.
Table 5.2 Correlations Between Free Thyroid Hormome
Measurements by Dialysis and Analogue RIA
in Pregnant and Non-pregnant Outpatients


































a) p<onroi, b) P<o.oi
5.1.4 Correlations Between Free Thyroid Hormone
Concentrations and Serum Albumin and NEfA Levels
Concentrations of albumin in serum decreased by
16? during pregnancy but NEFA levels did not change
significantly (Table 5.1). In contrast to serum albumin,
none of the free thyroid hormone measurements correlated
with NEFA levels in these non-fasting subjects. However,
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comparison of fT4 or fT3 with any other serum constituent
which also falls during pregnancy is likely to produce a
good correlation. Of more interest was the strong posi¬
tive correlation (p<0.001) observed between albumin and
free thyroid hormones in the shorter time-period of the
second trimester with the analogue kits, but not with
equilibrium dialysis (Table 5.3)• Highly significant
correlations (p<0.001) with albumin were also observed in
non-pregnant euthyroid out-patients for f?3 measured by the
Amerlex-M and Becton Dickinson kits. There was no corre¬
lation between fTty and albumin in these patients.
However, the range of albumin concentrations in this group
(43-53 g/1) was less than in the second trimester of
pregnancy (36-50 g/1).
Table 5.3 Correlation Between Free Thyroid Hormone and
Serum Albumin Concentrations in Pregnant and
Non-pregnant Subjects
Correlation with albumin (r)
Non-pregnant
Method Trimester of Pregnancy Euthyroid
Out-patients
I II III
n 37 32 24 63
Free Tzj
Dialysis-RIA -0.045 0.320 0.147 -0.146
Amerlex 0.018 0.575a 0.110 0.144
Amerlex-M 0.267 0.613a -0.040 -0.010
Corning Magic 0.192 0.608a -0.023 0.053
Becton Dickinson 0.156 0.572a -0.196 " 0.126
Coat A Count 0.305 0.723a 0.111 0.068
Free T3
Dialysis-RIA -0.199 0.178 -0.504 0.324
Amerlex 0.405 0.663a 0.325 0.295
Amerlex-M 0.270 0.649a 0.365 0.470a
Becton Dickinson 0.587a 0.481b 0.235 0.506a
Coat A Count 0.249 0.344 0.284 0.181
Significant correlations a) p<u.uu I, U p<U.U I
- 208 -
5.1.5 The In vitro Effect of Added Albumin on
Free Thyroid Hormone Values in Serum
The effect of albumin on free thyroid hormone
levels measured by dialysis-RIA and by the Amerlex kits
was examined by adding 3-19 g/1 human serum albumin
(Behring, Marburg, West Germany of 100% electrophoretic
purity) in 0.15 mM NaCl to aliquots of a low-albumin
pool of serum collected from hospital inpatients, to give
a final albumin concentration range of 30 - 50 g/1.
Insufficient reagents were available to repeat the experi¬
ment with the other free hormone kits.
Free thyroid hormone levels did not change signi¬
ficantly when measured by dialysis-RIA whereas linear,
dose-dependent increases in fT4 and fT3 were observed
using the Amerlex analogue methods (Figure 5.4). The
mean decrease in albumin of 7 g/1 which occurred during
pregnancy could, therefore, account for a decrease of 1.8
pmol/1 (11%) in fT4 concentration and 0.75 pmol/1 (13%) in
fTg concentration by Amerlex assay, as pregnancy pro¬
gressed. Despite the inclusion of an "albumin blocker"
in the Amerlex-M fT^ kit by the manufacturer, results were
affected by added albumin in a similar way to the Amerlex
kit. When the changes in free hormone levels in pregnant
women (Table 5.1) were corrected for this albumin effect,
the percentage changes observed in fT4 during pregnancy




Figure 5.ty The Effect of Added Human Serum Albumin on
Free Thyroid Hormone Concentrations in a
Human Serum Pool Using Dialysis and Analogue
RIA Methods.
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those measured by dialysis-RIA. However, there was still
marked disparity in fT3 levels between the analogue and
dialysis methods (Table 5.4).
Table 5.4 The Change in Free Thyroid Hormone Levels
by Analogue RIA after Correction for the"
Calculated Albumin Effect
Mean Change Between
Trimesters I - III
Analogue RIA








5.1.6 Basal TSH Measurements in Pregnancy
Results for SimulTRAC free T4/TSH RIA measure¬
ments in pregnancy are shown in Figure 5.5(A), demonstra¬
ting normal TSH concentrations in the presence of low
fTzj results by analogue RIA in the third trimester. With
this dual assay, therefore, interpretative problems with
respect to low fT4 values in pregnancy would be reduced.
However, SimulTRAC TSH values in these pregnant women were
signficantly higher (p<0.001; mean 4.0 mU/1, range 1.7 -
6.3) than those found in non-pregnant euthyroid out¬
patients (Figure 4.12) suggesting some residual cross-
reactivity problems due to high HCG levels in pregnancy.
This problem, coupled with the marked lowering of
fT4 values by analogue assay in pregnancy, could poten¬


























SimulTRAC Free T14/TSH RIA Results in
Pregnancy.
Reference ranges are indicated by dashed
lines.
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Figure 5.5(B) Basal TSH Concentrations by RIA and IRMA
in Pregnancy.
The upper reference limit ( ) and the
mean minimum detection limit for each
assay (—•—) are as indicated.
- 212 -
Results for basal TSH by single-analyte RIA and
the Boots-Celltech IRMA are shown in Figure 5.5(B). The
TSH IRMA results were lower than results by RIA in all
trimesters, and 3 values fell below the mean detection
limit, in early pregnancy (Table 5.5). There was a
significant increase in mean TSH IRMA values between the
first and third trimesters, the Becton Dickinson kit
showed no change, and values by the in-house assay
significantly decreased between the first and second tri¬
mesters (Table 5.1). The fact that no TSH results were
undetectable by RIA suggests a specificity problem with
these assays. Measurement of TSH in sera from 20 women
in the first trimester using the Amerwell IRMA produced
similar results to non-pregnant euthyroid values but three
women had low-detectable values at less than 13 weeks
gestation (Table 5.5).
5.1.7 Concentrations of HCG and TSH in Pregnancy
Measurements of HCG by RIA (Vaitukaitis et_ al. ,
1972) were performed by staff of the Centre for
Reproductive Biology, Edinburgh. This method employed an
antiserum directed against the y3 subunit of HCG, the
2nd HCG IRP for standardisation and a double-antibody
separation system.
Concentrations of HCG peaked in the first tri¬
mester of pregnancy (Figure 5.6(A)) with a subsidiary rise
in the third trimester. A low-order inverse correlation
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Figure 5.6 The Concentrations of HCG during Pregancy (A)
and the Relationship with TSH Concentrations
Measured by Boots-Celltech IRMA (B).
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(p<0.05) was observed between Boots-Celltech TSH IRMA
values and HCG in pregnancy, Figure 5.6b. However,
patients with undetectable TSH IRMA (Table 5.5) did not
have the highest HCG concentrations.
5.1.8 Summary and Discussion
Abnormal results for thyroid function tests were
found frequently in normal pregnancy. Measurements of
free rather than total thyroid hormones were of greater
value but often produced low results in the hypothyroid
range by analogue assay. The decrease in free thyroid
hormone concentrations as pregnancy progressed was
exaggerated by analogue RIA compared to equilibrium dialy¬
sis, in agreement with the study of Helenius & Liewendahl
(1983) but in contrast to that of Jackson & Ekins (1986),
who studied fewer patients. This decrease was also
greater than that of the TipTBG ratio, unlike a previous
report (Whitworth et_ al. , 1982) and, therefore, did not
support the accuracy of the analogue methods in pregnancy.
The difference between fTi| values in pregnancy by
the alternative methodologies could not be attributed to
raised NEFA concentrations in late pregnancy in this
study. The increase in NEFA reported by Burt (1960) was
0.4 mmol/1 above the mean of non-pregnant controls. It
is unlikely that such a small rise would be discernible in
the present study as non-fasting samples were taken.
Wilkins & Midgley ( 1982) also argued against high NEFA
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levels in pregnancy causing spuriously low values by ana¬
logue RIA and the recent work of Mendel et_ al. ( 1986) has
shown that increases in NEFA greater than 2 mmol/1 are
necessary for fT4 results by equilibrium dialysis to be
significantly affected.
A strong correlation between albumin and
fT/j concentrations was observed in the second trimester
using the analogue kits, but not with equilibrium dialy¬
sis. This may reflect the poorer precision of the
dialysis method and cannot be interpreted as an albumin
effect on the kit assays (Wilkins & Midgley 1982; Midgley
& Wilkins, 1983) although other workers have done so
(Amino et_ al., 1983 ; Hata et_ al., 1987). However, the
fact that this correlation was present for certain analo¬
gue assays in euthyroid non-pregnant out-patients supports
the view of Wilke (1984) that some assays may be unduly
influenced by physiological changes in the serum albumin
concentration in pregnancy. The demonstration i_n vitro
of increasing analogue fT4 and fT3 values with increments
of serum albumin within the reference range (36-46 g/1),
also supports this view. Correction of analogue values
for the measured albumin effect produced closer agreement
with the dialysis method, particularly for the change in
fT4 levels in pregnancy. This _in vitro effect has been
shown by others (Amino e_t al. , 1983 ; Bayer, 1983a;
Stockigt et al., 1983; Liewendahl et al., 1984) but
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Wilkins £t al. (1985) reported lower effects on the
Amerlex kits than found here and also suggested that this
effect was minimised by inclusion of the "albumin blocker".
This was not confirmed in the present study for the
Amerlex-M fTzj kit. The fact that results for clinical
samples show less albumin-dependence has led Wilkins et_
al. (1985) to suggest that alterations in the binding pro¬
perties of commercial preparations of albumin may be the
source of this discrepancy, but there is no experimental
evidence, as yet, to support this.
The fact that TSH concentrations were not ele¬
vated above normal in the third trimester confirmed the
adequacy of free thyroid hormone levels as sensed by the
pituitary gland. High HCG levels may cause cross-
reaction problems in TSH RIA and interference in TSH IRMA.
The former problem is well—recognised and often reduced by
prior absorption of the anti-TSH antiserum with LH so that
TSH RIA can be used effectively to detect hypothyroidism
if it occurs in pregnancy, but cannot be used to determine
physiological changes in TSH secretion as pregnancy
progresses. Measurement of TSH by IRMA may be affected
by high HCG levels due to disruption of the monoclonal
antibody sandwich (Figure 5.7) giving rise to spuriously
low levels. Kreutzer et_ al. (1986) confirmed this problem
with the Boots-Celltech IRMA. In pregnancy, this inter¬
















Figure 5.7 The Interference of HCG on TSH Levels
Measured by Boots-Celltech IRMA.
HCG is recognised by the radiolabelled mono¬
clonal antibody. At high HCG concentrations
there is insufficient radiolabelled mono¬
clonal to bind to TSH. Less radiolabel
becomes bound to the solid-phase and this is
interpreted as a low TSH value.
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decrease in TSH values, whereas negligible interference is
quoted for the Amerwell IRMA. The data shown here suggest
a greater lowering of Boots-Celltech TSH values than
accountable by methodological interference alone. However,
the inverse correlation demonstrated between the Boots-
Celltech TSH and HCG values in pregnancy could be due
either to methodological interference in the TSH assay or
a physiological decrease in TSH secretion when HCG levels
were highest. Recently, Newman et_ al. (19 8 5)» using an
in-house TSH IRMA, calculated that the negative inter¬
ference by HCG was not sufficient to account for the low
and undetectable values found in early pregnancy. Low TSH
values were reported in early studies using sensitive RIA
methods (Braunstein & Hershman, 1976; Yamamoto et_ al.,
1979; Weeke £t al., 1982) and, more recently, reduced
responses to TRH in the first few weeks of pregnancy have
also been demonstrated (Guillaume et_ al_. , 1985). An unde¬
tectable TSH (IRMA) level in early pregnancy may therefore
be of limited importance in the diagnosis of hyper¬
thyroidism .
It is known that HCG has some thyrotrophic acti¬
vity (Nisula & Ketelslegers, 1971) and this is affected by
the degree of its glycosylation (Amr et_ al., 1984). In
the first trimester, HCG levels increase and the hormone
is more highly glycosylated (Fein et al., 1980) which has
led to the theory that HCG partially drives the maternal
thyroid gland (Yamamoto et_ al., 1979; Weeke et al., 1982;
Guillaume et al., 1985).
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5.2 THYROID FUNCTION TESTS IN OTHER
ALTERED PROTEIN-BINDING STATES
5.2.1 Alterations in TBG Concentration
In patients with raised TBG concentrations due
to the OCP, free thyroid hormone concentrations by analo¬
gue RIA generally fall within reference limits as
discussed in Chapter 4, and this has been confirmed in
several larger studies (Waud et_ al., 1983 ; Kubasik et al.,
1983; Witherspoon et al., 1985). Such measurements,
therefore, offer a distinct advantage over total thyroid
hormone measurements. However, as shown for the FT4I
(Burr e_t al., 1977), there is some evidence that measure¬
ments by analogue RIA may not perform so well when there
are gross changes in TBG (Waud e_t £1. , 1983 ; Jackson &
Ekins, 1986).
Results for thyroid function tests and TBG in
patients with raised total T4 not due to oestrogens are
shown in Table 5.6 (patients 1-5). The high total
T4 concentrations found on routine screening in patients 1
- 4 raised the possibility of hyperthyroidism, although
these patients were clinically euthyroid. One patient
(patient 5) was diagnosed previously as having autoimmune
hypothyroidism on the basis of TSH measurements, autoan¬
tibody titres and free thyroid hormone concentrations and
is currently being maintained on 100 jug T4 daily. All of
these patients had raised TBG concentrations to a greater
or lesser extent and the majority (4/5) were women.
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Measurements of free thyroid hormones and TSH IRMA con¬
firmed the euthyroid status of these patients.
Results for patients found to have low concentra¬
tion of TBG (patients 6-10) are also detailed in Table
5.6. The majority (4/5) in this case were male, and
euthyroidism was confirmed in patients 6-9 by the measure¬
ment of normal free thyroid hormone and basal TSH con¬
centrations. One patient (patient 10) was suspected
clinically to be hyperthyroid but had a normal total
T4 concentration. The raised fT2| concentration by
analogue-RIA was confirmed by equilibrium dialysis at 50
pmol/1 and the patient had an undetectable TSH IRMA and
absent TSH response to TRH. The finding of the TBG con¬
centration at the lower limit of normal in this patient
may explain the normal total T4 concentration in the pre¬
sence of clinical hyperthyroidism.
The good performance of the Amerlex assays in
such patients confirms the findings of Wilke ( 1982) ,
Ramsden ejt al. ( 1982), Byfield et_ al. ( 1983) and
Franklyn et_ al. ( 1983). Jackson & Ekins ( 1986) however,
found some divergence from dialysis values which varied
between different analogue and non-analogue assays.
5.2.2 Abnormal Thyroid Hormone Binding to Albumin
During the course of this thesis, some patients
were identified who were clinically euthyroid but who had
- 223 -
increased fTz; values by analogue RIA with high or border¬
line-high total T4 concentrations. Thyroid function test
results for these patients are summarised in Table 5.7
(patients 1-5). Measurements of TBG, total T3, TSH IRMA
and dialysis fT4 were normal in these patients, and no
anti-T4 or anti-T3 antibodies were detected by the ammo¬
nium sulphate screening test (Section 2.3.1).
The serum from patient 1 was analysed by several
free thyroid hormone kits (Table 5.8). Free T4 values
ranged from being slightly raised (SimulTRAC) to being
greater than the top standard included with the kit. The
Becton Dickinson fT3 kit stood apart from the other
fT3 kits in giving a markedly elevated result. The inter¬
ference caused by this serum, therefore, varied between
different analogue RIA methods. Similar cases have been
reported by others (Braverman & Ingbar, 1982; De Nayer et_
al., 1984; Jackson & Ekins, 1986).
Table 5.8 Free Thyroid Hormone Concentrations by
Several Analogue RIA Methods in Patient 1
Method Reference Range Result
(pmol/1) (pmol/1)
Free T24:
Amerlex 10 - 22.5 38
Amerlex-M 10 - 21 45
Corning Magic 17 - 30 > 80
Becton Dickinson 8-17 >300
Coat A Count 11 - 23 48
SimulTRAC* 11 - 24 28
Free T^:
Amerlex 4.0 - 7.8 8.3
Amerlex-M 4.2 - 7.8 8.5
Becton Dickinson 5.3 - 10.0 20.0
Coat A Count 3.0 - 6.9 6.8
*SimulTRAC TSH = 3."8 mU/1 (Ref. range: 0.9 - fa. 7)
























































































Serum proteins from patients 1-5 were separated
by electrophoresis after prior incubation with radiola-
belled T4 and T3 to determine the distribution of thyroid
hormone binding (Figure 5.8). There was significantly
higher binding in the albumin zone and lower binding in
the inter-alpha zone compared to normal sera. In this
electro-phoretic system TBG is known to migrate in the
inter-alpha zone (Beckett et_ al. , 1983b). The differen¬
ces were more marked for T4- rather than T3~binding con¬
sistent with the greater distortion of total and free
T4 measurements in serum. Hennemann et_ al. (1982),
Braverman & Ingbar (1982) and Stockigt et_ al. (1982b) have
reported similar findings, and this abnormality is now
known as familial dysalbuminemic hyperthyroxinemia (FDH).
Patients with low TBG also had a shift of binding to albu¬
min (Figure 5.8) but this was more marked, and the binding
to TBG in the inter-alpha zone was substantially
decreased. Serum from hyperthyroid patients showed a
similar distribution of thyroid hormone binding to the
euthyroid patients with FDH (Figure 5.8) and, therefore,
dialysis free hormone measurements and TSH IRMA (or a TRH
test) were necessary to distinguish the two situations.
Patient 6 (Table 5.7) had a normal total T4 level
but grossly elevated total T3 and Amerlex fT3 values.
Concentrations of TSH IRMA and fT3 measured by dialysis
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Zone on Serum Electrophoresis
Figure 5.8 The Distribution of Thyroid Hormone Binding
to Serum Proteins in Normal Sera and in
Altered Protein-binding States.
- 227 -
a similar T^-binding pattern to patients 1-5 above
although there was slightly more binding of T4 in the pre¬
albumin zone (8.1$). The distribution of T^-binding,
however, showed greater differences with 45$ of bound
in the albumin zone and 47$ bound in the inter-alpha zone.
This represents a rare case of FDH since in most cases
only Tj|-binding is significantly affected (Pearce &
Byfield, 1986). The abnormality in FDH appears to be
transmitted as an autosomal dominant trait (Hennemann et
al. , 1982) and there is some evidence that there is an
increase in albumin with a particularly high affinity for
T4, normally present at a much lower concentration (Yabu
et al., 1985).
5.2.3 Abnormal Thyroid Hormone-Binding to
Anti-T4 and Anti-T^ Autoantibodies
Four patients who had total T4 concentrations in
serum which did not agree with the clinical impression
were further investigated (Table 5.9). In patients 1-3
the clinical suspicion of hypothyroidism was confirmed by
the raised TSH levels. Patient 1 had high titres of anti-
microsomal (1:10,000) and anti-thyroglobulin (1:320)
autoantibodies detected in his serum, patient 2 had been
thyrotoxic 30 years previously and patient 3 was thought
to have autoimmune hypothyroidism. Patients 1 and 2 have
shown clinical improvement with T4 replacement therapy.

































































Patient 4 had been commenced on carbimazole on the basis
of the raised total T4 level but this was stopped when
total T4 levels remained persistently raised and there was
no clinical improvement.
All of these patients had normal concentrations
of IgG, IgA and IgM in their serum,and total and fT3
concentrations were either normal or low. Free T4 by
Amerlex RIA was grossly elevated in all but patient 4. A
raised fTij value (>70 pmol/1) was also found for patient 3
by SimulTRAC assay. Free T4 values by dialysis-RIA were
low or borderline-low in those with raised TSH levels.
Sera from all of these patients gave a positive result for
T^-autoantibodies in the screening test and an increased
binding to Ti| in the $ -globulin region on electrophore¬
sis (Table 5.9). This was particularly evident for
patient 1 (Figure 5.8). The affinity and binding capa¬
city of the IgG T2|-autoantibody identified in this
patient's serum was characterised by Archbold jet al.(1986)
as having a Ka of 1.2 x 10^ 1/mol and a concentration of
0.3 pmol/1 giving a binding capacity approximately equiva¬
lent to that of TBG.
The normal Amerlex fT4 result obtained for
patient 4 was supported by the fact that when the Amerlex
125l-Ti| analogue was used in the autoantibody screening
test rather than a reduction in binding to 6%
compared to 3% for control sera was observed. In this
- 230 -
case, the anti-T^ antibodies did not appear to recognise
the analogue used in this fT4 kit, in contrast to the
other 3 patients where interference was much greater in
the analogue fT4 assay compared to the total T4 assay. A
similar case was described by Byfield et_ al. ( 1983) -
Autoantibodies to T3 have also been described which
cause spuriously abnormal results for total T3 and high
fTg results by analogue RIA (Staeheli et_ al., 1975;
Byfield ejt al., 1983 ; Beckett et_ al., 1983b; Rodriguez-
Espinosa et_ al., 1984). Abnormal antibody—binding is
commonly reported in patients with autoimmune thyroid
disorders (Beck-Peccoz et_ al. , 1982) and it is suggested
that thyroglobulin may act as the immunogen (Pearce e_t
al., 1981). The prevalence on routine screening however,
appears to be quite low i.e. 0.05% (Fielding, 1984).
5.2.4 Summary
Alterations in the binding of thyroid hormones to
serum protein may occur due to (a) alterations in the con¬
centration of binding proteins, particularly TBG (b)
alterations in their affinity e.g. FDH and (c) the
presence of abnormal thyroid hormone-binding antibodies.
Concentrations of total and free thyroid hormones by
analogue-RIA may deviate from normal in euthyroid patients
with these alterations and diagnostic confusion may arise
where there is underlying thyroid disease. In theory,
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measurements of free thyroid hormone concentrations should
reflect the true thyroid status in such patients but, in
practice, the presence of high affinity albumin, TBPA
(Skiest £t al., 1986) or autoantibodies to T4 and/or
T3 interfere with the analogue free hormone assays.
Measurements by equilibrium dialysis provide an accurate
measure of thyroid hormone status in these patients.
Methods which use microencapsulated antibodies, two-step
back titration or column adsorption chromatography also
appear to give accurate results (Beck-Peccoz £t al., 1982;
Shah & Shah, 1984; Jackson & Ekins, 19 8 6; Skiest et_ al. ,
1986; Archbold et_ al., 1986) . However, measurement of
TSH by IRMA clearly identified those patients with thyroid
dysfunction from euthyroid patients who had altered
hormone-binding and who did not require treatment. Basal
TSH (IRMA), therefore, represents the routine test of
choice in such patients.
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Chapter 6
THE ASSESSMENT OF THYROID STATUS IN PATIENTS
WITH NON-THYROIDAL ILLNESS
- 233 -
In this chapter, the results of thyroid function
tests in patients with non-thyroidal illness are presented.
Firstly, the test specificities in patients from a general
medical ward and in geriatric patients are investigated
followed by more detailed study of patients with chronic
obstructive airways disease and patients with chronic
renal failure.
6.1 THYROID FUNCTION TESTS IN PATIENTS
FROM A GENERAL MEDICAL WARD
6.1.1 The Age, Sex and Disease Distributions
of the Study Group
The patients studied were 264 consecutive
admissions to a general medical ward (137 males, 127
females) excluding those with a past history or clear
clinical evidence of thyroid disease. These patients
were older than the 97 euthyroid patients from the thyroid
clinic (Section 4.1) and their ages showed a skewed
distribution (range 16-96, mode 75 years; Figure 6.1).
Cardio/cerebrovascular, respiratory, liver and gastro¬
intestinal problems were the reason for admission in
40%, 19%, 9% and 8%, respectively. The remaining 24% of
patients were admitted with a variety of other illnesses.
Most patients were taking a variety of drugs as therapy
for chronic ailments or for treatment of their acute symp¬
toms. Serum samples were taken on the day of admission
and stored at -20°C until analysis.
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Figure 6.1 Age Distributions of Patients in a General
Medical Ward and the Reference Group.
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6.1.2 Results for Thyroid Function Tests
The number of patients with abnormal results for
total , fT4 (Amerlex), total Tg, fT-? (Becton Dickinson)
and TSH IRMA (Boots-Celltech) in serum are shown in
Table 6.1. The reference ranges used were: total T4
60-145 nmol/1, fT4 10.0-22.5 pmol/1, total T3 1.0-2.7
nmol/1, fT3 5.3-10.0 pmol/1 and TSH IRMA 0.14-5.9 mU/1.
These were derived from the results of 97 euthyroid
patients (Section 4.6), and now used as the reference
group.
Table 6.1 The Number of Abnormal Thyroid Function Tests




Total T4 21 (8%) 3 ( 1%)
fT4 40 (15%) 2 (<1%)
Total T3 50 (19%) 0
ft3 128 (49%) 2 (<1%)




A large proportion (49%) of patients had low fT3 values.
This test, therefore, lacked specificity for thyroid
disease in this group. In contrast to the other tests
which showed no dependence on age, patients with low total
T3 concentrations were significantly older than those with
normal total T3 levels (p<0.01,X^ test). Results for




























































































Figure 6.2 Serum Total T4, Free T4 (Amerlex) and Basal
TSH IRMA in Patients from a General Medical
Ward.
Results for patients with undetectable TSH
IRMA (o), overt hypothyroidism (A) and
elevated TSH IRMA but normal total T4 (x),
are as indicated. One patient (A) had
septicaemia and later died.
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(a) Patients with Low Total T4 and Raised TSH Levels
Eighteen patients had low total T4 and low
fT4 concentrations but only four of these had unequivo¬
cally high TSH concentrations who, on recall, showed
clinical evidence of hypothyroidism; these patients have
since commenced T4 replacement therapy. Two of these
patients had other diseases known to be associated with
primary hypothyroidism: one had pernicious anaemia and
the other had haemochromatosis. One other patient, who
died soon after admission, had low thyroid hormone con¬
centrations and a TSH IRMA result of 7.4 mU/1.
(b) Patients with Low Total T4 and Normal TSH Levels
Details of the 16 patients in this category are
given in Table 6.2. The majority also had low results for
fTzj, total T3 and fT3« Results for TSH were not clustered
towards the upper reference limit and in fact were signi¬
ficantly lower than those in the reference group (p<0.05,
Mann-Whitney test). Four patients were drug-free, those
with epilepsy were taking phenytoin or sodium valproate
and the remainder were receiving digoxin, diuretics or
antibiotics. Serum albumin and total protein concentr¬
ations were low in 9 and 5 of those patients tested,
respectively.
(c) Patients with Low Free Tn, Normal Total T11 and Normal
TSH Levels
In addition to the 13 patients with low
fT4 described in Table 6.2, 18 further patients had low
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fT4 with normal total T4 and TSH, Table 6.3. Thyrotrophin
results in patients with low fTij. were not significantly
different from the reference group. Serum albumin and
total protein concentrations were below reference limits
in 48% and 23% of these patients, respectively.
(d) Patients with Raised Concentrations of Thyroid Hormones
A small number of patients had slight elevations
in thyroid hormone concentrations; TSH IRMA was detectable
in all of these patients (Table 6.4). In two patients,
the high total T4 levels could be accounted for by
oestrogen-induced TBG synthesis: patient 1 was taking an
OOP and patient 2 was taking Tamoxifen, a drug known to
increase ovarian oestrogen synthesis by decreased feedback
inhibition of the pituitary (Fex et_ al. , 1981). A small
number of patients (2.5%) would also be expected to have
raised concentrations since the reference range was calcu¬
lated to include only 95% of euthyroid values.
(e) Patients with Raised TSH and Normal T4 Levels
Ten patients (8 females, 2 males; aged 56-86 yrs)
had TSH values greater than 7-0 mU/1 but normal total T4
concentrations; fT4 concentrations were low in 5 of these
patients (Figure 6.2. and Table 6.5). These low fT4
values could not be attributed to low serum albumin
concentrations or drugs known to lower Amerlex fT4 values.
One patient (patient 3) had repeat tests three months
after the first admission to hospital; his TSH concentra-
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tion remained elevated at 23 mU/1 although antithyroid
autoantibodies were not detected. This patient has since
died. Positive anti-thyroid microsomal titres were found
in 4 of the other patients' sera. Unfortunately, two
other patients died soon after their hospital admission
and the rest were lost to follow-up. The presence of mild
hypothyroidism could not, therefore, be firmly established
by follow-up study.
(f) Patients with Undetectable TSH IRMA Levels
Three patients with no clinical evidence of
hyperthyroidism at admission had undetectable basal TSH
concentrations by IRMA (Figure 6.2). Details of these
patients are given in Table 6.6 (patients 1-3)• One
patient had borderline-high total and free T^ concentr¬
ations on later testing by her general practitioner, con¬
sistent with subclinical hyperthyroidism; the remaining
two patients were lost to follow-up. Also shown in Table
6.6 are results for two patients (patients 4 and 5) who
were excluded from the study because of the finding of a
large multinodular goitre at examination.
In summary, many abnormal thyroid function test
results were identified in this series of patients raising
the question as to which measurement most accurately
reflects thyroid status in the presence of coexistent
illness. It was thought that a true measure of free
thyroid hormone concentrations by equilibrium dialysis
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might help answer this question since the influence of
changes in serum albumin concentration or drug effects on
values by analogue RIA may be substantial in these
patients, as discussed below.
6.1.3. The Effects of Non-thyroidal Illness
on Free Thyroid Hormone Measurements
(a) Results by Analogue RIA and Equilibrium Dialysis
Results for fT4 and fT3 by several methods are
shown in Figure 6.3 for the first 40 patients described in
Section 6.1. The Corning Magic, Becton Dickinson and Coat
A Count kits produced most fT4 values below reference
limits (6 or 7 patients). Dialysis of serum (1:20
dilution) revealed five patients with low fTi| of whom four
had low values by all of the analogue RIA methods. Three
patients had raised values by dialysis but normal results
by analogue RIA. One of these patients had an absent TSH
response to TRH but there were no other test results to
suggest hyperthyroidism and she died shortly after
admission to hospital with a chest infection (see later:
Table 6.9, patient 1).
A greater proportion of patients had low fT3
values by analogue assay ranging from 14 to 18 patients
depending on the kit (Figure 6.3). Dialysis of serum
(1:10 dilution) showed only six patients with fT3 values
below reference limits. However, fT3 values by dialysis
in these 40 sera (mean, 4.5 ± 1.2 pmol/1) were signifi¬































































Figure 6.3 Concentrations of Free T4 and Free T3 by
Different Methods in 40 Patients with Non-
thyroidal Illness.
One patient (A) had an elevated TSH con¬
centration and one patient (x) had an absent
TSH response to TRH.
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outpatients (n=15) analysed in the same dialysis runs
(mean, 5.2±0.6 pmol/1).
(b) Serum Albumin and Free Thyroid Hormone Results
The dependence of fT4 and fTg results by analogue
assay on the serum albumin concentration was demonstrated
previously (Section 5.1.5) by the iri vitro addition of
human albumin to serum. Measurements by dialysis were
not affected by added albumin. In the medical in¬
patients a greater range of albumin concentrations in
serum was present compared to the reference group of
euthyroid out-patients, and positive correlations with
fT4 (Amerlex) and fT3 (Becton Dickinson) were stronger
(Figures 6.4 and 6.5).
In the 40 sera with dialysis values for free
thyroid hormones, serum albumin ranged from 30-48 g/1
(mean 40.6±4.5 g/1) and, unlike analogue-RIA values,
dialysis fTjj and fT^ values did not correlate signifi¬
cantly with serum albumin (Table 6.7). Indeed, fT^
values by analogue-RIA correlated more strongly with
serum albumin than with dialysis values for fT3«
This and several other reports (Bayer 1983a;
Liewendahl £t al., 1984; Ooi & Sorisky, 1984; Csako et_
al., 1986) have confirmed the albumin-dependence of analo¬
gue RIA measurements reported originally by Stockigt £t
al., in 1981. In spite of reformulations by various
manufacturers, this problem has still to be resolved
completely (Wilkins et al., 1985; Beck et al., 1987).
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Figure 6.4 Correlations between Free (Amerlex) and
Serum Albumin.
(A) General medical in-patients.




Figure 6.5 Correlations between Free T3 (Becton
Dickinson) and Serum Albumin.
r=0-760,P<0001
Albumin (g/l)
(A) General medical in-patients.
(B) The reference group of euthyroid
patients.
- 250 -
Table 6.7 Correlations Between Analogue Free Thyroid
Hormone levels, Dialysis Values, Albumin and
NEFA Concentrations in Non-thyroidal Illness
Correlations( r) with:-
Dialysis Values Albumin NEFA
Free T4 Method
Dialysis 0.132 -0.225
Amerlex 0.539a 0.424^ -0.030
Amerlex-M 0.542a 0.455b 0.027
Corning Magic 0.522a 0.484b -0.093
Becton Dickinson 0.500b 0.504b -0.004
Coat A Count 0.542a 0.275 -0.163
Free T^ Method
Dialysis _ 0.313 -0. 494b
Amerlex 0.546a 0.826a -0.297
Becton Dickinson 0. 479b 0.887a -0.248
Coat A Count 0.575a 0.772a -0.391
a) p<0.001, b) p<0.01
Significant correlations with serum albumin were
also observed for total T3 (r=0.598, p<0.001) and total
Tj| (r=0.262, p<0.05) in patients from the medical ward
(Section 6.1, n=l60) but these were of lower order than
those for fT3 and fT4 by analogue RIA. Such correlations
with total thyroid hormone concentrations would be antici¬
pated since patients with low serum albumin concentrations
might also have low TBG concentrations due to generalised
protein loss or decreased protein synthesis. Values for
TSH IRMA did not correlate significantly with albumin con¬
centrations .
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(c) The Effect of Increased NEFA Concentrations in Serum
Heparin administration activates lipoprotein
lipase in the endothelial lining of blood vessels leading
to release of NEFA (Riemersma et_ al., 1981) resulting in
high fTj| levels measured by dialysis but low results by
analogue RIA (Wilkins _et £l., 1982; Ekins et_ al_., 1983 ;
Bayer, 1983b). A similar discrepancy exists in patients
with non-thyroidal illness (NTI) who may be catabolic with
high levels of circulating NEFA due to mobilisation of fat
from adipose tissue. Since NEFA bind to albumin in
blood, they may displace thyroid hormones leading to high
free hormone levels. The significance of the low results
by analogue assay remains unclear.
(i) In vitro effects
The effect of exogenous NEFA on the measurement
of fT4 and fT3 in serum was investigated by the addition
of oleic acid (Sigma) to aliquots of two serum pools to
produce an increase in NEFA of 0.2 - 30.0 mmol/1 with
minimal (<1%) dilution of the pools. Results by dialysis
-RIA and the Amerlex methods are shown in Figure 6.6.
The effects of added oleic acid on fTij were much greater
than for fT3 by both methods. There was little change in
Amerlex fT4 values until the NEFA concentration increased
by 2 mmol/1, and at 5 mmol/1 they had halved, which con¬
firms the findings of Wilkins e_t al., 1982 & 1985. At
NEFA levels >10 mmol/1, Amerlex fTjj values then increased
- 252 -
Figure 6.6 The Effect of Added Oleic Acid on Free
Thyroid Hormone Measurement in Two Serum
Pools (• and x).
Solid lines are equilibrium dialysis values.
Dashed lines are Amerlex values.
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rapidly. By equilibrium dialysis, fT4 values increased
exponentially and had risen by 80-100? for an increase of
2 mmol/1 NEFA; there was little change in fT3 levels until
the NEFA concentration exceeded 3 mmol/1, in agreement
with the early study of Hollander et_ al., 1967. Wilkins
et al. in 1986 recently confirmed the relative insen-
sitivity of the Amerlex fT3 method to added oleic acid
but found greater increases in fT3 than those shown in
Figure 6.6 for equilibrium dialysis and Amerlex methods
when NEFA levels exceeded 2 and 6 mmol/1, respectively.
(ii ) In vivo effects
Confirmation that high NEFA levels could affect
fT4 values i_n vivo was obtained by studying patients
undergoing coronary artery by-pass surgery where mobilisa¬
tion of fat stores occurs due to the fasting and stress of
surgery; some heparin anticoagulation is also given.
Dilution profiles for serum fT4 by equilibrium dialysis
are shown in Figure 6.7(a) for six patients post by-pass
operation. Concentrations of NEFA were markedly raised
(1-4 mmol/1) and an increase in fT4 values of 50-100?
above normal would be predicted from the in_ vitro effect
observed with oleic acid addition (Figure 6.6). The rank
order of dialysis fT4 values in_ vivo was not exactly the
same as that for the NEFA concentrations (Figure 6.7(a)),
but the dilution profiles were markedly different from






























x 1 x2 x20 xl x2
Dilution of serum
Figure 6.7 The Effect of Serum Dilution prior to the
Assay by Equilibrium dialysis (a) and Amerlex
RIA (b) of Free T4 and T3 in Patients with
High Concentrations of NEFA in Serum.
In (a) NEFA concentrations for each serum are
shown in brackets.
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(Figure 3.1*0. In the by-pass patients, fTi} values were
raised at low dilutions of serum and these decreased
progressively with dilution of serum prior to dialysis.
At a 1:20 dilution of serum, fT4 values exceeded the upper
reference limit in half of the patients studied. Values
for fT3 decreased by only 10% comparing 1:2 and 1:10 dilu¬
tions of serum (Figure 6.7(a)), and high values were found in
only 1 of the 6 sera studied. This is consistent with
the smaller effect of added oleic acid on serum fT3 found
in vitro .and supports the results of an earlier study of
the in_ vivo effects of heparin administration on dialysis
fTg values (Thomson e_t al. , 1977).
Dilution of these sera prior to Amerlex RIA
resulted in a dramatic fall in fT4 and fT3 values (Figure
6.7(b)). This has been reported as a general observation
for all patients' sera (Wilke, 1982; Swift & Ratcliffe,
1983) and has raised the question of the validity of these
tests. It has been argued, however, that the dilution
test is not an appropriate test of the validity of free
hormone measurements by analogue RIA because the use of an
antibody as a sampling device "narrows the dilution range
over which fT4 remains constant" (Wilkins, 1986). Aside
from this issue, it is clear that in these patients,
values by analogue RIA tended to be low, in agreement with
the findings of Bayer (1983b) in heparin-treated patients.
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In three patients, dilution profiles for fT4 by-
dialysis were performed before and after by-pass surgery
(Table 6.8). The fT4 dilution profiles were most
affected in sera taken after the operation, when NEFA
concentrations were highest.







Dialysis Free T4 (pmol/1)
Serum Dilution








8.6 7.2 6.3 5.0
13.0 8.3 7.3 6.7









19.8 18.7 18.3 17.5








In the medical ward, NEFA concentrations would
not, in general, be as high as in heparin-anticoagulated
patients post-surgery and, therefore, values for fT4 by
dialysis would be less affected by serum dilution (unless
other inhibitors of T4-binding were also present). In the
40 patients (Figure 6.3) where fT4 was measured by dialy¬
sis using serum diluted 1:20, NEFA values ranged from
0.2-2.2 mmol/1 (mean, 0.74*0.49). Free T4 values by both
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dialysis and analogue RIA did not correlate significantly
with NEFA concentrations (Table 6.7),and in those with the
highest dialysis fT4 values (28,24,22 pmol/1), NEFA levels
were 1.3» 0.2 and 2.2 raraol/1, respectively.
Paradoxically, fT^ dialysis values showed an
inverse correlation with NEFA levels i_n vivo (Table 6.7)
as did total T3 values but this was less significant than
with fTg by dialysis, r = — 0 .3 6 3 (p<0.05). In fasting
individuals, an increase in the peripheral conversion of
T4 to rT3 is known to occur resulting in low total
T3 concentrations (Braverman & Vagenakis, 1979) and in
prolonged fasting, the breakdown of lipid from adipose
tissue to NEFA occurs. The correlation observed here
between dialysis fT3 and NEFA concentrations may reflect
the change, in opposite directions, of these analytes
as a result of poor nutritional status.
In patients with co-existent illness, free
thyroid hormone status is difficult to assess by
analogue-RIA due to the low albumin concentrations in
serum of many patients. Fewer patients have low values
by dialysis-RIA but an increase in values, particularly
for fT4, occurs in situations where concentrations of
NEFA or other inhibitors of Tzj-binding in serum are high.
6.1.4 The Relationship Between Basal TSH IRMA and the
TSH Response to TRH in Non-thyroidal Illness
Seventy-four patients (47 males, 27 females; mean
age 66 years) from the medical ward had a TRH test performed
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in which serum TSH was measured by in-house RIA. The
good correlation between basal TSH (IRMA) and the TSH
increment 20 min after TRH found in euthyroid outpatients
was also present in patients with NTI (r=0.648, p<0.001),
although the scatter of points was greater (Figure 6.8).
Basal TSH (RIA) and the response to TRH were significantly
higher in female compared to male patients (Figure 6.9).
Diminished TSH (RIA) responses to TRH (less than
3.9 mU/1 TSH increment) were found in 30 patients and
predominantly in the older men (Mann-Whitney test, p<0.05).
Total and free Tzj concentrations in those with reduced
responsiveness to TRH were not significantly different
from those with TSH increments greater than 3*9 mU/1 in
the TRH test.
Two patients had absent TSH (RIA) responses to
TRH although basal TSH was detectable by IRMA (Table 6.9).
Both were elderly women who died soon after hospital
admission.






















Basal Serum TSH IRMA(mU/l)
Figure 6.8 The Relationship between Basal TSH (IRMA) and
~
the TSH Increment after TRH in the Reference
Group and Patients with Non-thyroidal
Illness.
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Minutes after TRH Injection
Figure 6.9 The TSH Response to TRH in Male and Female
Patients in a Medical Ward.
Significant differences between males (•)
and females (o) *p<0.005, **p<0.01.
Reference limits are shown by the dashed
lines.
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6.1.5 Effects of Illness, Sex and Age on Basal TSH IRMA
Concentrations of TSH in the 264 medical ward
patients were similar in males and females but slightly-
lower than the reference group (p = 0.02, Mann-Whitney
test). This analysis was performed after the exclusion of
the 4 patients with overt hypothyroidism and those
patients with abnormal TSH values (Tables 6.5 and 6.6).
When results for males and females were compared separa¬
tely with the reference group, it was shown that the
decrease in TSH was confined to the male patients
(p<0.002) and was age-related (r= -0.265, p<0.01). No
age-related decline in basal TSH was found for women in
the reference group or from the medical ward.
6.2 SCREENING FOR THYROID DISEASE IN THE ELDERLY
The distinction between features of hypothyroid¬
ism and those of old age and/or co-existent systemic
illness is difficult clinically, and since primary thyroid
disease is more prevalent in the elderly, there is an
increased need for a reliable biochemical screening test
in this group. Old age and illness may lower total
thyroid hormone concentrations in serum (Olsen et_ al.,
1978; Engler £t al., 1978; Chopra e_t al., 1983; Harman et_
al. , 1984) reducing their predictive value. The hyper¬
thyroidism of toxic multinodular goitre is less severe
than that of Graves' disease (Toft et al., 1981) and
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occurs more commonly in the elderly. Total thyroid hor¬
mone concentrations may, therefore, be misleadingly normal
in such patients or those with mild hyperthyroidism due to
a solitary nodule or to Graves' disease. The TRH test or
basal TSH IRMA, as shown in previous chapters, are more
sensitive tests of hyperthyroidism since they identify
subclinical disease. The role of basal TSH IRMA as a
screening test in geriatric patients is investigated in
this section.
6.2.1 Patients and Methods
All patients admitted to a geriatric unit (n=63)
as in-patients or assessed at a day hospital (n=49) over a
seven week period were studied, excluding any patient with
known thyroid disease. The mean age of the combined
group was 82.4 years (range 65-100) and 69% were women
with 31? males. These patients were significantly older
than patients from the medical ward, p<0.001 (Figure 6.1).
Medications and active problems were recorded in all
cases.
Blood was obtained from all patients for estima¬
tion of TSH (Boots-Celltech IRMA), total T4 and
fT4 (Amerlex-M) in serum. Patients with abnormal results
were re-tested 4-6 weeks later and a TRH stimulation test,
total T3, fT3 (Amerlex-M) and isotope thyroid scan per¬
formed, if appropriate.
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6.2.2 Total T4, Free T4 and Basal TSH IRMA Results
Abnormal concentrations of total T4, fT4 and TSH
were found in 9.8/6, 4.5% and 8.9% of patients, respec¬
tively (Figure 6.10).
(a) Patients with Abnormal Total or Free T4 but Normal TSH
Nine patients had low total T4 and/or fT^ (7
females, 2 males; age range 70-84 years). Four of these
patients died within 3 months of the study. Details of
their results and clinical problems are given in Table
6.10. One patient (patient 3) was known to have hypo¬
pituitarism and had low gonadotrophin levels in serum.
Free T4 concentrations were below the reference range in
only 4 of these patients. One patient (patient 9) had a
marginally low fT4 value but normal concentrations of
total T4 and TSH. In 3 patients re-tested 1-2 months
later, total and free T4 concentrations had returned to
normal.
One patient (female, 86 years) with normal TSH
(1.9 mU/1) had a raised total T4 (171 nmol/1) but normal
fT4 level (18.1 pmol/1) at first testing. This patient
had rheumatoid disease, dementia and confusion and was
taking iron tablets and Burinex K. The TBG concentration
in this patient's serum was raised (32.5 mg/1) which would
account, in part, for the raised total T4 level.
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Figure 6.10 Results for Total Ti\, Free T4 (Araerlex-M)
and TSH IRMA in 112 Geriatric Patients.
Patients with raised (x) or undetectable (o)
concentrations of TSH are as indicated.
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(b) Patients with Raised TSH Levels
Four patients had raised TSH concentrations with
normal serum thyroid hormone levels being present in three
(Table 6.11). Patient 4, who had low total T4 and anti¬
thyroid antibodies present in his serum, was commenced on
thyroxine. Raised TSH concentrations were confirmed 1-2
months later in patients 1-3 and, although total T4
concentrations remained within reference limits, low
fT^ levels were recorded in two patients.
(c) Patients with Undetectable TSH Levels
Five patients had undetectable TSH values (Table
6.12). None had clinical signs or symptoms of hyper¬
thyroidism. In one patient total T4 was raised; this
patient died before further investigation for possible
hyperthyroidism could be carried out. Normal con¬
centrations of gonadotrophins were found in her serum
making hypopituitarism an unlikely cause of the reduced
TSH secretion. In the remaining four patients, tests
were repeated 1-2 months later. A TSH (IRMA) response to
TRH of greater than 1 mU/1 was measured in patient 2, and
basal TSH was detectable suggesting some recovery of TSH
secretion; the other patients showed no measurable
response to TRH. Patient 3 had very low gonadotrophin
levels consistent with hypopituitarism but the fTij
concentration was above reference limits on the second
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This patient also had severe dementia, Parkinsonism and
depression, and she died subsequently. The two remaining
patients had normal isotope thyroid scans and neither had
detectable thyroid autoantibodies in serum. Patient 4 was
seriously ill and maintained on a complex drug regime;
these factors may have contributed to her low TSH secre¬
tion. Patient 5 was comparatively healthy but had a per¬
sistently elevated fTg concentration in serum.
Comparison of TSH (IRMA) values in the geriatric
group with the reference group showed no significant dif¬
ference (Mann-Whitney test, p=0.17): patients with unde¬
tectable TSH or values greater than 10 mU/1 were excluded
prior to this analysis.
6.2.3 Summary and Discussion
Relatively few geriatric patients (3 • 5%) had
raised TSH concentrations, as found in the medical ward
(6.0%) . This proportion was more consistent with the
known prevalence of primary hypothyroidism than that
suggested by the number of low results for thyroid hormone
measurements. However, the possibility that patients with
primary thyroid failure were missed using TSH due to drug-
or illness-related suppression of TSH secretion has to be
considered. None of the patients in the two studies who
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had low total but normal TSH were taking glucocor¬
ticoids or dopamine agonists, and only one patient was
taking phenytoin which may also suppress TSH secretion
(Franklyn et_ al., 1985). This reduces the possibility
that overt hypothyroidism was missed by the TSH measure¬
ment. Fasting may suppress TSH secretion into the
reference range in patients with mild hypothyroidism
(Borst e_t al 1983); and this cannot be excluded in the
patients studied. However, the basal TSH levels in those
patients with low total or free T4 but normal TSH were not
significantly higher than the reference group. The low
thyroid hormone levels could equally be due to the low
serum protein and albumin concentrations present and the
drug therapy used in these patients. Low total
Tjj concentrations were also related to higher mortality in
the geriatric patients as reported by Slag et_ al. (1981a).
Measurement of TSH provides a more specific test of hypo¬
thyroidism than measurement of thyroid hormones in elderly
patients and those with co-existent illness.
Thyrotrophin concentrations reportedly increase
during the recovery phase of systemic illness (Bacci et_
al., 1982) but this cannot account for the raised TSH
values in admission samples from patients in the medical
ward nor the persistently raised TSH concentrations
demonstrated in the study of geriatric patients.
Metaclopramide , a dopamine receptor blocking agent and
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anti-emetic, is reported to stimulate TSH secretion
(Scanlon et_ al., 1981) but none of the patients described
with raised TSH were taking this drug.
A larger proportion of geriatric patients than
medical inpatients had undetectable TSH concentrations.
Although an age-related decrease in basal TSH and the
response to TRH was demonstrated in men, undetectable
levels occurred most frequently in elderly women; thyroid
hormone results were consistent with the presence of sub¬
clinical hyperthyroidism in half of these patients. In
others, severe depression, dementia and prolonged fasting
may have contributed to the suppression of TSH secretion.
None of these patients were taking dopamine, glucocor¬
ticoids or phenytoin.
6.3 THYROID FUNCTION TESTS IN ELDERLY PATIENTS WITH
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE
Approximately 20% of admissions to the medical
ward (Section 6.1) were patients with respiratory dysfunc¬
tion, a proportion of whom had low serum concentrations
of total and free T4 by analogue assay (Tables 6.2 and
6.3). It has been suggested that chronic hypoxia in
patients with chronic obstructive airways disease (COAD)
can produce abnormalities of hypothalamic-pituitary func¬
tion (Semple et_ a7. , 1979 , 1981 , 1983), the main effects
being on the hypothalamic-pituitary testicular axis.
However, in contrast to reports of reduction (Snyder &
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Utiger, 1972b) and even failure (Davies et_ al. , 1985) of
TSH responses to TRH in the elderly with severe illness,
delayed TSH responses to TRH (i.e. 60 min TSH level
greater than that 20 min after TRH) have been reported in
hypoxic patients with COAD or pulmonary fibrosis (Semple
et al., 1981 & 1984). The contribution of hypoxia to
alterations in thyroid function tests and pituitary hor¬
mone secretion has been investigated in this section by
studying patients with severe COAD and age-matched control
patients with normal respiratory function.
6.3.1 Patients and Methods
Patients; The group with COAD comprised 20 patients (16
males, 4 females; mean age 68 years, range 42-81) admitted
to hospital with acute exacerbations of their disease.
The forced expiratory volume in one second (FEV-|) and the
forced vital capacity (FVC) expressed as percentages of
predicted normal values were less than 40% and 65%,
respectively in all 20 patients, indicating severe
respiratory impairment. The control group comprised 15
ambulatory patients (10 males, 5 females; mean age 73
years, range 57-83) about to be discharged from hospital.
These patients were convalescing from cardiovascular
problems (angina, syncope, cardiomyopathy, deep vein
thrombosis, small myocardial infarction), minor cerebro¬
vascular accidents which had occurred 6 months previously,
or dementia. All 15 had FEV1 and FVC measurements within
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20% of predicted normal values and had no sign of respira¬
tory disease. None of the 35 patients had clinical evi¬
dence of thyroid disease and none was receiving oral cor¬
ticosteroids or other drugs known to affect the hormone
measurements.
Methods: Weight and ideal weight were measured in all
those studied and blood gas analysis was performed on
arterial samples from the patients with COAD while
breathing room air. Reference ranges were those used
routinely and details of these are shown in Table 6.13•

































ND = Not determined
Blood samples were taken 2-3 days after hospital admission
in those with COAD. Venous blood was taken in the
afternoon at 0 min and then at 20 and 60 min after TRH
when patients were relaxed and resting.
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Basal measurements of total T4 and T3 were per¬
formed by in-house RIA and TSH by the Boots-Celltech IRMA.
Free thyroid hormones were measured by the Amerlex analo¬
gue methods. The TSH response to TRH was measured by in-
house RIA. Pituitary hormones (prolactin, growth hormone
(GH), LH, FSH) and testosterone were measured in serum by
staff at the Immunoassay Section of this department using
in-house RIA methods (Beckett e_t a_l., 1983a; Corker et_
al., 1978). Between-assay coefficients of variation for
these methods ranged from 4-12%. Reference ranges for
prolactin and GH were derived from middle-aged males and
females attending an outpatient endocrine clinic; those
for LH, FSH and testosterone in males were derived from
middle-aged healthy men attending for sterilisation or
vasectomy.
6.3.2 Thyroid Hormone and Basal TSH Results
Results for total and free thyroid hormones and
TSH (IRMA) are shown in Figure 6.11. None of these
measurements differed significantly (Mann-Whitney test)
between COAD and control patients. Several low results
for total and free T3 were found in both patient groups.
However, only patients with COAD had total T3 and
fTg values below 0.8 nmol/1 and 3.0 pmol/1, respectively.
Two patients had marginally elevated basal TSH levels:
one with COAD (8.2 mU/1) and one control (8.9 mU/1); total
and free thyroid hormone concentrations were within normal














































Figure 6.11 Thyroid Hormone and Basal TSH (IRMA)
Concentrations in Patients with Chronic
Obstructive Airways Disease (COAD) and
Controls.
Results are shown for male (•) and female
(o) patients; free thyroid hormones were
measured by Amerlex kits.
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6.3*3 TSH Responses to TRH
Results for TSH (RIA) pre- and post-TRH in
control patients and those with COAD are shown in Figure
6.12. In general, higher TSH increments 20 rain after TRH
were found in females than in males (p<0.05). There was
no significant difference in the TSH increment after TRH
between patients with COAD and controls, even excluding
the female patients (Table 6.14).
Three patients with COAD (2 males, 1 female) had
absent TSH responses to TRH (20 min increment less than
1 mU/1). The female patient died suddenly with acute
respiratory failure 3 days after the study. Eight other
patients with COAD (7 males, 1 female) had reduced respon¬
ses (less than 3.9 mU/1 increment). In the control
group, reduced responses were found in 8 male patients.
A delayed TSH response to TRH (60 min level greater than
the 20 min) was found in 2 patients with COAD and 5
controls.
6.3.4 The Secretion of Pituitary Hormones
and Testosterone
In normal individuals there is an increase in
serum prolactin (Cowden et_ a_l. , 1979) but little secretion
of GH in response to TRH (Gomez-Pan et al., 1979).
However, systemic illness may alter the release of
pituitary hormones in response to TRH as shown in patients
with chronic renal failure (Gomez-Pan et_ al_. , 1979;
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2.3(<0.9-8.2) 1.8(0.3-9.8) 6.2(1.0-30.6) 5.8(1.0-30.6) 212(<32-961) 589(103-2584) 487(103-1191) 2.1(<0.6-1 .2) 2.1(0-9.5) 1.9(0-9.5) 10.7(3-0-19.5) 9.8(2.3-14.9) 9.8(2.3-14.9) 8.8(2.7-30.5)
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In this study, there were no significant dif¬
ferences between basal concentrations of prolactin and GH
nor their increments after TRH, comparing COAD and control
patients (Table 6.14). Many patients showed a post-TRH
rise in prolactin of greater than 700 mU/1 (4 COAD, 6
controls) or a rise in GH of greater than 1 mU/1 (10 COAD,
7 controls). The peak responses for prolactin and GH
were greater in females than males (p<0.05) but exclusion
of the females from the data analysis still showed no dif¬
ference between the COAD and control groups.
Concentrations of basal LH, FSH and testosterone
in male patients did not differ significantly between the
groups (Table 6.14). One control patient had the lowest
testosterone concentration (1.8 nmol/1) and the highest
LH concentration (34.1 U/l) in the study, indicating pri¬
mary gonadal failure. Exclusion of this patient from the
statistical analysis revealed significantly higher LH
concentrations in COAD men compared to male controls
although testosterone concentrations remained similar
(Table 6.14). Low concentrations of testosterone were
found in 7 male patients with COAD and 5 control patients.
6.3.5 Correlations between Hormone Measurements,
Indices of Respiratory Function and Body Weight
None of the serum hormone measurements made in
the group with COAD correlated significantly with arterial
blood gas tensions (PaOp and PaC02), % FEV1 or % FVC.
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Patients with high arterial hydrogen ion concentrations
tended to have high basal GH levels but more patients
would need to be studied to improve the distribution of
data points and allow firm conclusions to be drawn (Figure
6.13). Significant correlations were observed for the
TSH (RIA) increment after TRH and the basal TSH measured
by IRMA when compared with the percentage ideal body
weight in patients with COAD (Figure 6.14). In the
correlation of TSH increment with percentage ideal weight
(Figure 6.14A), a logarithmic transformation of the data
was performed to normalise the data distribution; this
reduced the correlation coefficient from r=0.675 in a
linear plot to r=0.5l6, as shown. One patient (percent¬
age ideal weight 110, TSH IRMA 8.8 mU/1) was excluded from
Figure 6.14B as an outlier, reducing the correlation coef¬
ficient from r=0.724 originally, to r=0.465, as shown.
For both correlations, statistical significance (p<0.05)
was maintained.
In summary, both delayed and reduced TSH respon¬
ses to TRH were found in patients with COAD and controls.
Such changes were therefore not specific to hypoxic
patients. The fact that absent TSH responses were found
only in the patients with COAD and not controls may be
explained by the additional suppressive effect of mal-
nourishment as suggested by the correlation of TSH
response with percentage ideal weight. The changes
related to hypoxia reported by others may represent an
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Figure 6.13 Correlation between Growth Hormone
Concentrations and the Arterial Hydrogen
Ion Concentration in Patients with COAD.
A: Linear regression; B: Correlation




Figure 6.14 Correlations between (A) the Logarithm of
' ~~~
the TSH (RIA) Increment after TRH and (B)
Basal TSH IRMA with the % Ideal Weight
of Patients with COAD.
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early onset of age-dependent changes in COAD since the
male patients in this study were significantly older and
more underweight (p<0.01) than those studied previously by
Semple et al. (1979, 1981, 1983).
6.4 THYROID STATUS IN CHRONIC RENAL FAILURE
In patients with chronic renal failure (CRF),low
concentrations of total thyroid hormones have been
reported despite normal TBG concentrations (Lim et_ al.,
1977; Gomez-Pan ^t al., 1979; Beckett £t al., 1983a).
Measurements of fT4 using the FT4I or analogue RIA kits
have yielded low results (Lim et_ al. , 1977; Melmed e_t al. ,
1982; Beckett et_ al. , 1983a) while fTij measured by
indirect dialysis procedures have either been low (Melmed
et al. , 1982) or not significantly different from controls
(Beckett et_ al., 1983a). Using direct dialysis methods,
values have been reported as normal (Lewis, 1979) or high
(Liewendahl et_ al., 1984). The presence in serum of weak
inhibitors of protein-binding may account for the
disparity of dialysis fT4 results found in CRF since dif¬
ferent dilutions of serum have been employed by different
investigators. There is, as yet, no consensus on the
true levels of circulating free thyroid hormones in
patients with CRF.
The HPT axis appears to be abnormal in CRF and
the production of TSH in response to TRH is frequently
diminished. In contrast, GH and prolactin production
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is enhanced (Gomez-Pan et_ al. , 1979 ; Beckett et_ al.,
1983a). The clinical utility of sensitive TSH measure¬
ment by IRMA remains to be investigated in this group of
patients.
6.4.1 Patients Studied
Thirty-six patients (15 males, 21 females) with
CRF who were receiving treatment by intermittent haemo-
dialysis were studied. The age range was 14-70 years
(mean 45). Serum samples were collected prior to their
haemodialysis treatment to avoid artefacts in the measure¬
ment of thyroid hormones due to heparin-anticoagulation of
the patients. The results for the routine clinical che¬
mistry analyses are given in Table 6.15 demonstrating the
reduced excretion of urea, creatinine, uric acid,
potassium, phosphate, and the metabolic acidosis in these
patients. Some patients also had results suggestive of
hyperparathyroidism secondary to renal disease (i.e. low
serum calcium, raised serum alkaline phosphatase). Serum
protein concentrations were well-maintained in this group
of patients, values below the reference limits for total
protein and albumin occurring in only 4 and 2 patients,
respectively.
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Table 6.15 The Clinical Chemistry of Patients with CRF
Reference CRF Patients
Analyte Range (Mean ± SD)
Urea 2.5 - 6.6 mmol/1 30.4 (8.7)
Creatinine 55 - 150 jimol/l 1205.5 (242)
Uric acid (males) 0.12-0.42 mmol/1 0.55(0.12)
(females) 0.12-0.36 mmol/1
Na 132 - 144 mmol/1 137.8 (3.8)
K 3.3 - 4.7 mmol/1 5.5 (1.0)
Total CC>2 24 - 30 mmol/1 22.5 (4.3)
Calcium 2. 12-2.62 mmol/1 2.38(0.32)
Phosphate 0.8 -1.4 mmol/1 1.93(0.63)
Total protein 60 - 80 g/1 65.8 (5.3)
Albumin 36 - 47 g/1 40.2 (4.6)
Bilirubin 2-17 pmol/1 5. 1 (1.3)
ALT 10 - 40 U/l 20.2 (14.4)
Alkaline phosphatase 40 - 100 U/l 142.5 (158.2)
GGT (males) 10 - 55 U/l 23-9 ( 26.9)
(females) 5-35 U/l
6.4.2 Results for Thyroid Function Tests
The number of patients with abnormal concentr¬
ations of thyroid hormones and basal TSH by Boots-Celltech
IRMA are shown in Table 6.16. Compared with general
medical in-patients (Table 6.1), four to five times as
many patients with CRF had low concentrations of total
Tij or fT4 whereas the proportion of patients with
Table 6.16 The Number of Abnormal Thyroid Function
















low total or free T3 concentrations were similar.
Results for serum total T4, fT4 (Amerlex) and TSH are
shown in Figure 6.15. One female patient aged 50 years
had a marginally raised basal TSH concentration (7.7
mU/1). The patient with an undetectable TSH by IRMA also
had an absent response to TRH injection. She had been
treated with radioiodine in the past for Graves' disease.
Basal TSH concentrations in patients with CRF were not
significantly different from the reference group and no
sex-difference was found.
6.4.3 Measurement of Free Thyroid Hormones
Results for fT4 and fT3 in serum by different
analogue RIA methods and equilibrium dialysis are shown in
Figure 6.16. Most values for fT4 by dialysis using serum
diluted 1:20 were within reference limits, and the mean
fT4 value (10.6*2.9 pmol/1) in patients with CRF was not
significantly different from that of 40 euthyroid out¬
patients (11.7*2.8 pmol/1) whose sera were dialysed in the
same assays. Using the analogue fT4 kits, the majority of
patients had low results. The Becton Dickinson and
Corning Magic kits produced low fT4 results in more than
80% of patients.
Dialysis fT3 measurements were performed using
sera diluted 1:2 with buffer and low results were found in
47% of patients (Figure 6.16). The fT3 values in this































Figure 6.15 Total T4, Amerlex Free T4 and Basal
TSH (IRMA) Concentrations in 36 Patients
with Chronic Renal Failure.
One patient (o) had a past history of















































Figure 6.16 Free Thyroid Hormone Concentrations by
___
Dialysis and Analogue RIA Methods in
Patients with Chronic Renal Failure.
One patient (o) had an undetectable basal
TSH IRMA (see text).
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p<0.005) than values for 18 samples from euthyroid out¬
patients dialysed in the same assays. Low fT3 results
were found in more patients by analogue assay than by
equilibrium dialysis. The analogue method producing most
results within reference limits was the Becton Dickinson
kit. This may reflect the greater albumin-dependence of
fTg results by this method; the majority of these patients
had normal corjjhnt rat ions of serum albumin.
The possible effect of endogenous inhibitors of
thyroid hormone binding in CRF was evaluated by studying
the effect of serum dilution on fT4 and fT3 values
measured by dialysis-RIA. For sera containing a weakly
bound inhibitor, diluting the serum (and the inhibitor)
should allow more thyroid hormone to bind to serum protein
with a concomitant decrease in fT4 and fT3 as demonstrated
previously for NEFA (Figure 6.7) and various drugs e.g.
salicylate, furosemide (Nelson & Weiss, 1985; Stockigt _et
al. , 1985). Dilution profiles for 8 sera from patients
with CRF (NEFA concentrations, 0.56±0.4 mmol/1) showed a
decrease in fT4 with increasing serum dilution (Figure
6.17). However, unlike the situation with raised NEFA
A
levels in serum, high fT4 concentrations in undilute^serum
occurred in only one of the eight patients with CRF (NEFA
= 0.30 mmol/1). Comparison of fT4 values using neat
serum (13.3*^.6 pmol/1) and a 1:20 dilution of serum
(7.3*2.1 pmol/1) suggested a 50% decrease (p<0.01) whereas
fT3 values did not change significantly for dilutions up
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Figure 6.17 The Effect of Serum Dilution on Dialysis
Free T4 and T3 Values in Patients with
Chronic Renal Failure.
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to ten-fold (Figure 6.17). True fT4 values in CRF are
therefore unlikely to be lower than in healthy indivi¬
duals. Other workers have also reported slightly high
fT4 and low fT3 values by equilibrium dialysis in patients
with CRF (Liewendahl et_ al., 1984; Wang £t al., 1985).
6.4.4 Correlations with Plasma Urea Concentration
The relationship between thyroid function test
results and the plasma urea concentration used as an index
of the severity of renal failure was examined (Table 6.17).
The patient with a past history of Graves' disease was
excluded from this analysis. Correlations with plasma
creatinine concentrations were less significant.
Table 6.17 Correlations between Thyroid Function Test






Total T4 -0.545 p<0.01
Amerlex fT4 -0.341 p<0.05
Dialysis fT4 -0.280 NS
Dialysis fT3 -0.374 p<0.05
Amerlex fT3 -0.228 NS
Total T3 -0.167 NS
TSH IRMA -0.051 NS
6.4.5 Summary and Discussion
As demonstrated in these younger patients with
renal failure, fT3 concentrations (dialysis) as well as
total T3 concentrations decline in non-thyroidal illness.
This has been explained by increased peripheral conversion
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of T4 to rT3 (Chopra, 1975), and is thought to be a
general finding in sick euthyroid patients. However, it
probably depends on the severity of disease since Boye &
Weeke (1986) have found normal fT3 levels by ultra-
filtration-RIA of undilute^ serum taken from medical
admissions. Many of the low total T4 results seen in
patients from the medical ward may be due to low con¬
centrations of binding proteins. However, in patients
with CRF over 40% of patients had low total T4 but most
had normal concentrations of total protein and albumin in
serum. In contrast, patients with exacerbations of COAD
and chronic hypoxia maintained normal total T4 concentr¬
ations compared to age-matched controls, highlighting the
different effects on thyroid hormone levels in these two
chronic disease states. In both chronic illnesses
however, basal TSH measurement indicated euthyroidism.
This was consistent with the normal fT2j levels measured by
dialysis in patients with CRF. Free thyroid hormone
measurements by analogue RIA give misleadingly low results
in such patients.
In the specific disease groups studied and in the
patients from the general medical ward and the geriatric
hospital, basal serum.TSH concentrations measured by IRMA




THE BIOCHEMICAL MONITORING OF THYROID STATUS IN
PATIENTS TREATED FOR THYROID DISEASE
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In this chapter, the biochemical monitoring of
patients treated for primary thyroid disease is investi¬
gated with particular reference to the role of basal TSH
measurements by IRMA.
7.1 THYROID HORMONES AND THYROTROPH RESPONSIVENESS
AFTER TREATMENT FOR THYROTOXICOSIS
In the early months following treatment of
thyrotoxicosis, the return of thyrotroph responsiveness
to exogenous TRH lags behind the fall in thyroid hormone
levels (Ballabarba £t al., 1972) due to atrophy of the
thyrotrophs (Bakke et_ aJ. , 1964). Measurements of TSH
may not, therefore, identify the onset of hypothyroidism
and the need for T4 replacement after radioiodine or
thyroid surgery (Toft et_ al., 1974 & 1978). The high
sensitivity and specificity of immunometric methods for
measuring TSH allows more detailed assessment of
thyrotroph function. This was illustrated in Chapter 4
by the demonstration of partial thyrotroph responsiveness
to TRH in a proportion of patients with subclinical
hyperthyroidism who had undetectable basal TSH con¬
centrations by IRMA. This incomplete thyrotroph
suppression was not detected using TSH RIA. In the
following section, the time-course of thyrotroph recovery
after treatment of thyrotoxicosis is studied with measure¬
ments of TSH after TRH injection by RIA and IRMA.
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7.1.1 Patients and Methods
Twelve patients (11 female, 1 male; 11 with
Graves' disease and 1 with multinodular goitre) were
investigated before treatment with ^311 and thereafter at
four week intervals for 12 weeks. In addition, one woman
with Graves' disease was studied during treatment with
carbimazole. At each attendance a clinical assessment and
TRH test were performed. Thyrotrophin was measured by
in-house RIA and the Boots-Celltech IRMA. Total and free
thyroid hormone concentrations (Amerlex) were measured in
the basal sample.
7.1.2 Thyroid Function and TRH Test Results
As shown in Table 7.1, after treatment for thyro¬
toxicosis, 8 patients became symptomatically and biochemi¬
cally hypothyroid, 4 were clinically euthyroid with normal
thyroid hormone levels but absent TSH responses to TRH at
8 and 12 weeks post-therapy, and one patient remained
hyperthyroid.
The onset of hypothyroidism, as judged by low
total and free thyroid hormone levels, was noted at 4, 8
and 12 weeks post-therapy in 1, 5 and 2 patients, respec¬
tively (Table 7.1; patients 1-8), but high TSH "levels
occurred in only 5 of these 8 patients. In the
remaining 3 patients, TSH concentrations were either nor¬
mal or low and responses to TRH were absent in two
(patients 4 and 6) and normal in one (patient 5).
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Thyrotroph recovery indicated by a TSH increment (RIA or
IRMA) greater than 1 mU/1 after TRH was demonstrated in
these 8 patients at 4, 8 and 12 weeks in 1, 3 and 4
patients, respectively.
In three of those who became hypothyroid, a small
increment (<1mU/l) in TSH after TRH was detected by IRMA
but not the RIA (Table 7.2). The patient treated with
carbimazole (patient 11) also had a detectable basal TSH
concentration by IRMA.
Table 7.2 Thyroid Hormones and TRH Tests in Four
Patients after Treatment for Thyrotoxicosis
Patient
1 6 7 11
Treatment 1311 131i 131i CBZ
Weeks post-
treatment
8 8 4 12
Total T4
(60-145 nmol/1)
94 53 108 118
Total To
(1.1-2.7 nmol/1)
1. 1 0.6 1.8 2.1
fT4
(10-22.5 pmol/1)
16 8 15 18
fTo
(4.0-7.8 pmol/1)
4.4 2.4 5.9 6.9
TSH RIA (mU/1)
0 min (<5- 7)






















A small TSH response to TRH may, therefore, be
detected by IRMA but not RIA in patients treated for
thyrotoxicosis, representing partial thyrotroph recovery.
7.2 THE RELATIONSHIP BETWEEN PITUITARY AND OTHER
TARGET ORGAN RESPONSIVENESS IN HYPOTHYROID
patients receiving thyroxine replacement—
Many patients receiving T4 replacement have serum
TSH levels undetectable by sensitive assay (Wehmann e_t
al., 1983 ; Semple et_ al. , 19 8 5) consistent with their
absent TSH responses to TRH (Evered et_ al., 1973) •
However, the pituitary differs from some other tissues in
that t3 derived from local conversion from T4 within the
cell occupies a greater proportion of t3 nuclear receptors
than T3 derived from serum (Larsen, 1982). This greater
sensitivity of the pituitary to serum T4 has led to the
assumption that it is an unrepresentative tissue regarding
the assessment of over-treatment with T4. In this sec¬
tion, I have investigated whether thyrotroph suppression
may be used to assess over-replacement in hypothyroid
patients receiving T4.
7.2.1 Biochemical Markers of Thyroid Status
Some constituents of serum which can be measured
easily are known to alter in patients with overt thyroid
disease. High concentrations of ALT, (Ashkar et_ al♦,
1971), liver-specific GST (B1Bt) (Beckett et al., 1985),
SHBG (Anderson, 1974) and ACE (Smallridge et al., 1983)
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have all been described in hyperthyroidism, whereas con¬
centrations of TBG and creatinine may be decreased (Burr
et al., 1977; Bradley £t al., 1974). Raised con¬
centrations of CK are found in hypothyroidism (Doran &
Wilkinson, 1975). Levels of GST and ACE in sera from
patients attending a thyroid clinic (Section 4.1) are
shown in Figure 7.1, illustrating the higher values found
in hyperthyroid patients. Changes in the concentrations
of the above analytes reflect altered entry to (due to
changes in synthesis or membrane permeability) or
clearance from, the blood. In the following study, in
addition to measurements of total and free thyroid hor¬
mones (Amerlex) and basal TSH IRMA (Boots-Celltech),
measurements of GST (B1B1), ALT, GGT, Creatinine, SHBG,
TBG, CK and ACE were made to assess the suitability of the
T4 replacement dose in hypothyroid patients.
7.2.2 Patients Studied
Two groups of patients were studied. Group I
consisted of 21 hypothyroid patients (17 women, 4 men;
mean age 50 years, range 31-68) starting T4 replacement.
The causes of hypothyroidism in this group were: primary
atrophic disease (n=7), Hashimoto's thyroiditis (n=2), and
following radioiodine therapy for either Graves' disease
(n=11) or multinodular goitre (n=1). The average length
of time between radioiodine treatment and the start of









































Figure 7.1 Concentrations of ACE and GST in Serum from
Euthyroid and Hyperthyroid Patients.
Levels were significantly higher (Mann-
Whitney, p<0.001) in the hyperthyroid
patients. Levels of ACE in patients with
toxic nodules or multinodular goitres are as
indicated (x).
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dose was increased each month by 50 >ig increments to a
maximum of 200 pg/day. Blood samples were taken at the
end of each month. In addition, 5 group I patients had
samples taken pre- and post-radioiodine treatment before
Ti4 therapy was started.
To address the question of whether equilibration
of serum analytes had occurred in 1 month, nine patients
from group I were re-tested after 2 additional months of
Tu-treatment with the highest dose that each patient had
tolerated during the study.
Group II comprised 104 patients (91 women, 13 men;
mean age 51 years, range 17-85). Hypothyroidism was the
result of radioiodine or surgical treatment of thyro¬
toxicosis in 51 and 9 patients, respectively, and in the
remainder it was due to Hashimoto's thyroiditis (23
patients) or primary atrophic disease (21 patients). At
the time of investigation, all were clinically euthyroid
and had been receiving a constant replacement dose of T4
for at least 3 months (mean, 3*5 years), the majority
(>89%) had taken the same dose for more than 6 months.
The largest group (n=47) were taking 100 yg/day, the
others were taking 50 yig (n =5), 75 Hg (n=1), 150 ;jg (n = 28),
200 ;ag (n=19) or 300 }ig (n = 4) per day.
7.2.3 Patients Taking Increasing Doses of
Thyroxine (Group I)
Thyroid function tests; serum total and free T4 and T3
concentrations were restored to normal at a lower dose of
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T4 than that necessary to suppress TSH to within the
reference range and 10 patients with increased fT4 levels
had normal TSH concentrations (Figure 7.2). Normal TSH
results were achieved in 18 patients at the 50, 100, 150
and 200 jig dose in 1, 8, 8 and 1 patients, respectively.
Four patients could not tolerate the 200 jig/day dose for 4
weeks. Serum TSH became undetectable (<0.1 mU/1) in 17
patients; this first occurred at the 100, 150 and 200 jig
doses in 1, 7 and 9 patients, respectively. Serum
fT4 was above normal in all patients when TSH first became
undetectable whereas in most patients serum total T4,
total T3 and fT3 levels were normal at that time.
Conversely, if serum total T4, total T3 or fT3 were raised
TSH was always undetectable.
Serum markers from peripheral tissues: dose-dependent
increases (Wilcoxon matched-pairs; p<0.05) in GST, SHBG
and ACE occurred (Figure 7.3) > and levels of ALT at the
200 jig/day dose were higher than those at the 100 jig/day
dose (p<0.05); GGT increased slightly but not signifi¬
cantly. Significant reductions in TBG, CK and creatinine
also occurred with increasing T4 dose (Figure 7.3).
Levels of one or more of these markers became
abnormal in a total of 15 patients. Abnormally high GST,
SHBG, ALT, GGT and ACE levels were found in 10, 7, 4, 3
and 3 patients, respectively. The occurrence of these
I I 1 1 1
HYPO 50 100 150 200
T4 Dose Uig/day)
Figure 7.2 Thyroid Function Test Results in 21 Hypo-
thyroid Patients Receiving Increasing Doses
of Thyroxine at 4-week Intervals (Mean±SEM).
Reference ranges are indicated by the dashed
lines.
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Figure 7.3 Peripheral Tissue Markers Measured in Serum
from 21 Hypothyroid Patients Receiving
Increasing Thyroxine Doses at 4-week
Intervals (Mean±SEM).
*Significant differences from the previous
dose (p<0.05).
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abnormalities coincided with an undetectable TSH and
raised fT4 concentration in 9 patients, and in 4 further
patients TSH was undetectable and fT4 raised after the
next increment in T4 dose. By contrast, even at the
highest dose, fT^ and total T4 and T3 were raised in only
8, 6 and 1 of these 15 patients, respectively.
In the nine patients who were studied after an
additional two months, no further changes occurred in the
measured thyroid and tissue parameters, except for a
slight increase (p<0.05) in SHBG.
7.2.4 Changes in Tissue Markers in Thyrotoxic
Patients after Radioiodine Therapy
The changes in thyroid function tests and tissue
markers in 5 patients prior to radioiodine treatment and
during subsequent T4 replacement are shown in Figures 7-4
and 7.5, respectively. The levels of tissue markers at
the maximum T4 dose were not as abnormal as when patients
were thyrotoxic. However, as in group I, there were
trends towards higher SHBG, GST, ACE and lower TBG, CK and
creatinine levels when these patients were taking 200 jjg/
day T4 compared to the lower doses. Only one patient in
this subgroup had levels outside reference limits.
Values for tissue markers in the 5 thyrotoxic patients are
compared with those in the 21 group I patients (when
taking the maximum dose of T4 tolerated) and the reference
ranges in Table 7.3.
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Figure 7.4 Thyroid Function Test Results (Mean±SEM) in
5 Patients Who Became Hypothyroid After
Radioiodine Treatment for Thyrotoxicosis.
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Figure 7.5 Peripheral Tissue Markers in Serum from 5
Patients Pre- and Post-radioiodine Treatment
for Graves' Disease and During Thyroxine
Therapy (Mean±SEM).
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Table 7.3 Concentrations of Peripheral Tissue Markers
in Serum from Thyrotoxic Patients (n=5) and








GST, yg/l 0.5-4.0 5.9* 2.7 4.8* 2.5
SHBG, nmol/1 30-90 173*50 70±33
ALT, U/l 0.=3-10 ND 28±14
GGT, U/l 5-35 ND 21 ±21
ACE, U/l 11-109 129*22 83*22
TBG, mg/1 C\J.=!"1O 20± 3 21* 3
Creat., pmol/1 55-150 63* 9 82±16
CK, U/l 30-150 12± 9 44±26
*At maximum tolerated T4 dose. ND = Not determined.
7.2.5 Patients Stabilised on a Fixed Dose of Thyroxine
(Group IT)"
Thyroid function tests: measurement of TSH divided the
104 patients taking a constant dose of T4 into 3 groups;
37 patients with undetectable TSH levels (A), 42 with nor¬
mal TSH levels (B) and 25 patients with raised levels (C),
Table 7.4. Only one patient had a detectable TSH con¬
centration (0.13 mU/1) which was less than the absolute
range (0.14-5.9 mU/1) found in the reference euthyroid
population (Section 4.6.1). This patient was included in
Group B. There was no bias towards a particular cause of
the hypothyroidism between the groups or the duration of










































DifferencesfromgroupB;p<0.005a,p<0.001b,p<0.05c Referenceranges:TSH,0.14-5.9mU/1;fTij,10.0-22.5p ol ; fT3,4.0-7.8pmol/1;tota146 5n Total3,1.1-2.7nmol/1.
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therapy, but patients in group A were taking higher doses
of T4 than those in group B. From Table 7.4, a mean
reduction of 22$ in the dose of T4 would bring group A
patients to the same mean dose as those in group B.
Patients in group C had not been prescribed less T4 than
group B, but 7 were thought to be non-compliant with their
treatment. The prescribed dose did not correlate signifi¬
cantly with the patient's age or weight. For detectable
TSH values, the Spearman's correlation coefficients
(p<0.0001) for TSH versus free thyroid hormones were r =
-0.746 for fT4 (Figure 7.6) and r = -0.446 for fT^.
In group A; fT4, total T4, fT^ and total T3 were
high in 32, 13, 12 and 1 patient, respectively. In group
B, high fT4 levels were found in 14 patients and high
total T4 levels were found in 3. One patient in group B
had low total T4 and fTg results, and low levels of
thyroid hormones were found in 7 patients from group C.
Serum markers from peripheral tissues: the results for
serum ALT, GST, GGT, CK, TBG and SHBG are shown for the
three groups in Figure 7.7. For the TBG and SHBG data,
women taking an OCP and all men were excluded. By the
Mann-Whitney test, significantly higher ALT (p<0.001),
GST (p<0.02) and GGT (p<0.05) levels were found in group
A than in group B. Group A had lower CK levels than
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Figure 7.6 The Spearman's Correlation between Serum


































































































Figure 7.7 Peripheral Tissue Markers in Serum from 104
Patients Taking a Fixed Dose of Thyroxine
Grouped According to TSH (IRMA) Levels.
*Significant differences from Group B
(p<0.05). Patients with high (»), normal (o)
and low (4 ) fT4 levels are shown.
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had higher SHBG (p<0.001) and lower TBG levels (p<0.02).
ACE activities and creatinine levels did not differ signi¬
ficantly between the groups.
A total of 27 patients had an abnormally high
level of at least one of the following; ALT, GST, GGT,
SHBG. Most of these patients had an undetectable TSH
(67%) or raised fT4 (85%), whereas fTg was raised in only
33% and total T4 raised in 26%, respectively. Total
T3 concentrations were within reference limits in all 27
patients.
7.2.6 Thyroid Function Tests and Tissue Markers after a
Reduction in Thyroxine Dose in Group II Patients
Thirteen patients from Group II who had undetec¬
table TSH (IRMA) and raised fTi; levels and who lived
locally, were recalled for the performance of a TRH test
and a reduction in their dosage by 25-100 ;jg. All
patients had a TSH response less than 1 mU/1 after TRH by
RIA and IRMA before the dose was reduced (Table 7-5).
Basal TSH IRMA was <0.1 mU/1 in all but one patient whose
value was 0.4 mU/1 with an increment of 0.9 mU/1 after TRH.
Measurements of peripheral tissue markers, thyroid hor¬
mones and TRH tests were performed at two-month intervals
until increments in TSH after TRH, by RIA and IRMA, were
greater than 1 mU/1 in all patients. At the lower dose,
values for total T4, T3, fTzj and fT3 became abnormally low
in 0, 1, 1 and 2 patients, respectively. A significant
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change in tissue markers was discernible only for GST;
values in 6 out of 8 patients with raised GST levels were
reduced to reference levels after reduction in the dose of
T4 (Figure 7.8). The fall in SHBG concentrations did not
reach statistical significance (Table 7.5). The patient
whose GST concentration became increased further above
normal after the reduction in T4 (Figure 7.8) also had an
abnormal ALT concentration before (50 U/l) and after the
dose reduction (52 U/l).
7.2.7 Summary and Discussion
A relationship was demonstrated between the serum
markers used to assess thyroid status in peripheral
tissues and TSH levels by sensitive assay in patients
taking T4. Although the changes in SHBG, TBG, CK and
creatinine may reflect the return of peripheral tissues to
normal from the hypothyroid state, some patients had
abnormally high ALT, GST, GGT, SHBG and ACE levels at the
higher doses of T4. The majority of abnormalities were
found for GST. Although GST measurements correlate with
ALT concentrations (Figure 7-9) they provide a more sen¬
sitive index of hepatocellular damage than ALT (Beckett &
Hayes, 1984). These increased GST levels are not a
result of enzyme induction but reflect hepatic release
(Beckett et al., 1986).
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Figure 7.8 Concentrations of GST and SHBG in Serum
Before and After a Reduction of Thyroxine
Dose in Hypothyroid Patients.
With dose A, all patients had an absent TSH
response to TRH; with dose B, responses to
TRH were normal.
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Figure 7.9 The Correlation between Hepatic GST Con¬
centrations and ALT Levels in the Serum of
Group II Patients.
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The spectrum of abnormalities found in tissue
markers was not as great as those found in patients with
untreated overt hyperthyroidism but, in addition to the
complete suppression of TSH secretion, they provide evi¬
dence of a generalised tissue over-exposure to thyroid
hormones. The lack of complete concordance in the abnor¬
malities detected and pituitary suppression is not unex¬
pected in view of the wide range of sensitivities and spe¬
cificities to thyroid status of the tissue markers
measured. The results presented suggest that TSH secre¬
tion can be used as a sensitive and representative test of
peripheral tissue exposure to thyroid hormones in patients
taking T4 replacement therapy. In addition to the
biochemical abnormalities demonstrated in those with unde¬
tectable TSH (IRMA), such patients also tended to have
lower body weights and higher sleeping heart rates than
those with normal TSH (IRMA), although these differences
did not reach statistical significance.
Many patients with normal serum total and free
T3 concentrations had evidence of tissue hyperthyroidism
suggesting that such measurements are insensitive tests of
overtreatment. Although a greater proportion of patients
with evidence of tissue hyperthyroidism had raised fT4
concentrations than an undetectable TSH (IRMA) a sub¬
stantial proportion of patients required a high fTjj level
in order to reduce TSH secretion to normal. Adjustment
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of T4 dosage to normalise fT4 values might,therefore,lead
to problems of under-replacement. Reduction of T4 dosage
to give a detectable TSH (IRMA) level in 13 patients
resulted in normal TSH responsiveness to TRH and a signi¬
ficant reduction in the number of patients with abnormal
GST concentrations. Total and free thyroid hormone con¬
centrations remained within reference limits in the
majority of patients after the reduction in T4 dosage,
indicating sufficient replacement for other tissues.
Thus the data presented suggest that the object
of T4 replacement therapy should be to achieve detectable





General aspects of this thesis are discussed under
three main headings in this chapter. The analytical
validity and physiological relevance of the new thyroid
function tests are discussed initially followed by an
assessment of their clinical value and finally their role
in new test strategies.
8.1 THE VALIDITY AND RELEVANCE OF FREE THYROID
HORMONE AND SENSITIVE TSH MEASUREMENTS
8.1.1 Analytical Validity
There has been much recent debate about the ana¬
lytical validity of both the new analogue RIA methods and
the purported reference method of equilibrium dialysis for
measuring free thyroid hormones in serum. This is
discussed below followed by an assessment of the analyti¬
cal validity of sensitive TSH measurements.
(a) Equilibrium Dialysis Methods
The direct dialysis methods developed in this
thesis for fT4 and fT^ compared very well with other
reference methods in that they produced similar reference
ranges to other reports and, in addition, the biases of
fTZj. kit methods compared to dialysis were in agreement
with results found in a recent DHSS survey (Chapter 3).
Dialysis results were also unaffected by serum dilution
using out-patient samples (Chapter 3) and independent of
changes in the concentration and affinity of serum binding
proteins (Chapter 5), thus fulfilling the major criteria
for analytical validity of a free hormone measurement.
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Some authors, however, have questioned whether
direct dialysis is suitable as a reference technique since
it is cumbersome, relatively imprecise and may be par¬
ticularly susceptible to the presence of weak binding-
protein inhibitors in serum (Wilkins et_ al., 1982 & 1985).
All methods which result in serum dilution will give
incorrect results when such inhibitors are present.
Ultrafiltration of undiluted serum or equilibrium dialysis
against a small dialysate volume are therefore required
for valid measurements in this situation. However, it
has been argued that any non-dialysable inhibitor (e.g.
NEFA) will produce artificial elevation in fT4 measured by
dialysis because a concentration gradient of the inhibitor
is set up across the membrane which must be balanced ther-
modynamically by an opposite gradient of T4 (Wilkins et_
al., 1982 & 1985). This explanation was proposed to
account for major differences between dialysis results and
those found by analogue RIA methods in certain circumstan¬
ces but no experimental evidence or formal scientific
basis has been presented to support it; Jackson & Ekins
(1986) have concluded that it is the analogue RIA methods
which are analytically invalid in this situation. In
support of dialysis methods, it has been shown that high
NEFA concentrations in vitro and in vivo also produce high
fTZ| values by non-analogue two-step RIA (Bayer, 19838) and
by ultrafiltration methods (Wang et al., 1986).
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In some patient samples, the NEFA concentration
may increase _in vitro due to continued activity of
lipoprotein lipase and it is argued that the overnight
incubations at 37°C used in equilibrium dialysis will
accelerate this process leading to spuriously high
results. Higher fT4 values by dialysis have been
reported compared to ultrafiltration (Wang et al., 1986)
and the Clinical Assays two-step method (Bayer, 1983b) in
patients receiving heparin, providing some evidence for
this effect. However, this does not appear to be a
general problem since there is a high degree of correla¬
tion in thyroid clinic samples between dialysis values and
those by analogue RIA (Chapter 4; Liewendahl e_t al. , 1986)
and by non-analogue kit methods (Jackson & Ekins, 1986).
In conclusion, since the equilibrium dialysis and
ultrafiltration techniques have a sound- theoretical basis
and their limitations are well recognised, to date they
remain the most valid reference methods for free thyroid
hormone measurement.
(b) Free T4 and Free by Analogue RIA
Several major reservations have been expressed as
to the validity of analogue RIA methods centering on
theoretical arguments and experimental findings which have
primarily been directed at the Amerlex fT4 system since
this was the first analogue RIA developed (Stockigt et_
al., 1982a & 1983; Ekins et al., 1983 & 1984; Wilke, 1984;
Bayer, 1983a & 1984; Jackson & Ekins, 1986).
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These criticisms are:-
1. A significant proportion of the analogue is bound to
serum proteins during the RIA.
2. The antiserum binds a greater proportion of the total
hormone pool than is theoretically acceptable for a
valid fT4 measurement.
3. Since the serum is diluted in the RIA, analogue assays
will not measure fTi| accurately if weakly-bound inhi¬
bitors of thyroid hormone binding are present in serum.
The labelled analogue method was originally pre¬
sented as relying on the analogue being essentially
unbound to serum proteins. However, Ekins et_ al. (19B3)
and others have calculated from the amount of antibody
used in the assay that about 98% of the analogue is in
fact bound to serum proteins since otherwise too high a
proportion of the total T4 pool would be sampled by the
antibody leading to perturbation of the binding
equilibrium. It is now acknowledged by the manufacturers
that some residual binding of the analogue to serum pro¬
teins is necessary for measurement of fT4 by analogue RIA
(Midgley & Wilkins, 1983; Wilkins et_ al., 1985) - This
residual binding could explain why free hormone values (a)
decrease dramatically with serum dilution (Chapter 6), (b)
correlate significantly with the serum albumin level in
pregnancy (Chapter 5), NTI (Chapter 6) and in aiialbum-
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inemia (Stockigt et_ al., 1983), (c) increase proportion¬
ately with added albumin _in vitro (Chapter 5), (d) are
spuriously high in the presence of abnormal high-affinity
binding proteins (Chapter 5) and (e) decrease when inhibi¬
tors (e.g. oleic acid, salicylate) alter the usual analo¬
gue binding to serum proteins (Chapter 6; Wilke, 1986).
In the above situations, the amount of analogue available
to bind to the assay antibody may change significantly
relative to the kit standards: when binding to serum pro¬
tein is abnormally high, less of the analogue may take
part in the RIA and the converse may occur when serum pro¬
tein binding is low or when binding inhibitors (e.g. NEFA)
are present. In spite of the above findings, the propo¬
nents of the analogue RIA concept argue that the binding
of the analogue to serum proteins is insufficient to
distort Amerlex fT4 values in most patients (Wilkins £t
al. , 1985; Wilkins & Midgley, 19 8 6) . Their analogue binds
weakly to TBG and TBPA at 2-3%, and to albumin at 12-30%
of the affinity of T4, and it is maintained that in the
presence of antiserum, all of the analogue is readily
available to participate in the RIA (Midgley & Wilkins,
1983). The distribution of the-analogue binding is there¬
fore relatively insensitive to changes in TBG and TBPA and
distortion of fT4 results is only thought likely in rare
cases of variant albumin, high-titre anti-T4 antibodies,
analbuminaemia or when NEFA concentrations are massively
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increased. The manufacturers also conclude that only in
the latter two circumstances will greater than 5% of the
total T4 pool be sampled by the assay antibody (Wilkins e_t
al., 1985).
Although some of the above criticisms have been
largely theoretical and may not necessarily compromise the
clinical value of all analogue assays in all situations,
it has been suggested that these assays are unsuitable as
routine tests of thyroid status and should be removed from
laboratory practice (Wenzel _et al., 1985; Alexander 1986;
Jackson & Ekins, 19 8 6) . Attention has therefore focused
on the structure of the analogues to minimise effects due
to alterations in the serum binding proteins (Geiseler ejb
al. , 1986). Further modifications of the analogues to
achieve this, however, reduce their similarity to T4 and
may significantly alter their antibody-binding charac¬
teristics. The analogue assays produced by manufacturers
may therefore perform differently in various patients'
sera as evidenced in this study by:-
(a) different correlations with serum albumin.
(b) different numbers of low values found in pregnancy
and in NTI.
(c) different results for a patient with FDH.
(d) different biases compared to dialysis-RIA in patient
samples not accounted for by differences in standar¬
disation .
Albumin deficiency and heparin or salicylate therapy may
also affect the analogue assays to different extents
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(Wilke, 1984 & 1986). However, in agreement with the
manufacturers, Wilke (1984) found that the albumin effect
in the Araerlex fTjj assay was not sufficiently great to
invalidate its clinical utility when binding proteins in
serum were either normal or "moderately" abnormal. This
conclusion is supported by the excellent correlations with
direct dialysis values in patients from a thyroid clinic
reported in this thesis and by Liewendahl et_ a_l. , 1986.
The results from non-analogue kits are theoretically more
valid but they involve more manipulations and are less
precise (Jackson & Ekins, 1986 ; Csako et_ £l., 1986).
Therefore, although the analytical validity of analogue
free thyroid hormone assays is questionable, particularly
in certain circumstances outlined above, the question ari¬
ses whether, in a routine setting, they give results of
greater clinical value than total hormone measurements.
(c) Immunometric TSH Measurements
The introduction of immunometric assays for TSH
has met with relatively little criticism. The presence
of heterophilic (e.g. anti-mouse) antibodies in serum may,
however, produce more noticeable interference in two-site
assays than has been reported for RIA methods, since the
cross-linking of the assay monoclonal antibodies by multi¬
valent interfering substances may give falsely detectable
TSH values (Hunter & Budd, 1980) . Boscato & Stuart
(1986), report the prevalence of heterophilic antibodies
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in serum to be as high as 40%. However, effects may not
be apparent because (a) animal serum is present in the
assay reagents which saturate the binding sites of the
interferent and (b) there is higher relative binding of
the analyte. Isolated instances of assay interference
producing falsely high TSH values (Cusick et_ al., 1985;
Clark ejt al., 1985) or falsely detectable values in
Graves' hyperthyroidism have been found using the Amerwell
IRMA in this and other laboratories (Finlayson et_ al.,
1987; Gow et_ al., 1987) and with other two-site assays
(John & Henley, 1987); this interference is ameliorated in
the majority of cases by the inclusion of mouse serum in
the assay.
The measurement of TSH in sera from pregnant or
post-menopausal women has been improved by the greater
specificity of immunometric assays compared to RIA,
decreasing problems with cross-reactivity (Bruce et_ al.,
1986). However, significant negative interference due to
high HCG concentrations has been demonstrated for some
monoclonal combinations (Chapter 5). Differences in the
potency of monoclonal combinations to bind endogenous and
standard TSH may also account for systematic differences
in TSH concentrations by different kits which are
correctly standardised (Paterson et_ al., 1985; Biggart £t
al., 1985). Matrix effects have also proved responsible
for the persistent negative bias found in one TSH IRMA
(Clark et al., 1986) .
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There may also be divergence between immunologi¬
cal and biological activity of TSH (as with other peptide
hormones) highlighted by the increased use of immunometric
assays. Faglia et_ al. (1979) showed this by RIA in
patients with secondary hypothyroidism and it might not be
unexpected in cases of TSH-secreting tumour where struc¬
turally aberrant forms of TSH might be secreted. An
increased high molecular weight TSH with impaired biologi¬
cal activity has been reported in a euthyroid patient
(Spitz et_ al., 1981); two-site TSH assays might give
different results to RIA in such situations.
Immunoradiometric assays offer clear advantages
over RIA in terms of analytical sensitivity and working
range. Samples with high TSH levels can be analysed
without prior dilution and the use of coated wells and
non-isotopic labels will provide speed, robustness and
increased sensitivity due to the higher signals generated
compared to radiolabels (Woodhead & Weeks, 1985). It
remains to be seen whether increased analytical sen¬
sitivity will add significantly to the clinical value of
sensitive TSH measurements by IRMA.
8.1.2 Do Measurements of Free Thyroid Hormones and TSH
(IRMA) Accurately Reflect Thyroid Status?
Irrespective of the analytical validity of a hor¬
mone measurement, there is still some question as to
whether the free hormone concentration is the principal
determinant of the cellular action of thyroid hormone.
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There is some evidence in animals to suggest that thyroid
hormones may enter cells by active transport. If this is
the case in man then it will detract from the current
thinking concerning the importance of the free hormone
fraction since both free and bound fractions would be
available for entry into cells. In certain tissues e.g.
the liver and placenta, theoretical and experimental
models suggest that the protein-bound fraction is
available to cells.
That TSH secretion may not always accurately
reflect thyroid status is suggested by the fact that low
and undetectable levels can occur in clinically euthyroid
patients who have normal thyroid hormone concentrations in
serum e.g. in patients with solitary nodules or multi¬
nodular goitre, patients with severe illness and patients
taking replacement. Raised TSH levels have also been
found in clinically euthyroid patients either taking
Tj| replacement or during recovery from illness. The
question of the physiological relevance of TSH and free
hormone measurements in various patient groups will now be
discussed.
(a) Uncomplicated Patients
In patients attending thyroid clinics the clinical
and biochemical picture is not usually complicated by
effects of systemic illness and drug administration. In
contrast to total T4 and T3 measurements, free hormone
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measurements do not give misleading results in TBG excess
and deficiency and they therefore correlate better with
the nuclear T3 receptor content of peripheral tissue and
the clinical impression of thyroid status (Chapter 5;
Pearce & Byfield, 1986). They do not, however, provide
the most sensitive test of mild thyroid dysfunction.
With the exclusion of pituitary disease or TSH-
secreting tumours, measurements of TSH secretion
correspond well with thyroid status and also detect minor
degrees of thyroid dysfunction not evident from thyroid
hormone results. The fact that some changes in peripheral
markers of thyroid status occur in patients with mild
thyroid disease (Forfar et_ al., 1979; Bell £t al., 1983;
Cooper et_ al. , 1984) supports the premise that in
uncomplicated patients, abnormal TSH secretion is a more
accurate measure of thyroid status than thyroid hormone
tests and clinical judgement.
(b) Pregnancy
Many studies have now shown that total thyroid
hormone and free hormone values by analogue-RIA are not
accurate indicators of thyroid status in pregnancy, prin¬
cipally because of the physiological changes in TBG and
albumin concentration in serum (Chapter 5). The large
decrease in analogue free hormone values with gestation
cannot be ascribed simply to high NEFA concentrations in
late pregnancy (Chapter 5) and the NEFA:albumin ratio is
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unlikely to be high enough to significantly alter the
binding of thyroid hormones to serum binding proteins.
The decrease shown in free thyroid hormone values
within the reference range in pregnancy by equilibrium
dialysis is in agreement with other workers (Chapter 5).
Bounaud e_t al. ( 1986) also found this for fT4 measured by
column adsorption chromatography and RIA as did Kurtz et_
al. (1979) using a two-step back titration method. Some
decrease in values has been shown by other non-analogue
commercial methods (Jackson & Ekins, 1986).
Ekins (1984), has suggested that increased demand
for iodine by the foetus may cause this progressive fall
in free thyroid hormones. Alternatively, there may be a
resetting of the maternal HPT axis to lower circulating
free hormone levels (Smith & Bold, 1983). Kvetny &
Poulson (1984) have shown that there is a progressive
increase in the nuclear binding capacity for T3 and T4 in
human mononuclear cells with gestation. Whether this
represents compensation at the tissue level for the
slightly low circulating free hormone levels or, alter¬
natively, that free hormone levels are lowered to maintain
euthyroid nuclear-receptor occupancy when there is an
increase in receptor numbers during pregnancy, remains an
open question. The demonstration that free thyroid hor¬
mone levels decrease in post-menopausal women receiving
oestrogen therapy, has led some authors to suggest that
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the rise in oestrogen level in pregnancy triggers the
decrease in free hormone concentration (Abdalla et_ al.,
1984). This effect might be mediated directly at the
thyroid (Zaninovich et^ a_l. , 1982) or at the cellular level
in modulating cellular uptake or nuclear-receptor binding
(Franklyn et_ al., 1983; Kvetny & Poulson, 1984).
The fact that basal TSH concentrations rise
progressively within the normal range with gestation
(Chapter 5) is consistent with normal negative feedback
control at the pituitary. Recent evidence suggests that
the decrease in free hormones could be interpreted, in
part, as the return to normal values from a mild hyper¬
thyroidism in early pregancy due to the extra stimulation
of the thyroid by HCG. The borderline-high free hormone
values reported in early pregancy in some longitudinal
studies (Yamamoto et_ al_., 1979 ; Weeke et_ al., 1982;
Guillaume £t al., 1985) together with the low TSH results
by sensitive assay,.may therefore be an accurate measure
of thyroid status. In late pregnancy, the significance
of slightly low free hormone values is not fully
understood since the normal basal TSH concentrations and
clinical impression suggest euthyroidism.
(c) Non-thyroidal Illness
In NTI, the total T3 concentration in serum is
often low due to a decrease in extra-thyroidal conversion
of Ti| to T3 with an increase in serum rT3 levels. There
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may also be a reduction in the TSH response to TRH. Low
total T4 concentrations also occur particularly in more
severe illness and this is a poor prognostic sign (Chapter
6). The concentration of serum binding proteins may be
decreased with an increase in the desialated form of TBG,
which has low affinity for thyroid hormone (Reilly &
Wellby, 1983). The physiological relevance of these
changes is unclear and it has been assumed that free hor¬
mones are normal accounting for the normal basal TSH con¬
centrations and clinical euthyroidism in patients with
NTI. However, fT4 measurements by direct dialysis and
ultrafiltration suggest that values are often high in
undiluted serum and that they decrease with serum dilution
indicating the presence of an endogenous inhibitor of
T4-binding (Chopra et_ al., 1983; Nelson & Weiss, 1985;
Boye & Weeke, 1986). Although some recent studies
suggest that this is oleic acid (Chopra e_t al_., 1985)
other studies argue against the levels of oleic acid being
sufficiently high in severe NTI to account for the inhibi¬
tion (Mendel ert al., 1986).
Confusion in the literature as to the true
thyroid status in NTI has resulted from attempts to unify,
in one theory, the changes which occur in the HPT axis in
various different systemic diseases and in illness of dif¬
ferent severity. In this thesis, four groups of patients
were studied: general medical admissions, geriatric
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patients, patients with COAD and patients with CRF. In
this way,some specific disease-related changes could be
identified. The alterations in thyroid function tests
which occur in severely ill patients undergoing intensive
care were not studied, since thyroid status is usually of
minor concern in such patients. However, the findings
from other studies are discussed below.
(i) General medical admissions, geriatric patients and
patients with COAD
In general medical admissions (Chapter 6), dialy¬
sis fT4, NEFA, total T4 and basal TSH (IRMA) concentrat¬
ions did not differ greatly from normal whereas total
T3 and dialysis fT3 levels were low, consistent with
other studies in similar patients (Kaptein, 1982; Kaplan
et al., 1982; Liewendahl et_ al., 1984). The majority of
geriatric patients and those with COAD also had normal
concentrations of total T4 and TSH (IRMA), and the TSH
response to TRH in general medical admissions and patients
with COAD was also essentially normal. Hypoxia did not
appear to have a specific effect on the HPT axis in
contrast to previous reports. The patients in these
groups, therefore, typify those with the low T3 syndrome.
An increase in the number of nuclear T3 and T4 receptors
in mononuclear cells has been demonstrated in insulin-
dependent diabetics with the low T3 syndrome (Kvetny,
1983). This may provide a mechanism by which
euthyroidism is maintained in peripheral tissues. Low
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circulating fT3 concentrations may not, therefore, reflect
decreased hormone concentration at the nuclear receptor.
Measurements of the circulating fT4 and TSH (IRMA) con¬
centrations would appear to more accurately reflect the
thyroid status of such patients.
(ii) Patients in intensive care
In studies of the thyroid status of severely ill
patients, the effects of exogenous dopamine, glucocor¬
ticoids, heparin and other drugs e.g. frusemide may
obscure pathophysiological changes. However, obser¬
vations that TSH secretion in primary hypothyroidism is
reduced in patients with coexistent, severe illness
(Hooper, 1976; Slag et_ al., 1981b), that TSH con¬
centrations rise on recovery (Slag e_t al., 1981b; Bacci
et al. , 1982; Hamblin ejt al. , 19 8 6), and that the decline
in thyroid hormone levels is preceded by a decrease in TSH
secretion (Wehmann e_t al., 1985) suggest that altered TSH
secretion contributes to the low T4 syndrome. Peripheral
tissue markers of thyroid status e.g. serum ACE con¬
centrations (Brent et al., 1984) and tissue levels of T3
(Reichlin et_ al., 1973) are low in these patients and red
cell Na+/K+-ATPase activity is high (Dasmahapatra et_ al♦,
1985), which suggests the presence of a true secondary
hypothyroidism. This is likely to be an adaptive mecha¬
nism since administration of T4 or T3 does not improve
survival and may be contra-indicated since it may produce
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excessive catabolism and interfere with the timing of the
recovery which appears to require return of hypothalamic-
pituitary function (Brent & Hershman, 1986). Gonado¬
trophs secretion is also temporarily impaired indicating
wider disturbance of hypothalamic-pituitary function
(Quint & Kaiser, 1985; Woolf et_ a_l., 1985). These
endocrine changes in critical illness are thought to be
mediated by the release of endogenous stress hormones
(dopamine, glucocorticoids, endorphins, somatostatin)
in addition to the physiological response to fasting
(Hamblin et_ al., 1986).
(iii) Chronic renal failure
Patients with CRF are not critically ill but
invariably have low levels of total T4 and T3 with normal
rT^ concentrations in serum (Melmed et_ al., 1982;
Wartofsky, 1984). Reduced responses to TRH do not appear
to be due to reduced caloric intake nor increased dopamine
action since there is evidence that dopamine-receptor
interaction on both the thyrotroph and the lactotroph is
blocked in this disease (Weetman jet al. , 1981) . There is
some inhibition of Ti|-binding in this condition (Chapter
6) possibly due to metabolites e.g. phenols and indoles
which accumulate in uraemia (Spaulding & Gregerman, 1972).
Like the intensive care patients and those with less
severe NTI, dialysis fT3 levels were low in this condition
but in contrast to those in intensive care, TSH con-
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centrations were well-maintained and dialysis fT4 values
were borderline raised. Studies in a uraemic rat model
show a decrease in both the activity of certain intra¬
cellular enzymes as in hypothyroidism (Lim £t al., 1980)
and the T3~receptor binding in liver and kidney (Thompson
et al., 1980) whereas the pituitary T3 content is normal
(Lim et al., 1983). These patients, therefore, do not
have "compensated hypothyroidism" but appear to have some
physiological resetting of the HPT axis. Alternatively,
they may have impaired uptake of thyroid hormone by the
liver and peripheral tissues. This may be an adaptive
mechanism to spare essential protein as these patients are
in negative nitrogen balance (Utiger, 1980) .
It has recently been suggested that the high rT3
concentrations in severe illness may exert effects on the
rate of T3 formation in the pituitary and brain cortex
(St. Germain et_ al., 1986). Subtle differences in
pituitary physiology may, therefore, occur in CRF compared
to other low T4 syndromes since serum rT3 levels are nor¬
mal in this disease.
(d) Thyroxine Replacement Therapy
In patients taking T4, there may be a marked
divergence in the clinical impression of thyroid status
from that suggested by the results of biochemical tests
(Fraser et al., 1986). Basal TSH assay is accepted as
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the best test of inadequate replacement (Cotton et_ al.,
1971) but its use in indicating over-treatment is contro¬
versial. Clinical signs of excessive treatment are often
not apparent until total T3 concentrations are raised and
since T3 is the most active thyroid hormone, it is argued
that provided the serum total T3 or fT3 concentrations are
maintained within the reference range, over-treatment, if
it occurs, is of little consequence unless there are other
contraindications e.g. ischaemic heart disease (Pearce &
Himsworth, 1984; Rendell & Salmon, 1985; Fraser et_ al.,
1986). In this study, however, many patients with total
T3 and fT3 levels within reference limits had evidence of
tissue hyperthyroidism from measurement of various serum
constituents (Chapter 7). This is consistent with
reports where other end-organ responses have been studied
(Goolden et_ al., 1971; Jennings et_ al. , 1984; Beckett et_
al., 1985; Coindre et_ al. , 19 8 6 ; Wilcox & Levin, 19 8 6) but
in disagreement with studies using clinical signs alone
(Pearce & Himsworth, 1984; Fraser et_ al., 1986). A high
serum fT4 or undetectable TSH IRMA were better indicators
of these subclinical changes in tissue thyroid status.
Although the pituitary is more sensitive to circulating
T/} compared to other tissues, several authors have advo¬
cated maintaining the pituitary responsiveness to TRH,
since mild hyperthyroidism is difficult to detect clini¬
cally (Evered et al., 1973; Wehmann et al., 1983; Davis
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et al., 1984 ; Toft, 1985). As a result, lower daily-
doses of 100-125 >ug are being recommended for average
replacement requirements, particularly in the elderly
(Davis et al., 1984 ; Hennessey et_ al., 1986). Since some
patients require high fT4 levels to normalise TSH, and
fTg is an insensitive test of tissue hyperthyroidism, this
study shows that measurement of basal TSH by sensitive
assay provides a more accurate measure of thyroid status
in patients receiving T4.
(e) Special Cases
As discussed in Chapter 7, basal TSH measurements
do not accurately measure thyroid status for the first 3
months after therapy for hyperthyroidism due to delayed
recovery of the thyrotrophs. In addition, there are
rare instances of hyperthyroidism due to a TSH secreting
tumour or thyrotroph hyperplasia in which the usual -nega¬
tive feedback control is destroyed as in secondary
hypothyroidism. In these circumstances, although the TSH
measurement may be providing accurate information it
conflicts with the thyroid hormone status of the patient.
A rare condition termed peripheral resistance to
thyroid hormones has also been described where the high
total and free thyroid hormone concentrations may be
misinterpreted as hyperthyroidism. Such patients are
clinically euthyroid, have normal thyrotroph respon¬
siveness and normal basal TSH concentrations. The high
thyroid hormone concentrations are necessary to compensate
- 3^1 -
for a partial defect in either tissue-uptake, peripheral
Tty conversion or thyroid hormone receptors (Degroot, 1979;
Jansen £t al., 1982 ; Wortsman et_ al., 1983). Patients
treated with drugs e.g. iopanoic acid or amiodarone which
interfere with peripheral T4 conversion, may also have high
fTn concentrations which contradict the clinical impression
of euthyroidism and the normal fTg and basal TSH (IRMA)
concentrations found.
In the special circumstances described, one
biochemical test may be misleading but an alternative test
of free thyroid hormones in patients with hypothalaraic-
pituitary disease or a test of end-organ response (i.e.
TSH IRMA) in patients where there is peripheral
resistance, will give an accurate measure of thyroid sta¬
tus .
8.1.3 Conclusions
From the foregoing discussion, it would appear
that assessment of end-organ response by sensitive TSH
measurement should provide the most accurate indicator of
thyroid status in most situations. In general, measure¬
ment of fTjj by reference techniques also correlates with
the clinical impression and/or measurements of end-organ
response. However, free hormone measurements by analogue
assay give analytically invalid results in some patients
which may reduce their clinical value substantially.
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8.2 THE CLINICAL VALUE OF ANALOGUE FREE
THYROID HORMONE ASSAYS AND TSH IRMA"
In this section,the clinical value of analogue
free thyroid hormone tests and measurement of TSH IRMA
is assessed in the three main situations where requests
for thyroid function tests are made.
8.2.1 Reasons for Requesting Thyroid Function Tests
The main reasons for requesting thyroid function
tests are:-
(a) to confirm thyroid dysfunction when the clinical
suspicion is high.
(b) to screen for thyroid dysfunction.
(c) to monitor the response to treatment.
In patients referred to a thyroid clinic, the
clinician often has to distinguish hyperthyroidism, which
may require destructive therapy, from euthyroidism. In
this situation, the biochemical tests are required to con¬
firm the clinical impression and provide a measure of the
degree of dysfunction which will, in turn, influence
patient management. Biochemical tests, used for this
purpose, have to be highly specific and sensitive to avoid
a misdiagnosis. This is particularly important if unne¬
cessary thyroid ablation is to be avoided.
Unrecognised, untreated hypothyroidism is asso¬
ciated with a high degree of morbidity. In contrast,
the inappropriate treatment of euthyroid patients with
T4 is thought to have relatively low morbidity. Any
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biochemical test should, therefore, have high sensitivity,
particularly as in most cases of hypothyroidism assessment
and treatment will be initiated by a general practitioner
rather than an endocrinologist.
The biochemical screening of elderly patients can
be justified by the high prevalence (over 5%) of thyroid
disease in this group (Tunbridge et_ al. , 1977), and the
fact that classical symptoms of thyroid disease are often
absent or disguised by systemic illness. The yield of
detecting unsuspected disease with total T4 measurements
in the elderly has been rewarding unlike the screening
carried out in the general hospital population (Lancet
Editorial, 1983)- The latter practice places greater
demands on biochemical tests to have high specificity to
minimise the performance of fruitless further tests.
Wilke and Eastment ( 1986) recently recommended the FT4I as
the single best screening test but they did not evaluate
the performance of sensitive TSH measurements.
Thyroid function tests are also required in the
follow-up of patients treated for thyroid disease (a) to
detect relapse of hyperthyroidism or the onset of hypo¬
thyroidism and (b) to monitor compliance and the adequacy
of T4 replacement therapy.
8.2.2 Confirmation of Suspected Thyroid Dysfunction
The predictive values for TSH IRMA and free
thyroid hormone measurements by analogue assay were calcu¬
lated in Chapter 4 for patients referred to a thyroid
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clinic. The basal TSH (RIA) or response to TRH were used
as the gold standards to which the new tests were compared
This allowed assessment not only of their performance in
confirming the clinically obvious but also in identifying
subclinical disease.
Basal TSH measurements by IRMA showed excellent
correlation with the TSH (RIA) response to TRH (Chapter 4)
This confirms the early work of Wide & Dahlberg (1980) and
Wehmann et_ al. ( 19 8 3) who developed TSH RIA methods with
sensitivities of 0.3 mU/1, and is supported by the results
from other immunometric assays (Alexander et_ al., 1984;
Weeks et_ al., 1984; Paterson et_ aJ., 1985; Martino _et al.,
1986; Clark & Price, 1986). This test had the highest
diagnostic efficiency compared to total and free thyroid
hormone measurements and could be used to replace the TRH
test leading to less inconvenience for patients and
savings in material and staff costs.
Although free-hormone measurements identified
about 50% of patients with subclinical thyroid disease,
basal TSH IRMA distinguished all of these patients. This
is of clinical value since these patients should be
followed up as they may require treatment at a later date.
Indeed, half of the patients identified with subclinical
disease in this study have now been treated with Ti|
replacement or anti-thyroid therapy. In other studies,
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fTij measurement has proved a good test of subclinical
hypothyroidism (Faglia e_t al. , 1982; Symons £t al. , 1983;
Wilke & Eastment, 1986) but this was not confirmed here
(Chapter 4). Similarly, measurement of fT3, advocated by
some as a better test of hyperthyroidism (Carayon et_ al.,
1979 ; Franklyn e_t al., 1984) was no better than fT4 in
this study since most patients with T3~thyrotoxicosis had
raised fT4 concentrations, and patients with subclinical
disease more frequently had raised fT4 values, in
agreement with the findings of Weeke and Orskov ( 1979) -
Free hormone measurements are more sensitive tests of
thyroid status than total hormones in this situation
because they are unaffected by the small changes in TBG
concentration which occur as a result of thyroid dysfunc¬
tion (Burr et al., 1977).
In a proportion of patients referred to thyroid
clinics, the abnormal total T4 and T3 results are due to
high oestrogen levels and, more rarely, to the presence of
abnormal serum binding proteins (Table 8.1). Analogue
free hormone measurements provide a more specific test
when there are large changes in TBG concentration but give
spurious results in the presence of high affinity albumin
or TBPA variants and anti-thyroid hormone antibodies
(Chapter 5; Pearce & Byfield, 1986). The basal TSH IRMA
measurement gives an accurate measure of thyroid status in
all such patients (Chapter 5) and is of particular clini¬
cal value when underlying thyroid disease is present.
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Abnormally low analogue fT4 and fTg values may
"T
occur in the third trimester of pregnancy and although the
progressive fall in values with gestation agrees with
current understanding of the physiology, this is partly
due to methodological artefacts (Chapter 5). When tri¬
mester-related reference ranges are used, these measure¬
ments are of value in distinguishing hyperthyroidism from
euthyroidisra in pregnancy and may be of value in moni¬
toring anti-thyroid treatment (Momotani et_ al. , 1 986) .
A normal basal TSH IRMA excludes thyroid dysfunction in
pregnancy and this is particularly useful since the TRH
test is contra-indicated. However, in a few patients (5%),
there may be a physiological reduction in TSH secretion to
undetectable levels (Chapter 5). If free thyroid hormone
concentrations are within the appropriate reference limits
for gestation, subclinical hyperthyroidism cannot be
excluded by biochemical tests but this may not be of
pathological significance.
It is generally accepted that free rather than
total thyroid hormone measurements have greater clinical
value in uncomplicated patients (Wilke 1986; Pearce &
Byfield, 1 9 8 6 ) . Whether they significantly improve upon
the categorisation achieved by the FT4I or T^rTBG ratio is
disputed (Wilke, 1982; Braun £t a]^. , 1983 ; Wilke &
Eastment, 1986) but they allow significant savings in
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terms of time and labour. Basal TSH measurements by sen¬
sitive assay, however, have the best diagnostic efficiency
in uncomplicated patients.
8.2.3 Screening for Thyroid Disease
In general, in medical admissions to hospital and
patients with COAD or CRF (Chapter 6), free thyroid hor¬
mone measurements by analogue assay were of less clinical
value than total hormone measurements producing several
low results which reflected the concentration of albumin
and the albumin-binding of certain drugs rather than
thyroid status. This is in agreement with several other
authors e.g. Vermaak et_ al.( 1983). Nystrom et_ al.
(1986a) however, recently reported few misleading results
in non-hospitalized patients with NTI using analogue
fT4 RIA. Factors causing abnormal results are shown in
Table 8.1 and contrasted with effects on total hormone
measurements, the TRH test and basal TSH IRMA.
Measurements of fT24. and fT3 by non-analogue com¬
mercial methods give results of greater validity than ana¬
logue RIA in patients with NTI (Chan et_ al. , 1983;
Ordonez-Llanos et^ al., 1984; Lee et_ al., 1986; Jackson &
Ekins, 1986). Basal TSH (IRMA) measurement gave the
lowest number of abnormal results in keeping with the
known prevalence of thyroid disease (Chapter 6). Raised
concentrations were not due to lithium therapy or dopamine
antagonists and the patients were not in the recovery
phase from severe illness. Although not all of those
- 3^9 -
with raised TSH had anti-thyroid antibodies, a recent
study by Sawin et_ al. (1985) concluded that demonstration
of a clearly elevated TSH is a better approach to detect
early thyroid failure than measurement of autoantibodies,
particularly in the elderly. Although fasting and severe
NTI can suppress TSH secretion, this has only resulted in
normalisation of TSH levels in patients with subclinical
rather than overt hypothyroidism (Borst et_ al., 1983 ;
Hooper, 1976; Slag et_ a^l. , 1981b). Secretion of TSH is
much less affected by NTI and drugs than thyroid hormone
levels (Table 8.1) and, therefore, as with the uncompli¬
cated patient, provides the best test of primary
hypothyroidism.
In geriatric patients (Chapter 6), relatively few
patients had low total and free T4 levels which was unex¬
pected in view of their systemic illness and range of drug
therapies. However, recent studies suggest that total
and free T4 concentrations remain unchanged in old age
(Lindstedt et_ al. , 1983; Harman £t_ al., 1984),and since a
significant proportion of the patients studied were fully
mobile and attending a day clinic, the disease severity
was probably less in this group than seen in the
admissions to the general medical ward. Most geriatric
patients with low thyroid hormone results had normal TSH
concentrations and since TSH measurement has greater spe¬
cificity as discussed above, this is the test of choice to
screen for primary hypothyroidism in the elderly.
- 350 -
All of the thyroid function tests investigated
lacked specificity for hyperthyroidism to some extent in
patients with systemic illness (Table 8.1) and in the
elderly (Chapter 6). Measurements of total and free
thyroid hormones, however, may lack sensitivity in the
presence of NTI (Engler £t al., 1978; Forfar £t al.,
1979) and in the very old (Tibaldi eit a_l. , 1986). Un¬
detectable basal TSH (IRMA) levels occurred more fre¬
quently than high total or free thyroid hormone con¬
centrations and were found in 1% of medical ward patients
and 4.5% of geriatric patients; thyroid hormone results
were consistent with the presence of subclinical
hyperthyroidism in half of these patients but thyroid dys¬
function could not be firmly established. Boye & Weeke
(1986) have recently shown low TSH (IRMA) concentrations
with raised fT4 levels by ultrafiltration-RIA in several
patients with NTI. However, this thyrotroph suppression
may be temporary as demonstrated in two geriatric patients
in this study and by Davies et_ al. (1985) in elderly
patients with atrial fibrillation. The clinical value of
using basal TSH IRMA to screen for hyperthyroidism in the
elderly is, therefore, less well established but if one
test is to be used, it will produce a similar number of
follow-up requests as total T4 or fTi|, and provide a
specific test of hypothyroidism and a sensitive test of
hyperthyroidism.
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8.2.4 Monitoring the Response to Therapy
Sensitive TSH measurements have no clinical value
in testing for the occurrence of hypothyroidism in the
early months following treatment of hyperthyroidism.
Total and free T4 measurements performed equally well for
this purpose (Chapter 7). However, Martino et al. (1982)
demonstrated in methimazole-treated patients that nor¬
malisation of total T4 precedes that of fT4 and that the
fT4 results were in keeping with the persistence of clini¬
cal hyperthyroidism. These workers have suggested that
measurements of free thyroid hormones might provide a more
reliable index of thyroid status in these patients.
The results of the present study of biochemical
monitoring of T4 replacement therapy (Chapter 7),show that
changes in peripheral tissue markers indicative of over-
treatment occur when fT4 levels are high, basal TSH IRMA
is undetectable, and when total T4, total T3 and
fT3 levels are often normal. Abnormalities in these
markers (e.g. GST) can be reduced and levels of thyroid
hormones generally maintained within reference ranges by
adjusting the T4 dosage to give normal and detectable TSH
IRMA levels. Measurement of TSH can therefore indicate
both over- and under-replacement and be used to optimise
the replacement dose more accurately. Free or total
T4 measurement may be useful to indicate the amount of
adjustment required and to check for patient compliance.
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There are some circumstances where the thera¬
peutic aim in giving T4 is to suppress TSH secretion
completely e.g. in patients with thyroid cancer or goitre
due to Hashimoto's thyroiditis. Sensitive TSH measure¬
ments may provide a more accurate means for determining
the dose which gives complete suppression without inducing
mild hyperthyroid symptoms (Spencer et_ al., 1986).
8.3 NEW STRATEGIES OF THYROID FUNCTION TESTING
8.3.1 The Objectives of a Test Strategy
Ideally, the best assessment of thyroid status
would involve the provision of several tests on each
patient. Indeed Wilke and Eastment (1986) have suggested
that the combination of total T4, FT4I, total T3 and ana¬
logue fT^ tests provides the best screening of patients
when little information is available as to their possible
thyroid status. However, some compromise has to be
reached in terms of reagent and labour costs, and
diagnostic effectiveness. The operation of strategic
testing can result in a 50% cost-saving compared to
unrestricted requesting of thyroid function tests (Beck,
1986). To be diagnostically effective, any proposed stra¬
tegy should be applicable in the clinical situations
outlined in Section 8.2.1 and aim to exclude thyroid dys¬
function at an early stage to avoid the performance of
unnecessary tests.
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A new strategy of thyroid function testing is
proposed in Figure 8.1 as a result of the clinical studies
detailed in earlier chapters. Benefits of such an
approach include (a) simplification of test strategy, (b)
identification of relatively minor degrees of thyroid dys¬
function (i.e. good sensitivity), (c) a reduction in the
number of misleading abnormal results in patients with NTI
(i.e. good specificity) and (d) improved biochemical
control of patients taking T4 replacement. A single sen¬
sitive TSH measurement as the initial test divides
patients into those who are euthyroid (or adequately
replaced with T4) in whom no further tests should be
needed, and those with overt or subclinical thyroid dys¬
function (or sub-optimal T4-replacement). Free T4
(analogue assay) provides a slightly better second-line
test than total T4 for reasons discussed in Section 8.2.
The second-line test provides biochemical evidence of the
severity of the thyroid disturbance in those with an
abnormal TSH level. Measurement of fT3 or total T3 would
only be required in a small proportion of patients if TSH
was undetectable and fT4 normal, in order to exclude the
few cases of T^-thyrotoxicosis in which fT4 was not also
raised.
Analogue free hormone measurements may give
falsely low results in patients with NTI who may also have
undetectable TSH. However, this should be a signal to
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Figure 8.1 A Proposed New Strategy of Thyroid Function
Testing Using Sensitive TSH Measurement as
the First-line Test.
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suspend, where possible, further thyroid investigations
until the resolution of the systemic illness. The
occurrence of false negative results using TSH as a
first-line test is important but likely to occur only in
the relatively rare conditions of hypopituitarism or TSH-
secreting tumour. When hypopituitarism is suspected cli¬
nically or when anti-thyroid therapy has been given in the
previous 3 months, basal TSH measurement is inappropriate
and fTjj. measurement should be performed. A TRH test may
also be useful in suspected hypopituitarism.
The potential for non-thyroidal causes of an
undetectable TSH (Table 8.1) has led to some reservations
as to the use of TSH as the first-line test, particularly
in hospital in-patients (Kirkegaard et_ al. , 1985; Nystrom
et al., 1986b). However, Semple e_t al. ( 1985), using the
Boots-Celltech TSH IRMA for their routine workload
(endocrine clinic and general hospital), found only 9 out
of 3629 patients (0.25%) with values <0.1 mU/1 not expli¬
cable by hyperthyroidism, Tij-therapy, treatment of
hyperthyroidism or remission from Graves' disease.
Experience in this laboratory of operating a strategy of
Amerwell TSH IRMA as the first-line test, followed by a
total Tj| if TSH is abnormal for 1916 routine requests,has
yielded similar results: TSH was low (<0.3 mU/1) and
total Tij normal in 27 (1.4%) patients and, of these, 13
(<0.T%) were undetectable and could not be explained by
T4 replacement or clinically apparent thyroid disorder.
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The outcome of using a sensitive TSH measurement
as a first-line test is that it will identify a group of
previously unrecognised patients with subclinical disease.
The question must be asked as to whether this is an advan¬
tage. There is little dispute that the detection and
review of patients with subclinical hypothyroidism is
important since the natural history is progression to
overt disease and there is some evidence that there are
changes in end-organ function (Tunbridge et_ al. , 1977;
Cooper ^t_ al_., 1984). Although the outcome of long-term
replacement in asymptomatic patients has not been
assessed, there may be some benefit in patients with
abnormal myocardial contractility or symptoms consistent
with mild hypothyroidism (Cooper £t al., 1984). There is
less of a consensus in the view that subclinical
hyperthyroidism inevitably progresses to overt disease
(Studer et_ al., 1985),but studies in patients with soli¬
tary non-toxic autonomously-functioning thyroid nodules
indicate that these progress to toxic adenomata
(Hamburger , 1980 ; Lerro et_ al_., 1985) and there may be
slow progression to hyperthyroidism in patients with
multinodular goitre (Studer et_ al., 1985) - Treatment at
an early stage in such patients may, therefore, be con¬
sidered beneficial. Patients who are clinically
euthyroid, with normal thyroid scans and who are in sinus
rhythm would not be candidates for treatment but should be
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reviewed to exclude effects of NTI and to detect any
progression to overt thyroid disease (Semple et al., 1985).
The new strategy (Figure 8.1) would therefore increase the
need for follow-up of patients with minor degrees of
thyroid disease.
It has been calculated that the proposed strategy
(Figure 8.1) could halve the number of biochemical tests
performed in a thyroid clinic with additional savings due
to not performing TRH tests (Caldwell et_ al., 1985;
Martino £t al., 1986). However, for workloads derived
from populations with a low prevalence of thyroid disease,
such an analysis will not apply, particularly when in-
house total T4 assays are used as screening tests (Beck,
1986). Any analysis of the comparative cost of one stra¬
tegy compared with another has to take into account the
population served, the cost of running in-house assays
compared to commercial kits, staffing, equipment and
various local factors.
Developments in dual-isotope immunoassay provide
further scope for the simplification and improved effi¬
ciency of thyroid function testing. Single-tube, dual-
isotope methods for simultaneous measurement of TSH by
IRMA and fT4 by analogue RIA will soon supercede the dual
RIA evaluated in this thesis (Chapter 4). This proved
very effective in assessing the thyroid status of new
thyroid patients, pregnant women and patients with co-
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existent illness. Preliminary results in patients from a
thyroid clinic with such a dual TSH IRMA/fT^ RIA are shown
in Figure 8.2. In contrast to the performance of the
dual RIA kit (Figure 4.12), TRH testing might not be
necessary to distinguish euthyroidism from subclinical
hyperthyroidism. The performance of this assay as a
first-line test would lead to 9 possible combinations of
results (Figure 8.3); four of these combinations clearly
identify the thyroid status and no further tests would be
required: (a) overt hyperthyroidism (e) euthyroidism (f)
subclinical hypothyroidism (i) overt hypothyroidism.
Patients with low TSH IRMA but normal fT4 (Figure 8.3(d))
would require measurement of total or free T3 to identify
patients with T^-hyperthyroidism. Patients with low
fT4 and either low or normal TSH IRMA (Figure 8.3(g & h))
might require a TRH test if hypopituitarism is suspected
clinically. The main disadvantage of the combined test
would be in the detection of patients with euthyroid (or
hypothyroid) hyperthyroxinemia (Figure 8.3(b & c)) in whom
further tests might be required if the clinical findings
were equivocal. A TSH-secreting tumour would give a
similar combination of test results. The advantages of
this approach would be:-
1. A unified strategy (even suitable for monitoring
patients after treatment of hyperthyroidism).
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TSH IRMA (mU/l)
Figure 8.2 Preliminary Results for the Becton Dickinson
Dual-Isotope TSH IRMA/Free T4 RIA in New
Patients from a Thyroid Clinic.
Results in the hatched area had counts in the
TSH IRMA less than the zero standard.
Dashed lines indicate the absolute range of
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Figure 8.3 The Possible Combinations of Results Using
a Simultaneous TSH IRMA/Free T4 RIA and the
Requirement for Further Tests.
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2. Earlier indication of the degree of thyroid hormone
excess in untreated hyperthyroidism and in patients
taking T4.
3. Improved detection of hypothalamic-pituitary
dysfunction.
4. Easier laboratory processing of patient samples and
data.
Since such a dual assay might cost the equivalent
of either a commercial sensitive TSH measurement or analo¬
gue fTi} assay, such a strategy is likely to be most bene¬
ficial to the patient, clinician and the laboratory.
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8.4 CONCLUSIONS
In patients presenting to a thyroid clinic,
measurements of free thyroid hormones by analogue-RIA pro
vide a better test of thyroid status than total hormone
measurements. This is not the case for hospital in¬
patients primarily due to artefacts arising from the
methodology. Basal TSH measurement by immunometric assay
however, provides a more sensitive and specific test of
thyroid dysfunction and is therefore better suited as a
screening test and as a confirmatory test when the clini¬
cal suspicion is high. In hypothyroid patients treated
with T4, basal TSH measurement may now provide the best
biochemical indicator of both over- and under-replacement
The use of basal TSH as a first-line test has major advan
tages over using a measure of total or free T^ alone in a
decreasing the number of unnecessary tests and b) iden¬
tifying subclinical disease. In addition to having a
major impact on the design of strategies for thyroid func
tion testing, the new generation of sensitive TSH assays
will also provide a better tool in studies of hypothal¬
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Accuracy and Precision of Five Analog Radioimmunoassays for Free
Thyroxin Compared
S. M. Gow,1 H. A. Kellett,2 A. D. Toft,2 and G. J. Beckett1
We compared Ihe precision of free thyroxin (FT4) measure¬
ments by kits involving analog RIA and the use of antibody-
coated tubes (Becton Dickinson and Coat-A-Count), magnet¬
ic separation (Amerlex Magnetic and Corning Magic), or
centrifugation of antibodies linked to solid beads (Amerlex).
Results of kits with magnetic separation were the most
reproducible. Amerlex, Amerlex Magnetic, and Becton Dick¬
inson kits gave values comparing best with those obtained by
direct equilibrium dialysis. Coat-A-Count and Corning Magic
results differed significantly from dialysis values, both for
patients' samples and kit standards. The kits had equal
diagnostic efficiency in patients with suspected thyroid dis¬
ease. On measurement of FT4 some patients were reclassi¬
fied from "subclinical thyroid disease" to "overt disease."
Most patients with triiodothyronine thyrotoxicosis had in¬
creased FT4. Several kit values were low for pregnant
women and patients with nonthyroidal illness but the Amerlex
and Amerlex Magnetic assays had fewer low results. The
Amerlex Magnetic FT4 assay gave the best precision, agree¬
ment with the reference method, and diagnostic efficiency.
Additional Keyphrases: thyroid status ■ variation, source of
■ pregnancy ■ "kit" methods ■ diagnostic efficiency
Estimation of free thyroxin tFT4) in scrum is generally
considered to provide a more nearly accurate diagnostic test
of thyroid dysfunction than is measurement of total thyrox¬
in (T4) in serum or determination of the free thyroxin index
(FIT), particularly in conditions where there are changes in
the concentrations of thyroid hormone-binding proteins
such as in pregnancy {1-3).3 It is also currently held that
only the free fraction of thyroid hormones can gain access to
cells and thus exert metabolic effects (4, 5). The development
by Amersham International of the one-step RIA involving a
radiolabeled analog of thyroxin (6) has resulted in FT4
assays that are more precise and robust than earlier com¬
mercial methods involving microencapsulated antibodies
and two-step kinetic rate analysis (7). These advantages
have led many companies to adopt this methodology, and
several FT, RIA kits now marketed are based on the use of
different T4 analogs and separation systems.
Many studies evaluating individual FT4 kits have com¬
pared them with the FTI and other thyroid-function tests
rather than with a reference method for FT4. Equilibrium
dialysis of serum followed by RIA of T4 in the dialysate is
the reference method for FT4 but is unsuitable for routine
use (5). Here we report our assessment of five different FT4
analog assays having various separation systems. We have
University Departments of ' Clinical Chemistry and 1 Medicine.
The Royal Infirmary, Edinburgh EH3 9YW, Scotland, U.K.
3 Nonstandard abbreviations: Ff4, free thyroxin; FIT, free thy¬
roxin index; T4. total thyroxin; FT4(D), FT, as measured by RIA
after dialysis to equilibrium; TSH, thyrotropin (thyroid-stimulating
hormone); TRF, thyroliberin (thyrotropin-releasing factor); and T3.
triiodothyronine.
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compared these assays for (a) precision, (6) accuracy as
compared with a reference dialysis method, and (c) diagnos¬
tic efficiency in patients with suspected thyroid disease, in
pregnant women, and in patients with nonthyroidal illness.
Materials and Methods
FT4 by Equilibrium Dialysis
Samples were diluted 20-fold with pH 7.4 buffer contain¬
ing, per liter, 10 mmol of 4-(2-!.ydroxyethyl)-l-piperazine-
ethanesulfonic acid (hepes; Sigma Chemical Co.), 106 mmol
of NaCl, and 1 mmol of NaN3, then dialyzed against an
equal volume of this buffer at 37 °C in a "Dianorm" equilib¬
rium dialyzer (Diachema AG, Zurich, Switzerland) for at
least 18 h. The_T4 in the dialysates was then measured in
duplicate by RIA [FT4(D)1 with a pre-precipitated double-
antibody system (8). Between-run precision was assessed by
dialysis and RIA of three serum pools in 15 assays. The
mean precision (CV) was 11% for FF4 values in the range 7
to 27 pmol/L.
FT4 by Analog RIA
We studied FT4 kits from the following manufacturers:
Amerlex and Amerlex Magnetic (Amerlex-M) iAmersham
International, Amersham, Rucks., U.K.); Becton Dickinson
(Becton Dickinson UK Ltd., Cowley, U.K.); Coat-A-Count
(Diagnostic IVoducts (UK) Ltd., Wallingford, U.K.); and
Coming Magic (Coming Medical and Scientific, Halstead,
U.K.). The Amerlex-M kit, which contains the same analog
and standards as the Amerlex kit, became available after
the start of this study. Table 1 summarizes the assay
protocols. All assays were performed by one operator, using
an automatic diluter and dispensing sample with tracer in
one step within 10 min to minimize effects of drift, particu¬
larly in the coated-tube assays.
Subjects
Endocrine clinic patients. Samples were collected from
200 consecutive patients referred to an endocrine clinic.
These patients were categorized on the basis of clinical
examination by one consultant, and results of measure¬
ments of serum T4, total triiodothyronine (T3), basal thyro¬
tropin (TSH), and the TSH response 20 min after intrave-
Table 1. Comparison of FT4 Analog RIAs
Amerlex Becton- Coat-A- Corning
FT4 Amerlex Magnetic Dickinson Count Magic
Sample vol. 100 100 50 50 50
mL
Pipetting 2 2 1 12
steps
Incubation at 1 1 1.5 1 1
37 °C, h
Wash step No No Yes No No
Sepn. Centrifn. Magnetic Coated Coated Magnetic
method tube tube
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nous administration of 200 gg of TRF (TRF stimulation
test).
The results for 63 patients classified clinically and bio¬
chemically as euthyroid were normally distributed. We used
them to derive reference intervals (mean ± 2SD) for each
FT4 method. The 110 hyperthyroid patients had increased
concentrations of total thyroid hormones and a TSH re¬
sponse of <1 milli-int. unit/L in the TRF test. Five of these
patients had normal values for T4 but increased T3; they
were described as T3-thyrotoxic. Nine patients had a flat
TRF test response but normal concentrations of T4 and T3;
these were classified as having subclinical hyperthyroidism.
Eight patients with low T4 and increased TSH were classi¬
fied as having overt primary hypothyroidism. Ten patients
had normal T4 values but an above-normal TSH concentra¬
tion and were categorized as having subclinical hypothy¬
roidism.
Pregnant women. Samples were collected from 93 women
attending an antenatal clinic at various stages of pregnan¬
cy.
Patients with nonthyroidal illness. Two groups of patients
were studied: (a) 39 patients from a general medical ward,
including patients with cardiovascular, gastrointestinal,
liver, or respiratory disease, stroke, or diabetes mellitus,
and (6) 36 patients with chronic renal failure, who were
receiving dialysis treatment. All of these patients had
normal concentrations of TSH but 28% of the T4 and T3
results were low in group a and 67% of T4 and 36% of T3
results were low in group 6.
All sera were stored at -20 °C until analysis. We used
Student's paired and unpaired f-tests and the Wilcoxon
matched-pairs test for statistical analysis.
Results
Precision: Figure 1 illustrates the mean within-assay
precision profiles for 15 assays bv each method. These
profiles were derived from analysis of the duplicate mea¬
surements for samples (9). The relatively poor precision of
the dialysis method represents the combination of impreci¬
sion originating from the dialysis and RLA steps. The
Amerlex and Amerlex-M assays had the lowest profiles
compared with the coated-tube assays. The Corning Magic
kit was less precise at low values. For practical purposes the
precision attained with all of the kits was adequate between
3 and 100 pmol/L.
We assessed the between-assay precision for the analog
FT4 methods, using two control sera (riatrac ii and m,
Becton Dickinson) and a low-concentration serum pool (Ta¬
ble 2). In addition, a patient's sample from the previous run
was re-analyzed in the next assay (repeat-analysis control)
and, for values within the range 5 to 50 pmol/L, the
precision (CV) calculated from the two results on each
repeat-analysis control from 10 assays was: Amerlex 9%,
Amerlex-M 5%, Becton Dickinson 9%, Coat-A-Count 7%,
and Corning Magic 6%.
Each test was performed in duplicate, so we compared the
average number of tests per run where there was less good
agreement between replicates (duplicate error). A duplicate
error was indicated if the variance ratio of the replicate
counts to the mean counts exceeded the arbitrary value of 20
(9). For each kit the mean percentage of duplicate errors per
run was: Amerlex 27%, Amerlex-M 14%, Becton Dickinson
18%, Coat-A-Count 24%, Corning Magic 13%. This repre¬
sents the number of tests where the replicate values re¬
quired further scrutiny, to determine if re-analysis was
necessary.
Drift analysis: One sample in each of 10 assays was
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Fig. 1. Mean within-run CVs lor 15 assays ol FT., by each method
Reference intervals were: 11-23 (A. Coat A Count); 8-17 (•, Becton Dickinson
and A, equilibrium dialysis); 10-22 (■, Amerlex Magnetic); 10-21 (O, Amerlex);
17-30 (x. Corning) pmol/L Bars indicate 1 SD
Table 2. Between-Assay Precision of the FT4 Kits
Amerlex Bacton- Coat-A- Corning
Amerlex Magnetic CHcklnson Count Magic
Low-concn. pool
n 13 16 15 10 19
Mean, pmol/L 7 7 7 8 13
SD, pmol/L 0.3 0.3 0.6 0.6 0.8
CV, % 5 5 9 7 6
RIATRAC II
n 17 19 15 10 24
Mean, pmol/L 12 13 9 11 19
SD, pmol/L 0.6 0.6 0.8 0.8 0.9'
CV, % 5 5 9 7 5
RIATRAC III
n 15 16 16 10 24
Mean, pmol/L 35 31 21 28 38
SD, pmol/L 1.4 2.2 2.1 2.0 1.9
CV, % 4 7 10 7 5
riatrac ii and 111 are commercial control sera.
samples, each run in duplicate. There was no significant
drift in the Amerlex, Amerlex-M, and Corning Magic as¬
says, but both coated-tube assays showed a positive drift of 7
to 8% (p <0.05).
Accuracy: The standards provided with each kit were
measured by the equilibrium dialysis method. Regression
analysis showed that the supplier-assigned standard values
for Amerlex (or Amerlex-M) and Becton Dickinson fell on
the line of identity with values measured by dialysis. The
slopes of the regression lines for Coat-A-Count and Corning
Magic standards compared to FT4(D) differed significantly
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from 1.0 (p <0.001): FT4 (Coat A Count) = 0.82 x FT4(D) +
1.8 and FT4 (Corning Magic) = 0.79 x FT4(D) + 2.6.
Analog FT4 values compared toFT/D): Figure 2 summa¬
rizes the regression analyses comparing FT4 values ob¬
tained with four of the kits with those by FT4(D) for 150
endocrine clinic patients. Correlation coefficients exceeding
0.94 were obtained for all of the FT4 kits. The equations for
the regression lines were: Amerlex = (1.04 x FT4(D)] + 1.3,
= 6.9; Becton Dickinson = [0.97 x FT4(D)] - 0.5, S^ =
6.2; Coat-A-Count = [0.84* x FT4(D)] + 5.8*, S„ = 7.1;
Corning Magic = [1.00 x FT„(D)] + 10.0*, = 6.2
(•significant differences, p <0.001, from the 45 ° regression
line). Amerlex and Becton Dickinson FT4 values did not
differ significantly from dialysis values but Coat-A-Count
and Corning Magic values at low doses fell below the
regression line drawn, indicating that this relationship was
not rectilinear. For these patients, Amerlex-M values did
not differ significantly from Amerlex FT4 or FT4(D) values:
Amerlex-M = [0.97 x FT„(D)] + 2.3, = 5.7.
Diagnostic efficiency in patient samples: Figure 3 shows
data on the endocrine clinic patients as obtained with four of
the FT4 kits. With the Amerlex-M kit the patients were
categorized in exactly the same way as with the Amerlex kit
and therefore these data are not shown. The reference
intervals (in pmol/L) derived from 62 euthyroid patients
were: Amerlex 10-21; Amerlex-M 10-22; Becton Dickinson
8-17; Coat A Count 11-23; Coming Magic 17-30. The
reference interval for FT4(D) was 8^-17.
Two euthyroid women were taking an estrogen-contain¬
ing oral contraceptive, and both had increased T4 and T3 but
normal FT4 by all methods except the Coat-A-Count kit.
One euthyroid man had a normal value for T3, the TRF
stimulation test, and FT4(D), but above-normal values for T4
and FT4 with all the kits. His results were excluded when
we calculated the reference intervals. On electrophoresis of
his serum, this patient was shown to have increased T4
binding to albumin.
Two patients with overt hyperthyroidism were misclassi-
fied with all of the FT., kits. One patient had a normal value
for T4, but increased T3 and free T3, and was therefore T3
thyrotoxic. The other nonclassified patient had borderline
increases in total T4 and T3. Four of the five patients


















Fig. 3. Serum FT4 as measured with four analog kits in patients
classified as euthyroid, hypothyroid, or hyperthyroid, or as having
subclinical thyroid disease
Two patients were taking oral contraceptives (x); one patient (♦) with high FT,
had an abnormal high-aftinity albumm in the serum
concentrations as measured by all of the kits.
In the "subclinical" groups a proportion of FT4 results
were outside of the reference intervals (Figure 3). Of the 19
patients in these groups, FT4 results were abnormal in
seven to 10, depending on the kit.
In the pregnant group, mean FT4 values decreased signifi¬
cantly (p <0.001) between the first and the third trimesters,
by 24 to 27% as measured by all five kits. Table 3 shows the
number of values falling below the reference interval for
each kit.
Many of our patients with nonthyroidal illness and many
of those with chronic renal failure had low FT4 values as
measured with the kits (Table 3).
Discussion
In the new generation of commercial FT4 radioimmunoas¬
says, T4-analog radiolabels are used that, it is claimed, bind
Table 3. Number (and %) of Low FT4 Values for










Fig. 2. FT, values by analog RIA and equilibrium dialysis compared lor
serum from endocrine-clinic patients
Amerlex 5(5) 4 (10) 24 (67)
Amerlex Magnetic 4 (4) 4 (10) 24 (67)
Becton-Dickinson 4 (4) 7 (18) 30 (83)
Coat-A-Count 13 (14) 9 (23) 26 (72)
Corning Magic 11 (12) 7 (18) 29 (81)
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to the assay antibody but do not bind significantly to the
endogenous binding proteins in serum. The label thus only
equilibrates with the free T4 pool. These FT4 assays are all
relatively easy to perform and require short incubation
times. Different manufacturers have adopted different ana¬
logs, separation systems, and methods of standardization.
As we have demonstrated here, this has resulted in differ¬
ences in accuracy and precision.
The precision profiles (Figure 1) showed that all the kits
we studied are adequately precise over a wide range of
values, the Amerlex and Amerlex-M kits having the best
profiles. These kits, and the Corning Magic FT4 assay, had
better between-run precision than the coated-tube kits. In
part, the imprecision found with the latter kits could be
attributed to the drift effect seen in these coated-tube assays.
This drift problem could be alleviated by pipetting all the
samples first, followed by tracer, but this doubles the set-up
time and introduces errors arising from pipetting a small
sample volume. The kits in which magnetic separation is
used showpd fewer substantial differences between dupli¬
cates than did the other separation systems. The beads used
in the Amerlex separation step appear not to form a compact
pellet after centrifugation, which leads to loss of the anti¬
body at the decanting stage and thus to imprecision and to
an unacceptably high number of samples requiring re-
analysis. The lower number of disagreements between du¬
plicates with the Becton Dickinson kit as compared with the
Coat-A-Count kit may be due to the wash step used in the
former assay.
Analysis of the kit FT4 standards by equilibrium dialysis
showed that results for only the Amerlex (or Amerlex-M)
and Becton Dickinson standards were in agreement by both
kit and equilibrium dialysis, the reference method. Further
confirmation of poor accuracy with the Corning Magic and
Coat-A-Count methods was shown in patients' samples,
where a comparison of these methods with equilibrium
dialysis showed a poor fit of the data to the regression line
(Figure 2). In general, the Coat-A-Count kit gave lower
values than those by dialysis at high FT4 concentrations,
consistent with the results for standards. The Corning
Magic kit, however, gave higher values throughout than
dialysis, resulting in the higher reference range for this kit
This is not consistent with the negative bias of the kit
standard values as compared with those measured by dialy¬
sis, and it suggests that some other feature of this kit such
as the analog or the matrix for the standards is responsible
for the difference in accuracy for patients' samples.
Despite these differences, all the FT4 kits performed
equally well in categorizing patients with thyroid disease.
All but one kit correctly classified the two euthyroid women
who had increased T4 as a result of using an oral contracep¬
tive. However, the inadequate sample size does not permit
any conclusions to be drawn on the various kits' perform¬
ance in this situation. Three patients were misclassified by
all the kits. One patient had T:t thyrotoxicosis and another
had marginally increased T4 and T:) with a normal value for
FT4 by the kits and by dialysis. One euthyroid patient had
an abnormal high-affinity albumin in his serum; this inter¬
fered positively with results by all the FT4 kits, but this
patient had a normal value for FT4 as measured by equilib¬
rium dialysis. This condition of familial dvsalbuminemic
hyperthyroxinemia has been well described (10, 11) and our
data show that it affects the kit results to different extents
because of the different analogs used. This abnormality is
rare but, taken together with the incidence in the popula¬
tion of other abnormal binding proteins (e.g., anti-T4 anti¬
bodies), which similarly interfere with analog R1A (11. 12).
it must be recognized as a problem when these kit assays are
being used. TSH assays, dialysis FT4 measurement, and
electrophoretic studies can be used to investigate further a
patient with an unexpectedly high value for analog-assay
FT4 (12).
Of the five patients classified initially as being T3 thyro¬
toxic, with normal T4 but above-normal values for T3, four
had above-normal FT4. Therefore, replacement of T4 assay
by FT4 assay will apparently decrease the proportion of
patients previously described as being T3 thyrotoxic.
All of the FT4 kits resolved the borderline cases with
subclinical thyroid disease more clearly than did T4 and T3
measurement. Many patients had FT4 values more consist¬
ent with overt thyroid disease. This has therapeutic implica¬
tions, because some patients who were classified from T4
assay as having "subclinical" disorder, and therefore were
simply followed up, would be classified as having overt
thyroid disease on the basis of the FT4 measurement and be
candidates for treatment.
For pregnant women, all the FT4 kits showed results that
decreased significantly as gestation progressed. The Coat-A-
Count and Corning Magic kits gave a greater proportion of
abnormally low results than did the other kits (Table 3). In
practice, trimester-related reference ranges for FT4 must be
used in pregnancy if the test is to be correctly interpreted.
Low FT4 values were found with these analog kits for
several patients from a general medical ward, all of them
clinically euthyroid with normal basal values for serum
TSH. The occurrence of low values for T4 in patients with
nonthyroidal illness is a well-recognized diagnostic problem
(13, I'D. Contributing factors may include decreased binding
capacity (or affinity) of serum protein for T4, owing (e.g.) to
proteinuria, liver disease, or drugs binding to the binding
proteins. In theory, FT4 assays should not be as greatly
affected bv these changes and thus should more accurately
reflect thyroid status in such patients. In practice, FT, as
measured by analog RIA is affected by changes in albumin
concentration and binding capacity (15>. but our study
shows that FT., is still superior to T4 measurement in these
patients. The percentage of low results varied (Table 3) from
1055- (Amerlex'Amerlex-M) to 23T (Coat-A-Count). In the
patients with chronic renal failure, however, there was an
equal or greater proportion of low FT4 kit values as
compared with T4. Only two of our patients with chronic
renal failure had low albumin concentrations and low FT4
values have been confirmed by other dialysis methods in
this patient group (14). Because TSH secretion is not
increased, it has been argued that the thyroid axis may be
"down regulated" physiologically in some patients with
nonthyroidal illness, to conserve body protein and decrease
catabolism (16). Low concentrations of T3 in tissue, accom¬
panied by decreased activities of thyroid hormone-depen¬
dent enzymes, have been demonstrated in uremic rats (17).
In other studies an increase in the dialyzable fraction of T4
has been demonstrated and attributed to the presence of
inhibitors of protein binding in the sera of some patients 118.
19). It is becoming apparent that FT4 may be altered in
nonthyroidal illness, owing not only to method differences
but also to a true physiological change, particularly in
severe disease. Currently there is no clear evidence that
thyroxin-replacement therapy in such patients is beneficial.
If thyroid assessment is required in such patients, it there¬
fore is advisable to use the FT4 kit that gives the lowest
number of abnormal results, and in this study the Amerlex'
Amerlex-M assays fulfilled this criterion. Measurement of
TSH would distinguish the low FT4 of hypothyroidism from
that of a possible physiological adaptation in patients with
nonthyroidal illness.
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We conclude that although all of these kits must be used
with caution in patients with nonthyroidal illness, they
performed equally well in classifying patients attending a
thyroid clinic. However, better precision and accuracy were
obtained with the Amerlex Magnetic FT« kit, which we
consider to be the method of choice.
We thank the above-mentioned manufacturers for supplying us,
gratis, with kits used in this study.
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SimulTRAC™ Simultaneous Radioimmunoassay of Thyrotropin and Free
Thyroxin Evaluated
Sadie M. Gow,1 Gordon Caldwell,2 Anthony D. Toft,2 and Geoffrey J. Beckett1
We assessed the analytical and diagnostic performance of a
dual-isotope RIA for thyrotropin (TSH) and free thyroxin
(FT4) in serum. The mean interassay CVs for these analytes
were 7.9% and 5.0%, respectively. The mean minimum
detection limit for TSH was 0.25 milli-int. unit/L, the mean
analytical recovery 110%. There was good agreement with
values for TSH and FT4 measured by alternative RIA proce¬
dures. Euthyroid patients were well distinguished from those
with overt thyroid disease, although there was a small
overlap in the case of TSH. Combining the two results better
discriminated these categories and identified those patients
with subclinical thyroid disease who had abnormal TSH
concentrations but FT4 concentrations within reference lim¬
its. Euthyroid women taking estrogen-containing oral contra¬
ceptives had normal results for TSH and FT4, as did most
pregnant women studied. During the third trimester of preg¬
nancy, TSH concentrations of women with low FT4 concen¬
trations were within reference limits. Similarly, euthyroidism
was confirmed in patients with low FT4 due to nonthyroidal
illness by the simultaneous finding of a normal TSH concen¬
tration.
Additional Keyphrases: thyroxin analog method ■ thyroid status
reference interval ■ pregnancy
Measurement of thyrotropin (TSH, thyroid-stimulating
hormone) in serum is widely considered the most sensitive
hinrtiprni'-al test of primary hypothyroidism.3 In mild or
s"hHimeal hypothyroidism, total thyroxin (T4) concentra¬
tions in serum are within normal limits, indicating that an
increase in TSH secretion is the first measurable change to
occur when thyroid secretion declines (I, 2). In hyperthy¬
roidism, the concentration of thyroxin-binding globulin
(TBG) in serum decreases (3), making measurement of free
thyroid hormone concentrations more appropriate than as¬
says for protein-bound (total) thyroid hormones. Measure¬
ment offree thyroxin (FT4) appears to identify hyperthyroid
patients almost as well as measurement offree triiodothyro¬
nine (FT3), with the advantage of greater diagnostic value
than FT3 in patients with hypothyroidism (4-6). The "Si¬
mulTRAC free T4/TSII RIA," developed by Becton Dickin¬
son, is intended to combine the diagnostic strengths of these
individual measurements with the convenience of a single-
tube assay. In this dual-isotope RIA, the radioactivity of the
57Co-labeled thyroxin analog and 12rT-labeled TSH tracers is
measured in a gamma counter capable ofdistinguishing the
different scintillation energies of the two radioisotopes. The
University Departments of ' Clinical Chemistry and 2 Medicine,
The Royal Infirmary, Edinburgh EH3 9YW, Scotland, U.K.
3 Nonstandard abbreviations: TSH, thyrotropin; T4, total thyrox¬
in; FT4, free thyroxin; T3, total triiodothyronine; FT3, free triiodo¬
thyronine; TUG, thyroxin-binding globulin; IRP, International
(WHO) Reference Preparation.
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thyroxin analog is claimed not to bind significantly to the
natural binding proteins in serum but binds like thyroxin to
the assay antibody.
We have compared the diagnostic efficiency of this assay
with our current strategy for assessing the thyroid function
of patients attending an endocrine clinic. This current
strategy consists of clinical assessment; measurement of
total T4, total triiodothyronine (T3), and TSH in serum; and
measurement of the TSH response to thyroliberin (thyrotro-
pin-releasing factor) in cases of suspected hyperthyroidism.
Because of the current controversy regarding the validity
and diagnostic utility of one-step analog assays for FT4,
particularly in situations of altered concentrations and
affinities of hormone binding proteins (7-9), we also studied
pregnant women and patients with low T4 concentrations
related to nonthyroidal illness.
Materials and Methods
Assays
"SimulTRAC" Free T4 (57Col/TSH |125I] RIA kits (five
different lots) were supplied by Becton Dickinson Immuno-
diagnostics, Cowley, Oxford, U.K. The dual serum stan¬
dards contain TSH (0 to 45 milli-int. units/L), calibrated
against the WHO 1st International Reference Preparation
(IRP 68/38), and FT4 (0 to 125 pmol/L), calibrated by
equilibrium dialysis. In this study we used the 4-h high-
sensitivity incubation option; this omits the top standard
supplied, making 15 milli-int. units/L and 70 pmol/L the
highest standards assayed for TSH and FT4, respectively.
We incubated 200 pL of sample with 100 g L of rabbit dual
antibody for 2.5 li at 37 °C, then for 1.5 h more after adding
100 gL of dual tracer. Free ligand was separated from bound
by adding goat anti-rabbit antiserum and a precipitation
accelerator, polyethylene glycol, and centrifuging. Radioac¬
tivity from the two radioisotopes was counted simultaneous¬
ly in a gamma counter (LKB Wallac, Wallac Oy, Turku,
Finland) with <2% spill-over of counts between channels.
We interpolated the results by using a four-parameter
logistic curve fit (WHO immunoassay package) and an
Apple microcomputer. High TSH samples (>15 milli-int.
units/L) were re-assayed after fivefold dilution in the zero
concentration standard.
All sera were stored at -20 °C until assay. We used
Student's unpaired i-test and the Mann-Whitney test for
unpaired data in statistical analyses.
Subjects
Endocrine-clinic patients. We collected serum from 116
consecutive new patients referred to an endocrine clinic
with suspected thyroid disease or for treatment of hyperthy¬
roidism. All 56 patients with overt hyperthyroidism had
above-normal concentraUons of T4 and (or) T3 and an
increase in TSH of less than 1 niilli-int. unit L 20 min after
the intravenous injection of 200 gg of thyroliberin. Eight
patients had a flat response to this test but normal concen-
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trations of T4 and T3; they were classified as having
subclinical hyperthyroidism. Forty patients with normal
responses of TSH to thyroliberin were classified clinically
and biochemically as euthyroid, including seven women
who were taking an estrogen-containing oral contraceptive
and who had increased concentrations of total thyroid
hormones. Twelve patients had an increased concentration
ofTSH, which was associated with a low T4 concentration in
nine patients (overt hypothyroidism) and a normal T4 value
in three (subclinical hypothyroidism).
Pregnant women. Samples were collected from 26 women
at various stages of pregnancy who were attending an
antenatal clinic.
Patients with nonthyroidal illness. We assayed samples
from 12 patients with chronic renal failure who were
receiving treatment by dialysis and from 20 patients from a
general-medical ward. The latter group included patients
with cardiovascular, gastrointestinal, hepatic, or respira¬
tory disease. All of the patients with chronic renal failure




Precision. The mean intra-assay precision profiles (Figure
1) were calculated from results for duplicate sample analy¬
ses from 11 SimulTRAC assays (10). The FT4 assay had
excellent precision over a wide concentration range. The
TSH assay was less precise, with a mean CV of 10% at 1.0
milli-int. unitlL.
The interassay precision data (Table 1) were calculated
from duplicate analyses of pooled patients' sera and of
Lyphochek control sera (Bio-Rad Labs., Richmond, CA; lot
no. 07300) in 11 assays. The average bias for the Lyphochek
controls was calculated from the quoted values. For the
results for the in-house pools, we calculated bias from target
values established by the Amerlex-M FT4 assay (Amer-
"<K«
Table 1. Interassay Precision of the SimulTRAC
FT4/TSH Assay
Lyphochek Pooled sera








I II III a b c
Mean 1.5 10.9 30.2 3.0 9.0 42.9
Target 1.5 11.2 23.2 2.8 7.5 44.8
Bias, % 0 -3 + 30 + 7 + 20 -4
SD 0.1 1.0 2.7 0.2 0.5 2.2
CV, % 10.2 9.4 8.8 7.7 6.1 5.2
n = 11.
sham International, Amersham, U.K.) for pools 1 and 2 and
by an in-house TSH assay (1) for pools a-c. We diluted
Lyphochek III and pool c fivefold in zero standard beforr
measuring TSH.
Detection limit of the TSH assay. The detection limit
determined conventionally from the 95% confidence limit
for 20 replicate estimations of the zero standard, was 0.T
milli-int. unit/L. Because patients' samples are not assayei
in replicates of 20, a more meaningful estimate of 0.25 milli
int. unit/L was obtained from the mean precision profili
(Figure 1A) at a CV of 40%, which is equivalent to 2.5 SI
from the zero standard (10).
Analytical recovery ofTSH. Percentage recoveries of TS1
IRP standard (1, 4, and 20 milli-int. units/L final concentre
tion) added to pooled euthyroid serum were 113, 120, an'
97%, respectively.
Correlation with other methods. Regression analysis (
FT4 results obtained by SimulTRAC (y) and another analo
PT4 RIA (Amerlex-M, x) for 32 patients' samples analyze
in the routine diagnostic laboratory because of suspecte
alterations in protein binding (range of FT4 results 4-3
pmol/L) gave the equation:
y = 1.13x - 1.7 pmol/L (Syx = 1.9)
Comparison of SimulTRAC TSH iy') with our in-hou:
method (x') for values less than 10 milli-int. units/L (n = 5'
gave the regression equation:
y' = 1.08x' - 0.44 pmol/L (Sy, = 0.5).
These correlations differed significantly (p <0.001) from v
x for the x slope and the y" intercept.
Diagnostic Efficiency
The 95% confidence intervals calculated from the data <
40 euthyroid patients were 11.1-24.1 pmol/L for FT4 ai
0.6-5.7 (mean 1.8) milli-int. units/L for TSH, after logarit
mic transformation of the data. These intervals were n
notably different from those derived by the manufactui
from results for 146 individuals: FT4, 11.4-25.3 pmol
TSH, 0.9-6.7 milli-int. units/L. Use of the manufacture
reference range for TSH minimized the overlap between t
different categories of patients (Figure 2).
All hyperthyroid patients (overt and subclinical) had Tb
values <0.9 milli-int. unit/L and all hypothyroid patiei
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Fig. 2. SimulTRAC FT4/TSH results for 116 endocrine clinic patients,
including seven women taking an estrogen-containing oral contracep¬
tive (O.C.P.)
Reference limits: ---
L. With these reference limits, results overlapped for only
two euthyroid patients, who had low concentrations of TSH
(0.6 and 0.8 milli-int. unit/L).
All patients with overt hyperthyroidism had FT4 values
exceeding 24.1 pmol/L, and all those with overt hypothyroid¬
ism had FT4 values <11.1 pmol/L. All but two patients with
subclinical disease had FT4 concentrations within the refer¬
ence interval: one patient with subclinical hyperthyroidism
had a FT4 value of 24.8 pmol/L, and one with subclinical
hypothyroidism had a low result for FT4 (6.9 pmol/L). All
euthyroid patients whose T4 concentrations were increased
owing to an estrogen-induced increase in TBG, had normal
results by SimulTRAC. Compared with our standard strate¬
gy for investigating patients with possible thyroid dysfunc¬
tion, the SimulTRAC assay produced similar categorization
in 112/116 (96.5%) of the patients studied.
SimulTRAC FT4/TSH results for TSH in pregnant wom¬
en were significantly (p <0.0001) higher (mean 4.0 milli-int.
units/L, range 1.7-6.3) than in the nonpregnant euthyroid
patients, but none exceeded the upper reference limit (Fig¬
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Fig. 3. SimulTRAC FT4/TSH results for pregnant women and patients
with nonthyroidal illness
mean values in the third trimester, 10.8 (SD 1.5) pmol/L,
were significantly lower than values for women in the first
(p <0.0001) and second (p <0.01) trimesters and for non¬
pregnant euthyroid individuals (p <0.001).
For patients with nonthyroidal illness, TSII values were
slightly higher than in euthyroid endocrine-clinic patients
(mean 2.3 milli-int. units/L, range 0.8-6.3, p <0.05) but
none exceeded the upper reference limit (Figure 3). In
patients with normal T4 values, SimulTRAC FT4 results
did not differ significantly from those for euthyroid patients
attending the endocrine clinic, whereas those with low T4
values or with chronic renal failure had significantly lower
FT4 values (p <0.001). Results for FT4 were below the
reference interval in all 12 patients with chronic renal
failure and in four of the 10 patients from the general
medical ward who had low T4 concentrations.
Discussion
The SimulTRAC FT4/TSH assay is easy to perform, has
acceptable reproducibility, and gives results similar to those
from other analog one-step FT4 assays (//) and TS11 RIA
methods. The mean detection limit of 0.14 milli-int. unit/L,
derived conventionally for the TSH assay, compares favor¬
ably with values achieved by "high sensitivity" immunora-
diometric assays (.12), but not by the new generation of non-
isotopic TSH assays (13). In the SimulTRAC RIA, high
sensitivity is achieved, to some extent, at the expense of a
narrow working range. With use ofappropriate curve-fitting
procedures, the top standard probably could be included,
extending the TSH range to 40 milli-int. units/L. The vari¬
able bias figures for TSH at high concentrations (Table 1)
may be ascribable to the predilution of samples with TSH
>15 milli-int. units/L rather than to poor analytical recov¬
ery.
For patients attending an outpatient endocrine clinic, the
dual-analyte assay produced the same categorization as did
our present investigative strategy in 96.5C of cases. This
was achieved by using individual reference intervals for
FT4 and TSH without recourse to the more-complex linear
discriminant analysis that has been applied in the past to
combinations of older thyroid-function tests (14). All pa¬
tients with a flat result for the thyroliberin-stimulation test
had basal SimulTRAC TSH values of <0.9 milli-int. unit/L.
However, the fact that low TSH results were also found in
5% of euthyroid patients means that, unlike TSH measure¬
ment by more specific and sensitive assays (15, 16), Simul¬
TRAC basal TSH could not be used alone as a predictor of
the results of the stimulation test. Used in combination with
the FT4 result, however, it allowed all patients with overt
hyperthyroidism to be distinguished from euthyroid pa¬
tients.
In this study, we had no patients with "T3-thyrotoxico-
sis"—i.e., normal values for total T4 but above-normal
values for T3. Most such patients also have increased FT4
concentrations (11) and therefore are unlikely to be misclas-
sified by the SimulTRAC assay. Use of this assay could
therefore decrease the need for thyroliberin-stimulation
tests to those patients with normal FT4 but low TS11 results,
in order to distinguish euthyroid patients from those with
subclinical hyperthyroidism.
The 40% decline we observed in FT4 during pregnancy
agrees with that seen on use of other one-step analog assays,
which appear to exaggerate the decrease as measured by
equilibrium dialysis (17) and necessitates use of trimester-
related reference ranges. The presence of a normal TSH
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concentration with the SimulTRAC assay confirms euthy-
roidism in those with low FT4. The TSH results for our
pregnant women were significantly higher than in non¬
pregnant subjects. This may reflect a residual cross-reactiv¬
ity problem with the TSH assay, despite absorption of the
antiserum with human choriogonadotropin and the negligi¬
ble cross reactivity with this hormone, quoted by the manu¬
facturers, of (1.64 x 10~6)%.
Patients with nonthyroidal illness commonly had low FT4
results, particularly those with low total T4 concentrations.
As with other analog FT4 RIAs, changes in albumin concen¬
tration and the presence of drugs and binding protein
inhibitors in the serum of these patients may alter the
protein-binding of the analog compared to standards, lead¬
ing to low results (18,19). However, none ofour patients had
increased TSH concentrations by SimulTRAC, so this would
minimize the possibility of misdiagnosis of hypothyroidism
in this group. Increases in TSH have been described during
the recovery phase after systemic illness (20), which may
account for the slightly higher TSH values in this patient
group as compared with those attending the endocrine
clinic.
Spuriously high results for FT4 by analog assay have
been reported in rare cases, such as patients with high-
affinity albumin binding (21) or autoantibodies to T4 (22).
We used the SimulTRAC kit to analyze serum from two
patients with such abnormalities and found normal TSH
concentrations with a modest increase in FT4 (28.4 pmol/L)
in a patient with high-affinity albumin, and a gross increase
(FT4 >70 pmol/L) in a case with autoantibodies to T4. This
combination of SimulTRAC results in an apparently euthy¬
roid individual should alert the clinician to the possible
presence of an abnormal binding protein in serum. In such
patients, hyperthyroidism can be excluded by the demon¬
stration of a normal result in a thyroliberin-stimulation
test.
We conclude that the combined FT4/TSH test offers
advantage over our current strategy (T4, T3, TSH, or
stimulation test) by minimizing the need for thyroliberin-
stimulation tests and the total number of analyses while
providing the same diagnostic information. TSH measure¬
ment provides a better initial test of hypothyroidism than
assay of total T4, both in outpatient clinics and in the
hospital ward and, together with FT4 measurement, pro¬
vides a useful means for monitoring the adequacy of thyrox¬
in replacement therapy. For laboratories with small work¬
loads and those cautious about adopting a supersensitive
TSH measurement as their firstline thyroid-function test,
measurement of FT4 and TSH by dual RIA provides a
suitable alternative with advantages to the laboratory and
the clinician in terms of time savings and simultaneous
reporting of two complementary thyroid-function test re¬
sults.
We are grateful to Becton Dickinson Immunodiagnostics for
supplying kits free of charge, and to Professor L. G. Whitby and
Mrs. E. Ward for their help in preparing this manuscript.
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A sensitive immunoradiometric assay for serum thyroid
stimulating hormone: a replacement for the thyrotrophin
releasing hormone test?
JSETH, H A KELLETT, G CALDWELL, V M SWEETING, G J BECKETT, S M GOW, A D TOFT
Abstract
The value as a thyroid function test of a new, rapid, and
highly sensitive immunoradiometric assay for thyroid
stimulating hormone (TSH) was assessed in 188 con¬
secutive new patients "^vith suspected hyperthyroidism.
The diagnosis was made on clinical grounds and on the
basis of serum total triiodothyronine and thyroxine
concentrations and the response of TSH to thyrotrophin
releasing hormone (TRH) as measured by radioimmuno¬
assay. In all except one patient the basal TSH concentra¬
tion by immunoradiometric assay predicted the response
of TSH by radioimmunoassay to TRH, an undetectable
value being recorded in patients with a subnormal
response and a measurable value in those with a normal
test result. This clear relation was not observed for basal
TSH concentrations as measured by radioimmunoassay.
In a series of 39 hospital inpatients with acute or chronic
non-thyroldal illness, ofwhom 11 had low concentrations
of total thyroxine or triiodothyronine, or both, basal TSH
concentrations were detectable by both radioimmuno¬
assay and immunoradiometric assay in all cases and
were associated with normal responses to TRH.
The immunoradiometric assay for TSH, which is
commercially available, may therefore obviate the need
for the more time consuming TRH test and simplify the
approach to thyroid function testing in patients with
suspected hyperthyroidism.
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Introduction
Measurement of the basal serum concentration of thyroid
stimulating hormone (TSH) is an essential test in the investiga¬
tion of suspected vhypothyroidism. A raised concentration
confirms a primary cause of the disease, while a normal or low
concentration excludes it or, more rarely, indicates a pituitary
or hypothalamic cause. Except in thyrotoxicosis induced by
TSH, which is extremely rare, the basal serum TSH concentra¬
tion is suppressed in hyperthyroidism. These low TSH con¬
centrations, however, are of little diagnostic value as most
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radioimmunoassays for TSH have limited sensitivity (detection
limits 1-2 mU/1), so that concentrations are recorded as un¬
detectable not only in hyperthyroid patients but also in some
euthyroid patients. Measurement of serum TSH concentrations
before and after intravenous administration of thyrotrophin
releasing hormone (TRH) is therefore often required to
discriminate between euthyroidism and hyperthyroidism. A
normal T-SH response excludes a diagnosis of hyperthyroidism,
while a subnormal response is consistent with overt or sub¬
clinical hyperthyroidism.
The development of a sensitive immunoradiometric assay for
TSH (Boots-Celltech Sucrosep TSH IRMA, Boots-Celltech
Diagnostics Limited, Slough SL1 4ET, Berkshire) that is
claimed to detect TSH concentrations as low as 0-05 mU/1
raised the possibility that the assay might discriminate between
basal concentrations in euthyroid and hyperthyroid patients,
thereby avoiding the need for a TRH test. We describe our
experience in assessing this possibility.
Patients and methods
We studied 188 new patients consecutively referred to a thyroid
clinic with suspected hyperthyroidism. Their mean age was 48
(range 19-81). Thyroid state was assessed clinically by one of us
(ADT) and by measurement of serum concentrations of total triiodo¬
thyronine, total thyroxine, and TSH (by radioimmunoassay) before
and 20 minutes after intravenous administration of 200 /ig TRH
(TRH test). Basal TSH concentrations were also measured by the
immunoradiometric assay, but the results were not used to determine
the diagnostic categories of the patients. In 110 patients there was
evidence of hyperthyroidism with raised serum concentrations of total
triiodothyronine and thyroxine and a subnormal TSH response to
TRH. The hyperthyroidism was due to Graves' disease, multinodular
goitre, and solitary autonomously functioning thyroid nodule in 87,
20, and three patients respectively. Sixteen patients were considered
to have subclinical hyperthyroidism on the basis of normal thyroid
hormone concentrations and a subnormal TSH response to TRH.
Ten of these patients had a multinodular goitre, one a solitary thyroid
nodule that resolved spontaneously, two ophthalmic Graves' disease,
and three diffuse thyroid enlargement presumed to represent Graves'
disease in remission. Of the remaining 62 euthyroid patients, 13 had a
solitary thyroid nodule, 14 a multinodular goitre, and 35 no evidence
of thyroid disease. In these 62 patients normal concentrations of
total triiodothyronine and thyroxine were associated with a normal
TRH test result.
The above thyroid function tests were also performed within
36 hours after admission in 39 patients admitted consecutively as an
emergency to a general medical unit with acute or chronic non-
thyroidal illness. Their mean age was 61 (range 15-86), and none had
clinical evidence or a history of thyroid disease.
After collection of blood thp separated serum was stored at — 20"C
in aliquots for each assay. Serum total triiodothyronine and thyroxine
concentrations were measured by double antibody radioimmuno¬
assays,' the normal ranges being 1 -1-2-8 nmol/1 (0-7-1-8 ng/ml) and
70-150 nmol/1 (5-4-11-7 /jg/100 ml) respectively. Serum TSH
concentration was measured by the double antibody radioimmuno¬
assay routinely used in the laboratory,' the normal range being from
undetectable to 6 mU/1. The assay used a sheep anti-TSH antiserum
of good specificity such that there was no interference from follicle
stimulating hormone and luteinising hormone at postmenopausal
concentrations, or from human chorionic gonadotrophin at the
concentrations found in pregnancy.
TSH was also measured by the Boots-Celltech Sucrosep TSH
immunoradiometric assay using the protocol enclosed with the kit.
Both the radioimmunoassay and the immunoradiometric assay were
calibrated in terms of the TSH International Reference Preparation
68/38. The immunoradiometric assay had a substantially lower limit
of detection, wider working range, and better within assay precision
than the radioimmunoassay (table,I). Although our radioimmuno¬
assay has a lower limit of detection than many others, this is achieved
only at the expense of a relatively long assay time. There was an
excellent correlation between TSH concentrations measured by
radioimmunoassay and by immunoradiometric assay in a separate
series of 108 patients in whom values lay between 0-9 and 130 mU/1
(r- 0-99; p<0 001). There was no evidence of interference in the







luteinising hormone at postmenopausal concentrations, as shown by
basal TSH concentrations that were consistently undetectable in both
premenopausal and postmenopausal patients with thyrotoxicosis.
This was in agreement with the kit manufacturer's claim of cross
reactivities of less than 0 002% for both follicle stimulating hormone
and luteinising hormone.
TABLE I—Comparison of laboratory performance of radioimmunoassay and
immunoradiometric assay for TSH (mean values for 10 assays)
Immunoradiometric
Detection limit (mU/1)*
Range (mU/I) for a 10% coefficient
of variation
Within assay precision (coefficient
of variation)!
Between assay precision (coefficient
of variation);
Time required (days)
•Minimum concentration that can be distinguished from zero at 95 % confidence level.
tMean value from sample replicates.
{Mean value for serum pools 3 0, 71, 210, and 52 0 mU/1.
Results
The figure shows basal TSH concentrations measured by both
radioimmunoassay and immunoradiometric assay in the patients
attending the clinic and in those with non-thyroidal illness. Among
the 110 patients with hyperthyroidism TSH was undetectable by
radioimmunoassay (less than 0-9 mU/1) in 101, and in the nine
remaining patients concentrations of 10-1-7 mU/1 were recorded,
which overlapped the euthyroid range. In contrast, the more sensitive
immunoradiometric assay recorded undetectable concentrations (less
than 0 07 mU/1) in all patients. Among the 16 patients with subclinical
hyperthyroidism radioimmunoassay recorded undetectable TSH
concentrations in 13 and concentrations of 11, 10, and 10 mU/1 in
three; whereas immunoradiometric assay recorded undetectable
concentrations in all but one patient, in whom a value of 014 mU/1
was recorded (see Discussion). TSH concentrations were detectable
in 60 of the 62 euthyroid patients and in all 39 with non-thyroidal
illness when measured by radioimmunoassay, and in every patient
in these two groups when measured by immunoradiometric assay.
Comparison of basal TSH concentrations with the response of TSH
to TRH measured by radioimmunoassay (table II) showed that all
but one patient with a detectable basal TSH concentration on


















Scrum TSH concentrations measured by radioimmunoassay (O) and by
immunoradiometric assay ( •) in patients with thyroid disease and patients
with non-thyroidal illness. Broken lines indicate limits of detection for
radioimmunoassay (0-9 mU/1) and immunoradiometric assay (0 07 mU/1).
The asterisk indicates the single patient in whom the immunoradiometric
assay did not predict the result of the TRH test.
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Conversely, in all patients with an undetectable basal TSH con¬
centration on immunoradiometric assay there was a subnormal
response of TSH to TRH on radioimmunoassay. The same close
relation was not seen, however, between basal TSH concentrations
measured by radioimmunoassay and the result of the TRH test.
Thus two euthyroid patients with undetectable TSH concentrations
on radioimmunoassay gave normal responses to TRH, and nine
TABLE II—Relation between basal serum TSH and response of TSH to TRH












•TSH concentration (by radioimmunoassay) at 20 minutes of 1-0 mU/1 or more
above basal value.
hyperthyroid patients and three patients with subclinical hyper¬
thyroidism with detectable TSH concentrations on radioimmunoassay
showed a subnormal response to TRH.
In all 39 patients with non-thyroidal illness there were detectable
TSH concentrations on radioimmunoassay and immunoradiometric
assay associated with normal TRH test results, despite low concentra¬
tions of total thyroxine or triiodothyronine, or both, in 11.
Discussion
The important advantages of the immunoradiometric assay
compared with the radioimmunoassay—namely, higher
specificity, lower limit of detection, wider working range, and
speed of analysis—are a consequence of the fundamentally
different principles on which the assays are based. The Boots-
Celltech Sucrosep immunoradiometric assay uses a combination
of two monoclonal antibodies, each of which is specific for a
different epitope on the TSH molecule. One antibody is
bound to a solid matrix while the other is radiolabeled.
Simultaneous binding of both antibodies to TSH results in the
formation of a radiolabeled insoluble "sandwich," the con¬
centration of which is directly related to the amount of TSH
in the sample. The concentration of the insoluble sandwich is
indicated by the amount of radiolabel in the insoluble form.
The specificity derives from the requirement for binding by
two distincdy separate antibodies, while the other advantages
of low limit of detection, wide working range, and speed derive
from the use of excess reagents in the assay.
Although the immunoradiometric assay is superior to the
radioimmunoassay from the laboratory point of view, it is
important to assess whether these analytical advantages provide
real improvements for the investigation of thyroid disease. Our
results show that TSH concentrations as measured by the
immunoradiometric assay can reliably predict the response to
TRH and thereby simplify the assessment of thyroid function
in patients with suspected hyperthyroidism. Whereas basal
TSH concentration as measured by radioimmunoassay predicted
the response of TSH to TRH in 175 out of 188 patients, when
measured by immunoradiometric assay it predicted the response
in. 187 of the 188 patients. The exception was a patient who
presented with a solitary thyroid nodule that regressed
spontaneously after three months, suggesting a diagnosis of
haemorrhage into a cyst or adenoma. At presentation total
triiodothyronine and thyroxine concentrations were in the
middle of their respective normal ranges at 1-6 nmol/1 (1-0 ng/ml)
and 91 nmol/1 (7-1 pig/100 ml). The basal TSH concentration on
radioimmunoassay was 10 mU/1 and showed a marginally
subnormal increase to 1-9 mU/1 after administration of TRH.
Such a result was not expected on clinical grounds, and the
basal TSH concentration of 014 mU/1 as measured by immuno¬
radiometric assay was more consistent with the probable
diagnosis.
Our findings suggest that it may no longer be necessary to
perform the time consuming TRH test in patients referred with
possible hyperthyroidism and that clinical assessment and
measurement of total or free triiodothyronine and thyroxine
concentrations and of basal TSH concentrations by immuno¬
radiometric assay are sufficient. Like a subnormal response of
TSH (on radioimmunoassay) to TRH, an undetectable TSH
concentration on immunoradiometric assay would be consistent
with a diagnosis of hyperthyroidism but would also be recorded,
as in this series, irt patients with subclinical hyperthyroidism
associated with multinodular goitre, autonomous solitary
nodule, and ophthalmic Graves' disease.3 Undetectable con¬
centrations are also likely to be recorded in some patients
receiving replacement treatment with thyroxine and in the
presence of normal or even low concentrations of thyroid
hormones in the early weeks after treatment of hyperthyroidism
due to the delayed recovery of the previously suppressed
pituitary thyrotrophs.' A detectable result on immunoradiometric
assay would exclude hyperthyroidism. It is important to
consider the po":ble effects of non-thyroidal illness on immuno¬
radiometric assay of basal TSH concentrations. It is well
recognised that low thyroid hormone concentrations and a
reduced serum TSH response to TRH may occur in patients
with non-thyroidal illness, such as pneumonia, myocardial
infarction, or renal failure,5 and such abnormalities are a
common cause of difficulty in interpreting test results in
hospital patients. In all 39 cases in this series, however, detectable
basal TSH concentrations on immunoradiometric assay
correctly predicted a euthyroid state as defined by a normal
response of TSH to TRH.
Immunoradiometric assays are now increasingly being used
to measure peptide hormones. Although these new methods
are known to have several analytical advantages over radio¬
immunoassay, we believe that this study is the first to show an
appreciable clinical benefit from the new generation of immuno¬
assay technology.
References
1 Ratcliffe WA, Challand GS, RatclifTe JG. A critical evaluation of separation
methods in radioimmunoassays for total triiodothyronine and thyroxine in
uncxtracted human serum. Ann Clin Biochem 1974;11:224-9.
2 Irvine WJ, Toft AD, Hunter WM, Kirknam KE. An assessment of plasma TSH
radioimmunoassay and of TSH stimulation test in the diagnosis of 100 con¬
secutive patients with suspected hypothyroidism. Clin Endocrinol 1973;2:135-9.
3 Lamberg B-A, Gordin A. Abnormalities of thyrotropin secretion and clinical
implications of the thyrotrophin releasing hormone stimulation test. Ann Clin Res
1978;10:171-83.
4 Toft AD, Irvine WJ, Sinclair I, Mcintosh D, Seth J, Cameron EHD. Thyroid
function after surgical treatment of thyrotoxicosis. N EnglJ Med 1978;298:643-7.
5 Lim VS, Fang VS, Katz AI, Refetoff S. Thyroid dysfunction in chronic renal
failure. J Clin Invest 1977;60:522-34.
(Accepted 6 September 1984)
Printed in CJreai Britain by Bourne Offset Ltd . Iver, Rucks.
The Lancet • Saturday 18 May 1985
A NEW STRATEGY FOR THYROID FUNCTION
TESTING
G. Cai.dwf.ll H. A. Kellett
S. M. Gow G. J. Bf.ckf.tt
V. M. Sweeting J. Seth
A. D. Toft
University Departments oj Medicine and Clinical Chemistry, Royal
Infirmary, Edinburgh EH3 9YW
Summary In view of the increasing number of in-vitro
tests of thyroid function, rationalisation of
the biochemical assessment ofpatients with suspected thyroid
disease was attempted. In addition to clinical examination
of 285 consecutive new referrals to a thyroid clinic,
measurements were made of serum total and free
triiodothyronine (T,) and thyroxine (T4) and of thyrotropin
(TSH) by radioimmunoassay before and 20 min after
thyrotropin-releasing hormone (TRH) and basal TSH by
immunoradiometric assay (IRMA). Analysis of these results
demonstrated that: (i) a detectable and normal TSH (IRMA)
result indicates that the patient is euthyroid and obviates the
need for measurement ofthyroid hormones and (ii) a raised or
undetectable TSH (IRMA) level should be followed by
measurement of free T4 (and rarely also free T}) to
distinguish between subclinical and overt hypothyroidism
and hyperthyroidism. This policy would considerably reduce
the number of in-vitro thyroid function tests without
resulting in either a delay in diagnosis or a reduction in its
accuracy.
Introduction
The diagnosis of thyroid dysfunction is based on clinical
examination supported by appropriate in-vitro and, less
often, in-vivo tests. Since the early 1970s, the clinician has
had access to some, or all, of the following serum tests:
triiodothyronine uptake test, free thyroxine (T4) index, total
T4 (TT4), total T) (TTj), TT4/thyroxine-binding-globulin
ratio, free T4 (fT4), free T, (fT,), basal thyrotropin (TSH) by
radioimmunoassay (RIA), and TSH response to thyrotropin-
releasing hormone (TRH). The most recently developed test
is an immunoradiometric assay (IRMA) for TSH that is
sensitive enough to discriminate on a basal serum sample the
undetectable levels ofovert and subclinical hyperthyroidism
from those found in euthyroid patients, thereby making the
TRH test redundant.1 Commercial kits for these tests are
expensive, and it is therefore important to assess which of
those currently available should be recommended for use in
laboratories without their own in-house assays.
Patients and Methods
We studied 285 consecutive new patients referred to the
endocrine unit, Royal Infirmary, Edinburgh, either with suspected
thyroid disease or for therapy with iodine-131. There were 247
females and 38 males (age range 13-80 years, mean 47-6). The
diagnosis in each case was made on clinical grounds and on the basis
of measurements of TT4, TT,, basal TSH (RIA), and the TSH
response 20 min after the intravenous administration of 200 pg
TRH. In addition to these tests, blood was taken for measurement of
ff 3, and fr4, and TSH (IRMA). These latter measurements did not
contribute to the final diagnosis in any patient.
IT), TT4, and TSH were measured by in-house
radioimmunoassays,J'5 in which the between-assay coefficients of
variation (CV) were 6-6%, 4-9%, and 5-lco respectively. The
normal range for TTj was 1-1-2-8 nmol/1 and for TT4 60-150
nmol/1. The upper limit of normal for basal TSH (RIA) was 5-7
mU/1, and the normal range of response 20 min after intravenous
administration of200pgTRH was 3-9-25-3 mU/1.4 An increment
of less than I • 0 mU/1 above the basal value was considered an absent
response, consistent in this series with a diagnosis of overt or
subclinical hyperthyroidism.
ITj and fT4 were measured with radioimmunoassay using the
Amerlex kits (Amersham International), for which the between-
assay variations were 6% and 5% respectively in our own laboratory.
The normal ranges calculated from the 97 euthyroid patients in this
series were 4-8 pmol/1 for fT, and 10-22 pmol/1 for fT4. TSH
(IRMA) was measured with the Sucroscp assay system (Boots-
Celltech), in which the within-assay and bctween-assay coefficients
of variations were 5% and 8-5%. The levels ofTSH (IRMA) in the
97 euthyroid patients ranged from 0-14 to 5-9 mU/1 (mean 1-9
mU/1), and an undetectable level was not recorded in any euthyroid
patient.
Results
97 patients were euthyroid (normal TRH test using TSH
measured with radioimmunoassay), and the results from
these patients were used'to establish the normal ranges for
fT,, fT4, and TSH (IRMA). Hyperthyroidism was present in
147 patients (raised TT4 or TT„ absent TSH response to
84 38 The Lancet Ltd, 1985
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TABLE I—ASSESSMENT OF TSH (1RMA) AS A SCREENING TEST FOR
THYROID DYSFUNCTION
- Correct Incorrect
Exclusion of thyroid dysfunction 97 0
Indication for further test to distinguish
between:
a) subclinical and oven
hypothyroidism 25 0




TRH), and subclinical hyperthyroidism in 16 (normal TT4
and TT3i absent TSH response to TRH). Primary
hypothyroidism was present in 9 patients (low TT4, raised
TSH) and subclinical hypothyroidism in 16 (normal TT4,
raised TSH).
TSH (IRMA)
TSH (IRMA) alone correctly predicted the euthyroid state
in all 97 patients and indicated overt or subclinical
hyperthyroidism or hypothyroidism in all but 1 of the
remaining 188 patients (table I).
JT4 Comparedwith TTt
Overt andsubclinical hyperthyroidism.—4 levels showed a
greater rise than TT, in hyperthyroid patients. Results for
fT4 werd in excess of2 SD above the mean in 98% (compared
with 92-5% for TT4) and greater than 4 SD above the mean
in95%(comparedwith57%forTT4).Ofthe 11 patients with
"T^thyrotoxicosis", in whom TT4 levels were by definition
normal, fT4 levels were raised in 9. Ifdiagnosis had rested on
fT4 and not TT4 there would have been a reclassification
from subclinical to overt hyperthyroidism in 9 of the 16
patients (55%) (fig 1).
Overt and subclinical hypothyroidism.—hike TT4, fT4 was
low in all 9 patients with overt hypothyroidism and was also
reduced in 2 of the 16 patients considered to have subclinical
hypothyroidism.
JT3 Compared with TT3
Overt and subclinicalhyperthyroidism.—TV3 levels showed a
greater rise than TT3 in hyperthyroid patients. 97% of fT3
values were in excess of2 SD above the mean (compared with
89% for TT3), and 90% were in excess of 4 SD above the
mean (compared with 72% for TT3). Whereas all but 3 of the
147 patientswith hyperthyroidism had raised fT3 levels, TT3
was normal in 16, usually associated with drug treatment (eg,
propranolol) or non-thyroidal illness.
Overt and subclinical hypothyroidism.—In the 9 patients
with overt hypothyroidism the fT3 level was normal in.2 and
TT3 was normal in 5. A marginally low level offT3 (fig 2) was
found in 1 patient with subclinical hypothyroidism, whereas
TT3 levels were normal in all of this group.
fT3 Compared with }T4
From the above results it is evident that there is little to
choose between fT, and fT4 in suspected hyperthyroidism,
but fT4 is the better test for patients in whom hypothyroidism
is the possible diagnosis.
Discussion
At present, measurements of total or free thyroid hormones









Fig I—Thyroid hormone levels in tubciinical hyperthyroidism.
•Patient taking oral contraceptive pill.
Although free hormones have advantages over total
hormones in patients with binding-protein abnormalities,5,6
they share the disadvantage of no: alerting the clinician to
subclinical disease. This study suggests that for practical
purposes the best single screening test of thyroid function is
TSH measured with a sensitive imnunoradiometric assay. A
normal, detectable level would indicate the euthyroid state
and obviate the need for any further estimations of thyroid
hormones, although in patients with goitre it might be
necessary to use thyroid scanning and measurement of
thyroid autoantibody titres in order to arrive at a final clinical
diagnosis. If, however, a raised or undetectable level ofTSH
(IRMA) were recorded, it would be necessary to distinguish
between overt and subclinical hypothyroidism or
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Fig 2—Thyroid hormone levels in subclinical hypothyroidism.








Fig 3—Proposed strategy for investigation of thyroid function.
Which hormone should be measured to define thyroid
status in patients with abnormal TSH (IRMA) results? As
total hormone measurements were used in this study to
allocate patients to diagnostic categories, a direct comparison
of the performance of free and total T3 and T4 is not
appropriate. However, a higher proportion of free-hormone
results, compared with total-hormone results, were abnormal
in overt thyroid dysfunction, as reported in other studies.7,8 It
could be argued that fT3 should be used to separate
subclinical from overt hyperthyroidism and that fT, is the
measurement of choice in the presence of a raised TSH
(IRMA). However, the majority of patients with so-called
T3-thyrotoxicosis (normal TT4 but raised TT3 levels) were
found in this study to have raised fT4 values. It would
therefore seem appropriate to use fT4 as the arbiter ofthyroid
status in the presence of an abnormal TSH (IRMA) result.
The strategy we propose is shown in the form ofan algorithm
in fig 3. The need to measure fT3 would arise in about 3% of
cases. The routine use of fT4 in patients with an undetectable
or raised TSH (IRMA) will tend to reduce the proportion of
patients with subclinical disease (figs 1 and 2). This is not
clinically important, because in patients with subclinical
disease the natural history is progression to overt disease9,10
and there is an attraction in treating a disorder in anticipation
of possible future morbidity. Furthermore, there is some
evidence that subclinical hyperthyroidism and subclinical
hypothyroidism may be associated with changes in end-organ
function" 14 and are therefore mild forms of the more easily
recognised overt disease.
It must be borne in mind that the results of this study may
not apply to patients with non-thyroidal illness, since we
know ofno large studies which have assessed the performance
ofTSH (IRMA) in this group ofpatients. However, the TRH
test, and presumably TSH (IRMA), is more reliable in this
context than thyroid-hormone measurements.1,15 Even if
TSH (IRMA) were falsely undetectable in a small
proportion, the usual findings of low or low-normal fT 3 and
fT4 would prevent the diagnosis of hyperthyroidism, and
clinical examination should normally exclude the possibility
TABLE II—COMPARISON OF NO OF IN VITRO ANALYSES OF THYROID







No of patients 163 97 25 285
Present pohev:
Test used tt„tt4,trh tt.,tt4,trh TT..TSH
No of analyses 652 388 50 1090
Proposed strategy
Test used fT4, TSH(irma) TSH(irma) fT4, TSH(irma)
No of analyses 534* 98+ 50 482
•fT , analysis required irf 10 patients with undetectable TSH (IRMA) and hormal IT. (see
Hg 3).
+By TSH IRMA I subclinical hyperthyroid reclassified at euthyroid.
of hypopituitarism. Our proposed strategy would be
inappropriate for assessing thyroid status in patients on
thyroxine replacement therapy in whom the combination of
undetectable TSH (IRMA) and raised fT4 would not
necessarily imply overtreatment.
At present the routine measurements of(T3, fT4, and TSH
(IRMA) are only available commercially. There would be
little or no additional expense in changing to the investigative
strategy we have proposed for those laboratories which
depend upon commercial kits for measurement ofTT3, TT4,
and TSH (RIA). For larger centres with in-house assays for
TT3, TT4, and TSH (RIA), the change to the use ofTSH
(IRMA) supplemented when necessary by fT4 and fT3 might
appear expensive. However, the extra cost of these new
thyroid function tests may be offset in part by a considerable
reduction in the number of analyses which would be
required. As an illustration our TSH (RIA) has a lower
detection limit than many other RIA methods, but this is only
achieved at the expense of a relatively long assay time, and
results are not usually available to the clinician for at least a
week. It is, therefore, our current practice to measure TT3
and TT4 in addition to the TRH test in all patients, with the
exception of those with obvious clinical hypothyroidism, as
the thyroid hormone levels are available within 24-48 h.
This allows appropriate treatment to be instituted, if
necessary, before the result of the TRH test is available. TSH
(IRMA) results should be available within 24-48 h. The
number of analyses done in this series would have been
reduced by about 50% if diagnosis had relied on TSH
(IRMA) initially, followed by measurement of fT4 and
occasionally fT3 (table II). This reduction of in-vitro analyses
of thyroid function, combined with the fact that the TRH test
is now redundant,1 should reduce the cost differential
between current practice and the use of these newer tests in
those laboratories with in-house assays for TT3, TT4, and
TSH (RIA).
Correspondence should be addressed to A. D. T., Department ofMedicine,
Royal Infirmary, Edinburgh EH3 9YW.
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Value and Limitations of a Highly Sensitive Immunoradiometric Assay for Thyrotropin in the
Study of Thyrotroph Function
G. Caldwell,1 S. M. Gow,2 V. M. Sweeting,1 G. J. Beckett,1 J. Seth,2, and A. D. Toft1-3
Using a highly sensitive and specific immunoradiometric
assay for thyrotropin, we studied thyrotroph function in 232
new patients referred to a thyroid clinic and in 13 patients
after treatment for hyperthyroidism. Significant thyrotroph
responsiveness to thyroliberin (thyrotropin-releasing hor¬
mone, TRH) was found in all patients with values for basal
thyrotropin >0.1 milli-int unit/L. In no overtly hyperthyroid
patient was any increment in thyrotropin recorded at 20 min
after thyroliberin administration*. In seven patients, four sub-
clinically hyperthyroid and three who had received treatment,
increments in thyrotropin from undetectable basal values
were recorded, consistent with incomplete thyrotroph sup¬
pression. By use of assays with even higher sensitivity, one
may be able to distinguish these patients from overtly hyper¬
thyroid patients.
Additional Keyphrases: thyroid status ■ thyroliberin
A recently introduced immunoradiometric assay (irma)
for thyrotropin (TSH) is about 10-fold more sensitive than
are most radioimmunoassays (RIAs).4 Clinically it has the
advantage that the initially obtained value accurately pre¬
dicts the TSH (by RIA) response to thyroliberin (TRH),
obviating the need for the TRH test (1). The high sensitivity
and specificity of the irma should also allow more detailed
assessment of thyrotroph function. We were particularly
interested to investigate thyrotroph function when basal
values for TSH were between the lower detection limits of
the irma and the RIA (0.1 and 1 milli-int. unit/L, respective¬
ly), and in the months after treatment of hyperthyroidism,
to determine whether detectable basal concentrations of
TSH are always associated with thyrotroph responsiveness
to TRH, and undetectable concentrations always with unre¬
sponsiveness. We report our findings in 232 new patient




The study population consisted of 232 new patient refer¬
rals to our thyroid clinic: 207 women and 25 men, ages 17-
80 years. In each case the diagnosis was established on the
basis of clinical examination, measurement of total thyrox¬
in, triiodothyronine, and TSH by RIA before and 20 min
after intravenous administration of 200 pg of TRH. In
addition, serum was stored and analyzed later for TSH (by
irma), free thyroxin, and free triiodothyronine. In 124
patients there was evidence of hyperthyroidism: increased
concentrations of total thyroxin and triiodothyronine and an
University Departments of 1 Medicine and 2 Clinical Chemistry,
The Royal Infirmary, Edinburgh EH3 9YW, U.K.
3 Address correspondence to this author.
4 Nonstandard abbreviations: irma, immunoradiometric assay;
TSH, thyrotropin; TRH, thyroliberin.
Received April 29, 1986; accepted November 17, 1986.
absent response of TSH (by RIA) to TRH. Graves' disease
was diagnosed in 106 patients, a toxic multinodular goiter
in 11, and a solitary toxic nodule in seven. Six patients with
a multinodular goiter and six with Graves' disease were
considered to have subclinical hyperthyroidism; they had
normal total thyroxin and triiodothyronine and an absent
TSH (by RIA) response to TRH. Five patients were hypothy¬
roid (above-normal TSH by RIA and low total thyroxin),
four with Hashimoto's thyroiditis, and one with primary
atrophic hypothyroidism. A further 11 patients with Hashi¬
moto's thyroiditis had subclinical hypothyroidism (above-
normal TSH by RLA and normal values for total thyroxin).
The remaining 80 patients were euthyroid (normal total
thyroxin and total triiodothyronine and normal TRH test
result by RIA); in 39 of these there was no evidence of
thyroid disease, 18 had a multinodular goiter, 19 a solitary
thyroid nodule, three a simple goiter, and one endocrine
exophthalmos.
Group Two
Twelve hyperthyroid patients (11 female, one male; 11
with Graves' disease, and one with a multinodular goiter)
were seen before treatment with l31I and thereafter at four-
week intervals for 12 weeks. In addition, one woman with
Graves' disease was studied during treatment with gradual¬
ly decreased doses of carbimazole. At each attendance, in
addition to clinical assessment, a TRH test was performed,
with results analyzed by RIA and irma; the basal sample
was also analyzed for total thyroxin, total triiodothyronine,
free thyroxin, and free triiodothyronine.
Assays
Total thyroxin, total triiodothyronine, and TSH by RIA
were measured by in-house RIAs for which the respective
between-assay coefficients of variation (CVs) were 4.9%,
6.6%, and 5.1% (2,3). Free triiodothyronine and free thyrox¬
in were measured by RIAs with Amerlex kits (Amersham
International, Amersham, Bucks., U.K.), for which the
between-assay CVs were 6% and 5%, respectively. TSH by
irma was measured by using the "Sucrosep" system (Boots-
Celltech UK), for which the between-assay CV was 8% and
the mean lower limit of detection 0.1 milli-int unit/L (4).
Normal reference intervals established in our laboratory
were: total triiodothyronine 1.1-2.8 nmol/L, total thyroxin
60-150 nmol/L, free triiodothyronine 4—8 pmol/L, and free
thyroxin 10-22 pmol/L. The upper limit of the normal
reference interval for TSH by RIA was 5.7 milli-int units/L;
an increment of <1 milli-int unit/L by RIA 20 min after
TRH administration we considered to be no response.
Results
Group One
Thyrotropin by irma was initially undetectable in all
hyperthyroid and subclinically hyperthyroid patients. We
detected no increment in TSH by irma 20 min after TRH
administration in any overtly hyperthyroid patient. Twelve
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Table 1. TRH Test and Thyroid Hormone Values In Seven Patients Who Showed an Increment In TSH by irma from














1S11 0 min 20 min 0 min 20 min nmol/L pmol/L
MG <0.15 0.26 <1.1 <1.1 142 2.0 23.0 6.0
MG — <0.10 0.58 <0.7 1.0 92 2.1 19.3 7.8
MG — <0.13 1.30 <1.0 1.2 124 2.5 15.8 6.6
MG — <0.10 1.30 <0.9 1.8 106 1.6 22.8 6.2
Graves' 2 <0.14 0.28 <0.8 <0.8 94 1.1 16 4.4
Graves' 2 <0.13 0.20 <0.9 <0.9 53 0.6 8 2.4
Graves' 1 <0.13 0.30 1.4 1.4 108 1.8 15 5.9
MG, multinodular goiter; T3, triiodothyronine.
patients were subclinically hyperthyroid; in four of these, all
with multinodular goiters, a small increment in TSH from
undetectable values was recorded by irma (Table 1). In
these four patients, assay of TSH by RIA gave no increment
in TSH in one and increments of 0.3, 0.2, and 0.9 milli-int.
unit/L in the remaining three. In the four patients in whom
a small increment in TSH by irma was detected, the
concentrations of free thyroxin and free triiodothyronine
were, in general, lower than in the remaining subclinically
hyperthyroid patients (Figure 1). The initial value for TSH
by irma was detectable in all of the 96 patients who were
euthyroid, subclinically hypothyroid, or hypothyroid. For
patients with an initial value for TSH by irma >0.1 and
<50 milli-int. units/L, there was a strong correlation be¬
tween the increment in TSH by irma and the initial value



































Fig. 1. Concentrations of free thyroid hormones and thyrotroph respon¬
siveness to TRH in 12 subclinically hyperthyroid patients who did not
(O) or did (•) show an increment in TSH by irma after TRH
patients whose basal values for TSH by irma were below the
lower detection limit of the RIA (1 milli-int. unit/L) and
above the lower limit of detection of the irma (0.1 milli-int
unit/L). There was a substantial increment (>1 milli-int.
unit/L) in TSH by irma in all 17 of these patients (Figure 2),
ofwhom six had a multinodular goiter, five a solitary nodule
or cyst, one a simple goiter, one endocrine exophthalmos,
and four no evidence of thyroid disease.
Group Two
In the second group of patients, who were followed after
treatment for hyperthyroidism at 12 weeks, eight were
symptomatically and biochemically hypothyroid; four were
clinically euthyroid with normal concentrations of thyroid
hormone, but with no TSH responses to TRH by RIA and by
irma; and one patient remained hyperthyroid.
In the eight patients who developed hypothyroidism, the
response of TSH (by RIA) to TRH remained suppressed at
four weeks in seven of the patients and at eight weeks in
two. Three of these patients, one at one month and two at
two months of treatment, showed an increase in TSH by
irma from undetectable to detectable at a time when no
increment in TSH was detectable by the RIA (Table 1). The
patient treated with carbimazole had, by irma, after 12
weeks of treatment, a low detectable basal TSII of 0.15
milli-int. unit/L and a 20-min TSH of 1.1 milli-int. units/L
the values for TSH by RIA being 1.3 milli-int. units/L at 0
and 20 min after TRH administration.
Discussion
The highly sensitive and specific irma for TSH shoulo
allow for more precise study of thyrotroph function; as yet
™WL .
• BASAL TSH. mrfli tot units/L
Fig. 2. TRH test results in 17 patients with basal TSH by irma betwee
0.1 and 1.0 milli-int. unit/L
•, Basal TSH; O, TSH 20 min after TRH stimulation
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however, there have been few reports ofTRH tests with this
new assay (5).
In our study, new patient referrals with an initial value
for TSH by irma of >0.1 to <50 milli-int. units/L showed a
strong correlation of the increment in TSH 20 min after
TRH and the basal value of TSH by irma (r = 0.93). This
pattern of response was observed even when the basal
values for TSH by irma were <1 milli-int. unit/L. In these
patients, therefore, thebasal value for TSH by irma gives as
much information as the TRH test concerning thyrotroph
function. In hypothalamic and pituitary disease the same
correlation may not hold true, but we did not have an
opportunity to study such patients.
Thyrotropin by irma was below the detection limit of the
assay in 124 hyperthyroid and 12 subclinically hyperthyroid
patients at presentation; 132 showed no increment in TSH
by irma 20 min after TRH administration. The four patients
in whom an increment was detected had multinodular
goiters and were considered to be subclinically hyperthy¬
roid. Values for free thyroxin and free triiodothyronine were
in general lower than in the other eight subclinically
hyperthyroid patients, in whom no increment in TSH by
irma was detected. Probably, when there is no increment in
TSH by irma, the synthesis and secretion of TSH is com¬
pletely suppressed (6). A small increment in TSH by irma
from an undetectable value may indicate partial thyrotroph
suppression. We suggest that, in such cases, the thyroid
hormone values, although sometimes within the reference
range, have risen above the usual value for that patient and
have resulted in decreased synthesis and secretion of TSH.
Under these circumstances a TRH test with TSH assayed by
irma gives more information than the initial value for TSH
alone. We made a similar observation in three hyperthyroid
patients whose thyrotroph function returned after treat¬
ment with 131I. Some patients taking thyroxin for primary
hypothyroidism might also show this pattern of response.
In the study of thyrotroph function in thyroid disease, an
initial value for TSH by irma above the detection limit of
the assay gives as much information as a full TRH test;
when the value is below the detection limit of the assay,
however, some thyrotroph function can be demonstrated by
the TRH test in a few patients. Assays for TSH of even
higher sensitivity may be able to distinguish between
complete and partial suppression of thyrotrophs without the
need for a TRJH test (7).
References
1. Seth J, Kellett HA, Caldwell G, et al. A sensitive immunoradio
metric assay for serum thyroid stimulating hormone: a replacemen
for the thyrotropin releasing hormone test? Br Med J
1984;ii: 1334-6.
2. Ratcliffe WA, Challand GS, Ratcliffe JG. A critical evaluation o
separate methods in radioimmunoassays for total triiodothyronim
and thyroxine in unextracted human serum. Ann Clin Biochen
1974;11:224-9.
3. Irvine WJ, Toft AD, Hunter WM, Kirkham KE. An assessmeni
of plasma TSH radioimmunoassay and of TSH stimulation test ir
the diagnosis of 100 consecutive patients with suspected hypothy¬
roidism. Clin Endocrinol 1973;2:135-9.
4. Caldwell G, Gow SM, Sweeting VM, et al. A new strategy foi
thyroid function testing. Lancet 1985;i: 1117—9.
5. Kerr DJ,.Alexander WD. Is the TRH test usually unnecessary-
Lancet 1984;ii:l 161—2.
6. Bakke JL, Kaumer H, Lawrence N. EfTect of thyroid hormone oi
human pituitary thyroid stimulating hormone content. J Clii
Endocrinol Metab 1964;24:281-4.
7. Weeks I, Sturgess M, Siddle K, Jones MK, Woodhead JS. A higl
sensitivity immunochemiluminometric assay for human thyrotro
phin. Clin Endocrinol 1984;20:489-95.
CLIN. CHEM. 33/2, 305-307 (1987)
Salivary Amylase and Pancreatic Enzymes in Sjogren's Syndrome
B. Pal, I. D. Griffiths, A. Katrak,1 D. Junglee,1 and P. Dandona1-2
Concentrations of immunoreactive trypsin (IRT) and pancre¬
atic and salivary amylase activities were measured in 22
patients with primary Sjogren's syndrome (SS) and in 13
patients with secondary SS. Nineteen of the 22 patients with
primary SS had above-normal IRT, and six had above-
normal pancreatic isoamylase activity. Six of the 13 patients
with secondary SS had above-normal IRT; none had above-
normal isoamylase activities. Serum IRT and pancreatic
isoamylase were correlated significantly (r = 0.7; p
<0.0001). Above-normal values for IRT and pancreatic iso¬
amylase were more frequent in patients who had SS for
longer than 10 years, but were not related to the presence of
salivary gland autoantibodies or to salivary isoamylase activi¬
ty. We conclude that the concentration and activity of pancre¬
atic enzymes are frequently abnormal in SS; that the abnor¬
Department ofRheumatplogy, Royal Victoria Infirmary, Newcas-
tle-Upon-Tyne, and 1 Department of Chemical Pathology and Hu¬
man Metabolism, Royal Free Hospital and School of Medicine,
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mality is greater and more frequent in patients with primar
SS; and that it increases with the duration of the disease.
Additional Keyphrases: isoenzymes trypsin ■ rheumatok
arthritis • systemic lupus erythematosus
Sjogren's syndrome (SS) is characterized by progressive
destruction of the salivary and lacrimal glands by a chronii
inflammatory process (1, 2).3 This leads to a decrease ii
salivary flow, dryness of the mouth and eyes, and sometime:
other exocrine disturbances. SS is classically subdivided inte
two groups: primary SS (or sicca syndrome), where exocrine
disturbances occur in isolation, and secondary SS, where ;
well-characterized disorder of connective tissue is also pre
sent. This clinical subdivision is supported by clinical
immunological, and immunogenetic differences between tin
two groups.
Two previous studies-suggested that concomitant abnor
3 Nonstandard abbreviations: SS, Sjogren's syndrome; RA, rhev
matoid arthritis; SLE, systemic lupus erythematosus; IRT, immu
noreactive trypsin.
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Raised plasma glutathione S-transferase values in
hyperthyroidism and in hypothyroid patients receiving
thyroxine replacement: evidence for hepatic damage
G J BECKETT, H A KELLETT, S M GOW, A J HUSSEY, J D HAYES, A D TOFT
Abstract
Using plasma glutathione S-transferase measurements
hepatocellular integrity was assessed in groups of
hyperthyroid and hypothyroid patients before and
after treatment.
Ten of 14 hyperthyroid patients had clearly raised
plasma glutathione S-transferase values at presentation
and in each patient treatment with either iodine-131 or
carbimazole resulted in a significant fall in glutathione
S-transferase. The eight hypothyroid patients had
normal glutathione S-transferase values at presentation
and all showed a significant increase in these after
thyroxine replacement therapy. In three of these patients
in whom standard doses of replacement therapy were
associated with a raised free thyroxine (T4) concentra¬
tion but normal total and free triiodothyronine (T3)
values glutathione S-transferase was increased. Similar
though less consistent changes were seen In the results of
standard chemical tests of liver function.
It is concluded that hyperthyroidism may produce
subclinical liver damage in a high proportion of patients
and that this resolves with effective treatment. More
Important, the data suggest that hypothyroid patients
receiving thyroxine replacement therapy may have
similar subclinical liver damage.
Patients receiving thyroxine should be monitored by
the measurement of free, not total hormone concentra-
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tions, and in those in whom free T4 is raised the dose of
thyroxine should be reduced. It would also be expedient
to include periodic biochemical assessment of liver
function in patients receiving thyroxine.
Introduction
Before the advent of effective treatment for hyperthyroidism
serious hepatobiliary complications were commonly associated
with the disease. Liver biopsy samples taken from hyperthyroid
patients often showed morphological changes which included
glycogen depletion, fatty change, and cirrhosis. These associated
hepatic problems have been attributed to many factors, including
cardiac failure, infection, hypoxia, and malnutrition, and are
not thought to be due to a direct effect of thyroid hormones on
the liver.'
Prolonged and severe hyperthyroidism now occurs only
occasionally and, as a consequence, severe- hepatobiliary
dysfunction associated with hyperthyroidism is rare. There is,
however, evidence that hyperthyroidism may still produce
associated minor hepatic abnormalities, and electron microscopy
of liver biopsy samples shows non-specific changes in the
hepatocyte organelles.* Biochemical evidence of hepatic dys¬
function may still be seen in some patientswith hyperthyroidism.
In one study retention of sulphobromophthalein was abnormal
in 8% of patients, and abnormalities in bilirubin and alanine
aminotransferase values also were observed, but less frequently.*
There is little evidence to suggest that hypothyroidism affects
liver function, but these patients will subsequently receive
levothyroxihe replacement therapy. As a result many will have
raised plasma total and free thyroxine (T4) concentrations with
normal total and free triiodothyronine (T3) concentrations.' Of
particular interest is the question whether these patients, who
appear euthyroid clinically, have tissue hyperthyroidism.'
Measurement of the changes which occur in cardiac and pituitary
response in these patients suggests that tissue hyperthyroidism
does result from this treatment.* Nevertheless, thyroxine
replacement therapy has not been shown to have a detrimental
effect on hepatic function.
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The measurement of plasma glutathione S-transferase by
radioimmunoassay offers an extremely' sensitive method of
investigating hepatocellular damage, both in animals andman.'"'
These measurements are non-invasive and the results correlate
well with the histological findings in the liver.' In drug induced
liver damage plasma glutathione S-transferase measurements
appear to be some 10 times more sensitive at detecting damage
than measurements of aminotransferase activities.'
We report the use of plasma glutathione S-transferase
measurements and standard chemical tests of liver function to
investigate the hepatocellular integrity of patients with thyroid
diseases. We have also examined the effect of thyroxine re¬
placement on hepatocellular integrity in hypothyroid patients.
Patients and methods
HYPERTHYROID PATIENTS
We studied two groups of patients with hyperthyroidism. The
first group consisted of five women aged 46-75 years (cases 1-5;
see table I) who were trc.-ied with iodine-131. All had raised plasma
concentrations of total T4 and total T3 at presentation, and all
showed a basally suppressed thyroid stimulating hormone con¬
centration which did not rise by more than I mU/1 20 minutes after
an intravenous injection of 200 pg thyrotrophin releasing hormone.
The second group consisted of nine younger women (aged 19-
45 years; cases 6-14) in whom a study had been undertaken to assess
the merits of different treatment schedules with carbimazole. These
schedules were (a) 15 mg carbimazole three times a day for one
month, subsequently reduced in the light of clinical and biochemical
response, and (6) administration of a continuous blocking dose of
15 mg carbimazole three times a day with triiodothyronine replace¬
ment (20 ^g thrice daily) being added after roughly one month to
prevent hypothyroidism. As in the first group, all patients had raised
total T4 and total T3 concentrations at presentation with a lack of
response of thyroid stimulating hormone to injection of thyrotrophin
releasing hormone.
In all patients blood was taken at presentation and plasma stored
at — 20"C for the subsequent measurement of total and free T4
values, total and free T3, glutathione S-transferasc, aspartate amino¬
transferase, y-glutamyltransferase, and alkaline phosphatase. In the
first group of patients a second sample was taken when they had been
rendered euthyroid. In the patients treated with carbimazole more
frequent sampling was employed.
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HYPOTHYROID PATIENTS
The hypothyroid group of patients comprised eight women aged
20-64 year* (cases 15-22) presenting with primary atrophic (four
patients) or Hashimoto's hypothyroidism. Each patient was assessed
at diagnosis and at intervals from three to nine months after be¬
ginning thyroxine replacement therapy (see table II). One patient
(case 15) was taking the combined oral contraceptive pill.
MEASUREMENTS
Concentrations of total T4 and total T3 were measured by radio¬
immunoassay using a double antibody system." Free T4 and free
T3 concentrations were measured with commercial kits (Amersharr
International PLC). Reference ranges derived from 98 clinically anc'
biochemically euthyroid patients were: total T4, 65-145 nmol/1
(5-1-11-3 pg/100 ml); total T3, 1-2-2-8 nmol/1 (0-8-1-8 ng/ml); frc
T4, 10-22 pmol/l (7 8-171 pg/ml); free T3, 4 0-7 8 pmol/1 (2-6
5-1 pg/ml).
Plasma glutathione S-transferase was measured by radioimmuno
assay." The concentration of hepatic glutathione S-transfcras
B,B," (previously teferred to as basic glutathione S-transferase'
was measured with a specific antiserum which showed no cros
reactivity with the anionic forms of glutathione S-transferase fount
in red cells, muscle, or lung. The upper limit of the reference rang
for glutathione S-transferase B,B, was 4-0 jxg/1 and was derive*
from 135 blood donors and 40 laboratory volunteers.
The activities of alkaline phosphatase and y-glutamyltransferas
in plasma were measured by a sequential multiple analysis wit:
computer system (SMAC II, Technicon Instrument Corporatior
Basingstoke). The activity of aspartate aminotransferase was measure
with a centrifugal fast analyser and a kit method (Merckotcst t
E Merck, Darmstadt).
The between and within batch coefficient of variation was <9";
for each assay.
Statistical analysis was by Wilcoxon's matched pairs test.
Results
HYPERTHYROID PATIENTS GIVEN 1111
Three of the five patients treated with "'I initially had rais<
plasma glutathione S-transferase values. After treatment all show*
a significant (p<0-05) fall in values to within the reference ranf
TABLE 1—Liver function values in hyperlhyroid patients before and after '"/ or carbimazole treatment and in hypothyroid patients before and after thyroxine replai
ment therapy. (Reference ranges given in parentheses.) For clarity abnormal values given in italics
Before treatment After treatment
Care No Aspartate Alkaline y- Glutathione Aspartate Alkaline Y- Glutathione
aminotransferase phosphatase glutamyltranlferasc S-transferase aminotransferase phosphatase glutamyltransferase S-transfcras
(10-35 U/l) (4O-100 U/l) (5-35 U/l) (<4 0ug/l) (10-35 U/l) (40-100 U/l) (5-35 U/l) (<40pg/l
111 / treated hypertkyroid patients
1 47 213 63 102 33 99 16 4 0
2 39 270 101 6 8 44 248 30 2 4
3 40 306 217 4 4 36 377 86 13
4 30 172 29 35 38 133 15 16
5 24 91 10 24 18 132 9 18
. Carbimaxole treated hyperthyrotd patientt •
6 44 42 37 6 2 23 51 12 3 7
7 23 117 23 9 8 18 127 9 3 8
8 27 111 18 8 4 19 82 6 39
9 29 73 10 too 23 88 8 4 0
10 25 60 10 100 18 71 10 7 0
11 32 110 36 110 21 118 12 8 8
12 21 89 9 9 4 21 50 15 6 3
13 24 73 16 5 2 24 87 10 3 8
14 24 61 13 9 3 28 89 9 14 0
Thyroxine treated hypothyroid patientt
15 16 40 5 10 28 46 6 10
16 20 65 15 12 23 80 17 2 3
17* 23 56 17 17 23 59 41 7 9
18* 35 95 41 2 6 43 94 94 15 6
19 17 44 9 15 21 70 8 3 0
20 33 99 <5 2 4 72 125 25 114
21 28 106 16 17 35 109 14 2 9
22* 26 53 <5 2 3 21 77 8 7 7
•Patient with raised free T4 concentration after replacement therapy.
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(fig 1). In one patient (case 1) the glutathione S-transferase value was
at the upper limit of the reference range after treatment, but in this
patient the U,I had produced hypothyroidism necessitating thyroxine
replacement therapy.
Table I gives the results of the standard liver function tests. The
three patients in whom glutathione S-transferase was raised also
showed abnormalities in aspartate aminotransferase, alkaline phos¬
phatase, and y-glutamyltransferase activities. In addition, one


















activity. Patients did not show a significant fall in aspartate amino¬
transferase or alkaline phosphatase after treatment, but Y-glutamyl-
transferase activities did fall significantly (p<0-05) with treatment. ■
HYPERTHYROID PATIENTS GIVEN CARBIMAZOLE
All patients treated with carbimazole initially had raised plasma
glutathione S-transferase values. After treatment all showed a sig¬
nificant (p<0 01) fall in values. Although the fall in plasma gluta¬
thione S-transferase tended to parallel the fall in total and free T4
concentrations, equivocal or raised glutathione S-transferase values
were still found up to five months after the start of treatment (fig 2).
No significant difference in glutathione S-transfcrase values after
treatment were observed between the different carbimazole treatment
regimens.
In several patients there was a transient rise in glutathione S-
transferase after the initiation of treatment (fig 2). In one (case 14),
who showed a sensitivity reaction of a skin rash and arthralgia, the
rise was pronounced. In this patient subsequent treatment with
propylthiouracil produced a similar rise in glutathione S-transfcrase
with a concomitant sensitivity reaction (fig 3). In this patient treat¬
ment was subsequently changed to '"I.
Although glutathione S-transferase values were raised in all
patients before treatment, only four showed abnormalities in standard
liver function values (table I). After treatment with carbimazole
there was a significant (p<005) fall in activities of aspartate amino¬
transferase and Y-glutamyltransferase, normal values being found in
all treated patients.
FIG I—Plasma glutathione S-trans-
ferasemeasurements in five patients
before and after treatment with
131I for hyperthyroidism. Dashed
line represents upper limit of
reference range.
PATIENTS WITH HYPOTHYROIDISM
Each of the eight patients with hypothyroidism initially had normal
plasma glutathione S-transferase values (fig 4) and all had raised
concentrations of thyroid stimulating hormone and low concentrations
of total and free T4. The concentration of total or free T3 was
Case 8
FIG 2—Sequential plasma measurements of total T4 ( u) and glutathione S-transferase ( •) in eight patients treated for hyperthyroidism with carbi¬
mazole. Three patients (cases 6-8) had dose of carbimazole reduced from 15 mg thrice daily in light of clinical and biochemical response. Remaining
patients received continual blocking dose of carbimazole (15 mg thrice daily) and began triiodothyronine replacement (20 /ig) after one month. Dashed
lines represent upper limit of reference range for glutathione S-transfcrase. Reference range for total T4, 65-145 nmol/1.
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TABLE II—Thyroid hormone concentrations before and after thyroxine replacement therapy in eight consecutive patients with primary hypothyroidism. (Reference
ranges given in parentheses)
Before thyroxine After thyroxine
T4 T3 T4 T3 1 hyroxine Duration
Case No dose (months)
Total Free Total Frre Total Free Total Free (till24 h)
(65-145 nmol/1) (10-22 pmol/1) (12-2 8 nmol/1) (4 0-7 8 pootl) (65-145 nmol/1) (10-22 pmol/1) (1*2-2-8 nmol/1) (4 0-7 8 pmol/1)
15 43 5 1^> 5 2 112 21 14 5 9 100 8
16 55 7 16 4 2 108 17 13 4 1 100 8
17" <25 2 0 7 < 1 6 176 35 19 7 1 200 9
18* 27 4 13 35 136 28 19 7 1 150 3
19 65 9 1-5 44 121 19 13 4 2 150 8
20* <20 4 11 3 7 91 16 18 53 100 5
21 31 4 16 32 109 17 17 5 4 150 8
22* <20 < 1 <0 5 1 4 116 31 18 7-7 200 6
•Palienu with abnormal glutathione S-transftraae value after replacement therapy.
Conversion: SI so traditional unut—Total T4: 1 nmol/1 3 0 08 pg/100 ci. Free T4: 1 pmol/1 =r0-8 pg/ml. Total T3: 1 nmol/l~0-7 ng/ml. Free T3: 1 pmol/1 c0 7 pg/ml.
subnormal in five of these patients (table II). While three patients
showed clearly abnormal free T4 concentrations after treatment, only
one showed an abnormal total T4 value (table II).
After thyroxine replacement therapy all patients showed a sig¬
nificant (p<00l) rise in plasma glutathione S-transferase ffcg 4). In
four patients clearly raised values were found, similar to those
observed in the hyperthyroid patients. During thyroxine replacement







FIG 3—Case 14. Sequential total T4 ( O) and glutathione S-transterase ( #)
measurements in patient treated for hyperthyroidism with cxrbtmazole
and subsequently with propylthiouracil and supported with triiodeehyronine.
After treatment with carbimazole and propylthiouracil (arrowed pronounced
sensitivity teaclion occurred. Dashed line represents upper limit of reference
range for glutathione S-transfcrase.
raised glutathione S-transferase values were found. The patient in
whom free T4 was normal and glutathione S-transferase raised had
been receiving long term treatment with mefenamic aod. This
patient also showed abnormalities in aspartate aminotransferase and
alkaline phosphatase activities after treatment with thyroxine. In all
other patients normal free T4, total T4, and glutathione S-transferase
values were found after treatment. All eight patients hid normal
concentrations of free and total T3 and either normal or suppressed
concentrations of thyroid stimulating hormone. There appeared to
be no association between glutathione S-transferase values after
treatment and the dose or duration of thyroxine replacement therapy.
After thyroxine replacement therapy there was a significant
(p<0 05) increase in alkaline phosphatase activity (table I). Two of
the patients with raised free T4 concentrations after treatment had
abnormalities in y-glutamyltransferasc, and in one of these patients









FIG 4—Plasma glutathione S-trans-
ferasc measurements in hypothyroid
patients before and after thyroxine re¬
placement therapy. A — Patients with
raised free T4 concentrations after treat¬
ment (actual values shown in pmol/1).
All patients had normal total and free
T3 values after treatment.
Conversion: SI to traditional units-
Free T4: 1 pmol/13:0-8 pg/ml
Discussion
It is generally thought that hepatic dysfunction is no long!
a common complication of hyperthyroidism, since abnormalitii
in results of the standard chemical tests of liver function ai
found infrequently. We,'however, have- shown that a hip
proportion of patients with untreated hyperthyroidism hai
greatly increased plasma glutathione S-transferasc values ar
that successful treatment with "'I or carbimazole results in
Tall in these values which roughly parallels the fall in total '1
concentration.
Unlike aspartate aminotransferase, plasma glutathione
transferase values appear to correlate well with the histologic
picture in patients with chronic active liver disease,' and al
unlike alanine aminotransferase the incidence of abnorn
glutathione S-transferase values in patients with paracetan
poisoning' agrees well with the incidence of abnormal hisi
logical findings in the livers of these patients." In this cont<
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>ur finding of a high incidence of raised plasma glutathione
S-transferase values in hyperthyroidism agrees with the pre¬
viously reported observation, with electron microscopy, that
ninor structural abnormalities commonly occur in the organelles
)f the hepatocytes of patients with this disease.* Our observa-
:ions are therefore consistent with the hypothesis that minor
lepatocellular dysfunction may still be a common though
;ubclinical complication in hyperthyroidism.
Glutathione S-transferases arc a "multigene" group of
rnzymes that are concerned in' the cellular detoxification of a
vide range of electrophiles. In human liver and kidney the
nain forms of the enzymes are cationic (pi 8-4-8-9), while in
)ther tissues an anionic form (pi 4-8) predominates. These
:nzymes are dimeric, and in human liver two cationic subunits,
3, and B„ have been identified. The radioimmunoassays
vhich we use are specific for either the B, or B, monomers
ind do not react with the anionic forms of glutathione S-
ransferase. As well as the plasma values of hepatic glutathione
»-transferase B,B, we also measured hepatic glutathione
>-transferase B,B, (previously called N/A2b)." " For clarity
hese data have not been included but in all cases abnormal
>asic glutathione S-transferase B,B, values were associated
vith abnormal values of glutathione S-transferase B,B,. The
ubunit forms of glutathione S-transferase which we have
neasured specifically by radioimmunoassay are confined
>rcdominantly to the hepatocyte and the renal tubules, little
>f these subunit forms being found in tissues such as muscle,
ed cells, or lung."
We have considered the possibilities that the raised plasma
;lutathione S-transferasc values found in the hyperthyroid
>atients were a consequence of hepatic enzyme induction by
hyroxine or may merely have reflected extrahepatic tissue
iamagc. Both these possibilities seem unlikely. Firstly, when
hyroxine is administered to hypothyroid or euthyroid animals
ither a small decrease or no change in hepatic glutathione
>-transferase is observed." Secondly, as the cationic forms of
;lutathione S-transferase are relatively specific to the liver and
udney, and since renal damage is not found in hyperthyroidism,
t appears that the abnormal plasma values of both B, and
3. originate from hepatic damage.
The cause of the hepatic lesions observed in hyperthyroidism
s not clear but is believed to be multifactorial, with selective
ind general hypoxia as contributory factors.1 Thyroxine itself
tas not been reported as directly hepatotoxic. Nevertheless,
>ur observation that prolonged administration of thyroxine to
typothyroid patients resulted in significant increases in plasma
;lutathione S-transferase in all patients has implications for the
ong term management of these patients. It is also relevant to
he controversy about the importance of raised plasma free T4
roncentrations in patients receiving thyroxine.
In our study all of the treated hypothyroid patients with
■aised free T4 concentrations had associated abnormalities in
slasma glutathione S-transfcrase values. Our data may indicate
hat administration of thyroxine in doses which result in
'aised plasma concentrations of free T4 may produce a hepatic
esion similar to that seen in hyperthyroidism. Jennings el al
lave shown that hypothyroid patients who are receiving
hyroxine replacement and in whom free and total T4 concentra-
ions are raised have a decreased systolic time interval, which
:uggests that they have a "tissue thyrotoxicosis."' Our data
suggest that they may also have a "liver thyrotoxicosis."
The thyroid gland secretes approximately 90 pg thyroxine a
lay into the peripheral circulation. Patients who are receiving
>ral replacement therapy will receive roughly this amount as a,
ingle dose. Administered in this way, high concentrations of
hyroxine are presented to the liver, through the portal vein.
Thus, although peripheral blood concentrations of thyroid
lormone may appear satisfactory, it is possible that in these
>atients liver thyrotoxicosis results from an exposure to high
■ortal concentrations of thyroxine.
Plasma glutathione S-transferase values returned to normal
a hypcrthyroid patients treated with "'I, but in patients
treated with carbimazole they remained raised even five months
after treatment began. In roughly half of the carbimazole
treated patients glutathione S-transferase values were increased
in the first sample after treatment; in one patient this rise was
pronounced and associated with physical signs of a sensitivity
reaction. It appears that carbimazole may cause transient
subclinical liver damage in some patients, and hepatobiliary
problems associated with carbimazole, methimazole, and
propylthiouracil have been reported in a few."-" Our data,
however, do not show that carbimazole is necessarily hazardous,
since the rises in plasma glutathione S-transferase after carbi¬
mazole were transient and patients are unlikely to receive
carbimazole for long periods. On the other hand, our finding
that hepatic abnormalities may occur in patients receiving
thyroxine replacement is of concern, since for these patients
treatment will be life long. Hepatic function should therefore
be considered and assessed periodically in such patients.
Measurement of the plasma glutathione S-transferasc value by
radioimmunoassay appears to provide the most sensitive and
specific method of assessing hepatic function in these patients.
Nevertheless, the availability of glutathione S-transferasc
assays is restricted to a few centres, and it is therefore re¬
assuring to note that three of the four hypothyroid patients
who had raised glutathione S-transferase values after treatment
would have been detected by the standard liver function tests.
These tests may offer a satisfactory alternative to glutathione
S-transferase measurements in clinical practice.
In conclusion, our data, and those of others,1 indicate that
the thyroxine dose should be lowered in patients who have
raised free thyroid hormone concentrations in order that free
T3 and free T4 may revert to normal.
We arc grateful to Dr D B L McClelland and Dr P L Yap, of the
Edinburgh and South East Scotland Regional Blood Transfusion
Service, for supplying blood donor samples to derive the reference
range for glutathione S-transfcrase. This work was supported by a
Scottish Home and Health Department grant awarded to GJB and
JDH. We also thank Professor L G Whitby and Dr A F Smith for
help and advice in the preparation of this manuscript, and Mrs E
Ward for secretarial work.
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ABSTRACT. This study was undertaken to compare the sen¬
sitivity of the thyrotrophs to that of other tissues to T, treatment
in hypothyroid patients. To do so, we measured serum total and
free thyroid hormones and TSH, in addition to several serum
markers of peripheral tissue response to thyroid status, in 21
hypothyroid patients treated with 50-jig increments of T, to a
maximum of 200 ng daily (group I) and in 104 clinically euthyroid
patients receiving a long term constant replacement dose (group
II).
In group I patients, dose-dependent increases (P < 0.05) in
serum glutathione S-transferase, sex hormone-binding globulin,
and angiotensin-converting enzyme occurred, whereas serum T,-
binding globulin, creatine kinase, and creatinine levels decreased
(P < 0.05). In both patient groups, abnormally high levels of
glutathione S-transferase, sex hormone-binding globulin, angio¬
tensin-converting enzyme, alanine aminotransferase, and 7-glu-
tamyl transferase were found in some patients during treatment.
One or more of these biochemical abnormalities suggestive of
hyperthyroidism occurred in 15 (71%) group I patients and 27
(26%) group II patients. These were associated with an unde¬
tectable serum TSH (<0.1 /iU/ml) and raised free T, concentra¬
tions in 13, and raised free Tj, T,, and Ta concentrations in only
8, 6, and 1 group I patients, respectively. In group II patients,
they were more closely associated with an undetectable TSH
(67%) or raised free T< (85%) level than with raised concentra¬
tions of free T3 (33%), T, (26%), or T3 (0%).
The use of high sensitivity TSH assays will permit more
accurate adjustment ofT, replacement and minimize abnormal¬
ities in peripheral tissue biochemistry indicative of overtreat-
ment. (J Clin Endocrinol Metab 64: 364, 1987)
THE REPLACEMENT dose of T4 for primary hy¬pothyroidism has gradually been reduced from 200-
400 to 100-200 pg daily as better tests for monitoring
therapy have been introduced. However, overtreatment
is difficult to assess by measurement of serum T4 alone,
since to achieve normal serum TSH levels, sufficient T4
to raise serum T4 (and free T4) concentrations above
reference limits may be needed (1). TSH measurements
performed by RIA allow titration of the dose of T4 such
that TSH is no longer elevated (2, 3), but due to the poor
sensitivity and specificity of most of these assays, such
measurements cannot be used to identify overtreatment.
It has been argued that since T3 is the most active thyroid
hormone (4), the aim of T4 replacement therapy should
be to normalize serum total or free T3 concentrations (5,
6). When this is done, many patients have increased
serum free T4 concentrations, but since few have clinical
signs of hyperthyroidism, it has been assumed that they
Received July 22, 1986.
Address all correspondence and requests for reprints to: Dr. <1. J.
Beckett, Department of Clinical Chemistry, The Royal Infirmary,
Edinburgh EH3 9YW, Scotland, United Kingdom.
* This work was supported by a Scottish Home and Health Depart¬
ment grant.
suffer no deleterious effects. However, some such p;
tients have altered responses at the tissue level, e.,
diminished activity of the red cell sodium pump (7, 8
histological bone changes indicative of osteoporosis (9
abnormalities in biochemical tests of liver function (10
and increases in myocardial contractility, with systol
time intervals in the thyrotoxic range (11).
Recently, highly sensitive assays for serum TSH ha^
been developed. These assays can reliably distinguish tl
undetectable (<0.1 /xU/ml) levels found in thyrotox
patients from normal levels (12). Many patients receivii
T4 replacement have serum TSH levels undetectable 1
a sensitive assay (13) consistent with their absent TS
responses to TRH (1). However, the pituitary diffe
from some other tissues in that T3 derived from loc
conversion from T4 within the cell occupies a great
proportion of T3 nuclear receptors than T3 derived fro
serum (14). This greater sensitivity of the pituitary
serum T4 has led to the assumption that it is an uni
presentative target -tissue regarding the assessment
overtreatment with T4.
As alternatives to the more sophisticated measui
ments of peripheral tissue responses described (7-9, 1
364
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ve have used simple measurements of constituents in
serum known to be altered in patients with overt thyroid
lisease and related these to TSH secretion. High concen-
rations of alanine aminotransferase (ALT), liver-spe-
:ific glutathione S-transferase (GST), sex hormone-
jinding globulin (SHBG),' and angiotensin-converting
snzyme (ACE) have all been described in hyperthyroid-
sm (10, 15-17), whereas concentrations of T4-binding
[lobulin (TBG) and creatinine may be decreased (18,
:9). Raised concentrations of creatine kinase (CK) are
ound in hypothyroidism (20). Changes in the concentra-
ions of these analytes reflect altered entry to (due to
:hanges in synthesis or membrane permeability) or clear-
ince from the blood. These markers are arguably crude
ind insensitive indicators of thyroid status which cannot
lerve to assess thyroid status in an individual. However,
vhen many of these markers are measured in groups of
)atients with overt hyperthyroidism, unequivocal statis-
ically significant abnormalities are found. In this study
ve measured these markers in groups of patients receiv-
ng T4 replacement therapy to provide evidence of the
suitability of the T4 dose and compared the results with




Two groups of patients were studied. Group I consisted of 21
lypothyroid patients (17 women and 4 men; mean age, 50 yr;
■ange, 31-68) starting T, replacement. The causes of hypothy¬
roidism in this group were primary atrophic disease (n = 7),
Hashimoto's thyroiditis (n = 2), and 13'I therapy for either
Graves' disease (n = 11) or multinodular goiter (n = 1). The
average length of time between radioiodine treatment and the
start of T, treatment was 5 months (range, 2-11). The T4 dose
ivas increased each month by 50-ng increments to a maximum
■)( 200 /ag/day. Blood samples were taken at the end of each
month. In addition, 5 group I patients had samples taken pre-
and postradioiodine treatment before T4 therapy was started.
To address the question of whether equilibration of serum
analytes had occurred in 1 month, nine patients were retested
after 2 additional months of treatment with the highest dose
of T4 that they had tolerated during the study.
Group II comprised 104 patients (91 women and 13 men;
mean age, 51 yr; range, 17-85). Hypothyroidism was the result
of "'I or surgical treatment of thyrotoxicosis in 51 and 9
patients, respectively, and in the remainder was due to Hashi¬
moto's thyroiditis (23 patients) or primary atrophic disease (21
oatients). At the time of investigation all were clinically euthy¬
roid and had been receiving a constant replacement dose of T4
for at least 3 months (mean, 3.5 yr); the majority (>89%) had
taken the same dose for more than 6 months. The largest group-
(n = 47) was taking 100 ^g/day; the others were taking 50 /ig
(n = 5), 75 Mg (n = 1), 150 pg (n = 28), 200 Mg (n = 19), or 300
Mg (n = 4) per day.
Methods
Serum total T4 and T3 levels were measured by in-house
RIAs (21). Serum free T, and free T3 levels were measured
using Amerlex-M kits (Amersham International, Amersham
Bucks, United Kingdom). Serum TSH was measured by an
immunoradiometric assay (IRMA; Boots-Celltech, Slough,
Berks United Kingdom), which has a minimum detection limit
of 0.1 pU/ml. The hepatic (B,Bi) form of GST was measured
by RIA (22). Serum ALT, GGT, and creatinine were measured
using a Technicon sequential multichannel analyzer with com¬



















Fig. 1. Mean (±se) thyroid function test results in 21 hypothyroid
patients (HYPO) receiving increasing T4 doses at 4-week intervals.
Reference ranges are indicated by the dashed lines.
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FlO. 2. Mean (±SE) peripheral tissue
markers measured in serum from 21 hy¬
pothyroid patients (HYPO) receiving in¬
creasing T4 doses at 4-week intervals.
*, Significant difference from the pre¬
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cial kits were used for SHBG (Farmos Diagnostica, SF-90460
Oulunsalo, Finland), TBG (RIA-gnost, Behringwerke AG, Mar¬
burg, Germany), and CK (Randox Laboratories Ltd., Crumlin,
Co. Antrim, Northern Ireland) determinations. ACE was meas¬
ured using a method based on that of Maguire and Price (23).
The between-assay coefficients of variation for all of these
analytes were less than 10%.
Laboratory-derived reference ranges were used for T4 (5.6—
12.0 pg/dl), T3 (77-182 ng/dl), ALT (10-40 U/liter), GGT (5-
35 U/liter), CK (30-150 U/liter), ACE (7-109 U/liter), creati¬
nine (0.6-l'.6 mg/dl), and GST (0.5-4.0 pg/liter). The manufac¬
turers' suggested reference ranges were used for SHBG (30-90
nmol/liter) and TBG (10-42 mg/liter). Reference ranges for
free thyroid hormones (free T4, 0.8-1.8 ng/dl; free T3, 0.28-0.55
ng/dl) and TSH IRMA (0.14-5.9 jzU/ml) were derived from 97
clinically and biochemically euthyroid patients classified using
total thyroid hormone levels and the TSH response to TRH,
measured by RIA. Group I patient results were analyzed using
the Wilcoxon matched pairs test, and group II results were
analyzed using the Mann-Whitney test for unpaired data.
Results
Patients taking increasing dvses of 1\ (group I)
Thyroid function tests. Serum total and free T< and T3
concentrations were restored to normal at a lower T4
dose than that necessary to suppress TSH to within the
reference range (Fig. 1). Normal TSH (IRMA) results
were achieved in 18 patients at the 50-, 100-, 150-, and
200-/rg doses in 1,8, 8, and 1 patients, respectively. Four
patients could not tolerate the 200 ^g/day dose for 4
weeks. Serum TSH (IRMA) became undetectable (<0.1
pU/ml) in 17 patients; this first occurred at the 100-,
150-, and 200-pg doses in 1, 7, and 9 patients, respec¬
tively. Serum free T4 was above normal in all patients
when TSH (IRMA) first became undetectable, whereas
in most patients, serum T4, T3, and free T3 levels were
normal at that time. Conversely, if serum T4, T3, or free
T3 levels were raised, TSH (IRMA) was always unde¬
tectable, but 10 patients with increased free T4 levels had
normal TSH (IRMA) concentrations.
Serum markers from peripheral tissues. Dose-dependent
increases in GST, SHBG, and ACE (P < 0.05) occurred
(Fig. 2), and ALT levels at the 200 jtg/day dose were
higher than those at the 100 Mg/day dose (P < 0.05).
Significant reductions in TBG, CK, and creatinine also
occurred with increasing T4 dose (Fig. 2). GGT increased
slightly but not significantly.
Levels of 1 or more of these markers became abnormal
in a total of 15 patientsv Abnormally high GST, SHBG,
ALT, GGT, and ACE levels were found in 10, 7, 4, 3,
and 3 patients, respectively. The occurrence of these
abnormalities coincided with an undetectable TSH and
raised free T4 concentration in 9 patients, and in 4
further patients, TSH was undetectable and free T4 was
raised after the next incremental T4 dose. By contrast,
even at the highest dose, free T3 and total T4 and T3
TSH AND T4 REPLACEMENT 367
~~3 50 lio l4o 200
Post1311 (months) T4 Dos«(,ug/day)
TOXIC 1 5 5 50 xio 1^0 200
• ► I ►
Post1311(months) T4 Dom (/og/day)
Fig. 3. Mean (±SE) peripheral tissue markers in five patients pre- and
postradioiodine treatment for hyperthyroid Graves' disease and during
T, therapy.
Table 1. Comparison of patient details and thyroid function tests in
group II patients subdivided according to TSH concentrations







n 37 42 25
Dose (hr) 162 (60)° 127 (43) 116 (47)
Age (yr) 53 (13) 63 (14) 49 (14)
Wt (kg) 66 (14) 69 (13) 72 (12)
Duration (yr) 3.2 (0.3-15) 3.8 (0.3-22) 3.7 (0.5-21)
TSH (f/U/ml) <0.1' 1.4 (0.13-5.9) 24.3 (6.4-103)'
Free T, (ng/dl) 2.8 (1.4)' 1.7 (0.3) 1.2 (0.4)'
Free T3 (ng/dl) 0.5 (0.2)' 0.4 (0.1) 0.3 (0.1)'
T4 (r-g/dl) 11.9 (3.5)' 9.5 (1.6) 7.4 (2.3)'
T, (ng/dl) 126 (28)' 105 (17.5) 96 (23.1)
Reference ranges: TSH, 0.14-5.9 pU/ml; free T4, 0.8-1.8 ng/dl; free
T3, 0.28-0.55 ng/dl; T„, 5.6-12.0 pg/dl; Ts, 77-182 ng/dl.
° /> < 0.005 us. group B.
b P < 0.001 us. group B.
' P < 0.05 us. group B.
were raised in only 8, 6, and 1 of these 15 patients,
respectively.
In the nine patients who were studied after an addi¬
tional 2 months, no further changes occurred in the
measured thyroid and tissue parameters, except for a
slight increase (P < 0.05) in SHBG.
The changes in tissue markers in five patients before
radioiodine treatment and during T4 replacement are
shown in Fig. 3. The levels of these markers at the
maximum T4 dose were not as abnormal as when patients
were overtly hyperthyroid. However, as with the com¬
plete group, there were trends toward higher SHBG,
GST, and ACE and lower TBG, CK, and creatinine levels
when these patients were taking 200 Rg/day T4 compared
to the lower doses. Only one patient in this subgroup had
levels outside reference limits.
Patients stabilized on a fixed dose of thyroxine (group II)
Thyroid function tests. Measurement of TSH (IRMA)
divided the 104 patients receiving a constant T4 dose
into 3 groups: 37 patients with undetectable TSH levels
(A), 42 with normal TSH levels (B), and 25 with raised
levels (C; Table 1). Only 1 patient had a detectable TSH
concentration (0.13 ^U/ml) which was less than the
absolute range (0.14-5.9 ^U/ml) in a reference euthyroid
population (12). This patient was included in group B.
There was no bias toward a particular cause for the
hypothyroidism between the groups or the duration ot
therapy, but patients in group A were receiving higher
T4 doses (P < 0.005) than those in group B. From Table
1, a mean reduction of 22% in T4 dose would bring group
A patients to the same mean dose as those in group B.
Patients in group C had not been prescribed less T4 than
those in group B, but 7 were thought to be noncompliant
with their treatment. The prescribed dose did not corre¬
late significantly with the patient's age or weight. For
detectable TSH values, Spearman's correlation coeffi¬
cients (P < 0.0001) for TSH vs. free thyroid hormones
were r = —0.746 for free T4 and r = -0.446 for free T3.
In group A, free T4, T4, free T3, and T3 were high in
32, 13, 12, and 1 patients, respectively. In group B, high
free T4 levels were found in 14 patients, and high T4
levels were found in 3. One patient in group B had low
T4 and free T3 results, and low levels of thyroid hormones
were found in 7 group C patients.
Serum markers from peripheral tissues. The results for
serum ALT, GST, GGT, CK, TBG, and SHBG are shown
for the three groups in Fig. 4. For the TBG and SHBG
data, all women taking an estrogen-containing oral con¬
traceptive and men were excluded. Significantly higher
ALT (P < 0.001), GST*(P < 0.02), and GGT (P < 0.05)
levels were found in group A than in group B. Lower CK
levels were found in group A compared to group B (P <
0.05). Compared' with group C, group A patients had
higher SHBG (P < 0.001) and lower TBG levels (P <
0.02). ACE activities and creatinine levels did not differ
significantly among the groups.
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FlO. 4. PeriphcrBl tissue markers in se¬
rum from 104 patients taking a fixed T<
dose grouped according to TSH (IRMA)
concentrations. Upper reference range
values (ALT, GST, GGT, and CK) and
reference ranges (TBG and SHBG) are
indicated by the dashed lines. *, Signifi¬
cant difference from group B (P < 0.05).
Values for patients with high (•), nor¬






































A total of 27 patients had an abnormally high level of
at least 1 of the following: ALT, GST, GGT, and SHBG.
Most of these patients had an undetectable TSH IRMA
(67%) or raised free T< (85%), whereas free Ta was raised
in only 33%, and T4 was raised in 26%.
Discussion
We clearly demonstrated a relationship between the
serum markers used to assess tissue thyroid status and
TSH levels measured by a sensitive -assay in patients
taking T4. Such a relationship was not found between
the serum markers and free T3 measurements. Although
the changes in SHBG, TBG, CK, and creatinine may
reflect the return of peripheral tissues to normal from
the hypothyroid state, some patients had abnormally
high ALT, GST, GGT, SHBG, and ACE levels at the
higher T4 doses. These abnormalities were not as marked
as those in patients with untreated overt hyperthyroid-
TSH AND T4 REPLACEMENT 369
ism, but in addition to the complete suppression of TSH
secretion, they provide evidence of a generalized tissue
overexposure to thyroid hormones. The lack of complete
concordance in the abnormalities we detected and pitui¬
tary suppression is not unexpected in view of the wide
range of sensitivities and specificities to thyroid status
of the tissue markers measured.
It might be argued that the changes observed in tissue
markers in our group I patients were not related to the
changes in T4 dose, but, rather, to the duration of T4
replacement. Indeed, although the majority of studies of
effects of T4 replacement were dpne using incremental
doses at 3- to 6-week intervals (1-3, 6, 24), it has been
reported that with increasing T4 dosage a steady state
may not be reached for several months (25). However, in
nine patients in whom we monitored tissue markers and
thyroid function tests for a further 2 months, we could
not demonstrate any further changes, except a slight
increase in SHBG levels with time. These criticisms of
the steady state achieved in our group I patients Cannot
ae related to the group II patients in whom constant T4
ioses had been taken for at least 3 months in all and for
more than 6 months in the majority (>89%).
It has been suggested that sensitive TSH measure¬
ments cannot be used to indicate excessive treatment
because of the increased sensitivity of the pituitary to T4
compared to the sensitivities of other tissues (26). How¬
ever, several reports have highlighted the need for main¬
taining pituitary responsiveness to TRH in T4-treated
patients, since mild hyperthyroidism cannot be detected
by clinical means alone (1, 24, 27). Our findings indicate
that TSH secretion can be used as a sensitive and rep¬
resentative test of peripheral tissue exposure to thyroid
hormones in patients receiving T4 replacement therapy.
In group II patients, 35.5% would require, on the average,
a reduction in dose of 22% to restore TSH levels to
normal. These patients (group A) tended to have lower
body weight than those with normal or high TSH levels,
although the difference was not statistically significant.
However, this observation in itself may reflect increased
metabolism due to mild hyperthyroidism.
Many patients with normal serum total and free T3
concentrations had evidence of tissue hyperthyroidism
in this study. This is consistent with reports where other
end organ responses were studied (7-11), but in disa¬
greement with studies using clinical signs alone (5, 6).
Although a greater proportion of patients with evidence
of tissue hyperthyroidism had raised free T4 concentra¬
tions than undetectable TSH (IRMA), a substantial pro¬
portion of patients required a high free T4 level to reduce
TSH secretion to normal. TSH secretion correlated more
strongly with serum free T4 tHan free T3 concentrations,
consistent with the known greater sensitivity of the
pituitary to T4 (14), but as shown in both groups, most
patients with a normal serum TSH (IRMA) had normal
total and free T3 concentrations, indicating sufficient
replacement for other tissues. A normal TSH (IRMA)
concentration, therefore, indicates optimal T4 replace¬
ment and makes measurement of serum thyroid hor¬
mones unnecessary. In patients in whom TSH (IRMA)
is undetectable, we propose the use of a serum free T4
measurement to provide a confirmatory test and an
indication of the degree of overtreatment so that the T4
dose could be adjusted accordingly.
There are some circumstances where the therapeutic
aim in giving T4 is to suppress TSH secretion completely,
e.g. in patients with thyroid cancer or goiter due to
Hashimoto's thyroiditis. However, in the majority, it
would be advisable to achieve a normal TSH level, as
measured by a sensitive assay. This would avoid the
subclinical tissue changes that occur as a result of over¬
exposure to T4.
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Summary
Sensitive immunoradiometric assays (IRMA) for TSH and radioimmunoassay
(RIA) kits for free thyroid hormones (fT4, fT,) are becoming increasingly used for
routine thyroid investigations. We have assessed these tests in 93 euthyroid pregnant
women. Mean fT4 and fT, values decreased with gestation by 24-27% and 14-35%,
respectively, using several analogue RIA kits. Some patients had free hormone
values which fell below the reference range derived from non-pregnant euthyroid
patients. By contrast, the fT4 concentrations measured by direct equilibrium dialysis
fell by only 16% with all values within the reference range.
Serum non-esterified fatty acid (NEFA) levels (non-fasting) did not correlate with
fT4 and fT, but a spurious effect of serum albumin levels on the free hormone kits
was suggested. TSH results showed that the majority of subjects had lower values
measured by IRMA than by RIA. Three patients had basal TSH (IRMA) below the
mean detection limit of the assay; this could have been falsely interpreted as
indicating hyperthyroidism.
We conclude that, as with longer established thyroid function tests, special care
must be taken in interpreting results of these new thyroid function tests in preg¬
nancy.
Introduction
The diagnosis of hyperthyroidism in pregnancy may be difficult since the clinical
features of tachycardia and heat intolerance may be due to the pregnancy itself.
Measurement of serum total thyroxine (TT4) and tri-iodothyronine (TT,) may
0009-8981/85/S03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division)
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provide little help in clarifying thyroid status, since high levels of circulating
oestrogens induce the synthesis of thyroxine-binding globulin (TBG), thereby caus¬
ing elevated TT4 and TT, levels. Free thyroid hormone concentrations are indepen¬
dent of TBG levels, and have been advocated as alternative biochemical tests in this
situation.
The TRH test discriminates hyperthyroid from euthyroid patients most reliably
but it is time-consuming and may produce undesirable reactions in a small number
of patients [1], However, the recent introduction of the sensitive IRMA for measur¬
ing TSH has led to the suggestion that a basal TSH. by IRMA, may replace the
TRH test [2],
Earlier studies of fT, in pregnancy using indirect dialysis methods have reported
unchanged, increased and decreased values [3], Recently, more reliable, direct
dialysis methods have been developed in which the concentration of T4 in the serum
dialysate is measured directly by RIA. Using this technique, decreases in fT4 with
gestation have been shown by the majority of studies [4-6], although unchanged
values were reported in one study of 39 pregnant women [7]. Direct dialysis remains
the reference method for free hormone measurement.
Several commercial assays for fT4 and FT, are now available; these are based on
different principles and techniques. Many are RIA methods which use chemically
modified radiolabels that do not bind appreciably to the endogenous serum binding
proteins. Most studies using these analogue kit methods have shown decreased fT4
and fT, levels as pregnancy progresses [7-10]. These findings have led to the use of
trimester-related reference ranges which, in late pregnancy, overlap with the hypo¬
thyroid range. A TSH test is then required to confirm euthyroidism when low free
thyroid hormone levels are found. Recent studies have shown that some analogue
fT4 assays are spuriously affected by changes in albumin and NEFA levels [10-13],
but it is unclear whether the decreased albumin and raised NEFA levels reported in
late pregnancy contribute to the low analogue fT4 values.
In the present study, we have measured fT4 levels in the three trimesters of
pregnancy using a direct equilibrium dialysis RIA, and several commercial analogue
methods for fT4 and fT, analysis. The relationship between free hormone concentra¬
tions and albumin and NEFA levels has been investigated. We have also examined
the possibility that basal TSH measurement performed by a highly sensitive IRMA
could overcome the problems associated with total and free thyroid hormone
measurements, and thus become the first-line test of thyroid function in pregnancy.
Patients and methods
Ninety-three pregnant women in the first (7-12 wk. n = 37), second (13-27 wk,
n = 32) and third (28-40 wk, n = 24) trimesters of pregancy were studied. Con¬
centrations of TT4 and TT, in serum were measured by RIA [14], fT4 was measured
by a direct dialysis method (fT4(D)) as described by Giles [6] and by equilibrium
RIA using kits supplied by Amersham International (Amerlex fT4(A), Amerlex
Magnetic fT4(AM)), Corning Medical (Corning Magic fT4(C)), Diagnostic Products
Corp. (Coat A Count fT4(CC)) and Becton Dickinson fT4(BD); free T, was also
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measured by kits supplied by Amersham International, Diagnostic Products Corp.,
and Becton Dickinson. TSH was measured in serum by a sensitive IRMA (Boots
Cell-Tech), by a commercial RIA (Becton Dickinson), and by an in-house RIA [15].
Between-batch coefficients of variation (CV) over the concentration ranges mea¬
sured were < 10% for all of the above assays except fT4(D) which had a CV < 15%.
Reference ranges were derived for each method from 63 euthyroid, non-pregnant
patients classified on the basis of clinical examination, normal TT4, TT, and TRH
tests.
Albumin was measured using a Bromocresol green dye-binding method on a
RA1000 discrete analyser (Technicon Instruments Corp.) and NEFA levels using a
Wako NEFAC kit (Wako Chemicals GmbH) on a Cobas Bio centrifugal analyser
(Roche Diagnostics); the CV was < 3%.
The effect of albumin on fT4(D), fT4(A) and fT4(AM) levels was examined by
adding increasing amounts of human serum albumin from Behring, Marburg, FRG
TABLE I
Thyroid function, albumin and NEFA tests in the three trimesters of pregnancy
Trimester u Mean % change
I II 111 I-III
TT4(nmol/l) 136 (19.5) 152 (22.8) ** 147 (24.9) * + 8%
TT,(nmol/l) 2.2 (0.4) 2.6 (0.3) *** 2.5 (0.5)** + 15%
fT,(pmol/l):
Dialysis 13.4 (1.8) 12.1 (1.9) ** 11.3 (1.6) *** -16%
Amerlex 16.8 (1.6) 14.7 (3.1)*** 12.6 (2.2) *** -25%
Ameriex Magnetic 16.1 (1.6) 14.3 (2.9)*** 11.8 (2.1) *** -27%
Corning 23.2 (2.0) 20.2 (3.9) *** 17.6 (2.0) *** -24%
Coat A Count 16.5 (2.3) 14.1 (3.4) *** 12.1 (2.1) *** -27%
Becton Dickinson 12.8 (1.8) 11.5 (2.5)* 9.7 (1.6)*** -24%
fT,(pmol/l):
Amerlex 6.2 (0.8) 5.0 (1.0) *** 4.0 (0.5)*** -35%
Coat A Count 5.0 (1.0) 4.8 (0.9) 4.3 (0.8) ** -14%
Becton Dickinson 6.8 (1.2) 5.8 (1.0) *** 4.8 (0.9) *** -29%
Albumin (g/1) 45 (2.4) 42 (3.3) *** 38 (1.7) *** -16%
NEFA (mmol/1) 0.44 (0.26) 0.34 (0.17) 0.36 (0.11) ns
TSH (mU/1):
Boots Cell-tech 1.0 (0.8) 1.3 (1.0 1.6 (0.9) * + 65%
IRMA
Becton Dickinson 3.2 (0.9) 3.1 (1.1) 3.3 (1.0) ns
RIA
In-house RIA 2.8 (0.7) 2.5 (0.6) * 2.6 (0.6) ns
Free thyroid hormones were measured by equilibrium dialysis and a number of commercial kits as
indicated. Serum TSH was measured by both RIA and IRMA methods.
a Mean values (±SD) are shown for each trimester together with the mean percentage change in the
analyte between trimester I and III. Significant differences in measurements made in the second and third
trimester when compared with the first trimester are indicated by: * p < 0.05; ** p < 0.01; *** p < 0.001;
ns, not significant.
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of 100% electrophoretic purity (3-19 g/1) in 0.15 mmol/1 NaCl to a low albumin
plasma pool collected from hospital inpatients. Insufficient reagents were available
to repeat the experiment with the other free hormone kits.
Student's t test was used for statistical analysis.
Results
Total thyroid hormone levels
TT4 and TT, increased by 12% and 18% respectively between the first and second
trimesters. These elevated levels were maintained in the third trimester (Table I).
Free thyroxine levels
Free T4 levels fell significantly during pregnancy although the decrease between
first and third trimesters was less by fT4(D) than by the kits (Table 1). No fT4(D)






































Fig. 1. (T4 levels in the 3 trimesters of pregnancy. Reference limit ( ).
329




0J 1 II III I II III I II ' III
trimester
Fig. 2. fT, levels in the 3 trimesters of pregnancy. Reference limit ( ).
were found using the analogue kits although the percentage of these subnormal
levels varied with the kit used; i.e. fT4(A) 5%, fT4(AM) 4%, fT4(C) 12%, fT4(CC)
14%, fT4(BD) 4% (Fig. 1).
Free tri-iodothyronine levels
Mean fT, levels also decreased during pregnancy. There were marked differences
in the magnitude of this fall measured by the various kits, with fT,(CC) showing the
smallest change. The percentage of values falling below the reference range were;
fT,(A) 14%, fT,(BD) 35%, fT,(CC) 1% (Fig. 2).
TABLE II
The effect of added albumin on free T4 measurement
Albumin (g/1) fT4(A) fT4(AM) fT4(D) (pmol/i)
31 * 8.6 8.4 9.4
34 9.1 9.2 9.2
37 10.3 9.7 8.6
40 11.3 10.4 8.9
44 12.1 11.9 8.6
50 13.9 12.9 9.0
4 fT4/(7 g/1 albumin) + 1.9 + 1.7 ns
Free T4 levels measured by two analogue RIA methods and by equilibrium dialysis in a low albumin
plasma pool before, *, and after albumin addition to give the final concentrations shown. AfT4 represents
the calculated effect on fT4(A) and fT4(AM) values when a change ofJ7 g/1 in albumin concentration































Fig. 3. TSH levels in the 3 trimesters of pregnancy. Upper reference limit (-
( )•
-). Mean detection limit
Albumin and NEFA levels
Mean albumin levels decreased by 16% during pregnancy but NEFA (non-fast¬
ing) levels did not change significantly (Table 1). Free T4 correlated strongly
(p < 0.001) with albumin levels in the second trimester, as measured by all the kits,
whereas fT4(D) did not. Free T,(A) and fT,(BD) also showed this correlation
( p < 0.001, p < 0.01) unlike fT,(CC). None of the free hormone tests correlated with
the NEFA levels found in these non-fasting subjects.
The in vitro effect of added albumin on free hormone levels
The addition of albumin to a low albumin plasma pool did not significantly affect
fT4(D) values. However, significant increases were found with the analogue kits
tested (Table II). The mean decrease in albumin of 7 g/1 during pregnancy could
therefore cause an additional decrease of 11% in fT4(A) and fT4(AM) values.
TS/I levels
The TSH results for each trimester are shown in Fig. 3. The detection limit shown
for each of the assays is the mean from 5 consecutive assays and defined as the
minimum concentration distinguishable from zero at the 95% confidence level. By
this criterion, the TSH IRMA was ten times more sensitive than the in-house RIA.
The TSH IRMA results were lower than results by RIA in all trimesters, and 3
values fell below the mean detection limit. There was a significant increase in mean
TSH IRMA between the first and the third trimesters, but TSH(BD) showed no
change and the TSH (in-house) values significantly decreased between the first and
the second trimesters (Table I).
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Discussion
The decrease in free thyroid hormones with gestation shown by the analogue kits
used in this study is in general agreement with the manufacturers' data and other
studies. However, the magnitude of the fall and proportion of values below non¬
pregnant reference limits described here differs from some previous reports. For
example, Tuttlebee found 55% of third trimester women to have fT4(A) below the
reference range compared to only 8% in our study [8], Our reference dialysis method
confirmed that a decrease in fT4 does occur throughout pregnancy, but the mean fall
of 16% was considerably less than that shown by any of the kit fT4 values (24-27%);
no fT4(D) values fell beiow the reference range. The decrease in fT, measured by
analogue kit methods was more diverse (14-35%), and was probably due to greater
differences in the binding characteristics of the different T, radiolabeled analogues.
Significant rises in NEFA levels have been reported in fasting, pregnant women
[16] and it has been suggested that low fl4 values, obtained by analogue kit methods,
might result from the displacement of residually-bound labelled T4 analogue from
albumin by NEFA [11]. However, Wilkins and Midgley estimated that even the
highest levels seen in the third trimester would only reduce fT4(A) by 4% at most
[17], The majority of studies, as here, have not used fasting subjects; under
nonfasting conditions, we could not demonstrate a change in NEFA levels with
gestation, nor any correlation between NEFA and fT4 levels. Since any effect of
NEFA on the fT4 equilibrium should be dependent on the NEFA concentration at
the time of sampling, and not on the fasting NEFA level, our data indicate that
changes in NEFA concentrations are not responsible for the subnormal fT4 values
shown by the analogue kits in pregnancy.
We have clearly demonstrated, by equilibrium dialysis, that fT4 concentrations do
fall during pregnancy, so comparison of fT4 with any other plasma constituent which
also falls during pregnancy is likely to produce a correlation. A strong correlation
between albumin and fT4 concentration was observed in the second trimester using
the analogue kits, but not with equilibrium dialysis. However, this probably reflects
the poorer precision of the fT4(D) method and cannot be interpreted as an albumin
effect on the kit assays. Nevertheless, the difference in the magnitude of the fall in
fr4 during pregnancy, as measured by these two techniques, does suggest that some
factor may be causing an additional fall in fT4, when measured by the analogue kit
assays.
Albumin has been implicated as this factor by other studies where the addition of
albumin to analbuminaemic sera increased fT4(A) but not fT4 dialysis results [12],
We have shown that increasing the albumin concentration of a low albumin pool by
small increments, to give values within the normal range (36-47 g/1), did not affect
1T4(D) values but increased the fT4 values measured by the analogue kit methods
tested. The fT4(AM) kit, unlike the fT4(A) kit, contains an 'albumin blocker' which,
in a study by the manufacturer, reduced the fall in fT4 seen in pregnancy from 30%
(fT4(A)) to 15% (fT4(AM)) (Amersham Technical Bulletin). We did not observe this
difference, and both Amersham kits were affected by added albumin in a parallel
manner in this study. Correction of our pregnancy data for this albumin effect
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would reduce the fall seen in fT4 during pregnancy to 14% (fT4(A)) and 16%
(fT4(AM)), resulting in closer agreement with the dialysis method. Our data there¬
fore suggest that low albumin levels in late pregnancy may exaggerate the physio¬
logical fall in free hormones as measured by analogue kits.
Abdalla et al, showed a decrease in fT4(A) in postmenopausal women treated
with oestrogens, suggesting that oestrogens may be the physiological cause of the low
free T4 values in pregnancy [18], An increase in the maximal nuclear binding
capacity for T4 and T, in mononuclear blood cells has been demonstrated in late
pregnancy, together with reduced fT4(A) and FT, (A), suggesting a mechanism by
which euthyroidism is maintained in these subjects at the tissue level [19],
It has been suggested that sensitive basal TSH IRMA tests could replace the TRH
test and serve as the first-line test of thyroid function [2], Our TSH IRMA results,
however, were considerably lower in pregnant subjects than those measured by two
RIA methods reported to have negligible cross-reaction to HCG. The fact that no
TSH results by RIA were undetectable suggests that a specificity problem with
pregnancy sera was .still present in these assays. Of particular concern was the
observation that 3 of our patients had undetectable levels of TSH when measured by
IRMA. These results may have been incorrectly interpreted as indicating hyper¬
thyroidism. High HCG levels in early pregnancy are known to cause a reduction in
TSH IRMA values due to cross-reactivity with the solid-phased monoclonal anti¬
body. This is claimed by the manufacturer to result in a mean 13% decrease in TSH
levels. Our data suggest greater interference, since mean levels between the first and
third trimesters differed by 35%.
What can we conclude concerning the value of these new tests when assessing
thyroid status in pregnancy? Firstly, it would appear that, irrespective of the
particular analogue kit method used, free hormone levels below the non-pregnant
reference range will be obtained in pregnancy. Interpretative difficulties will there¬
fore occur if such methods are used without trimester-related reference ranges. In
some cases, a TSH test may be necessary to distinguish a pathological from a
methodological cause of low free thyroid hormones. Secondly, the sensitive TSH
IRMA described here also has limitations in some patients, particularly in early
pregnancy, since an undetectable TSH IRMA with a normal free thyroid hormone
level may be due either to subclinical hyperthyroidism or to HCG interference in the
TSH assay in a euthyroid patient. The possibility that low albumin levels in a
hyperthyroid pregnant woman could produce normal free thyroid hormone results
by RIA should also be considered. Although a normal TSH IRMA result in a
pregnant patient is good evidence against hyperthyroidism, an undetectable level
requires further investigation, by means of the TRH test.
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Summary
We have compared the results of serum thyrotrophin (TSH) measurements using
a sensitive immunoradiometric assay (IRMA) with those of conventional thyroid
function tests in 299 hospital inpatients with a range of non-thyroidal illnesses.
Levels of total thyroxine (T4), free T4, total tri-iodothyronine (T3) and free T3 in the
hypothyroid range were recorded in 8%, 15%, 19% and 49% of patients, respectively,
whereas TSH (IRMA) was abnormally low in 1%. Furthermore, basal TSH (IRMA)
accurately predicted the result of the thyrotrophin-releasing hormone test in,72 of
the 74 patients in whom this test was performed and, unlike thyroid hormone
measurement, identified patients with subclinical thyroid disease.
It would appear that a single basal TSH (IRMA) measurement is the most
appropriate screening test for thyroid dysfunction in patients with concomitant
acute or chronic illness.
Introduction
Measurements of both total and free thyroid hormones frequently produce
misleading results in patients with acute or chronic non-thyroidal illness particularly
if used as screening tests for thyroid disease [1], Systemic illness affects thyroid
hormone measurement due to alterations in binding protein concentrations and
affinities, the increased peripheral conversion of T4 to T3 and to drug effects [2].
Changes in albumin concentration can have marked effects on one-step analogue
assays for free thyroid hormones and the validity of these measurements is now
seriously questioned [3]. The poor diagnostic accuracy of thyroid hormone measure-
0009-8981/86/$03.50 © 1986 Elsevier Science Publishers B.V. (Biomedical Division)
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ments in such patients may lead to unnecessary further investigations and, occasion¬
ally, to inappropriate thyroxine replacement therapy or anti-thyroid treatment [4],
Serum thyrotrophin (TSH) levels measured by radioimmunoassay, and the TSH
response to thyrotrophin-releasing hormone (TRH), are more reliable indicators of
thyroid status in these patients [1], The TSH response to TRH, although modified
by age [5], illness such as chronic renal failure [6] and drugs such as corticosteroids,
rarely gives false positive results. However, it has not been widely accepted as a
screening test due to the need for an intravenous injection and for a second sample
of blood to be taken 20 min later.
We have shown that basal serum TSH, measured by a sensitive immunoradiomet-
ric assay (fRMA), can accurately predict the TSH response to TRH when TSH is
measured by radioimmunoassay [7] and have suggested that basal serum TSH
(IRMA) measurement could be used as a screening test in patients with suspected
thyroid disease [8]. The patients in these previous reports had all been referred to an
out-patient clinic with suspected thyroid disease alone. The purpose of the present
study was to assess whether the same approach could be applied to hospital
in-patients with non-thyroidal illness.
Patients and methods
A total of 299 patients were studied; none had a past history or clear clinical
evidence of thyroid disease. Group I patients comprised 264 consecutive admissions
to a general medical ward (137 males, 127 females), who were receiving a wide range
of drug treatments. Cardio/cerebrovascular, respiratory, liver and gastrointestinal
problems were the reason for admission in 40%, 19%, 9% and 8%, respectively. The
remaining 24% of patients were admitted with a variety of other illnesses. The ages
of these patients showed a modal distribution (range 16-96 yr, mode 75 yr). Group
II consisted of 35 patients (15 males, 20 females) with chronic renal failure who
were receiving treatment by intermittent haemodialysis; they had an age range of
14-70 yr (mean 45 yr).
Serum total thyroxine (T4) and triiodothyronine (T3) were measured in all
patients by radioimmunoassay (RIA) [9], Free T4 (fT4) was measured by the
Amerlex kit (Amersham International, UK) and free T3 (fT3) by the Becton
Dickinson kit (Becton Dickinson UK Ltd). Basal serum TSH was measured by a
sensitive IRMA (Boots-Celltech, UK) and had a minimum detection limit of 0.1
mU/1. In addition, the TSH response 20 min after the intravenous administration of
200 jag TRH was measured in 74 of the patients in Group I using a TSH RIA which
had a minimum detection limit of 0.9 mU/1 [10]. The upper limit of normal was 5.7
mU/1 and the normal range of response 20 min after TRH was 3.9-25.3 mU/1 for
the TSH RIA [11]. A TSH increment of < 1 mU/1 above basal was considered to
be an absent response. Between-assay coefficients of variation (CV) were < 8% for
all of these methods.
Reference ranges were derived from 91 female and 6 male patients (age range
16-77 yr, mean 43), referred to an endocrine clinic with suspected thyroid disease
but in whom no clinical evidence of thyroid disease was present when examined by
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one experienced Endocrinologist. In addition, basal serum TSH levels and the TSH
response to TRH measured by RIA, was normal in every case. Reference ranges
were: 60-145 nmol/1 for T4, 1.0-2.7 nmol/1 for T3, 10.0-22.5 pmol/1 for fT4 and
5.3-10.0 pmol/1 for fT3. Basal serum TSH concentrations by IRMA ranged from
0.14-5.9 mU/1.
The Mann-Whitney test for unpaired data was used for statistical analysis.
Results
Abnormalities in thyroid function tests in patients with nonthyroidal illness
Figures 1 and 2 show the results of serum T4, fT4 and basal TSH IRMA tests in
Group I and Group II patients, respectively. In Group I, a substantial number of
patients had low T4 and fT4 levels but only four had unequivocably high TSH levels
and on recall showed clinical evidence of hypothyroidism; these patients are now
receiving treatment with thyroxine. One other patient, who died subsequently, had
low thyroid hormone results and a TSH IRMA level of 7.4 mU/1. A further 10
patients (8 female, 2 males; aged 56-86 yr) had basal TSH levels > 7.0 mU/1 but
normal T4 levels; fT4 levels were low in 5 of these patients.
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Fig. 1. Serum T4, fT4 and basal TSH IRMA results in patients from Group I. Results for patients with
undetectable TSH IRMA (O), overt hypothyroidism (a) and elevated TSH IRMA but normal T4 (X),
















Fig. 2. Serum T4, fT4 and basal TSH IRMA in patients with chronic renal failure (Group II). The results
for a patient with an elevated TSH IRMA ( x) are as indicated.
In those patients with low T4 but normal TSH concentrations, the main diagno¬
ses were; liver dysfunction (« = 3), respiratory disease (n = 3), cardiovascular dis¬
ease (n = 3), diabetes (n — 2), epilepsy (n = 2), acute renal failure (n = 1), nephrotic
syndrome {n = 1) and ulcerative colitis (n = 1). Four patients were drug free, the
two epileptic patients were taking phenytoin or sodium valproate and the remainder
were receiving digoxin, diuretics or antibiotics. Serum total protein concentrations
less than 60 g/1 and albumin concentrations less than 36 g/1 were found in 5 and 9
patients, respectively.
Two women in Group I, who had elevated T4 and normal fT4 levels, were taking
an oestrogen-containing oral contraceptive.
Three patients had undetectable basal TSH levels by IRMA; the results of their
other tests are shown in Table I (patients 1-3). One patient had borderline high T4
and fT4 levels on later testing by her general practitioner, consistent with subclinical
hyperthyroidism; the remaining two patients were lost to follow-up.
In the group II patients, the prevalence of abnormal T4 and fT4 results was even
greater, although only one patient had an abnormal TSH IRMA (Fig. 2).
Table II compares the number of abnormal results by each test in the two patient
groups. The TSH IRMA clearly showed the lowest number of abnormal results.
A significant decrease in basal TSH IRMA was shown in Group I patients
(p = 0.02) but not in Group II patients when compared to the reference group after





































































Fig. 3. The correlation of the serum TSH R1A increment after TRFI with basal serum TSFI IRMA in the
reference group and in patients with nonthyroidal illness (Group I).
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TABLE II
The number of patients with abnormal thyroid funciton tests
Result Group I (264 patients) Group II (35 patients)
Low High Low High
T4 21 (8%) 3 (0.1%) 15 (43%) 0 -
fr4 40(15%) 2 ( < 0.1%) 24 (69%) 0 -
T3 50(19%) 0 - 10 (29%) 0 -
rr3 128 (49%) 2 ( <0.1%) 25 (71%) 0 -
TSH IRMA 3 (l%)a 15 (6%) 0 - 1 (3%)
a Undetectable.
excluding the abnormal TSH results discussed above. Further analysis showed that
this decrease was confined to males (p< 0.002) and was age-related (r = —0.265,
p < 0.01).
Relationship between basal TSH (IRMA) and TSH response to TRH in nonthyroidal
illness
There was a highly significant correlation between the basal TSFI (IRMA) and
the TSH (RIA) increment after TRH in the reference group (r = 0.802; p < 0.001)
and in 74 Group I patients (r = 0.648, p < 0.001) although the scatter of points was
greater in the latter (Fig. 3). Diminished TSH (RIA) responses to TRH of < 3.9
mU/1 at 20 min, were found chiefly in the older male patients (Mann-Whitney,
p < 0.05). In those patients with diminished responses (n = 30), T4 and fT4 con¬
centrations were low in 10% and 13%, respectively.
Two patients had absent TSH (RIA) responses to TRH although basal TSH was
detectable by IRMA (Table I, patients 4, 5). Both were women who later died in
hospital.
Discussion
Thyroid function tests are frequently requested in hospital in-patients often with
little clinical justification and despite reports that the diagnostic yield of this
'screening' approach only proves rewarding in the elderly, where there is an
increased prevalence of thyroid disease [12-14]. However, since such requests are
likely to continue, there is a need for a screening test which is unaffected by the
presence of non-thyroidal illness.
In this study the basal serum TSH measurement by IRMA gave the lowest
number of abnormal results out of the tests performed in the group I patients, most
of whom were elderly. This was even more marked in those patients with chronic
renal failure (group II), where reliable tests of thyroid status are essential since
clinical features of hypothyroidism may be present. The possibility that patients
with thyroid disease were missed using this test has to be considered. However, the
number of abnormal results using basal TSH (IRMA) agrees well with the reported
prevalence of 5% for thyroid disease in the elderly [15].
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It has been argued that TSH may be inappropriately low in glucocorticoid
treated patients [16], during phenytoin therapy [17] and in fasting subjects [18]. In
this study, only one patient with a low T4 and normal TSH received phenytoin and
none were receiving glucocorticoids. It has also been shown that the suppressive
effect of fasting on TSH secretion is only sufficient to normalise TSH secretion in
mild rather than overt hypothyroidism [18], Although we cannot exclude such a
suppression in our low T4 patients, the basal TSH IRMA levels in those patients
with low T4 but normal TSH, were not significantly higher than the reference group.
The low T4 or fT4 levels in the presence of a normal TSH IRMA could equally be
due to the low serum protein and albumin concentrations present and the drug
therapy used in these patients.
Four patients with overt hypothyroidism were identified by all the tests. A
further 10 group I patients, 8 of whom were elderly females, had > 7.0 mU/1 basal
TSH but normal T4 and T3 levels, consistent with the presence of subclinical
hypothyroidism. Elevations in basal TSH levels have been reported during the
recovery phase after systemic illness [19], This is unlikely to account for the raised
results found here, as all blood samples were taken on admission to hospital. In
addition, 5 of the 10 patients had low fT4 levels and these could not be attributed to
low serum albumin or medication known to lower Amerlex fT4 values. It would be
expedient, however, to repeat the TSH measurement in such patients after resolu¬
tion of the systemic illness before T4 replacement therapy were considered.
An illness-associated reduction in basal TSH levels has been reported in cancer
patients undergoing bone marrow transplantation [20], but in general this reduction
was not observed in either of our patient groups. In addition, low T4 or fT4 levels
did not occur more frequently in those Group I patients with diminished TRH
responsiveness. Transient secondary hypothyroidism may be a feature of more
critically ill patients, for example, in an intensive care unit, where routine investiga¬
tion of thyroid status would not be a major concern. In chronic renal failure,
pituitary TSH secretion is inappropriately low for the measured thyroid hormone
levels. Whether this is due to the presence of altered binding proteins and endoge¬
nous inhibitors which affect conventional measurement of T4 and fT4 [2] or to
non-pituitary tissues being maintained in a state of hypothyroidism as a physiologi¬
cal response to the illness [6], remains unclear.
Our study revealed 1% of patients with undetectable serum TSH (IRMA). One
patient had continued biochemical evidence of hyperthyroidism after discharge. The
other two patients were lost to follow-up and we were unable to determine if their
undetectable TSH (IRMA) was due to subclinical hyperthyroidism or to their
non-thyroidal illness. Nevertheless, in the population studied, fewer patients re¬
quired confirmatory tests of thyroid function using TSH (IRMA) as the first-line
test, than if T4 or fT4 levels had been used. Also, T4 measurement does not detect
patients with subclinical thyroid disease who may benefit from follow-up and later
treatment [21-23]. A measurement of basal TSH by IRMA has the advantage of
identifying such patients [8].
We have shown that the strong positive correlation between basal TSH (IRMA)
and the TSH response to TRH is generally maintained in patients with non-thyroidal
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illness, providing a sound theoretical basis for the use of basal TSH (IRMA) in the
investigation of these patients. Disparity occurred in only 2 out of 74 patients tested
where the basal TSH (IRMA) was detectable but the TSH (R1A) response to TRH
was absent. As both patients subsequently died, we could not repeat the tests on
recovery from the systemic illness. However, in a recent study, Davies et al showed
that 80% of elderly, euthyroid patients with non-thyroidal illness who had no TSH
response to TRH on presentation, showed TSH responsiveness at subsequent
follow-up [24], The majority of their patients (9/10) had detectable basal TSH
levels. The use of a basal TSH IRMA measurement may, therefore, provide a more
specific test to exclude thyroid disease than the TRH test in patients with non-
thyroidal illness.
The measurement of basal serum TSH by a sensitive assay should supercede
conventional thyroid function tests as the first-line test of thyroid function in
patients admitted to a general medical ward.
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